



R

RESEARCH OPPORTUNITIES ALERT

Issue 26: Volume 1b



GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (NIH)

(Quarter: July - September, 2016)

A Compilation by the

RESEARCH SERVICES UNIT
OFFICE OF RESEARCH, INNOVATION AND DEVELOPMENT (ORID)
UNIVERSITY OF GHANA

JUNE 2016

Research Grants

Innovation Grants

Academic-Industry Grants

Collaborative Opportunities

Technology Development Grants



TABLE OF CONTENT

OPPORTUNITIES FOR JULY 2016

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R01)	29
CORE INFRASTRUCTURE AND METHODOLOGICAL RESEARCH FOR CANCER EPIDEMIOLOGY COHORTS (U01)	31
IMAGING AND BIOMARKERS FOR EARLY DETECTION OF AGGRESSIVE CANCER (U01)	32
INNOVATIVE BASIC RESEARCH ON ADDUCTS IN CANCER RISK IDENTIFICATION AND PREVENTION (R21)	33
INNOVATIVE BASIC RESEARCH ON ADDUCTS IN CANCER RISK IDENTIFICATION AND PREVENTION (R01)	34
TRANSLATIONAL RESEARCH ON ADDUCTS IN CANCER RISK IDENTIFICATION AND PREVENTION (U01)	35
HIV VACCINE RESEARCH AND DESIGN PROGRAMME (P01)	35
RESEARCH PARTNERSHIPS FOR SCALING UP MENTAL HEALTH INTERVENTIONS IN LOW AND MIDDLE-INCOME COUNTRIES (U19)	36
EXTENDED DEADLINE: CLINICAL AND TRANSLATIONAL EXPLORATORY OR DEVELOPMENTAL STUDIES (R21)	38
RESEARCH EDUCATION PROGRAMME FOR CLINICAL RESEARCHERS AND CLINICIANS (R25)	39
ADULT MATURATIONAL CHANGES AND DYSFUNCTION IN EMOTION REGULATION (R21)	39
ADULT MATURATIONAL CHANGES AND DYSFUNCTION IN EMOTION REGULATION (R01)	40
GRAND OPPORTUNITY IN MEDICATIONS DEVELOPMENT FOR SUBSTANCE-USE DISORDERS (U01)	41
STRATEGIC ALLIANCES FOR MEDICATIONS DEVELOPMENT TO TREAT SUBSTANCE USE DISORDERS (R01)	42
FAST-TRACK DEVELOPMENT OF MEDICATIONS TO TREAT CANNABIS USE DISORDERS (UG3/UH3)	43
IMMUNITY IN NEONATES AND INFANTS (U01)	44
AVANT-GARDE AWARD PROGRAMME FOR HIV/ AIDS AND DRUG USE RESEARCH (DP1)	45



UNDERSTANDING HIV REBOUND (P01)	46
ANIMAL-ASSISTED INTERVENTIONS FOR SPECIAL POPULATIONS (R21)	47
ANIMAL-ASSISTED INTERVENTIONS FOR SPECIAL POPULATIONS (R03)	48
INNOVATION FOR HIV VACCINE DISCOVERY (R01)	49
NEURONEXT CLINICAL TRIALS (U01)	50
PREVENTION INNOVATION PROGRAMME THREE (R01)	51
IDENTIFICATION OF SMALL MOLECULES FOR SUSTAINED-RELEASE ANTI-HIV PRODUCTS (R01)	52
CLINICAL SEQUENCING EVIDENCE-GENERATING RESEARCH - CLINICAL SITES WITH ENHANCED DIVERSITY (U01)	53
CLINICAL SEQUENCING EVIDENCE-GENERATING RESEARCH - CLINICAL SITES (U01)	55
RESEARCH DISSERTATION FELLOWSHIP FOR AUD AUDIOLOGISTS (F32)	56
NINDS CREATE BIO DISCOVERY TRACK: OPTIMISATION IN PREPARATION FOR DEVELOPMENT OF BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (U01)	57
NINDS CREATE BIO DEVELOPMENT TRACK: PRECLINICAL AND EARLY-PHASE CLINICAL DEVELOPMENT FOR BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (UH2/UH3)	58
BLUEPRINT NEUROTHERAPEUTICS NETWORK: SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT FOR DISORDERS OF THE NERVOUS SYSTEM (UH2/UH3)	59
TRANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R03)	60
TRANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R01)	61
TRANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R21)	62
UTILISING THE PLCO BIOSPECIMENS RESOURCE TO BRIDGE GAPS IN CANCER AETIOLOGY AND EARLY-DETECTION RESEARCH (U01)	63
EXPLORATORY STUDIES OF SMOKING CESSATION INTERVENTIONS FOR PEOPLE WITH SCHIZOPHRENIA (R21/ R33)	64
EXPLORATORY STUDIES OF SMOKING CESSATION INTERVENTIONS FOR PEOPLE WITH SCHIZOPHRENIA (R33)	65
PROVOCATIVE QUESTIONS IN CANCER WITH AN UNDERLYING HIV INFECTION (R21)	66
PROVOCATIVE QUESTIONS IN CANCER WITH AN UNDERLYING HIV INFECTION (R01)	67



CLINICAL TRIAL READINESS FOR RARE NEUROLOGICAL AND NEUROMUSCULAR DISEASES (U01)	68
CUTTING-EDGE BASIC RESEARCH AWARDS (R21)	69
INTERNATIONAL RESEARCH IN INFECTIOUS DISEASES (R01): AIDS-RELATED	70
PLANNING FOR REGIONAL CENTRES OF RESEARCH EXCELLENCE IN NON-COMMUNICABLE DISEASES IN LOW AND MIDDLE INCOME COUNTRIES (P20)	71
PLANNING GRANT FOR FOGARTY HIV RESEARCH TRAINING PROGRAMME FOR LOW- AND MIDDLE-INCOME COUNTRY INSTITUTIONS (D71)	72
FOGARTY HIV RESEARCH TRAINING PROGRAMME FOR LOW- AND MIDDLE-INCOME COUNTRY INSTITUTIONS (D43)	73
INFRASTRUCTURE DEVELOPMENT TRAINING PROGRAMMES FOR CRITICAL HIV RESEARCH AT LOW- AND MIDDLE-INCOME COUNTRY INSTITUTIONS (G11)	74
HIV INFECTION OF THE CENTRAL NERVOUS SYSTEM (R01)	76
RESEARCH ON MALIGNANCIES IN THE CONTEXT OF HIV/ AIDS (R01)	76
DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R01): AIDS-RELATED	77
HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R01): AIDS-RELATED	79
BIOLOGY OF MANUAL THERAPIES (R21): AIDS-RELATED	87
NEI RESEARCH GRANT FOR VISION RELATED SECONDARY DATA ANALYSIS (R21): AIDS-RELATED	88
PRESCRIPTION DRUG ABUSE (R21): AIDS-RELATED	88
HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R21): AIDS-RELATED	89
HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R03): AIDS-RELATED	90
PILOT AND FEASIBILITY CLINICAL TRIALS IN DIABETES, AND ENDOCRINE AND METABOLIC DISEASES (R21): AIDS-RELATED	91
EXPLORATORY/DEVELOPMENTAL BIOENGINEERING RESEARCH GRANTS (R21): AIDS-RELATED	92
BIOENGINEERING RESEARCH GRANTS (R01): AIDS-RELATED	93
BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R01): AIDS-RELATED	94
BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R03): AIDS-RELATED	95



MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R21): AIDS-RELATED.....	96
MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R01): AIDS-RELATED.....	97
RESEARCH PROJECT GRANT (PARENT R01): AIDS-RELATED	98
MOLECULAR GENETICS OF DRUG ADDICTION AND RELATED CO-MORBIDITIES (R01): AIDS-RELATED.....	99
PRESCRIPTION DRUG ABUSE (R01): AIDS-RELATED	100
FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAs IN DRUG ADDICTION (R21): AIDS-RELATED	101
INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R21): AIDS-RELATED	102
INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R03): AIDS-RELATED	103
SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/ AIDS (R21).....	104
SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/ AIDS (R03).....	105
NEUROSCIENCE RESEARCH ON DRUG ABUSE (R01): AIDS-RELATED	106
NEUROSCIENCE RESEARCH ON DRUG ABUSE (R21): AIDS-RELATED	107
NEUROSCIENCE RESEARCH ON DRUG ABUSE (R03): AIDS-RELATED	108
DEVELOPMENT OF ASSAYS FOR HIGH-THROUGHPUT DRUG SCREENING FOR USE IN PROBE AND PRE-THERAPEUTIC DISCOVERY (R01): AIDS-RELATED.....	109
DEVELOPMENT OF ANIMAL MODELS AND RELATED BIOLOGICAL MATERIALS FOR RESEARCH (R21): AIDS-RELATED	110
KIDS-SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (R03)	111
BIOENGINEERING RESEARCH PARTNERSHIPS (U01): AIDS-RELATED	111
BIOLOGY OF MANUAL THERAPIES (R01): AIDS-RELATED	112
NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R01): AIDS-RELATED	113
NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R03): AIDS-RELATED	114
NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R21): AIDS-RELATED	115
SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R01): AIDS-RELATED.....	116
SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R21): AIDS-RELATED.....	117
SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R03): AIDS-RELATED.....	118



THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R01): AIDS-RELATED.....	118
GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R01): AIDS-RELATED.....	120
GENETIC EPIDEMIOLOGY OF SUBSTANCE USE DISORDERS (R03): AIDS-RELATED.....	121
GENETIC EPIDEMIOLOGY OF SUBSTANCE USE DISORDERS (R21): AIDS-RELATED.....	122
NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH SMALL GRANT PROGRAMME FOR NEW INVESTIGATORS (R03): AIDS-RELATED.....	123
HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R21): AIDS-RELATED.....	123
HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R01): AIDS-RELATED.....	124
EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R01): AIDS-RELATED ..	125
EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R21): AIDS-RELATED ..	126
INTERNATIONAL RESEARCH COLLABORATION ON ALCOHOL AND ALCOHOLISM (U01): AIDS-RELATED	127
PROGRAMME FOR EXTRAMURAL OR INTRAMURAL ALCOHOL RESEARCH COLLABORATIONS (U01): AIDS-RELATED.....	128
NLM EXPRESS RESEARCH GRANTS IN BIOMEDICAL INFORMATICS (R01): AIDS-RELATED.....	129
EPIDEMIOLOGY OF DRUG ABUSE (R01): AIDS-RELATED	130
EPIDEMIOLOGY OF DRUG ABUSE (R21): AIDS-RELATED	131
EPIDEMIOLOGY OF DRUG ABUSE (R03): AIDS-RELATED	132
SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R03): AIDS-RELATED.....	133
SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R01): AIDS-RELATED.....	134
BEHAVIOURAL OR SOCIAL INTERVENTION CLINICAL PLANNING GRANT (R34): AIDS-RELATED.....	135
METHODOLOGY AND MEASUREMENT IN THE BEHAVIORAL AND SOCIAL SCIENCES (R01): AIDS-RELATED.....	136
RESEARCH TO ADVANCE VACCINE SAFETY (R01): AIDS-RELATED.....	137
RESEARCH TO ADVANCE VACCINE SAFETY (R21): AIDS-RELATED.....	138
PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN UROLOGIC DISORDERS (R21): AIDS-RELATED.....	139



SECONDARY ANALYSES IN OBESITY, DIABETES, DIGESTIVE AND KIDNEY DISEASES (R21): AIDS-RELATED.....	140
TARGETED BASIC BEHAVIOURAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R21)	160
SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIOURAL AND SOCIAL SCIENCES (R01): AIDS-RELATED.....	161
SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIOURAL AND SOCIAL SCIENCES (R21): AIDS-RELATED.....	162
BUILDING GENETICS AND GENOMIC KNOWLEDGE ABOUT DENTAL, ORAL AND CRANIOFACIAL DISEASES AND DISORDERS (R01): AIDS-RELATED	163
TARGETED BASIC BEHAVIOURAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R01)	164
ALCOHOL IMPAIRMENT OF IMMUNE FUNCTION, HOST DEFENSE AND TISSUE HOMEOSTASIS (R01): AIDS-RELATED.....	171
HIGH THROUGHPUT SCREENING TO DISCOVER CHEMICAL PROBES (R01): AIDS-RELATED.....	172
THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R03): AIDS-RELATED.....	173
THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R21): AIDS-RELATED.....	174
PILOT HEALTH SERVICES AND ECONOMIC RESEARCH ON THE TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R34): AIDS-RELATED.....	175
DEVELOPMENT AND TESTING OF NOVEL INTERVENTIONS TO IMPROVE HIV PREVENTION, CARE, AND PROGRAMME IMPLEMENTATION (R34).....	176
PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS: EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R01): AIDS-RELATED.....	177
PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS – EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R21): AIDS-RELATED.....	178
CLINICAL DEVELOPMENT OF MINIMALLY INVASIVE BIOASSAYS TO SUPPORT OUTPATIENT CLINICAL TRIALS OF THERAPEUTICS FOR SUBSTANCE USE DISORDERS (R01): AIDS-RELATED.....	179
ETHICAL ISSUES IN RESEARCH ON HIV/ AIDS AND ITS CO-MORBIDITIES (R21).....	180
ETHICAL ISSUES IN RESEARCH ON HIV/ AIDS AND ITS CO-MORBIDITIES (R01).....	181
LYMPHATICS IN HEALTH AND DISEASE IN THE DIGESTIVE SYSTEM, KIDNEY AND URINARY TRACT (R01): AIDS-RELATED	182



EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R01) AIDS-RELATED.....	183
ADVANCING ERYTHROID CELL BIOLOGY (R01): AIDS-RELATED	184
DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R03): AIDS-RELATED	185
RESEARCH EDUCATION PROGRAMME FOR CLINICAL RESEARCHERS AND CLINICIANS (R25): AIDS-RELATED.....	186
REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R21): AIDS-RELATED	186
REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R03): AIDS-RELATED	187
REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R01): AIDS-RELATED	188
THE EFFECTS OF MODULATING CHRONIC LOW GRADE INFLAMMATION ON GERIATRIC CONDITIONS - SECONDARY DATA OR BIOSPECIMEN ANALYSES AND ANCILLARY STUDIES IN ONGOING OR COMPLETED CLINICAL TRIALS (R01) AIDS- RELATED.....	189
RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R03): AIDS-RELATED.....	190
RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R21): AIDS-RELATED.....	191
RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R01): AIDS-RELATED.....	192
SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R21): AIDS-RELATED	193
SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R03): AIDS-RELATED	193
IMPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING- RELATED BEHAVIOURS AND PREVENTION RESEARCH (R21): AIDS-RELATED	194
SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R01): AIDS-RELATED	195
IMPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING- RELATED BEHAVIOURS AND PREVENTION RESEARCH (R01): AIDS-RELATED	196
SYNERGISING OMIC AND SYMPTOM SCIENCE (R01): AIDS-RELATED	197
SYSTEMIC AMYLOIDOSIS: BASIC, TRANSLATIONAL AND CLINICAL RESEARCH (R01): AIDS-RELATED.....	198



BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R21): AIDS-RELATED.....	199
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R03): AIDS-RELATED.....	200
THE ROLE OF THE CYTOSKELETON IN CELLULAR AGEING (R21/R33): AIDS-RELATED	201
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R01): AIDS-RELATED.....	202
BEHAVIOURAL AND SOCIAL SCIENCE RESEARCH ON UNDERSTANDING AND REDUCING HEALTH DISPARITIES (R21): AIDS-RELATED	203
BEHAVIOURAL AND SOCIAL SCIENCE RESEARCH ON UNDERSTANDING AND REDUCING HEALTH DISPARITIES (R01): AIDS-RELATED	204
BUT MICROBIOTA-DERIVED FACTORS IN THE INTEGRATED PHYSIOLOGY AND PATHOPHYSIOLOGY OF DISEASES WITHIN NIDDK'S MISSION (R01): AIDS-RELATED .	205
AUDACIOUS GOALS INITIATIVE HIGH PRIORITY RESEARCH AREA – INTERSECTION OF AGEING AND BIOLOGICAL MECHANISMS OF EYE DISEASE (R01): AIDS-RELATED	206
STRATEGIC ALLIANCES FOR MEDICATIONS DEVELOPMENT TO TREAT SUBSTANCE USE DISORDERS (R01): AIDS-RELATED	207
MECHANISMS OF ALCOHOL AND STIMULANT CO-ADDICTION (R21): AIDS-RELATED	208
MECHANISMS OF ALCOHOL AND STIMULANT CO-ADDICTION (R01): AIDS-RELATED	208
EXPLORATORY/DEVELOPMENTAL CLINICAL RESEARCH GRANTS IN OBESITY (R21): AIDS-RELATED.....	209
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R03): AIDS-RELATED	210
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R21): AIDS-RELATED	211
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R01): AIDS-RELATED	212
EARLY-CAREER AWARD IN CHEMISTRY OF DRUG ABUSE AND ADDICTION (R21/R33): AIDS-RELATED.....	213
ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R03): AIDS-RELATED..	214
ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R21): AIDS-RELATED..	215
MODELLING SOCIAL BEHAVIOUR (R01): AIDS-RELATED.....	217



NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (COLLABORATIVE R01): AIDS-RELATED	218
NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (R01): AIDS-RELATED.....	219
PUBLIC HEALTH IMPACT OF THE CHANGING POLICY/LEGAL ENVIRONMENT FOR MARIJUANA (R01): AIDS-RELATED.....	220
NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R21): AIDS-RELATED.....	221
NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R01): AIDS-RELATED.....	222
SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/ AIDS (R03): AIDS-RELATED.....	223
SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/ AIDS (R01): AIDS-RELATED.....	224
ERADICATION OF HIV-1 FROM CENTRAL NERVOUS SYSTEM RESERVOIRS (R01)	225
CLINICAL VISION RESEARCH: RESOURCE CENTRE GRANT (UG1): AIDS-RELATED.....	226
CLINICAL VISION RESEARCH: CHAIR'S GRANT (UG1): AIDS-RELATED.....	227
CLINICAL VISION RESEARCH: CLINICAL CENTRE GRANT (UG1): AIDS-RELATED	228
CLINICAL VISION RESEARCH: COORDINATING CENTRE GRANT (UG1): AIDS-RELATED	229
SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R03): AIDS-RELATED	229
SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R21): AIDS-RELATED	230
SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R01): AIDS-RELATED	231
FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R01): AIDS-RELATED.....	232
FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R21): AIDS-RELATED.....	233
ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R21): AIDS-RELATED	233
PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R34): AIDS-RELATED.....	243



PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R21): AIDS-RELATED	244
NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R21): AIDS-RELATED	245
PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R01): AIDS-RELATED	246
NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R01): AIDS-RELATED	247
COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R21): AIDS-RELATED	248
COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R01): AIDS-RELATED	248
ESTABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R21): AIDS-RELATED .	249
ESTABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R01): AIDS-RELATED .	250
EARLY STAGE DEVELOPMENT OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01): AIDS-RELATED	251
EXTENDED DEVELOPMENT, HARDENING AND DISSEMINATION OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01): AIDS-RELATED	252
TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R21): AIDS-RELATED	253
RANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R01): AIDS-RELATED	254
EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R21): AIDS-RELATED	255
EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R03): AIDS-RELATED	256
EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R01): AIDS-RELATED	257
CLINICAL TRIAL PLANNING GRANT FOR INTERVENTIONS AND SERVICES TO IMPROVE TREATMENT AND PREVENTION OF HIV/ AIDS (R34)	258
MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R21): AIDS-RELATED	259
MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R01) AIDS-RELATED	260



EXPLORATORY CLINICAL TRIALS OF MIND AND BODY INTERVENTIONS FOR NCCAM HIGH PRIORITY RESEARCH TOPICS (R34) AIDS-RELATED	260
UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R01): AIDS-RELATED	262
NK CELLS TO INDUCE IMMUNOLOGICAL MEMORY TO PREVENT HIV INFECTION (R01)	263
FC RECEPTOR AND ANTIBODY EFFECTOR FUNCTION IN HIV VACCINE DISCOVERY (R01)	263
HIV VACCINE VECTOR-HOST INTERACTIONS: UNDERSTANDING THE BIOLOGY AND IMMUNOLOGY (R21)	264
HIV VACCINE VECTOR-HOST INTERACTIONS: UNDERSTANDING THE BIOLOGY AND IMMUNOLOGY (R01)	265
CLINICAL EVALUATION OF ADJUNCTS TO OPIOID THERAPIES FOR THE TREATMENT OF CHRONIC PAIN (R01) AIDS-RELATED.....	266
ADVANCING RESEARCH IN VOICE DISORDERS (R21) AIDS-RELATED	267
ADVANCING RESEARCH IN VOICE DISORDERS (R01) AIDS-RELATED	268
BASIC RESEARCH ON HIV PERSISTENCE (R21): AIDS-RELATED	269
MULTIDISCIPLINARY STUDIES OF HIV AND VIRAL HEPATITIS CO-INFECTION (R21)..	270
MULTIDISCIPLINARY STUDIES OF HIV AND VIRAL HEPATITIS CO-INFECTION (R01)..	270
NINDS CREATE BIO DISCOVERY TRACK: OPTIMISATION IN PREPARATION FOR DEVELOPMENT OF BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (U01): AIDS- RELATED.....	271
INDS CREATE BIO DEVELOPMENT TRACK: PRECLINICAL AND EARLY-PHASE CLINICAL DEVELOPMENT FOR BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (UH2/UH3): AIDS-RELATED	272
BLUEPRINT NEUROTHERAPEUTICS NETWORK: SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT FOR DISORDERS OF THE NERVOUS SYSTEM (UH2/UH3): AIDS- RELATED.....	273
ARTS-BASED APPROACHES IN PALLIATIVE CARE FOR SYMPTOM MANAGEMENT (R01): AIDS-RELATED.....	274
PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R03) AIDS-RELATED.....	275
PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL, AND PAEDIATRIC CARE (R21): AIDS-RELATED.....	277
MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R21): AIDS-RELATED.....	278



MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R01): AIDS-RELATED.....	279
PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R01) AIDS-RELATED.....	280
SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R21): AIDS-RELATED.....	281
SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R21): AIDS-RELATED.....	282
NIDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY PLANNING GRANT (R34): AIDS-RELATED.....	283
SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R01): AIDS-RELATED.....	284
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R21): AIDS-RELATED.....	285
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R03): AIDS-RELATED.....	286
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R01): AIDS-RELATED.....	287
BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R21): AIDS-RELATED.....	288
BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R01): AIDS-RELATED.....	289
BIOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R21): AIDS-RELATED.....	290
BIOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R01): AIDS-RELATED.....	291
DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R21): AIDS-RELATED.....	293
DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R03): AIDS-RELATED.....	294
DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R01): AIDS-RELATED.....	295
UNDERACTIVE BLADDER IN AGEING (R03): AIDS-RELATED.....	296
UNDERACTIVE BLADDER IN AGEING (R21): AIDS-RELATED.....	297
UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R21): AIDS-RELATED.....	298
NIDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY COOPERATIVE AGREEMENT (U01): AIDS-RELATED.....	299



BUILDING ON HIGH IMPACT BASIC NEUROBIOLOGY THROUGH ASSAY DEVELOPMENT: ADVANCING TOOLS FOR THERAPEUTIC DISCOVERY (R01): AIDS- RELATED.....	300
INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): ASSAY DEVELOPMENT AND THERAPEUTIC AGENT IDENTIFICATION AND CHARACTERISATION TO SUPPORT THERAPEUTIC DISCOVERY (R21/R33): AIDS- RELATED.....	301
INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): PHARMACODYNAMICS AND IN VIVO EFFICACY STUDIES FOR SMALL MOLECULES AND BIOLOGICS/BIOTECHNOLOGY PRODUCTS (R21/R33): AIDS-RELATED	302
ACADEMIC-INDUSTRIAL PARTNERSHIPS FOR TRANSLATION OF TECHNOLOGIES FOR CANCER DIAGNOSIS AND TREATMENT (R01): AIDS-RELATED	303
PREVENTION RESEARCH IN MID-LIFE ADULTS (R21): AIDS-RELATED	304
PREVENTION RESEARCH IN MID-LIFE ADULTS (R01): AIDS RELATED.....	305
REDUCTIONS IN ILLICIT DRUG USE AND FUNCTIONAL OUTCOMES (R21/R33): AIDS- RELATED.....	306
MATERNAL NUTRITION AND PRE-PREGNANCY OBESITY: EFFECTS ON MOTHERS, INFANTS AND CHILDREN (R01): AIDS-RELATED	307
ROLE OF EXOSOMES IN HIV PATHOGENESIS (R21).....	308
EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R03): AIDS- RELATED.....	308
EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R21): AIDS- RELATED.....	310
ADVANCING TRANSLATIONAL AND CLINICAL PROBIOTIC OR PREBIOTIC AND HUMAN MICROBIOME RESEARCH (R01): AIDS-RELATED.....	311
EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R01): AIDS- RELATED.....	312
FUNCTIONAL WELLNESS IN HIV – MAXIMISING THE TREATMENT CASCADE (R21) AIDS-RELATED.....	313
FUNCTIONAL WELLNESS IN HIV – MAXIMISING THE TREATMENT CASCADE (R01) AIDS-RELATED.....	314
PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN KIDNEY DISEASES (R21): AIDS-RELATED.....	315
IMPROVING DIET AND PHYSICAL ACTIVITY ASSESSMENT (R21): AIDS-RELATED	316
DIET AND PHYSICAL ACTIVITY ASSESSMENT METHODOLOGY (R01): AIDS-RELATED	316



IMMUNE SYSTEM PLASTICITY IN THE PATHOGENESIS AND TREATMENT OF COMPLEX DENTAL, ORAL, AND CRANIOFACIAL DISEASES (R21) – AIDS RELATED	317
IMMUNE SYSTEM PLASTICITY IN THE PATHOGENESIS AND TREATMENT OF COMPLEX DENTAL, ORAL, AND CRANIOFACIAL DISEASES (R01) – AIDS-RELATED	318
DEVELOPING THE THERAPEUTIC POTENTIAL OF THE ENDOCANNABINOID SYSTEM FOR PAIN TREATMENT (R01): AIDS-RELATED	319
STUDIES AT PERIVIALE GESTATION (R03) – AIDS-RELATED	320
STUDIES AT PERIVIALE GESTATION (R21) – AIDS-RELATED	321
STUDIES AT PERIVIALE GESTATION (R01) – AIDS-RELATED	322
HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R03) – AIDS-RELATED	323
HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R21) – AIDS-RELATED	324
HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R01) – AIDS-RELATED	325
FAST-TRACK DEVELOPMENT OF MEDICATIONS TO TREAT CANNABIS USE DISORDERS (UG3/UH3) – AIDS-RELATED	326
EXPLOITING RNA AS A TARGET FOR HIV INTERVENTIONS (R21)	327
HARNESSING BIG DATA TO HALT HIV (R01)	328
BIOENGINEERING RESEARCH PARTNERSHIP – NON- OR MINIMALLY-INVASIVE METHODS TO MEASURE BIOCHEMICAL SUBSTANCES DURING NEONATAL AND PERINATAL PATIENT CARE AND RESEARCH (R01): AIDS-RELATED	328
END-OF-LIFE AND PALLIATIVE NEEDS OF ADOLESCENTS AND YOUNG ADULTS WITH SERIOUS ILLNESSES (R21): AIDS-RELATED	329
END-OF-LIFE AND PALLIATIVE NEEDS OF ADOLESCENTS AND YOUNG ADULTS WITH SERIOUS ILLNESSES (R01) AIDS-RELATED	330
ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS (R21)	331
ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS (R21) AIDS-RELATED	332
ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS (R01)	333
ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS (R01) AIDS-RELATED	334
SMALL RESEARCH GRANTS FOR ORAL HEALTH DATA ANALYSIS AND STATISTICAL METHODOLOGY DEVELOPMENT AIDS-RELATED (R03)	335



RESEARCH ON THE MECHANISMS AND BEHAVIOURAL OUTCOMES OF MULTISENSORY PROCESSING (R01) AIDS-RELATED.....	336
PERSONALISED STRATEGIES TO MANAGE SYMPTOMS OF CHRONIC ILLNESS (R21) AIDS-RELATED.....	337
PERSONALISED STRATEGIES TO MANAGE SYMPTOMS OF CHRONIC ILLNESS (R01) AIDS-RELATED.....	338
EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R21) AIDS-RELATED.....	340
HIV AND AIDS HIGH PRIORITY DRUG ABUSE RESEARCH (R01)	341
INNOVATIVE QUESTIONS IN SYMPTOM SCIENCE AND GENOMICS (R21): AIDS- RELATED.....	341
INNOVATIVE QUESTIONS IN SYMPTOM SCIENCE AND GENOMICS (R01): AIDS-RELATED	342
INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS – DEVELOPMENT AND VALIDATION OF MODEL SYSTEMS AND PHARMACODYNAMIC MARKERS TO FACILITATE THE DISCOVERY OF NEUROTHERAPEUTICS (R21/R33): AIDS- RELATED.....	343
APPLYING METABOLOMICS TO DRIVE BIOMARKER DISCOVERY IN SYMPTOM SCIENCE (R21): AIDS-RELATED.....	344
APPLYING METABOLOMICS TO DRIVE BIOMARKER DISCOVERY IN SYMPTOM SCIENCE (R01): AIDS-RELATED.....	345
ANCILLARY STUDIES TO MAJOR ONGOING CLINICAL RESEARCH STUDIES TO ADVANCE AREAS OF SCIENTIFIC INTEREST WITHIN THE MISSION OF THE NIDDK (R01): AIDS-RELATED	346
NATURAL HISTORY OF DISORDERS IDENTIFIABLE BY SCREENING OF NEWBORNS (R01): AIDS-RELATED	347
ANCILLARY STUDIES TO THE NIDDK INTESTINAL STEM CELL CONSORTIUM (R01): AIDS-RELATED	348
CLINICAL DEVELOPMENT OF MINIMALLY INVASIVE BIOASSAYS TO SUPPORT OUTPATIENT CLINICAL TRIALS OF THERAPEUTICS FOR SUBSTANCE USE DISORDERS (R01): AIDS-RELATED.....	349
OCYTE MITOCHONDRIAL FUNCTION IN RELATION TO FERTILITY, AGEING AND MITOCHONDRIAL DISEASES (R21): AIDS-RELATED	350
OCYTE MITOCHONDRIAL FUNCTION IN RELATION TO FERTILITY, AGEING AND MITOCHONDRIAL DISEASES (R01): AIDS-RELATED	351
MULTIDISCIPLINARY RESEARCH IN VULVODYNIA (R03): AIDS-RELATED	352
MULTIDISCIPLINARY RESEARCH IN VULVODYNIA (R21): AIDS-RELATED	354



MULTIDISCIPLINARY RESEARCH IN VULVODYNIA (R01): AIDS-RELATED	355
MODELLING OF INFECTIOUS DISEASE AGENT STUDY RESEARCH PROJECTS (R01): AIDS-RELATED	356
DEADLINE BROUGHT FORWARD: IMPROVEMENT OF ANIMAL MODELS FOR STEM- CELL-BASED REGENERATIVE MEDICINE (R21): AIDS-RELATED	357
IMPROVEMENT OF ANIMAL MODELS FOR STEM-CELL-BASED REGENERATIVE MEDICINE (R01): AIDS-RELATED	358
ROLE OF ASTROCYTES AND ASTROCYTIC NETWORKS IN DRUG ABUSE (R21): AIDS- RELATED	359
POPULATION HEALTH INTERVENTIONS: INTEGRATING INDIVIDUAL AND GROUP LEVEL EVIDENCE (R21): AIDS-RELATED	360
ROLE OF ASTROCYTES AND ASTROCYTIC NETWORKS IN DRUG ABUSE (R01): AIDS- RELATED	361
POPULATION HEALTH INTERVENTIONS: INTEGRATING INDIVIDUAL AND GROUP LEVEL EVIDENCE (R01): AIDS-RELATED	362
TAILORING DENTAL TREATMENT FOR INDIVIDUALS WITH SYSTEMIC DISEASES THAT COMPROMISE ORAL HEALTH (R21): AIDS-RELATED	363
UNDERSTANDING FACTORS IN INFANCY AND EARLY CHILDHOOD THAT INFLUENCE OBESITY DEVELOPMENT (R01): AIDS-RELATED	364
RESEARCH DISSERTATION FELLOWSHIP FOR AUD AUDIOLOGISTS (F32): AIDS- RELATED	365
PRECLINICAL RESEARCH ON MODEL ORGANISMS TO PREDICT TREATMENT OUTCOMES FOR DISORDERS ASSOCIATED WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (R01): AIDS-RELATED	366
OUTCOME MEASURES FOR USE IN TREATMENT TRIALS FOR INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (R01): AIDS-RELATED	367
CLINICAL SEQUENCING EVIDENCE-GENERATING RESEARCH - CLINICAL SITES WITH ENHANCED DIVERSITY (U01): AIDS-RELATED	368
CLINICAL SEQUENCING EVIDENCE-GENERATING RESEARCH - CLINICAL SITES (U01): AIDS-RELATED	369
METABOLIC REPROGRAMMING TO IMPROVE IMMUNOTHERAPY (R01): AIDS-RELATED	371
NON-HEALING ULCERATIVE WOUNDS IN AGEING (R01): AIDS-RELATED	372
FACTORS UNDERLYING DIFFERENCES IN FEMALE AND MALE PRESENTATION FOR DENTAL, ORAL AND CRANIOFACIAL DISEASES AND CONDITIONS (R01): AIDS- RELATED	373



NOVEL STRATEGIES FOR TARGETING HIV-CNS RESERVOIRS WITHOUT REACTIVATION (R21)	374
NOVEL STRATEGIES FOR TARGETING HIV-CNS RESERVOIRS WITHOUT REACTIVATION (R01)	375
BIOENGINEERING RESEARCH PARTNERSHIPS (U01).....	376
NIAID CLINICAL TRIAL PLANNING GRANT (R34)	377
NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01).....	378
NIAID CLINICAL TRIAL IMPLEMENTATION GRANT (R01).....	379
ROLE OF MOBILE GENETIC ELEMENTS IN CANCER (R21)	380
PHYSICAL SCIENCES-ONCOLOGY NETWORK: PHYSICAL SCIENCES-ONCOLOGY PROJECTS (U01)	381
MULTILEVEL INTERVENTIONS IN CANCER CARE DELIVERY: BUILDING FROM THE PROBLEM OF FOLLOW-UP TO ABNORMAL SCREENING TESTS (U01)	382
PANCREATIC CANCER DETECTION CONSORTIUM (U01)	383
DESIGN AND DEVELOPMENT OF NOVEL TECHNOLOGIES FOR HEALTHY INDEPENDENT LIVING (R21)	384
TECHNOLOGIES FOR HEALTHY INDEPENDENT LIVING (R01)	385
CLINICAL VISION RESEARCH: RESOURCE CENTRE GRANT (UG1)	385
CLINICAL VISION RESEARCH: CHAIR'S GRANT (UG1)	386
CLINICAL VISION RESEARCH: CLINICAL CENTRE GRANT (UG1).....	387
CLINICAL VISION RESEARCH: COORDINATING CENTRE GRANT (UG1).....	388
GENOMIC RESOURCE GRANTS FOR COMMUNITY RESOURCE PROJECTS (U41)	389
INNOVATIVE TECHNOLOGIES FOR CANCER-RELEVANT BIOSPECIMEN SCIENCE (R21)	390
ADVANCED DEVELOPMENT AND VALIDATION OF EMERGING MOLECULAR AND CELLULAR ANALYSIS TECHNOLOGIES FOR BASIC AND CLINICAL CANCER RESEARCH (R33)	391
VALIDATION AND ADVANCED DEVELOPMENT OF EMERGING TECHNOLOGIES FOR CANCER-RELEVANT BIOSPECIMEN SCIENCE (R33)	392
FROM ASSOCIATION TO FUNCTION IN THE ALZHEIMER'S DISEASE POST GENOMICS ERA (R01).....	393
FROM ASSOCIATION TO FUNCTION IN THE ALZHEIMER'S DISEASE POST GENOMICS ERA (R21).....	394
IMPACT OF AGEING IN HUMAN CELL MODELS OF ALZHEIMER'S DISEASE (R01)	395



PREDICTIVE MULTISCALE MODELS FOR BIOMEDICAL, BIOLOGICAL, BEHAVIOURAL, ENVIRONMENTAL AND CLINICAL RESEARCH (INTERAGENCY U01).....	396
EXTENDED DEADLINE: CLINICAL AND TRANSLATIONAL EXPLORATORY OR DEVELOPMENTAL STUDIES (R21)	397
RESEARCH EDUCATION PROGRAMME FOR CLINICAL RESEARCHERS AND CLINICIANS (R25)	398



JULY 2016

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The National Institutes of Health invites applications for their patient safety in the context of perinatal, neonatal and paediatric care programme. This R01 funding opportunity announcement encourages collaborative research projects related to patient safety in the context of perinatal, neonatal and paediatric care both in routine hospital settings and in the intensive care units. Proposals may address:

- the epidemiology of errors and adverse events in neonatal and paediatric care hospital units;
- medication errors;
- diagnostic errors;
- procedure-related errors;
- human factor and fatigue;
- promotion of a safety culture;
- other working conditions and systems issues;
- risk reduction and disclosure practices.

Eligibility is unrestricted. This funding opportunity uses the NIH research project grant (R01) mechanism and runs in parallel with one of identical scientific scope, PA-14-313, which solicits applications under the NIH small grant (R03) mechanism.

Applicants requesting US\$500,000 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The total project period may not exceed five years.

Ref: NIH PA-14-312 (replaces PAR-11-225).

Closing date: 05 Jul 16

Deadline information: Applications are invited from 5 September 2014 and are due by 5pm local time of applicant organisation.

Posted date: 07 Aug 14

Award type: Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-312.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-312>

Eligibility profile

Country of applicant institution: Any

Disciplines

Psychology; Paediatrics; Nursing; Standards of Care; Patient Care & Education; Law; Medical Research of Selected Fields; Medical & Diagnostic Tests; Safety & Accident Investigation; Health Psychology; Medical Effectiveness & Patient Outcomes; Hospitalisation; Public Health, Health Services & Primary Care; Allied Health Professions; Quality of Care; Paediatric Nursing; Business & Management Studies; Maternal Health; Health & Medical Informatics; Neonatal Disorders; Clinical Decision-making & Analysis; Health Systems, Risk Management; Telemedicine; Public Health & Medical Law; Primary Care;



Pregnancy & Birth; Health Professions & Workforce

Contact Details

NIH
Pregnancy and Perinatology Branch

Eunice Kennedy Shriver National Institute of Child and Human Development
6100 Executive Blvd, 4B03D
Bethesda MD 20892
Tel: +1 301 435 6873
Fax: +1 301 496 3790
Email: kosomari@mail.nih.gov



CORE INFRASTRUCTURE AND METHODOLOGICAL RESEARCH FOR CANCER EPIDEMIOLOGY COHORTS (U01)

NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its core infrastructure and methodological research for cancer epidemiology cohorts call (U01) funding opportunity announcement. This announcement provides targeted infrastructure support for the core functions of cancer epidemiology cohorts and methodological research.

This infrastructure can support existing or new CECs. This FOA qualifies the following two types of CECs:

- CECs with at least 10,000 study participants that are capable of supporting studies to examine the effects of multiple exposures and study participants' characteristics on the risk of multiple types of cancers and cancer mortality; •cohorts of cancer patients or survivors of at least 5,000 participants across multiple cancer sites or at least 2,000 participants diagnosed with the same or narrowly related cancer sites, to support research addressing determinants of cancer progression, recurrence, mortality, incidence and other cancer or health-related outcomes.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The maximum budget is US\$2.5 million in direct cost per year. The maximum project period is five years.

Ref: PAR-15-104 (reissue of PAR-14-160).

Closing date: 08 Jul 16

Deadline information: Applications due by 5pm local time of applicant organisation on 1 April, 8 July and 10 November 2015, 11 March, 8 July and 10 November 2016 and 10 March 2017.

Posted date: 02 Feb 15

Award type: Networking/collaboration, Research centres, Directed grants to institutions, research groups etc

Award amount max: \$12,500,000

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-104.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PAR-15-104>



Eligibility profile

Country of applicant institution: Any

Disciplines

Cancer Studies & Oncology

Contact Details

NCI
BG 9609 Room 4E206
9609 Medical Centre Drive
Rockville MD 20850
Tel: +1 240 276 6818
Email: joanne.elena@mail.nih.gov

I MAGING AND BIOMARKERS FOR EARLY DETECTION OF AGGRESSIVE CANCER (U01)

NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its imaging and biomarkers for early detection of aggressive cancer (U01) funding opportunity announcement. This announcement seeks collaborative research project applications to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk and cancer diagnosis aimed at integrating multi-modality imaging strategies and multiplexed biomarker methodologies into a singular complementary approach. The purpose is to establish a consortium for imaging and biomarkers to perform collaborative studies, exchange information, share knowledge and leverage common resources. The research will be conducted by individual multidisciplinary research teams, hereafter called units. All units are expected to participate in collaborative activities with other units within the consortium. The specific objective is to stimulate and support cancer imaging and biomarker research to develop, optimise and clinically validate novel methods to:

- detect aggressive cancers at the earliest stages possible;
- reduce overdiagnosis;
- reduce false positive tests and identify lethal cancers from non-lethal disease.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect actual needs of the project. The maximum project period is five years.

Ref: PAR-16-089 (replaces PAR-13-189).

Closing date: 11 Jul 16

Deadline information: Applications open on 11 June and are due by 5pm local time of applicant organisation, 11 July and 14 December 2016, 10 July and 11 December 2017, 10 July and 11 December 2018.

Posted date: 26 Jan 16

Award type: Networking/collaboration, Research centres, Directed grants to institutions, research groups etc

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-089.html>

Eligibility profile

Country of applicant institution: Any



Contact Details

Tel: +1 240 276 7126

Email: richard.mazurchuk@nih.gov

Disciplines

Biochemical Markers; Cancer Studies & Oncology; Radiology & Medical Imaging

INNOVATIVE BASIC RESEARCH ON ADDUCTS IN CANCER RISK IDENTIFICATION AND PREVENTION (R21)

NIH: National Cancer Institute

Description:

The National Cancer Institute and the National Institute of Environmental Health Sciences invite applications for their innovative basic research on adducts in cancer risk identification and prevention (R21) funding opportunity announcement. This R21 announcement encourages research projects focused on adductomic approaches and those that address aspects of the totality of adducts. The overall objective is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The ultimate goal is to discover and characterise the utility of adductomic-based exposure indicators for cancer detection, cancer prevention and assessing cancer risks. This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with two of identical scope: PAR-15-308 which solicits applications under the NIH research project (R01) grant mechanism and PAR-15-307 which solicits applications under the NIH research project – cooperative agreements (U01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Direct costs are limited to US\$275,000 over a maximum project period of two years. No

more than US\$200,000 may be requested for any single year.

Ref: PAR-15-309.

Closing date: 11 Jul 16

Deadline information: Applications are due by 5pm local time of applications organisation. Deadlines on: 23 November 2015, 11 July 2016, 22 November 2016, 11 July 2017, 21 November 2017, 11 July 2018.

Posted date: 27 Jul 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-15-309.html>

Application form:

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

Eligibility profile

Country of applicant institution: Any

Contact

NCI

BG 9609 RM 5E566

9609 Medical Center Drive

Rockville, MD 20850

Tel: +1 240 276 7117

Email: wangw@mail.nih.gov



Disciplines

Cytopathology; Cancer Studies & Oncology;
Preventive Medicine; Health Systems, Risk
Management



INNOVATIVE BASIC RESEARCH ON ADDUCTS IN CANCER RISK IDENTIFICATION AND PREVENTION (R01)

NIH: National Cancer Institute

Description:

The National Cancer Institute and the National Institute of Environmental Health Sciences invite applications for their innovative basic research on adducts in cancer risk identification and prevention grants (R01) funding opportunity announcement. This R01 announcement encourages research focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. The priority is on projects that will focus on adductomic approaches and address some aspects of the totality of adducts. The ultimate goal is to discover and characterise the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and assessing cancer risks. This FOA uses the R01 research project grant mechanism and runs in parallel with two of identical scope: PAR-15-309 which solicits applications under the NIH exploratory/developmental (R21) grant mechanism and PAR-15-307 which solicits applications under the NIH research project – cooperative agreements (U01) grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-15-308.

Closing date: 11 Jul 16

Deadline information: Applications are due by 5pm local time of applicant organisation. Deadlines on: 23 November 2015, 11 July 2016, 22 November 2016, 11 July 2017, 21 November 2017, 11 July 2018.

Posted date: 27 Jul 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-308.html>

Application form:

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

Eligibility profile

Country of applicant institution: Any

Contact Details

NCI

BG 9609 RM 5E566

9609 Medical Center Drive

Rockville, MD 20850

Tel: +1 240 276 7117

Email: wangw@mail.nih.gov

Disciplines



Cytopathology; Cancer Studies & Oncology;
Preventive Medicine; Health Systems, Risk

Management

T RANSLATIONAL RESEARCH ON ADDUCTS IN CANCER RISK IDENTIFICATION AND PREVENTION (U01)

NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its translational research on adducts in cancer risk identification and prevention (U01) funding opportunity announcement. This U01 announcement encourages research focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. The priority is on projects that will focus on adductomic approaches and address some aspects of the totality of adducts. The goals should be centred on linking adductomic-based indicators of exposures to exogenous and endogenous cancer risk factors identification for prevention. This FOA uses the U01 research project – cooperative agreements grant mechanism and runs in parallel with two of identical scope: PAR-15-309 which solicits applications under the NIH exploratory/developmental (R21) grant mechanism and PAR-15-308 which solicits applications under the NIH research project (R01) grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-15-307.

Closing date: 11 Jul 16

Deadline information: Applications are due by 5pm local time of applicant organisation. Deadlines on: 23 November 2015, 11 July 2016, 22 November 2016, 11 July 2017, 21 November 2017, 11 July 2018.

Posted date: 27 Jul 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-15-307.html>

Application form:

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

Eligibility profile

Country of applicant institution: Any

Disciplines

Cytopathology; Preventive Medicine; Health Systems, Risk Management; Cancer Studies & Oncology

Contact Details

NCI

BG 9609 RM 5E566

9609 Medical Center Drive

Rockville, MD 20850

Tel: +1 240 276 7117

Email: wangw@mail.nih.gov



HIV VACCINE RESEARCH AND DESIGN PROGRAMME (P01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites applications for its HIV vaccine research and design programme (P01) funding opportunity announcement. This announcement supports multi-component, multidisciplinary projects that address scientific questions relevant to Aids prophylactic vaccine discovery research.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget is US\$5 million in fiscal year 2016, to fund one to three awards. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PAR-15-164 (reissue of PAR-14-206).

Closing date: 15 Jul 16

Deadline information: Applications open on 15 May and are due by 5pm local time of applicant organisation on 15 July 2015, 15 July 2016 and 14 July 2017. Applicants requesting US\$500,000 or more in direct costs in any year must contact a scientific contact at least 6 weeks before submitting the application.

Posted date: 01 Apr 15

Award type: Directed grants to institutions, research groups etc

Award budget total: \$5,000,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-164.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do?TYPE=33554433&REALMOID=06-58b5535a-f2c3-40ec-b9ff-a06a3ed4ee18&GUID=&SMAUTHREASON=0&METHOD=GET&SMAGENTNAME=-SM-938PYmoLVb4VrDeXo04LZUDVDvc%2b3899ByInEAjuSUvWNIGfB2zRpWiCivYGCogG&TARGET=-SM-http%3a%2f%2fpublic%2eera%2enih%2egov%2fassist>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/ Aids

Contact Details

NIAID

Room 5138, MSC-7628

6700-B Rockledge Drive

Bethesda, MD 20892-7616

Tel: +1 240 292 6169

Email: schultzam@mail.nih.gov



R **ESearch PARTNERSHIPS FOR SCALING UP MENTAL HEALTH INTERVENTIONS IN LOW AND MIDDLE-INCOME COUNTRIES (U19)**

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health invites applications for its research partnerships for scaling up mental health interventions in low and middle-income countries (U19) funding opportunity announcement. This announcement is for projects that address implementation questions facing designated low and middle-income countries in their efforts to scale up sustainable, evidence-based mental health interventions and eliminate the mental healthcare treatment gap for children, women and men. The mental health treatment gap refers to the proportion of persons who need, but do not receive care. Projects should include implementation research and research capacity-building activities in LMICs in any one of the following geographical regions: East Asia and the Pacific; Europe and Central Asia; Latin America and the Caribbean; Middle East and North Africa; South Asia; Sub-Saharan Africa. The programme does not support research that can be conducted primarily in or by the US or other high income country institutions. Applications must address a locally relevant aspect of scaling up at a national or regional level within a designated LMIC. The five elements below must be included in all applications:

- propose a research partnership to conduct research and capacity-building activities that includes representatives from one or more academic institutions, government agencies, and non-governmental agencies;
- propose implementation research on scaling up sustainable, evidence-based mental health interventions within one or more LMICs;
- provide evidence that the proposed implementation research is aligned

with the designated LMIC's scale-up efforts, and there is adequate funding and other material public and private support to ensure that the designated LMIC's scale-up efforts will proceed or continue to proceed as planned;

- propose a plan for building capacity in two or more LMICs, including the lead LMIC in which the implementation research is to take place, and one or more additional countries in order to conduct implementation research and use science-based methods and information to develop mental health policies and programs;
- provide evidence that the proposed research and capacity-building activities are responsive to local needs, interests and capacities.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$500,000 in direct costs per year. The maximum project period is five years.

Ref: PAR-16-174 (replaces RFA-MH-16-350).

Closing date: 15 Jul 16

Deadline information: Applications open on 15 June and are due by 5pm local time of applicant organisation on 15 July 2016.

Posted date: 11 Apr 16

Award type: Development (Africa/Caribbean), Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: \$2,500,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-174.html>



Eligibility profile

Country of applicant institution: Any

Disciplines

Health Systems in Developing Countries;
Mental Health; Psychiatric & Mental Health

Nursing; Access to Health Care; Mental Illness

Contact Details

Tel: +1 301 451 5132

Email: ish.amarreh@nih.gov

EXTENDED DEADLINE: CLINICAL AND TRANSLATIONAL EXPLORATORY OR DEVELOPMENTAL STUDIES (R21)

NIH: National Cancer Institute

Description:

*** The National Cancer Institute has extended the expiration date for its clinical and translational exploratory or developmental studies (R21) funding opportunity announcement. The previous expiration date of 23 March 2018 has been extended to 23 March 2019. All other call information remains unchanged. ***

This announcement supports new exploratory research in cancer diagnosis, treatment, imaging, symptom or toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom or toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies. The use of new clinically-relevant models and imaging technologies are sought as they could lead to first-in-human clinical trials. Clinical and preclinical studies that focus on the development and testing of anti-cancer, symptom management, and cancer prevention agents, including combinations; discovery of new molecular targets; diagnostic and treatment methodologies; and predictive biomarkers are appropriate for projects submitted to this FOA. The following studies are appropriate for this call:

- clinical studies;
- correlative studies or biomarker development;
- target and agent discovery and development;
- model development and analysis.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$275,000 in direct costs per year for the maximum period of two years. No more than US\$200,000 may be requested in any single year.

Ref: PAR-16-176.

Closing date: 19 Jul 16

Deadline information: Applications open 19 June 2016 and due by 5pm local time of applicant organisation, every 19 July, 22 November and 22 March until 23 March 2019.

Posted date: 19 Apr 16

Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$275,000

**Website:**

<http://grants.nih.gov/grants/guide/notice-files/NOT-CA-16-037.html>

Tel: +1 240 276 6130

Email: william.timmer@nih.gov

Eligibility profile

Country of applicant institution: Any

Contact Details**Disciplines**

Biochemistry & Molecular Biology;
Biochemical Markers; Drug Design; Cancer
Studies & Oncology; Diagnostic Sciences;
Animal Models

R ESearch Education Programme for Clinical Researchers and Clinicians (R25)

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its research education programme for clinical researchers and clinicians (R25) grants. This R25 funding opportunity announcement supports educational activities that complement and enhance the training of a workforce to meet the nation's biomedical, behavioural and clinical research needs. The announcement is intended to support research education activities that enhance the knowledge of substance abuse and addiction research. The programme is intended for those in clinically focused careers or those training for careers as clinicians or service providers, clinical researchers or optimally a combination of the two. This mechanism may not be used for support of non-research-related clinical training.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US\$350,000 in direct costs allowed in any single year. The maximum project period is five years.

Ref: PAR-16-224 (replaces PAR-13-084).

Closing date: 21 Jul 16

Deadline information: Applications due by 5pm local time of applicant organisation. Deadlines on: 21 July 2016, 21 July 2017, 20 July 2018.

Posted date: 06 May 16

Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc

Award amount max: \$1,750,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-224.html>

Eligibility profile

Country of applicant institution: Any

Contact Details

Tel: +1 301 402 1533

Email: bsims@nida.nih.gov

Disciplines

Drug & Substance Abuse; Medical Education;
Addiction



ADULT MATURATIONAL CHANGES AND DYSFUNCTION IN EMOTION REGULATION (R21)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute on Aging invites applications for their adult maturational changes and dysfunction in emotion regulation (R01) funding opportunity announcement. This announcement seeks applications for mechanistic research on how age- and sex-related changes in emotion processing develop over the adult life course and how these changes may interact with and inform the understanding of affective dysregulation in adult mental disorders and Alzheimer's disease. Research that will leverage the already established normative backdrop of generally improved emotion regulation with ageing, as well as research that will expand this evidence base is particularly sought. One aim is to clarify the trajectories of change in emotion processing and linked neurobiological and neurobehavioral factors in ageing adults who experience mood and anxiety disorders. Equally important aims are to advance understanding of the factors involved in normative maturational shifts in these processes and of sources of individual variation therein, and to clarify how such shifts may relate to irregularities in the integrative neural-behavioural mechanisms of affect regulation seen in these adult mental disorders and in Alzheimer's disease. It is anticipated that proposed studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention strategies might be optimally applied to normalise emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, RFA-MH-17-

405, which solicits applications under the NIH research project (R01) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

The NIMH intends to commit US\$3.3 million and the NIA US\$750,000 in fiscal year 2017 to fund approximately eight to 12 awards in response to this and its companion R01 announcement. Application budgets are limited to US\$275,000 over the maximum period of two years. No more than US\$200,000 may be requested in any single year.

Ref: RFA-MH-17-400.

Closing date: 22 Jul 16

Deadline information: Applications open 22 June and are due by 5pm local time of applicant organisation, 22 July 2016.

Posted date: 31 Mar 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: \$4,050,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-400.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Geriatrics & Gerontology; Alzheimer's Disease & Senile Dementia; Psychology of Ageing; Mental Illness; Emotion

Contact Details

Tel: +1 301 443 9123

Email: gniedere@mail.nih.gov



ADULT MATURATIONAL CHANGES AND DYSFUNCTION IN EMOTION REGULATION (R01)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute on Aging invites applications for their adult maturational changes and dysfunction in emotion regulation (R01) funding opportunity announcement. This announcement seeks applications for mechanistic research on how age- and sex-related changes in emotion processing develop over the adult life course and how these changes may interact with and inform the understanding of affective dysregulation in adult mental disorders and Alzheimer's disease. Research that will leverage the already established normative backdrop of generally improved emotion regulation with ageing, as well as research that will expand this evidence base is particularly sought. One aim is to clarify the trajectories of change in emotion processing and linked neurobiological and neurobehavioral factors in ageing adults who experience mood and anxiety disorders. Equally important aims are to advance understanding of the factors involved in normative maturational shifts in these processes and of sources of individual variation therein, and to clarify how such shifts may relate to irregularities in the integrative neural-behavioural mechanisms of affect regulation seen in these adult mental disorders and in Alzheimer's disease. It is anticipated that proposed studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention strategies might be optimally applied to normalise emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, RFA-MH-17-400, which solicits applications under the NIH exploratory or

developmental research (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

The NIMH intends to commit US\$3.3 million and NIA US\$750,000 in fiscal year 2017 to fund approximately eight to 12 awards in response to this and its companion R21 announcement. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years, however, applicants are strongly encouraged to limit their proposed project to three or four years.

Ref: RFA-MH-17-405.

Closing date: 22 Jul 16

Deadline information: Applications open 22 June and are due by 5pm local time of applicant organisation, 22 July 2016.

Posted date: 31 Mar 16

Award type: Directed grants to institutions, research groups etc

Award budget total: \$4,050,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-405.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Alzheimer's Disease & Senile Dementia;
Geriatrics & Gerontology; Mental Illness;
Psychology of Ageing; Emotion

Contact Details

Tel: +1 301 443 9123

Email: gniedere@mail.nih.gov



G **RAND OPPORTUNITY IN MEDICATIONS DEVELOPMENT FOR SUBSTANCE-USE DISORDERS (U01)**

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its grand opportunity in medications development for substance-use disorders (U01). This U01 funding opportunity announcement will support a diverse array of preclinical and clinical projects to accelerate the development of medication for the treatment of substance-use disorders. The goal is to fund medication studies that will have a high impact and quickly yield the necessary results to advance medications closer to approval by the US Food and Drug Administration. The aim is to enable critical medications development studies that would not be possible using traditional means.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

The NIH intends to commit US\$10 million to fund two to three awards in fiscal year 2013. Application budgets are limited to US\$5m a year over a three-year period. PAR-13-270

Closing date: 28 Jul 16

Deadline information: Applications due by 5pm local time of applicant organisation on every deadline Deadlines on: 27 March 2014, 28 July 2014, 27 March 2015, 28 July 2015, 28 March 2016, 28 July 2016.

Posted date: 12 Jul 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$15,000,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-270.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-13-270>

Eligibility profile

Country of applicant institution: Any

Contact Details

Division of Pharmacotherapies and Medical Consequences of Drug Abuse

NIDA

NIH

9000 Rockville Pike

Bethesda, MD 20892

Tel: +1 301 443 8639

Email: imontoya@mail.nih.gov

Disciplines

Primary Care; Pharmacy & Pharmacology; Clinical Medicine; Drug Design; Clinical Pharmacy & Pharmacology; Diagnostic Sciences; Human Biological Sciences; Pharmaceutical Drugs; Drug & Substance Abuse; Public Health, Health Services & Primary Care





STRATEGIC ALLIANCES FOR MEDICATIONS DEVELOPMENT TO TREAT SUBSTANCE USE DISORDERS (R01)

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its strategic alliances for medications development to treat substance use disorders (R01). The purpose of this R01 funding opportunity announcement is to support research that advances compounds towards US Food and Drug Administration approval by leveraging NIDA funds with the strengths and resources of outside organisations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

Application budgets for direct costs may be up to \$3 million per year, but need to reflect the actual needs of the proposed project. The maximum period of support is three years. PAR-13-334 (Reissue of PAS-12-122).

Closing date: 28 Jul 16

Deadline information: Applications due by 5pm local time of applicant organisation.

Posted date: 20 Aug 13

Award type: Directed grants to institutions, research groups etc, Academic-Industry links, Clinical trials, Networking/collaboration

Award amount max: \$6,000,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-334.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-334>

Eligibility profile

Country of applicant institution: Any

Contact Details

Division of Pharmacotherapies and Medical Consequences of Drug Abuse

NIDA

6001 Executive Boulevard

Bethesda, MD 20892-9561

Tel: +1 301 443 8096

Email: jb168r@nih.gov

Disciplines

Pharmacy & Pharmacology; Pharmaceutical Drugs; Diagnostic Sciences; Drug & Substance Abuse; Methods of Drug Delivery; Drug Desig

FAST-TRACK DEVELOPMENT OF MEDICATIONS TO TREAT CANNABIS USE DISORDERS (UG3/UH3)

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its fast-track development of

medications to treat cannabis use disorders (UG3/UH3) funding opportunity announcement. This announcement aims to



accelerate the discovery and development of medications to treat cannabis use disorders. Studies should focus on the following topics:

- new chemical entities;
- already-marketed pharmacotherapies
- biologics, for example immunotherapies such as vaccines and antibodies, enzymes and gene therapies;
- combinations of medication or new delivery devices and technologies.

The UG3/UH3 phase innovation awards cooperative agreement involves two phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the two-year period. The UH3 is to provide funding for three years to a project that successfully completed the milestones set in the UG3. Investigators responding to this FOA must address both UG3 and UH3 phases.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget of US\$3 million for fiscal year 2016 funds three awards. Application budgets are limited to US\$1m in direct costs per year. The maximum project period is two years for the UG3 phase and three years for the UH3 phase.
Ref: PAR-15-267.

Closing date: 28 Jul 16

Deadline information: Applications open on 28 June and are due by 5pm local time of applicant organisation on 28 July 2015, 28 March and 28 July 2016, 28 March and 28 July 2017 and 28 March 2018.

Posted date: 28 May 15

Award type: Directed grants to institutions, research groups etc, Academic-Industry links

Award amount max: \$1,000,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-267.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276828>

Eligibility profile

Country of applicant institution: Any

Contact Details

NSC BG Room 4131
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 8639

Email: imontoya@mail.nih.gov

Disciplines

Drug Design; Methods of Drug Delivery;
Drug & Substance Abuse

IMMUNITY IN NEONATES AND INFANTS (U01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Environmental Health Sciences as well as the

office of Research on Women's Health invite applications for their immunity in neonates and infants (U01) funding opportunity announcement. This announcement aims to advance current knowledge of the developing immune system during the first year of life



and to encourage innovative approaches to more fully understand the distinct characteristics of neonatal and infant immune responses. Applications are invited from institutions and organisations to participate in a co-operative research group, focusing on elucidating mechanisms regulating the development and function of the immune system in neonates and infants, including immune mechanisms triggered by non-pathogenic or pathogenic microbes, vaccines, exposure to allergens, or alterations in immune function due to environmental exposures to pollutants.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Issuing IC and partner components intend to commit an estimated total of US\$8.05 million to fund 10 to 12 awards. Application budgets for studies proposing to use non-human primates are limited at US\$350,000 in direct costs per year; US\$300,000 in direct cost per year for all other applications. The maximum project period is five years.
Ref: RFA-AI-16-001 (replaced RFA-AI-11-010).

Closing date: 29 Jul 16

Deadline information: Applications are invited between 29 June and 5pm local time of applicant organisation, 29 July 2016.

Posted date: 08 Mar 16

Award type: Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: \$1,750,000

Award amount min: \$1,500,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-001.html>

Eligibility profile

Country of applicant institution: Any

Contact Details

Tel: +1 240 627 3534

Email: mprabhudas@mail.nih.gov

Disciplines

Infection Agents & Pathogens; Infant Paediatrics; Immunology; HIV/Aids; Immunisation Programmes & Vaccination



VANT-GARDE AWARD PROGRAMME FOR HIV/AIDS AND DRUG USE RESEARCH (DP1)

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites for its avant-garde award programme for HIV/Aids and drug use research. This DP1 funding opportunity supports individual scientists of exceptional creativity who propose innovative, high-impact basic research that will open new areas of HIV/Aids research or lead to new avenues for prevention and treatment of HIV/Aids among drug abusers. Research may lead to improved prevention interventions or

therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.

US or foreign for-profit and non-profit organisations may apply.

NIDA intends to commit US\$2 million in FY2015, to fund two to three awards each year. Applicants may request direct costs of



up to US\$500,000 per year, over a maximum of five years.

Ref: RFA-DA-15-004 (reissue of RFA-DA-14-008).

Closing date: 29 Jul 16

Deadline information: Applications due by 5pm local time of the applicant organisation. Deadlines on: 29 July 2014, 29 July 2015, 29 July 2016.

Posted date: 14 Feb 14

Award type: Innovation grants, Directed grants to institutions, research groups etc

Award amount max: \$2,500,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-15-004.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application->

[package.html#download=true&oppNum=RFA-DA-15-004](#)

Eligibility profile

Country of applicant institution: Any

Contact Details

NIDA

6001 Executive Boulevard

Rockville, MD 20852

Tel: +1 301 443 1470

Email: jnormand@nida.nih.gov

Disciplines

General Practice & Family Health; HIV/Aids; Preventive Medicine; Primary Care; Drug & Substance Abuse; Diagnostic Sciences; Public Health, Health Services & Primary Care; Medical Effectiveness & Patient Outcomes

UNDERSTANDING HIV REBOUND (P01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their understanding HIV rebound (P01) funding opportunity announcement. This announcement supports multidisciplinary, programme project applications aimed at understanding specific mechanisms, biomarkers and pathways associated with rebound of HIV viremia. Research should focus on viral rebound in: HIV/SIV-positive hosts who initiated antiretroviral therapy early after infection, had fully suppressed viremia for an extended period, and who later stopped therapy, HIV/SIV-positive hosts receiving an intervention aimed at controlling or delaying HIV rebound or HIV/SIV-positive hosts receiving an intervention aimed

at diminishing or eradicating viral reservoirs. The scope of research can span from basic science questions related to spontaneous latency reversal and the nature of the functional viral reservoir to in vivo studies of viral rebound in animal models and from clinical samples. Modelling of viral rebound in either non-human primates or humanised mice may be included. Clinical trials are not permitted under this programme, however, samples may be used from observational cohorts in which individuals have stopped therapy for reasons not associated with this programme or from clinical trials that are conducted through separate programmes. Examples of appropriate research topics include:



- modelling and defining the parameters that affect time to HIV rebound and the slope of the rebound curve;
- identification of the cellular and anatomical sources of rebound virus;
- determination of the timing of establishment of the latent reservoir in paediatric individuals and the cell types involved;
- elucidation of the mechanisms that govern spontaneous activation of latent infectious HIV provirus in vivo or in primary cells isolated from infected individuals;
- identification of the immune correlates associated with reservoir clearance or control versus those associated with viral rebound;
- determination of whether or how reservoirs expand following treatment interruption;
- identification of biomarkers that predict HIV rebound.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

NIAID intends to commit US\$4 million; NIMH intends to commit US\$500,000 in fiscal year 2017 to fund two to three awards. Application budgets are limited to US\$1m in

direct costs and need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: RFA-AI-16-028.

Closing date: 29 Jul 16

Deadline information: Applications open 29 June and are due by 5pm local time of applicant organisation, 29 July 2016.

Posted date: 20 Apr 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$1,000,000

Award amount min: -

Award budget total: \$4,500,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-028.html>

Eligibility profile

Country of applicant institution: Any

Contact Details

Tel: +1 240 627 3201

Email: elizabeth.church@nih.gov

Disciplines

Biochemical Markers; Virology; HIV/Aids



NIMAL-ASSISTED INTERVENTIONS FOR SPECIAL POPULATIONS (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its animal-assisted interventions for special populations (R21) grant. This supports research to examine the safety and efficacy of the inclusion of animals in therapy and

rehabilitation for children and individuals with disabilities, neurological conditions, behavioural, emotional and mental health issues and related health outcomes, as well as the adaptation of healthy behaviours and the enhancement of learning in special need and at-risk populations. The goal is to spur the field to move beyond case study and



descriptive studies of animal-assisted interventions to employ rigorous experimental and quasi-experimental designs capable of quantifying the impact of such interventions. The objective is to build the empirical evidence base around animal-assisted interventions in special need and at-risk populations to better determine which interventions are effective for whom and under what conditions. Multi-disciplinary teams of researchers are strongly encouraged.

This funding opportunity uses the NIH exploratory or developmental (R21) research grant mechanism and runs in parallel with one of identical scientific scope, RFA-17-HD-014, which solicits applications under the NIH research project (R03) grant mechanism. Applications are accepted from foreign institutions and foreign components of US organisations.

The combined budget for direct costs for the two year project period may not exceed US\$275,000. No more than US\$200,000 may be requested in any single year. The total project period may not exceed two years.
REF: RFA-17-HD-015

Closing date: 30 Jul 16

Deadline information: Applications are invited between 29 June and 5pm local time of applicant organisation, 30 July 2016.

Posted date: 11 Apr 16

Award type: Directed grants to institutions, research groups etc

Award budget total: \$275,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-17-015.html>

Eligibility profile

Country of applicant institution: Any

Contact Details

NICHHD

Tel: +1 301 435 6888

Email: espositl@mail.nih.gov

Disciplines

Cognitive & Behavioural Therapies;
Emotional Rehabilitation; Psychotherapy;
Mental Health; Social Rehabilitation;
Population Studies, Medical; Intellectual Disabilities



ANIMAL-ASSISTED INTERVENTIONS FOR SPECIAL POPULATIONS (R03)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its animal-assisted interventions for special populations (R03) grant. This supports research to examine the safety and efficacy of the inclusion of animals in therapy and rehabilitation for children and individuals with disabilities, neurological conditions, behavioural, emotional and mental health issues and related health outcomes, as well as

the adaptation of healthy behaviours and the enhancement of learning in special need and at-risk populations. The goal is to spur the field to move beyond case study and descriptive studies of animal-assisted interventions to employ rigorous experimental and quasi-experimental designs capable of quantifying the impact of such interventions. The objective is to build the empirical evidence base around animal-assisted interventions in special need and at-risk populations to better determine which



interventions are effective for whom and under what conditions. Multi-disciplinary teams of researchers are strongly encouraged.

This funding opportunity uses the NIH exploratory or developmental (R03) research grant mechanism and runs in parallel with one of identical scientific scope, RFA-17-HD-015, which solicits applications under the NIH research project (R21) grant mechanism. Applications are accepted from foreign institutions and foreign components of US organisations.

NICHHD intends to commit US\$1 million between this FOA and the companion funding opportunity announcement, RFA-HD-17-015 (R21), in fiscal year 2017 to fund five to seven awards. No more than US\$50,000 in direct costs may be requested in any single year. The total project period may not exceed two years.

REF: RFA-17-HD-014

Closing date: 30 Jul 16

Deadline information: Applications are invited between 29 June and 5pm local time of applicant organisation, 30 July 2016.

Posted date: 11 Apr 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-17-014.html>

Eligibility profile

Country of applicant institution: Any

Contact Details

NICHHD

Tel: +1 301 435 6888

Email: espositl@mail.nih.gov

Disciplines

Emotional Rehabilitation; Cognitive & Behavioural Therapies; Social Rehabilitation; Mental Health; Psychotherapy; Intellectual Disabilities; Population Studies, Medical





AUGUST 2016

I NNOVATION FOR HIV VACCINE DISCOVERY (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites applications for its innovation for HIV vaccine discovery (R01) funding opportunity announcement. This announcement supports innovative, high risk, high impact research to identify novel HIV vaccine concepts and targets. It also encourages the design and development of an effective immunogen that may provide long-term safe protection from either acquisition of or ongoing infection by HIV. This call explicitly encourages applications from new investigators and investigators new to the HIV vaccine field, and seeks to promote interdisciplinary cross-collaborations among virologists, immunologists, molecular and systems biologists, microbiologists, clinical scientists and other relevant specialists. Applicants are required to identify within the application go/no-go decision criteria to be achieved for the year two progress report in order to obtain year three and four of funding. Achievement of the stated goals will enable a total of four years of support, while failure to achieve the stated goals will result in negotiation of a reduced budget for year three and award close out. Applications that do not include go/no-go decision criteria will not be reviewed.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to a total of US\$350,000 in direct costs per year. An

additional US\$150,000 may be requested in direct costs per year when research in nonhuman primate or humanised mice models is required.

The maximum project period is four years.
Ref: PAR-16-171 (replaces RFA-AI-15-019).

Closing date: 01 Aug 16

Deadline information: Applications open on 1 July and are due by 5pm local time of applicant organisation, 1 August 2016.

Posted date: 08 Apr 16

Award type: Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration, Directed grants for individual investigators

Award amount max: \$350,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-171.html>

Eligibility profile

Country of applicant institution: Any

Contact Details

Tel: +1 240 627 3032

Email: jwarren@niaid.nih.gov

Disciplines

HIV/Aids; Animal Models; Immunisation Programmes & Vaccination



NEURONEXT CLINICAL TRIALS (U01)

NIH: National Institute of Neurological Disorders and Stroke

Description:

The National Institute of Neurological Disorders and Stroke invites applications for its NeuroNEXT clinical trials (U01) funding opportunity announcement. This announcement encourages applications for exploratory clinical trials of investigational agents that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies or for proof of mechanism clinical studies. Applications for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach or act upon the designated target, or that its mechanism of action is such that it is expected to be of benefit in ameliorating a specific aspect of the disease. Studies may include:

- evaluating and optimising the dose, formulation, safety, tolerability or pharmacokinetics of an intervention in the target population;
- evaluating whether an intervention produces sufficient evidence of short-term activity in a human proof of concept trial;
- selecting or ranking the best of two or more potential interventions, or dosing regimens to be evaluated in a subsequent trial, based on tolerability, safety data, biological activity, or preliminary clinical efficacy;
- evaluating biological activity relative to clinical endpoints;
- for medical devices, informing the next phase of development, usually by finalising the device design, establishing operator technique, or finalising the choice of study

endpoints for the design of a pivotal clinical trial.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but need to reflect actual needs of the project. The maximum project period is five years.

Ref: PAR-16-155 (replaces PAR-13-343).

Closing date: 02 Aug 16

Deadline information: Applications open 2 July 2016 and are due by 5pm local time of applicant organisation, 2 August 2016, 6 December 2016, 4 April 2017 and 3 August 2017.

Posted date: 29 Mar 16

Award type: Clinical trials, Directed grants to institutions, research groups etc

Award amount max: -

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-155.html>

Eligibility profile

Country of applicant institution: Any

Contact Details

Tel: +1 301 496 9135

Email: conwitr@ninds.nih.gov

Disciplines

Medical Devices; Pharmaceutical Drugs; Biological Markers & Sensor Mechanisms; Biochemical Markers; Disease Models; Drug Design



P

REVENTION INNOVATION PROGRAMME THREE (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites applications for its preclinical innovation programme (R01) funding opportunity announcement. This announcement encourages research applications in non-vaccine biomedical prevention research. The programme is intended to support high-risk or innovative R&D efforts to establish and maintain a sustainable pipeline for the prevention of HIV acquisition or transmission. The programme supports:

- discovery and development of novel and under-explored nBP candidates or strategies;
- discovery and development of nBP drug delivery systems;
- studies of the impact of nBP prevention products and DDS on genital and gastrointestinal mucosa function;
- development of emerging technologies to support and facilitate nBP prevention product, and DDS discovery and development;
- development of age appropriate formulation strategies;
- development of multipurpose prevention technologies for prevention of HIV acquisition or transmission.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

NIAID intends to commit US\$1.8 million in fiscal year 2017 to fund two to three awards. Application budgets are limited to US\$400,000 in direct costs per year over a maximum period of four years.

Ref: RFA-AI-16-025 (replaces RFA-AI-13-059).

Closing date: 03 Aug 16

Deadline information: Applications open 3 July and are due by 5pm local time of applicant organisation, 3 August 2016.

Posted date: 30 Mar 16

Award type: Innovation grants, Directed grants to institutions, research groups etc, Technology innovation/development

Award amount max: \$1,600,000

Award amount min: -

Award budget total: \$1,800,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-025.html>

Eligibility profile

Country of applicant institution: Any

Contact Details

Tel: +1 301 451 2732

Email: jturpin@niaid.nih.gov

Disciplines

Preventive Medicine; HIV/Aids; Methods of Drug Delivery; Biomedical Engineering



IDENTIFICATION OF SMALL MOLECULES FOR SUSTAINED-RELEASE ANTI-HIV PRODUCTS (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invite applications for its identification of small molecules for sustained-release anti-HIV products (R01) funding opportunity announcement. This announcement seeks applications from single institutions, or consortia of institutions, to identify existing anti-HIV molecules, or discover new highly potent and selective anti-HIV small molecules, with the potential for development as sustained release products with a dosing interval from once a week to once every three months or longer. Proposed research should include a development plan designed to achieve a SRP for an oral, implantable, injectable or transdermal delivery system; and studies to provide proof-of-concept validation of the proposed small molecules incorporated into a delivery system relevant to a selected dosing interval. Areas of interest include:

- discovery, through chemical synthesis, of new active pharmaceutical ingredients that exhibit highly potent and selective in-vitro anti-HIV activity;
- identification and further development of existing APIs with established antiviral activity and HIV resistance patterns.
- pre-formulation studies that include chemical and physical characterisation of the selected API and DDS;
- in-vitro and in-vivo studies designed to assess the potential toxicity and safety of selected APIs and DDSs;
- PK and PD studies designed to characterise in-vivo release of the SRP for its proposed dosing interval;
- studies with proposed SRP to assess local tissue concentrations of the API

and studies to document local cellular and tissue reactions.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

The NIAID intends to commit US\$2 million in fiscal year 2017 to fund two to four awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: RFA-AI-16-024.

Closing date: 03 Aug 16

Deadline information: Applications open 3 July and are due by 5pm local time of applicant organisation, 3 August 2016.

Posted date: 08 Apr 16

Award type: Networking/collaboration, Directed grants to institutions, research groups etc

Award budget total: \$2,000,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-024.html>

Eligibility profile

Country of applicant institution: Any

Contact Details

Tel: +1 240 627 3087

Email: dlivnat@niaid.nih.gov

Disciplines

Antivirals; Molecular & Protein Engineering; Methods of Drug Delivery; Biochemistry & Molecular Biology; HIV/Aids



CLINICAL SEQUENCING EVIDENCE-GENERATING RESEARCH – CLINICAL SITES WITH ENHANCED DIVERSITY (U01)

NIH: National Human Genome Research Institute

Description:

The National Human Genome Research Institute, the National Cancer Institute and the National Institute on Minority Health and Health Disparities invite applications for its clinical sequencing evidence-generating research – clinical sites with enhanced diversity (U01) funding opportunity announcement. This announcement aims to establish clinical sites with enhanced diversity that collectively encompass a broad spectrum of healthcare settings and serve ancestrally and socioeconomically diverse patients with a wide range of clinical conditions.

The main objectives of this call are to:

- define, generate and analyse evidence regarding the clinical utility of genome sequencing;
- research the critical interactions among patients, family members, health practitioners, and clinical laboratories that influence implementation of clinical genome sequencing;
- identify and address real-world barriers to integrating genomic, clinical, and healthcare utilisation data within a healthcare system to build a shared evidence base for clinical decision-making.

Applicants are expected to recruit a minimum of 60 per cent of patients who come from racial or ethnic minority populations, underserved populations, or populations who experience poorer medical outcomes.

This funding opportunity uses the NIH research project – co-operative agreements (U01) mechanism and runs in parallel with two of identical scientific scope, RFA-HG-16-010, which solicits applications under the same NIH (U01) mechanism and RFA-HG-16-

012, which solicits applications under the NIH resource-related research projects – co-operative agreements mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

NHGRI intends to commit up to US\$20.8 million to support two related FOAs establishing clinical sites with enhanced diversity. It is expected that three to six awards will be supported under this call and three to six awards under RFA-HG-16-010. NCI intends to commit up to US\$1m total costs per year to co-fund applications relevant to the NCI mission. Applications may be submitted to either the general clinical sites with enhanced diversity FOA or the general clinical sites FOA RFA HG-16-010. NIMH intends to commit up to US\$2.3m total costs per year to co-fund applications relevant the NIMHD mission. Application budgets are limited to US\$2.5m in direct costs per year for a total period of four years.

Ref: RFA-HG-16-011 (replaces RFA-HG-12-009).

Closing date: 05 Aug 16

Deadline information: Applications open 6 July and are due by 5pm local time of applicant organisation, 5 August 2016.

Posted date: 09 May 16

Award type: Directed grants to institutions, research groups etc, Research centres

Award amount max: \$10,000,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-16-011.html>

Eligibility profile

Country of applicant institution: Any



Contact Details

Tel: +1 240 271 1509

Email: hindorffl@mail.nih.gov

Disciplines

Diagnostic Sciences; Preventive Medicine; Chronic Care; Health of Minority Groups; Clinical Decision-making & Analysis; Genomics; Disadvantaged & Minority Groups

CLINICAL SEQUENCING EVIDENCE-GENERATING RESEARCH - CLINICAL SITES (U01)

NIH: National Human Genome Research Institute

Description:

The National Human Genome Research Institute and the National Cancer Institute invite applications for its clinical sequencing evidence-generating research – clinical sites (U01) funding opportunity announcement. This announcement aims to establish clinical sites with enhanced diversity that collectively encompass a broad spectrum of healthcare settings and serve ancestrally and socioeconomically diverse patients with a wide range of clinical conditions.

The main objectives of this call are to:

- define, generate and analyse evidence regarding the clinical utility of genome sequencing;
- research the critical interactions among patients, family members, health practitioners, and clinical laboratories that influence implementation of clinical genome sequencing;
- identify and address real-world barriers to integrating genomic, clinical, and healthcare utilisation data within a healthcare system to build a shared evidence base for clinical decision-making.

Applicants are expected to recruit a minimum of 25 per cent of patients who come from racial or ethnic minority populations, under-

served populations, or populations who experience poorer medical outcomes.

This funding opportunity uses the NIH research project – co-operative agreements (U01) mechanism and runs in parallel with two of identical scientific scope, RFA-HG-16-011, which solicits applications under the same NIH (U01) mechanism and RFA-HG-16-012, which solicits applications under the NIH resource-related research projects (U24) – co-operative agreements mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

NHGRI intends to commit up to US\$20.8 million to support two related FOAs establishing clinical sites with enhanced diversity. It is expected that three to six awards will be supported under this call and three to six awards under RFA-HG-16-011. NCI intends to commit up to US\$1m total costs per year to co-fund applications relevant to the NCI mission. Applications may be submitted to either the general clinical sites with enhanced diversity FOA or the general clinical sites FOA RFA HG-16-011. Application budgets are limited to US\$2m in direct costs per year for a total period of four years.

Ref: RFA-HG-16-010 (replaces RFA-HG-12-009).

Closing date: 05 Aug 16



Deadline information: Applications open 5 July and are due by 5pm local time of applicant organisation, 5 August 2016.

Posted date: 09 May 16

Award type: Directed grants to institutions, research groups etc, Research centres

Award amount max: \$8,000,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-16-010.html>

Eligibility profile

Country of applicant institution: Any

Contact Details

Tel: +1 240 271 1509

Email: hindorff@mail.nih.gov

Disciplines

Preventive Medicine; Diagnostic Sciences; Health of Minority Groups; Chronic Care; Disadvantaged & Minority Groups; Clinical Decision-making & Analysis; Genomics

R **ESearch DISSERTATION FELLOWSHIP FOR AuD AUDIOLOGISTS (F32)**

NIH: National Institute on Deafness and other Communication Disorders

Description:

The National Institute on Deafness and Other Communication Disorders invites applications for its research dissertation fellowship for AuD audiologists (F32). This enables scientists to undertake comprehensive and rigorous biomedical research training and dissertation research leading to a research doctorate in the biomedical, behavioural, or clinical sciences. The overall goal of the NIH Ruth L. Kirschstein national research service award programme is to help ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to address the Nation's biomedical, behavioural, and clinical research needs. NRSA fellowships support the training of pre- and postdoctoral scientists, dual-degree investigators, and senior researchers. The training plan should facilitate the fellow's transition to the next stage of his or her career.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Applicants may receive up to five years of support at the pre-doctoral level and up to six years for dual degree training; three years of support at the postdoctoral level including any combination of support from institutional training grants and an individual fellowship award.

Ref: PAR-16-210.

Closing date: 08 Aug 16

Deadline information: Applications open 8 July 2016 and are due by 5pm local time of applicant organisation, every 8 December, 8 April and 8 August until 8 May 2019.

Posted date: 22 Apr 16

Award type: Equipment and materials, Directed grants to institutions, research groups etc, Personal development, Directed grants for individual investigators, Travel to conferences, meetings etc., Postdoctoral training fellowships

Award amount max: -

Award amount min: -

Award budget total: -

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-210.html>

Eligibility profile

Country of applicant institution: Any

Contact

Tel: +1 301 496 1804

Email: riverara@nidcd.nih.gov

Disciplines

Bio/Medical

NINDS CREATE BIO DISCOVERY TRACK: OPTIMISATION IN PREPARATION FOR DEVELOPMENT OF BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (U01)

NIH: National Institute of Neurological Disorders and Stroke

Description:

The National Institute of Neurological Disorders and Stroke invites applications for its cooperative research to enable and advance translational enterprises for biotechnology products and biologics discovery track: optimisation in preparation for development of biotechnology products and biologics (U01) grants. The purpose of this U01 funding opportunity announcement is the discovery of therapeutic biotechnology products and biologics for disorders that fall under the NINDS mission. This FOA supports the optimisation of therapeutic leads showing convincing proof-of-concept. At the end of the funding period, projects that successfully advance through support from this programme will have identified an optimised candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy or target engagement, and other favourable properties that are consistent with the desired clinical application, and will be ready for entry into the CREATE bio development track for further development to enable filing for an investigational new drug. The NINDS CREATE bio programme is dedicated to biotechnology product and biologics- based therapies, which broadly include modalities such as peptides, proteins, oligonucleotides, gene therapies and cell therapies.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but must reflect the actual needs of the proposed project. Budgets will normally remain under US\$500,000 in direct costs in any given year. The project period is typically three years and may not exceed four years.

Ref: PAR-14-286.

Closing date: 11 Aug 16

Deadline information: Applications open on 21 September 2014 and are due by 5pm local time of applicant organisation on 21 October 2014, 11 February and 11 August 2015, 11 February and 11 August 2016, and 8 February 2017.

Posted date: 21 Jul 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-286.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PAR-14-286>



Eligibility profile

Country of applicant institution: Any

Contact Details

NIH/NINDS
Neuroscience Center, Room 2106
6001 Executive Blvd MSC
Bethesda MD 20892
Tel: +1 301 496 1779
Email: createnquiries@mail.nih.gov

Disciplines

Protein Synthesis, Modification & Turnover;
Methods of Drug Delivery; Gene Therapy;
Neuropharmacology; Neurobiology;
Biological Sciences; Pharmacotherapy;
Clinical Medicine; Primary Care; Public
Health, Health Services & Primary Care;
Toxicology; Pharmacokinetics; Cell
Physiology & Metabolism; Clinical Pharmacy
& Pharmacology; Neurology; Pharmacy &
Pharmacology; Chemistry; Drug Design;
Diagnostic Sciences

NINDS CREATE BIO DEVELOPMENT TRACK: PRECLINICAL AND EARLY-PHASE CLINICAL DEVELOPMENT FOR BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (UH2/UH3)

NIH: National Institute of Neurological Disorders and Stroke

Description:

The National Institute of Neurological Disorders and Stroke invites applications for its NINDS cooperative research to enable and advance translational enterprises for biotechnology products and biologics development track: preclinical and early-phase clinical development for biotechnology products and biologics (UH2/UH3) grants. The purpose of this UH2/UH3 funding opportunity announcement is the development of therapeutic biotechnology products and biologics for disorders that fall under the NINDS mission. An identified candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy or target engagement, and other favourable properties that are consistent with the desired clinical application, is required for entry to the CREATE bio development track. The FOA supports investigational new drug-enabling studies for the candidate and early-phase clinical trials. At the end of the funding period, a successful project should have an IND application submitted to the US Food and Drug Administration, at a minimum. The NINDS CREATE bio programme is dedicated to biotechnology product and biologics- based

therapies, which broadly include modalities such as peptides, proteins, oligonucleotides, gene therapies and cell therapies.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Applications should rarely exceed US\$1million in direct costs per year during the UH2 phase and US\$1.5million in direct costs per year during the UH3 phase. The proposed project period for the UH2 phase may not exceed two years and the UH3 phase may not exceed four and a half years. The total duration of UH2 and UH3 phases may not exceed five years.

Ref: PAR-14-288.

Closing date: 11 Aug 16

Deadline information: Applications open on 21 September 2014 and are due by 5pm local time of applicant organisation on 21 October 2014, 11 February and 11 August 2015, 11 February and 11 August 2016, and 8 February 2017.

Posted date: 21 Jul 14

Award type: Directed grants to institutions, research groups etc



Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-288.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PAR-14-288>

Eligibility profile

Country of applicant institution: Any

Contact Details

NIH/NINDS

Neuroscience Center, Room 2106

6001 Executive Blvd MSC

Bethesda MD 20892

Tel: +1 301 496 1779

Email: createnquiries@mail.nih.gov

Disciplines

Pharmacotherapy; Diagnostic Sciences; Cell Physiology & Metabolism; Methods of Drug Delivery; Gene Therapy; Protein Synthesis, Modification & Turnover; Neuropharmacology; Clinical Medicine; Drug Design; Pharmacokinetics; Neurology; Primary Care; Public Health, Health Services & Primary Care; Biological Sciences; Pharmacy & Pharmacology; Neurobiology; Clinical Pharmacy & Pharmacology; Toxicology; Chemistry

B BLUEPRINT NEUROTHERAPEUTICS NETWORK: SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT FOR DISORDERS OF THE NERVOUS SYSTEM (UH2/UH3)

NIH: National Institute of Neurological Disorders and Stroke

Description:

A total of nine participating institutes and centres of the National Institutes of Health invite applications for their blueprint neurotherapeutics network: small molecule drug discovery and development for disorders of the nervous system (UH2/UH3) grants. The purpose of this UH2/UH3 funding opportunity announcement is to help neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organisations that specialise in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under good manufacturing practices, and phase I clinical testing.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The combined duration of the UH2 and UH3 award cannot exceed five years.

Ref: PAR-14-293.

Closing date: 11 Aug 16

Deadline information: Applications open on 21 September 2014 and are due by 5pm local time of applicant organisation on 21 October 2014, 11 February and 11 August 2015, 11 February and 11 August 2016, and 8 February 2017.

Posted date: 23 Jul 14

Award type: Directed grants to institutions, research groups etc

Award budget total: -

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-293.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PAR-14-293>

Eligibility profile

Country of applicant institution: Any

Contact Details

NIH: National Institute of Neurological Disorders and Stroke
Division of Extramural Research
6001 Executive Boulevard Suite 3309

Bethesda, MD 20892- 9531

Tel: +1 301 496 1779

Email: farkasr@ninds.nih.gov

Disciplines

Central Nervous System; Chemistry; Biological Sciences; Neurobiology; Pharmacy & Pharmacology; Gene Therapy; Protein Synthesis, Modification & Turnover; Diagnostic Sciences; Neurology; Pharmacokinetics; Neuropharmacology; Toxicology; Drug Design; Methods of Drug Delivery; Clinical Medicine; Primary Care; Clinical Pharmacy & Pharmacology; Cell Physiology & Metabolism; Pharmacotherapy; Public Health, Health Services & Primary Care

T RANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R03)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The National Institute of Child Health and Human Development invites applications for translational research in paediatric and obstetric pharmacology (R03) grants. This R03 funding opportunity announcement funds translational and clinical research and clinical trials to advance knowledge about the underlying mechanisms of drug action, response and safety in children and developing fetuses. The overall goals of this funding opportunity announcement are:

- to improve the safety and effectiveness of current drugs for paediatric or obstetric patients;
- to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.

This FOA will use the R03 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-309 that encourages applications under the R01 grant mechanism and PAR-13-311 that encourages applications under the R21 grant mechanism. Budgets for direct costs of up to US\$50,000 per year and a project duration of up to two years may be requested. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR-13-310 (replaces PAR-11-247).

Closing date: 16 Aug 16

Deadline information: Applications due by 5pm proposer's local time.

Posted date: 06 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000



Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-310.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-13-310>

Eligibility profile

Country of applicant institution: Any

Disciplines

Pharmacy & Pharmacology; Genomics; Primary Care; Pregnancy & Birth; Epigenetics; Paediatrics; Foetal Health & Prenatal Development; Obstetrics & Gynaecology;

Maternal Health; Translational Medicine; Biological Sciences; Diagnostic Sciences; Biological Markers & Sensor Mechanisms; Public Health, Health Services & Primary Care; Neonatal Disorders; Medical Genetics; Clinical Medicine; Cancer Genetics

Contact Details

Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD

6100 Executive Boulevard

Room 4A01D MSC 7510

Bethesda, MD 20892-7510

Tel: +1 301 402 9340

Email: zren@mail.nih.gov

T RANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The National Institute of Child Health and Human Development invites applications for its translational research in paediatric and obstetric pharmacology (R01) grants. This R01 funding opportunity announcement funds translational and clinical research and clinical trials to advance knowledge about the underlying mechanisms of drug action, response and safety in children and developing fetuses. The overall goals of this funding opportunity announcement are:

- to improve the safety and effectiveness of current drugs for paediatric or obstetric patients;
- to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.

This FOA will use the R01 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-310 that encourages applications under the R03 grant mechanism and PAR-13-311 that encourages applications under the R21 grant mechanism. Application budgets are not limited but need to reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR-13-309 (replaces PAR-11-246).

Closing date: 16 Aug 16

Deadline information: Applications due by 5pm proposer's local time.

Posted date: 06 Aug 13



Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-309.html>

Application

form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-309>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biological Sciences; Pregnancy & Birth; Foetal Health & Prenatal Development; Genomics; Cancer Genetics; Translational Medicine;

Public Health, Health Services & Primary Care; Neonatal Disorders; Paediatrics; Diagnostic Sciences; Biological Markers & Sensor Mechanisms; Epigenetics; Clinical Medicine; Primary Care; Medical Genetics; Maternal Health; Pharmacy & Pharmacology; Obstetrics & Gynaecology

Contact Details

Obstetric and Paediatric Pharmacology and Therapeutics Branch

NICHD

6100 Executive Boulevard

Room 4A01D MSC 7510

Bethesda, MD 20892-7510

Tel: +1 301 402 9340

Email: zren@mail.nih.gov

T RANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The National Institute of Child Health and Human Development invites applications for translational research in paediatric and obstetric pharmacology (R21) grants. This R21 funding opportunity announcement funds translational and clinical research and clinical trials to advance knowledge about the underlying mechanisms of drug action, response and safety in children and developing fetuses. The overall goals of this funding opportunity announcement are:

- to improve the safety and effectiveness of current drugs for paediatric or obstetric patients;
- to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet

emerging clinical needs for these special populations.

This FOA will use the R21 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-310 that encourages applications under the R03 grant mechanism and PAR-13-309 that encourages applications under the R01 grant mechanism. Direct costs are limited to US\$275,000 over an R21 two-year period. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR-13-311 (replaces PAR-11-248).

Closing date: 16 Aug 16



Deadline information: Applications due by 5pm proposer's local time.

Posted date: 06 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-311.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-311>

Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care; Neonatal Disorders; Pregnancy & Birth; Cancer Genetics; Biological Sciences; Public Health, Health Services & Primary Care; Biological Markers & Sensor Mechanisms; Paediatrics; Diagnostic Sciences; Translational Medicine; Genomics; Foetal Health & Prenatal Development; Clinical Medicine; Maternal Health; Pharmacy & Pharmacology; Obstetrics & Gynaecology; Medical Genetics; Epigenetics

Contact Details

Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard
Room 4A01D MSC 7510
Bethesda, MD 20892-7510
Tel: +1 301 402 9340
Email: zren@mail.nih.gov

UTILISING THE PLCO BIOSPECIMENS RESOURCE TO BRIDGE GAPS IN CANCER AETIOLOGY AND EARLY-DETECTION RESEARCH (U01)

NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its utilising the PLCO biospecimens resource to bridge gaps in cancer aetiology and early-detection research (U01) funding opportunity announcement. This announcement seeks to advance research in cancer aetiology and early-detection biomarkers, using the advantages of the unique biorepository resources of the NCI-sponsored prostate, lung, colorectal and ovarian cancer screening trial. The repository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from trial participants and a one-time collection of buccal cells from the control arm participants.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are not limited, but need to reflect actual needs of the project. The maximum project period is five years.

Ref: PAR-15-297 (replaces PAR-13-036).

Closing date: 16 Aug 16

Deadline information: Applications due by 5pm local time of applicant organisation on deadline dates.

Posted date: 15 Jul 15

Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa->



files/PAR-15-297.html#_Section_II._Award_1

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-036>

Eligibility profile

Country of applicant institution: Any

Disciplines

Pathogenesis; Biological Markers & Sensor Mechanisms; Lung Cancer; Cancer Diagnosis; Prostate & Testicular Cancers; Gynaecological Cancers; Colorectal, Pancreatic & Stomach Cancers

Contact Details

Tel: +1 240 276 7013

Fax: +1 240 276 7848

Email: zhucla@mail.nih.gov

EXPLORATORY STUDIES OF SMOKING CESSATION INTERVENTIONS FOR PEOPLE WITH SCHIZOPHRENIA (R21/R33)

NIH: National Institute on Drug Abuse

Description:

A total of four institutes and offices of the NIH invite applications for their exploratory studies of smoking cessation interventions for people with schizophrenia (R21/R33) grants. The purpose of this R21 and R33 funding opportunity is to provide support for grant applications to generate and conduct preliminary tests of targeted smoking cessation treatments for individuals with schizophrenia. This funding opportunity announcement provides support for grant applications designed to generate novel treatments and improve existing treatments and conduct preliminary tests of novel and improved behavioural, pharmacological, and combined smoking cessation treatments for individuals with schizophrenia by examining the mechanisms of nicotine addiction in individuals with schizophrenia as putative intervention targets. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. The NIH intends to fund an estimate of six to nine awards corresponding to a total of US\$3,5 million for fiscal year 2015. The R21 phase may not exceed two years or US\$275,000 in direct costs, with no more than US\$150,000 in direct costs in any single year

of the R21 phase. The R33 phase may not exceed three years or US\$450,000 in direct costs, with no more than US\$225,000 in direct costs in any single year of the R33 phase. The maximum period is five years.

Ref: PAR-14-230.

Closing date: 16 Aug 16

Deadline information: Applications due by 5pm local time of applicant organisation on 15 August, 16 December 2014, 15 April, 17 August, December 15, 2015, 15 April, 16 August, 15 December, 2016, 17 April until 8 September 2017.

Posted date: 20 May 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: \$3,500,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-230.html>

Application form:

<http://www.grants.gov/applicants/apply-for-grants.html>

Eligibility profile



Country of applicant institution: Any

HIV/Aids; Pharmaceutical Drugs; Smoking & Tobacco; Health Disparities

Disciplines

Mental Health; Psychiatry; Addiction; Economic & Social Environment; Mental Illness; Primary Care; Biomedical Engineering; Schizophrenia & Other Psychotic Disorders; Public Health, Health Services & Primary Care; Psychology; Drug & Substance Abuse; Medical Sociology; Sociology;

Contact Details

NIH
6001 Executive Boulevard
Room 5213
Bethesda, MD 20892-9561
Tel: +1 301 443 2235
Fax: +1 301 443 7397
Email: lisaonken@nih.gov

EXPLOATORY STUDIES OF SMOKING CESSATION INTERVENTIONS FOR PEOPLE WITH SCHIZOPHRENIA (R33)

NIH: National Institute on Drug Abuse

Description:

A total of four institutes and offices of the NIH invite applications for their exploratory studies of smoking cessation interventions for people with schizophrenia (R33) grants. The purpose of this R33 funding opportunity is to provide support for grant applications of two major types. Type I will conduct exploratory testing of novel, targeted treatments for smoking cessation for individuals with schizophrenia. Type II will conduct exploratory testing of targeted implementation strategies of existing efficacious treatments at the service-delivery system level. Ultimately, this R33 funding mechanism intends to speed the translation of emerging basic science findings of mechanisms and processes underlying treatments or implementation strategies into novel intervention approaches that can be efficiently tested for their promise to promote smoking cessation in individuals who have schizophrenia or promote the adoption of experimentally-supported smoking cessation interventions within organisations that provide services to smokers with schizophrenia.

Domestic and foreign for-profit and non-profit organisations and public or private

institutions are eligible to apply. The NIH intends to fund an estimate of six to nine awards, corresponding to a total of US\$3.5 million for fiscal year 2015. The budget may not exceed US\$450,000 in direct costs over the three year project period, with no more than US\$225,000 in direct costs in any single year. The maximum period is three years.

Ref: PAR-14-231.

Closing date: 16 Aug 16

Deadline information: Applications due by 5pm local time of applicant organisation. Deadlines on: 15 August 2014, 16 December 2014, 15 April 2015, 17 August 2015, 15 December 2015, 15 April 2016, 16 August 2016, 15 December 2016, 17 April 2017.

Posted date: 20 May 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: \$3,500,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-231.html>

Application form:

<http://www.grants.gov/applicants/apply-for-grants.html>



Eligibility profile

Country of applicant institution: Any

Disciplines

Schizophrenia & Other Psychotic Disorders;
Drug & Substance Abuse; Mental Illness;
Smoking & Tobacco; Primary Care; Public
Health, Health Services & Primary Care;
Sociology; Biomedical Engineering;
Psychiatry; Addiction; Health Disparities;
Medical Sociology; HIV/Aids; Mental Health;

Pharmaceutical Drugs; Economic & Social
Environment; Psychology

Contact Details

NIH
6001 Executive Boulevard
Room 5213
Bethesda, MD 20892-9561
Tel: +1 301 443 2235
Email: lisaonken@nih.gov

PROVOCATIVE QUESTIONS IN CANCER WITH AN UNDERLYING HIV INFECTION (R21)

NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its provocative questions in cancer with an underlying HIV infection (R21) funding opportunity announcement. This announcement supports projects that contribute to the understanding of the risks, development, progression, diagnosis and treatment of malignancies observed in individuals with an underlying HIV infection or Aids through research directed at addressing one of several of the institute's proposed provocative questions. Projects must address one, and only one, of the following considerations:

- the unique features of HIV-associated inflammation and whether these contribute to cancer incidence or outcome;
- other than immune dysfunction, identify HIV-mediated mechanisms that underlie differential cancer risk in individuals with HIV infection;
- other than immune dysfunction, and known oncogenic mechanisms or risk factors that affect HIV-uninfected individuals, identify the mechanisms that play a role in the differential

cancer risk in individuals with well-treated HIV infection;

- how biology of ageing and HIV infection interact in the development of various cancers;
- the differences between analogous tumours of the same tissue type or subtype in HIV versus non-HIV infected patients and whether these differences can inform prognosis or treatment decisions;
- why only certain cancer types are increased whereas others are unchanged or even decreased in people with HIV infection.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, RFA-CA-15-012, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.



The total budget of approximately US\$8 million for fiscal years 2016 and 2017 funds approximately 18 to 20 awards.

Application budgets are limited to a total of US\$275,000 in direct costs, with up to US\$200,000 in direct costs per year. The maximum project period is two years.

Ref: RFA-CA-15-013.

Closing date: 18 Aug 16

Deadline information: Applications open on 18 July and are due by 5pm local time of applicant organisation on 18 August 2015 and 18 August 2016. Deadlines on: 18 August 2015, 18 August 2016.

Posted date: 15 May 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: \$8,000,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-15-013.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/ Aids; Cancer Studies & Oncology

Contact Details

BG 9609 Room 6W534
9609 Medical Center Drive
Rockville MD 20850
Tel: +1 240 276 6190
Email: bconnole@mail.nih.gov

PROVOCATIVE QUESTIONS IN CANCER WITH AN UNDERLYING HIV INFECTION (R01) NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its provocative questions in cancer with an underlying HIV infection (R01) funding opportunity announcement. This announcement supports projects that contribute to the understanding of the risks, development, progression, diagnosis and treatment of malignancies observed in individuals with an underlying HIV infection or Aids through research directed at addressing one of several of the institute's proposed provocative questions. Projects must address one, and only one, of the following considerations:

- the unique features of HIV-associated inflammation and whether these

contribute to cancer incidence or outcome;

- other than immune dysfunction, identification of HIV-mediated mechanisms that underlie differential cancer risk in individuals with HIV infection;
- other than immune dysfunction and known oncogenic mechanisms or risk factors that affect HIV-uninfected individuals, identification of the mechanisms that play a role in the differential cancer risk in individuals with well-treated HIV infection;
- how the biology of ageing and HIV infection interact in the development of various cancers;



- the differences between analogous tumours of the same tissue type or subtype in HIV versus non-HIV infected patients and whether these differences can inform prognosis or treatment decisions;
- why only certain cancer types are increased whereas others are unchanged or even decreased in people with HIV infection.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, RFA-CA-15-013, which solicits applications under the NIH exploratory/developmental (R21) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget of approximately US\$8 million for fiscal years 2016 and 2017 will fund approximately 10 to 12 awards. Application budgets are not limited but must reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: RFA-CA-15-012.

Closing date: 18 Aug 16

Deadline information: Applications open on 18 July and are due by 5pm local time of applicant organisation on 18 August 2015 and 18 August 2016.

Posted date: 15 May 15

Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: \$8,000,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-15-012.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276593>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Cancer Studies & Oncology

Contact Details

BG 9609 Room 6W534
9609 Medical Center Drive
Rockville MD 20850
Tel: +1 240 276 6190
Email: bconnole@mail.nih.gov

CLINICAL TRIAL READINESS FOR RARE NEUROLOGICAL AND NEUROMUSCULAR DISEASES (U01)

NIH: National Institute of Neurological Disorders and Stroke

Description:

The National Institute of Neurological Disorders and Stroke invites applications for its clinical trial readiness for rare neurological and neuromuscular diseases (U01) funding opportunity announcement. This announcement supports clinical studies that will fill gaps in the design of upcoming

clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers or by characterising cohorts of relevant patients. The goal is to accelerate the initiation of clinical trials for rare diseases and to increase the likelihood of success in those trials. The



studies supported through this call should be clinical observational studies, and no intervention studies are allowed.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-16-020.

Closing date: 18 Aug 16

Deadline information: Applications open on 18 January 2016 and due by 5pm local time of applicant organisation, 18 February and 18 August 2016, 17 February and 17 August 2017, and 15 February and 17 August 2018.

Posted date: 30 Oct 15

Award type: Directed grants to institutions, research groups etc, Clinical trials

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-020.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Neurology; Preventive Medicine; Muscle Diseases

Contact Details

Tel: +1 301 496 5745

Email: glen.nuckolls@nih.gov

UTTING-EDGE BASIC RESEARCH AWARDS (R21)

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its cutting-edge basic research awards (R21) funding opportunity announcement. This announcement aims to foster highly innovative or conceptually creative research related to drug abuse and addiction and how to prevent and treat them. Awards support research that is high-risk and potentially high-impact that is underrepresented or not included in NIDA's current portfolio. The proposed research should:

- test a highly novel and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would have a substantial impact on current thinking;

- develop or adapt innovative techniques or methods for addiction research, or that have promising future applicability to drug abuse research.

Domestic and foreign for-profit and non-profit organisations and public or private institutions may apply.

Application budgets are limited to US\$125,000 per year in direct costs over a maximum two-year project period.

Ref: PAR-15-079 (replaces PAR-12-086).

Closing date: 19 Aug 16



Deadline information: Applications are due at 5pm local time of applicant organisation on each deadline date. Deadlines on: 20 August 2015, 18 December 2015, 19 August 2016, 20 December 2016, 18 August 2017, 20 December 2017.

Posted date: 09 Jan 15

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$250,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-079.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-15-079>

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse; Addiction

Contact Details

NIDA

NSC Building, Room 4253

6001 Executive Boulevard

Rockville, MD 20852

Tel: +1 301 435 1315

Email: svolman@mail.nih.gov

INTERNATIONAL RESEARCH IN INFECTIOUS DISEASES (R01): AIDS-RELATED

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites applications for funding for international research in infectious diseases. This Aids-related R01 funding opportunity announcement solicits applications from organisations and institutions in resource-constrained countries that propose research related to infectious diseases. The intent is to advance the development of local scientific expertise, build local research infrastructure and to increase collaborative research partnerships at NIAID international sites.

For-profit or non-profit organisations and public or private institutions in developing countries may apply. Principal investigators may not currently hold a NIH funded grant. Collaborative projects involving investigators and institutions from international sites and

the US are particularly encouraged, but a US partner is not a requirement.

Grants are worth up to US\$125,000 per year over a period of up to five years.

PAR-14-080 (replaces PAR-11-145).

Closing date: 19 Aug 16

Deadline information: Application due by 5pm local time of applicant organisation.

Posted date: 31 Jan 14

Award type: Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: \$625,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-080.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-145>

Eligibility profile

Country of applicant institution: Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries

Disciplines

Microbiology; Allied Health Professions; Pathogenesis; Influenza; Blood Tests; Malaria; Human Biological Sciences; Diagnostic Sciences; Respiratory Medicine; Public Health, Health Services & Primary Care; Virology; Epidemiology; Biological Sciences; Immunopathology; Infectious Diseases;

Pathology; Physiology; Parasitology; Infection Agents & Pathogens; Drug Resistance; Primary Care; International Health; Tropical & Neglected Diseases; Immunology; Biostatistics; Venereology & Sexually Transmitted Diseases; Gastroenterology; Tuberculosis; HIV/Aids

Contact Details

Division of Microbiology and Infectious Diseases

NIAID

Room 3807, MSC-6603

6610 Rockledge Drive

Bethesda, MD 20892-6603

Tel: +1 301 496 1884

Email: ps31g@nih.gov

P LANNING FOR REGIONAL CENTRES OF RESEARCH EXCELLENCE IN NON-COMMUNICABLE DISEASES IN LOW AND MIDDLE INCOME COUNTRIES (P20)

NIH: National Cancer Institute

Description:

The National Cancer institute invites applications for its planning for regional centres of research excellence in non-communicable diseases in low and middle income countries (P20) funding opportunity announcement. This announcement aims to facilitate the planning, designing and initial research focus of Regional Centers of Research Excellence for non-communicable disease including cancer in low and middle-income countries. The planning efforts must demonstrate an understanding of the region's research capabilities and a commitment to enhance these capabilities with a focus on basic, translational, clinical and population science research for non-communicable diseases. Activities will be implemented through collaborative partnerships between investigators from institutions in high-income countries or upper- middle-income countries

and investigators, research administrators and other stakeholders from LMICs.

At least two institutions, one in the HIC or UMIC and one in a LMIC must be involved as partners in the grant application.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

The NCI intends to commit a total of US\$2 million for fiscal year 2016 to fund two to four awards and two to four new awards, corresponding to a total of US\$2m for fiscal year 2017. Application budgets are limited to US\$400,000 for the maximum project period of two years. No more than US\$200,000 in direct costs may be requested in any single year. At least 60 per cent of the proposed direct cost budget must be for costs in the



LMIC. F&A costs requested by consortium participants are not included in the direct cost limitation.

Ref: RFA-CA-15-007.

Closing date: 23 Aug 16

Deadline information: Applications open on 10 November 2015 and are due by 5pm local time of applicant organisation. Deadlines on: 10 December 2015, 23 August 2016.

Posted date: 15 Sep 15

Award type: Directed grants to institutions, research groups etc, Clinical trials, Networking/collaboration

Award amount max: \$400,000

Award amount min: -

Award budget total: \$4,000,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-15-007.html>

Eligibility profile

Country of applicant institution: Any
Country of applicant institution: Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries

Disciplines

Cancer Studies & Oncology; Health Systems in Developing Countries; Non-Communicable Diseases

Contact Details

Tel: +1 240 276 5810

Email: shannon.silkensen@nih.gov

P LANNING GRANT FOR FOGARTY HIV RESEARCH TRAINING PROGRAMME FOR LOW- AND MIDDLE-INCOME COUNTRY INSTITUTIONS (D71)

NIH: Fogarty International Center

Description:

The Fogarty International Center, the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse and the National Institute of Mental Health invite applications for the planning grant for Fogarty HIV research training programme for low- and middle-income country institutions (D71) funding opportunity announcement. This D71 funding opportunity announcement supports research training that will strengthen the HIV research capacity of institutions in low- and middle-income countries. The objectives of the planning grant are to:

- engage new or solidify existing relationships with individual and institutional partners who will be involved in the envisioned research training programme;

- define an organisational structure to support the future research training programme;
- define the pool of potential trainees from the LMIC or, if relevant, from the LMIC Network sites, to be recruited for a future research training programme;
- design research training approaches that address the selected HIV scientific focus;
- organise and submit an application in response to D43 funding opportunity announcement.

This funding opportunity uses the NIH research training planning grant (D71) mechanism and runs in parallel with two funding announcement opportunities of



identical scientific scope, PAR-16-279, which solicits applications under the NIH international research training grant (D43) mechanism and PAR-16-280, which solicits applications under the NIH extramural associate research development award (G11) mechanism.

Institutions in low and middle-income countries are eligible to apply.

Application budgets are limited to US\$28,000 per year for a maximum of two years.

Ref: PAR-16-281 (replaces PAR-13-214).

Closing date: 25 Aug 16

Deadline information: Applications open 25 July and are due by 5pm local time of applicant organisation, 25 August 2016. Deadlines on: 25 August 2016, 23 August 2017, 23 August 2018.

Posted date: 24 May 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$56,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-281.html>

Eligibility profile

Country of applicant institution: Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries

Disciplines

Health Service Providers; HIV/Aids; Medical Education

Contact Details

Tel: +1 301 496 1492

Email: jeanne.mcdermott@nih.gov

FOGARTY HIV RESEARCH TRAINING PROGRAMME FOR LOW- AND MIDDLE-INCOME COUNTRY INSTITUTIONS (D43)

NIH: Fogarty International Center

Description:

A total of five institutes and offices of the National Institutes of Health invite applications for their Fogarty HIV research training programme for low- and middle-income country institutions (D43) funding opportunity announcement. This aims to strengthen the scientific capacity of institutions in low- and middle-income countries to conduct HIV research relevant to the evolving HIV epidemic in their country. This FOA supports training for a broad range of HIV research areas:

- basic, epidemiologic, clinical, behavioural and social science

research across HIV prevention, care and treatment;

- pathophysiology and therapeutics research to address HIV infection, the effects of HIV on body systems and HIV's interaction with other co-morbidities and co-infections;
- implementation, operations, health services and health systems research to improve the HIV prevention, care and treatment care continuum;
- research on HIV co-infections, AIDS-defining and HIV-related cancers, neurological and neuro-psychiatric morbidities and other co-morbidities



and health conditions, both infectious and non-infectious, that contribute to HIV transmission or poor health in HIV-infected individuals, including HIV infected substance users;

- research on integrated bio-behavioral HIV prevention, care and treatment among high risk populations, including polysubstance drug and alcohol use;
- community-based HIV research, HIV research on complex or multi-component interventions, structural interventions, and comparative effectiveness and HIV research on impact evaluation or health economics;
- cross-disciplinary HIV research among vulnerable or under-researched LMIC populations, including women, substance users, men who have sex with men, transgendered populations, ageing populations, orphans, and children;
- clinical research for team members to support HIV clinical research and HIV clinical trials;
- bio-statistics for HIV research design and methodology;
- bioinformatics, data analysis, data management, data quality assurance and control to support HIV research;
- laboratory capacity, including bio-safety and maintenance of lab quality assurance for HIV clinical research.

This funding opportunity uses the NIH international research training D43 grant mechanism and runs in parallel with two of identical scientific scope, PAR-16-281, which solicits applications under the NIH international research training D71 grant mechanism and PAR-16-280, which solicits applications under the NIH extramural associate research G11 development award.

Institutions in low- and middle-income countries are eligible to apply, alone or in collaboration with a US higher education institution.

Application budgets are limited to US\$280,000 per year over five years.

Ref: PAR-16-279 (replaces PAR-13-126).

Closing date: 25 Aug 16

Deadline information: Applications open 25 July 2016 and are due by 5pm local time of applicant organisation, 25 August 2016, 23 August 2017 and 23 August 2018.

Posted date: 24 May 16

Award type: Travel to conferences, meetings etc., Directed grants to institutions, research groups etc

Award amount max: \$1,400,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-279.html>

Eligibility profile

Country of applicant institution: Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries
Country of applicant institution: United States

Disciplines

Preventive Medicine; HIV/Aids; Lesbian, Gay, Bisexual & Transgender Studies; Diagnostic Sciences; Epidemiology; Data Analysis; Statistics

Contact Details

Tel: +1 301 496 1492

Email: jeanne.mcdermott@nih.gov

INFRASTRUCTURE DEVELOPMENT TRAINING PROGRAMMES FOR CRITICAL HIV RESEARCH AT LOW- AND MIDDLE-INCOME COUNTRY INSTITUTIONS (G11)

NIH: Fogarty International Center

Description:

The Fogarty International Center, the National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their infrastructure development training programmes for critical HIV research at low- and middle-income country institutions (G11) funding opportunity announcement. This G11 funding opportunity announcement is to strengthen the scientific capacity of institutions in low- and middle-income countries to conduct HIV research on the evolving HIV epidemic in LMICs. This funding opportunity announcement encourages collaborative applications from US and LMIC institutions to support training to achieve technical, administration and financial management expertise required for one of the six research infrastructure functions considered critical to a successful high quality research environment:

- research administration and management;
- research integrity oversight;
- ethical review of research for the protection of human subjects;
- laboratory animal welfare oversight;
- health sciences library and information services;
- information and communications technology systems for research.

This funding opportunity uses the NIH extramural associate research development award (G11) mechanism and runs in parallel with two funding announcement opportunities of identical scientific scope, PAR-16-279, which solicits applications under the NIH international research training grant

(D43) mechanism and PAR-16-281, which solicits applications under the NIH research training planning grant (D71) mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to US\$92,000 per year for a maximum of three years.

Ref: PAR-16-280 (replaces PAR-13-215).

Closing date: 25 Aug 16

Deadline information: Applications open on 25 July and are due by 5pm local time of the applications organisation on deadline dates.

Posted date: 24 May 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$276,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-280.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Health Service Providers; Medical Education

Contact Details

Tel: +1 301 496 1492

Email: jeanne.mcdermott@nih.gov

SEPTEMBER 2016

HIV INFECTION OF THE CENTRAL NERVOUS SYSTEM (R01)

NIH: National Institute of Mental Health

Description

The National Institute of Mental Health, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Allergy and Infectious Disease, the National Institute on Drug Abuse and the National Institute of Neurological Disorders and Stroke invite research applications for their HIV infection of the central nervous system (R01) grants. This R01 funding opportunity announcement focuses on defining the pathogenic mechanisms involved in human immunodeficiency virus-1 associated neurocognitive disorders and identifying therapeutic strategies to treat and prevent the neurobehavioral and neurological effects of HIV-1 on the CNS. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PA-14-094 (replaces PA-11-014).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 12 Feb 14

Award type: Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-094.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-094>

Eligibility profile

Country of applicant institution: Any

Disciplines

Psychology; Nucleus & Organelles; Public Health, Health Services & Primary Care; Primary Care; Cellular Interactions; Human Biological Sciences; General Practice & Family Health; Physiology; Infectious Diseases; Molecular Genetics; Clinical Medicine; Virology; Diagnostic Sciences; Neuropsychology; Infection Agents & Pathogens; Neurobiology; Neurology; Medical & Diagnostic Tests; Neuroimaging; Pathogenesis; HIV/Aids; Preventive Medicine; Biological Sciences; Proteomics & Molecular Interactions; Central Nervous System

Contact Details

NIMH

6001 Executive Boulevard

Bethesda, MD 20892

Tel: +1 301 443 6100

Email: jjeymoha@mail.nih.gov



RESEARCH ON MALIGNANCIES IN THE CONTEXT OF HIV/AIDS (R01)

NIH: National Cancer Institute

Description:

The National Cancer Institute and the National Institute of Dental and Craniofacial Research invite applications for their research on malignancies in the context of HIV/Aids (R01) grants. The purpose of this R01 funding opportunity announcement is to advance understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency infection or acquired immune deficiency syndrome. NCI and NIDCR seek to encourage research in areas such as the study of the aetiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both Aids-defining and non-Aids-defining malignancies in diverse populations in the context of an underlying HIV infection. This FOA invites research efforts that will: provide information on the clinical outcomes of such cancers in the HIV-infected population; and identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers.

This FOA will use the research project grant (R01) award mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-378, which solicits applications under the R21 exploratory/developmental grant mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PA-13-377 (replaces PA-10-290).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on

every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 23 Oct 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-377.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-377>

Eligibility profile

Country of applicant institution: Any

Disciplines

Molecularly Targeted Therapy; Breast Cancer; Diagnostic Sciences; General Practice & Family Health; Pathogenesis; HIV/Aids; Colorectal, Pancreatic & Stomach Cancers; Gynaecological Cancers; Physiology; Immunopathology; Non-cancerous Tumours; Cancer Immunology; Oncology Nursing; Nursing; Health Systems, Risk Management; Medical & Diagnostic Tests; Brain Cancer; Chemotherapy; Carcinogenesis; Melanoma & Other Skin Cancers; Leukaemia & Other Blood Cancers; Cancer Studies & Oncology; Public Health, Health Services & Primary Care; Lung Cancer; Pathology; Prostate & Testicular Cancers; Human Biological Sciences; Clinical Medicine; Cancer Cell Biology; Primary Care

Contact Details

NCI

9609 Medical Center Drive

Rockville, MD 20850

Tel: +1 301 276 6226

Email: bconnole@mail.nih.gov

D RUG ABUSE PREVENTION INTERVENTION RESEARCH (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its drug abuse prevention intervention research (R01) funding opportunity announcement. This Aids-related announcement aims to support research that will employ rigorous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan.

This FOA encourages investigations of cognitive, behavioural, and social processes as they relate to:

- development of novel prevention approaches;
- efficacy and effectiveness of prevention interventions or programmes;
- processes that optimise the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
- methodologies appropriate for studying complex aspects of prevention science.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This FOA uses the research project grant (R01) funding mechanism and runs in parallel with two opportunities of identical scientific scope, PA-15-080 and PA-15-081 which respectively use the exploratory/developmental grant (R21) and the small grant programme (R03) funding mechanism.

Application budgets are not limited, but should reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-15-082 (reissue of PA-11-311).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 12 Jan 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-082.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true?oppNum=PA-15-082>

Eligibility profile

Country of applicant institution: Any

Disciplines

Smoking & Tobacco; HIV/Aids; Alcoholism; Drug & Substance Abuse

Contact Details

Prevention Research Branch

Division of Epidemiology, Services and Prevention Research

NIDA

6001 Executive Blvd, Suite 5160

Bethesda, MD 20892-9589

Tel: +1 301 443 6504

Fax: +1 301 443 2636

Email: pconway@nida.nih.gov

H HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite proposals for their health services and economic research on the prevention and treatment of drug, alcohol and tobacco abuse (R01) funding opportunity announcement. This Aids-related announcement supports rigorous health services and economic research to maximise the delivery of efficient, high-quality drug, tobacco and alcohol prevention, treatment and recovery support services. The following subjects are of specific interest to the NIDA and NIAAA:

- clinical quality improvement;
- quality improvement in service organisation and management;
- implementation research;
- economic research;
- implications of policy change for service quality;
- methods, technology and other tools.

Applicants are strongly encouraged to contact scientific staff prior to submitting an application.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with several of identical scientific scope, PA-15-252, PA-15-253 and PA-15-250, which solicit applications under the NIH small grant programme (R03), the NIH exploratory/developmental (R21) and the NIH planning (R34) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but should reflect the actual costs of the proposed project. The maximum project period is five years.

Ref: PA-15-251 (reissue of PA-12-127).

Closing date: 07 Sep 16

Deadline information: Applications are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 11 May 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-251.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276470>

Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism; Smoking & Tobacco; Access to Health Care; Quality of Care; Social Services Delivery; Standards of Care; HIV/Aids; Health Economics; Drug & Substance Abuse

Contact Details

Tel: +1 301 443 4715

Email: djones1@nida.nih.gov





INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its international research collaboration on drug abuse and addiction research (R01) research opportunity announcement. This Aids-related announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Special opportunities include access to unusual talent, resources, populations or environmental conditions in other countries that will speed scientific discovery. Projects must have relevance to the mission of NIDA and where feasible should address NIDA's scientific priority areas. Priority areas include: linkages between HIV/Aids and drug abuse; prevention, initiation and treatment of nicotine and tobacco use; the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact.

This funding opportunity uses the NIH research project grant programme (R01) mechanism and runs in parallel with two of identical scientific scope, PA-15-141 and PA-15-143 which respectively solicit applications under the NIH small grant programme (R03) mechanism and the NIH exploratory/developmental grant (R21) mechanism.

Research must be conducted by US investigators in collaboration with non-US based investigators. Projects must include significant contributions of resources by each participant. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the actual needs of the proposed project. The maximum project period is five

years. Applicants requesting US\$500,000 or more for direct costs in any year must contact NIH programme staff at least six weeks before submitting the application.

Ref: PA-15-142 (reissue of PA-12-040).

Closing date: 07 Sep 16

Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 18 Mar 15

Award type: Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-142.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275229>

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse; Smoking & Tobacco; Alcoholism; HIV/Aids

Contact Details

National Institute on Drug Abuse
NSC BG Room 4274
6001 Executive Boulevard
Rockville MD 20852
Fax: +1 301 443 6480
Email: ipdirector@nida.nih.gov



DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R21): AIDS-RELATED

NIH: National Institute of Mental Health

Description:

A total of 17 participating institutes and centres of the National Institutes of Health invites applications for their dissemination and implementation research in health (R21) aids-related funding opportunity announcement. This aids-related R21 funding opportunity announcement encourages investigators to submit research grant applications that will identify, develop, test, evaluate or refine strategies to disseminate and implement evidence-based practices, such as behavioural interventions, prevention, early detection, diagnostic, treatment and disease management interventions, quality improvement programs, into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

This aids-related funding announcement will use the R21 exploratory/developmental award mechanism, and runs in parallel with two funding announcement of identical scientific scope, PAR-16-238, which encourages applications under the R01 research project grant mechanism, and PAR-16-237, which encourages applications under the R03 small grant programme mechanism.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US\$275,000 over a two-year period, with no more than

US\$200,000 in direct costs allowed in any single year.

Ref: PAR-16-236 (replaces PAR-13-054).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 08 May 2019.

Posted date: 11 May 16

Award type: Directed grants to institutions, research groups etc, Publish, edit, translate, disseminate

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-236.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Medical Effectiveness & Patient Outcomes; Health Promotion; Clinical Medicine; HIV/Aids; Public Health, Health Services & Primary Care

Contact Details

Tel: +1 240 276 5090

Email: dchamber@mail.nih.gov



I MAGING - SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (R03) AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse and the National Institute of Biomedical Imaging and Bioengineering invite applications for their imaging - science track award for research transition (R03) funding opportunity announcement. This Aids-related announcement facilitates the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programmes, to enable them to conduct small proof of concept studies. Funding covers research that deals with any area of brain imaging and drug abuse.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

The award covers direct costs of up to US\$150,000 for a maximum project period of one year.

Ref: PAR-15-326 (replaces PAR-12-066).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 September 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.

Posted date: 10 Aug 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$150,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-326.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse; Neuroimaging; HIV/Aids

Contact Details

Tel: +1 301 443 4877

Email: sgrant@nida.nih.gov

S MALL RESEARCH GRANT PROGRAMME (PARENT R03): AIDS-RELATED

NIH: National Human Genome Research Institute

Description:

A total of eleven institutes and offices of the National Institutes of Health invite applications for their small research grant programme (parent R03): Aids-related. This Aids-related announcement supports small research projects that can be carried out in a short period of time with limited resources.

This programme supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.



Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$50,000 in direct costs per year. The maximum project period is two years.

Ref: PA-16-162 (replaces PA-13-304).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm

local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 01 Apr 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-162.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/ Aids; Medicine & Health

Contact Details

Tel: +1 301 402 7469

EXPLORATORY OR DEVELOPMENTAL RESEARCH GRANT PROGRAMME (PARENT R21): AIDS-RELATED NIH: National Institutes of Health

Description:

A total of 18 institutes and offices of the National Institutes of Health invite applications under the exploratory or developmental research grant programme (parent R21): Aids-related. This Aids-related announcement encourages exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioural or clinical research.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$275,000 for a two-year period, with no more than US\$200,000 in any year.

Ref: PA-16-161 (replaces PA-13-303).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 01 Apr 16

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-161.html>

Eligibility profile

Country of applicant institution: Any



Disciplines

Medicine & Health; HIV / Aids

Contact Details

Tel: +1 301 402 7469

D RUG ABUSE PREVENTION INTERVENTION RESEARCH (R21): AIDS-RELATED NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its drug abuse prevention intervention research (R21) funding opportunity announcement. This Aids-related announcement aims to support research that will employ rigorous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan.

This FOA encourages investigations of cognitive, behavioral, and social processes as they relate to:

- development of novel prevention approaches;
- efficacy and effectiveness of prevention interventions or programmes;
- processes that optimise the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
- methodologies appropriate for studying complex aspects of prevention science.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This FOA uses the exploratory/developmental grant (R21) funding mechanism and runs in parallel with two opportunities of identical scientific scope,

PA-15-081 and PA-15-082 which respectively use the small grant programme (R03) and the research project grant (R01) funding mechanism.

Direct costs are limited to US\$275,000 over an R21 two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

Ref: PA-15-080 (reissue of PA-11-312).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 12 Jan 15

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-080.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true?oppNum=PA-15-080>

Eligibility profile

Country of applicant institution: Any

Disciplines



Drug & Substance Abuse; Alcoholism;
Smoking & Tobacco; HIV/Aids

Contact Details

NIDA

NSC BG Room 5171
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6504
Email: hperl@mail.nih.gov

D RUG ABUSE PREVENTION INTERVENTION RESEARCH (R03): AIDS-RELATED NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its drug abuse prevention intervention research (R03) funding opportunity announcement. This Aids-related announcement aims to support research that will employ rigorous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan.

This FOA encourages investigations of cognitive, behavioural, and social processes as they relate to:

- development of novel prevention approaches;
- efficacy and effectiveness of prevention interventions or programmes;
- processes that optimise the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
- methodologies appropriate for studying complex aspects of prevention science.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This FOA uses the small grant programme (R03)

funding mechanism and runs in parallel with two opportunities of identical scientific scope, PA-15-080 and PA-15-082 which respectively use the exploratory/developmental grant (R21) and the research project grant (R01) funding mechanism.

Direct costs of up to US\$50,000 per year and a project duration of up to two years may be requested.

Ref: PA-15-081 (reissue of PA-11-313).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 12 Jan 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-081.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true?oppNum=PA-15-081>



Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Smoking & Tobacco; Drug & Substance Abuse; Alcoholism

Contact Details

NIDA
NSC BG Room 5171
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6504
Email: hperl@mail.nih.gov

R ESearch ON Malignancies in the Context of HIV/Aids (R21) NIH: National Cancer Institute

Description:

The National Cancer Institute and the National Institute of Dental and Craniofacial Research invite applications for their research on malignancies in the context of HIV/Aids (R21) grants. The purpose of this is to advance understanding of the risks, development, progression, diagnosis and treatment of malignancies observed in individuals with an underlying human immunodeficiency infection or acquired immune deficiency syndrome. NCI and NIDCR seek to encourage research in areas such as the study of the aetiological factors, cofactors, immunopathogenesis, diagnosis, and consequences of both Aids-defining and non-Aids defining malignancies in diverse populations in the context of an underlying HIV infection. This FOA invites research efforts that will: provide information on the clinical outcomes of such cancers in the HIV-infected population; and identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers.

This FOA will use the exploratory/developmental grant (R21) mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-377, which solicits applications under the research project R01 research project grant mechanism. Direct

costs are limited to US\$275,000 over an R21 two-year period, with no more than US\$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-13-378 (replaces PA-10-291).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 23 Oct 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-378.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Prostate & Testicular Cancers; Lung Cancer; Cancer Studies & Oncology; Human Biological Sciences; Cancer Cell Biology;



Pathogenesis; General Practice & Family Health; Carcinogenesis; Nursing; Brain Cancer; Public Health, Health Services & Primary Care; Chemotherapy; Non-cancerous Tumours; Leukaemia & Other Blood Cancers; Colorectal, Pancreatic & Stomach Cancers; Health Systems, Risk Management; Medical & Diagnostic Tests; Oncology Nursing; Molecularly Targeted Therapy; Clinical Medicine; Immunopathology; HIV/Aids; Breast Cancer; Primary Care; Cancer

Immunology; Melanoma & Other Skin Cancers; Physiology; Diagnostic Sciences; Gynaecological Cancers; Pathology

Contact Details

NCI
9609 Medical Center Drive
Rockville, MD 20850
Tel: +1 301 276 6226
Email: bconnole@mail.nih.gov



BIOLOGY OF MANUAL THERAPIES (R21): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The National Center for Complementary and Alternative Medicine invites Aids-related applications for its call on biology of manual therapies (R21). This Aids-related R21 funding opportunity announcement supports studies of the basic science and mechanisms of action underlying the neurophysiological, immunological, endocrinological or biomechanical consequences of manual therapies such as spinal manipulation, mobilisation and massage therapy.

This FOA uses the R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-168, which solicits applications under the R01 mechanism.

Eligible institutions include domestic and foreign for-profit and non-profit organisations and public or private institutions.

Direct costs are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in direct costs allowed in any single year.

Ref: PA-14-167 (replaces PA-10-210).

Closing date: 07 Sep 16

Deadline information: Deadlines by 5pm proposer's local time every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 31 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-167.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-167>

Eligibility profile

Country of applicant institution: Any

Disciplines

Folk, Complementary & Alternative
Medicine; Mechanical Engineering;



Traumatology, Accidents & Injury; Physiology; Aerospace Engineering & Avionics; Electrophysiology; Medical Research of Selected Fields; Endocrine & Neuroendocrine Cancers; Hormones & Endocrinology; Growth & Growth Factors; Cancer Cell Biology; HIV/Aids; Biomechanics; Manufacturing & Industrial Engineering; Human Biological Sciences; Central Nervous System; Clinical Medicine;

Diagnostic Sciences; Immunology; Therapy Evaluation

Contact Details

NCCAM
6707 Democracy Blvd, Suite 401
Bethesda, MD 20892
Tel: +1 301 594 3462
Fax: +1 301 401 1587
Email: patrap.khalsa@nih.gov



N NIH RESEARCH GRANT FOR VISION RELATED SECONDARY DATA ANALYSIS (R21): AIDS-RELATED NIH: National Eye Institute

Description:

The National Eye Institute invites applications for its research grant for vision related secondary data analysis (R21): Aids-related programme. This Aids-related announcement encourages applications that propose to conduct vision-related secondary data analyses utilising existing database resources. The purpose of this FOA is for secondary data analysis from vision related clinical trials, epidemiologic and other clinical research studies. The goal is to fund meritorious vision related research projects that involve secondary data analyses using existing database resources. The development of statistical methodology necessary for improving methods to analyse vision health data using existing vision data may also be proposed.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$275,000 for a maximum period of two years. No more than US\$200,000 may be requested in any single year.

Ref: PAR-16-168 (replaces PAR-13-035).

Closing date: 07 Sep 16

Deadline information: Applications open 5 May 2016 and due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September 7 until until 8 May 2019.

Posted date: 07 Apr 16

Award type: Directed grants to institutions, research groups etc, Clinical trials

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-168.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Medical Statistics; Data Analysis; Vision Science; HIV/Aids

Contact Details



Tel: +1 301 451 2020
Fax: +1 301 402 0528

Email: everettd@mail.nih.gov

PRESCRIPTION DRUG ABUSE (R21): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its prescription drug abuse (R21): Aids-related funding opportunity announcement. This Aids-related announcement aims to develop innovative research on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterise the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioural and pharmacological treatments. Studies on individual- and patient-level factors, prescriber factors, and health system factors are encouraged, as are studies on all classes of prescription drugs with high abuse liability, including analgesics, stimulants, sedative or hypnotics and anxiolytics. Researchers are further encouraged to study the relationship between the prescription medication, the indication for which the medication was prescribed and the environmental and individual factors contributing to abuse.

This FOA uses the NIH exploratory or developmental (R21) award mechanism and runs in parallel an FOA of identical scientific scope, PA-16-233, which solicits applications under the research project grant (R01) mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$275,000 over a two-year period. No more than US\$200,000 may be requested in any single year.

Ref: PA-16-232 (replaces PA-13-016).

Closing date: 07 Sep 16

Deadline information: Applications open 16 May 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May, 7 September until 8 May 2019.

Posted date: 11 May 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-232.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Drug & Substance Abuse; Pharmaceutical Drugs; Neuroscience; Animal Models; Pain Management

Contact Details

Tel: +1 301 402 7469



HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite proposals for their health services and economic research on the prevention and treatment of drug, alcohol and tobacco abuse (R21) funding opportunity announcement. This Aids-related announcement supports rigorous health services and economic research to maximise the delivery of efficient, high-quality drug, tobacco and alcohol prevention, treatment and recovery support services. The following subjects are of specific interest to the NIDA and NIAAA:

- clinical quality improvement;
- quality improvement in service organisation and management;
- implementation research;
- economic research;
- implications of policy change for service quality;
- methods, technology and other tools.

Applicants are strongly encouraged to contact scientific staff prior to submitting an application.

This funding opportunity uses the NIH exploratory/developmental (R21) mechanism and runs in parallel with several of identical scientific scope, PA-15-251, PA-15-252 and PA-15-250 which solicit applications under the NIH research project (R01), the NIH small grant programme (R03) and the NIH planning (R34) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US\$275,000 in direct costs with up to US\$200,000 in direct costs per year.

The maximum project period is two years.

Ref: PA-15-253 (reissue of PA-12-128).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 11 May 15

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-253.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276474>

Eligibility profile

Country of applicant institution: Any

Disciplines

Social Services Delivery; Access to Health Care; Standards of Care; Quality of Care; Health Economics; HIV/Aids; Smoking & Tobacco; Drug & Substance Abuse; Alcoholism

Contact Details

Tel: +1 301 443 4715

Email: djones1@nida.nih.gov



HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R03): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite proposals for their health services and economic research on the prevention and treatment of drug, alcohol and tobacco abuse (R03) funding opportunity announcement. This Aids-related announcement supports rigorous health services and economic research to maximise the delivery of efficient, high-quality drug, tobacco and alcohol prevention, treatment and recovery support services. The following subjects are of specific interest to the NIDA and NIAAA:

- clinical quality improvement;
- quality improvement in service organisation and management;
- implementation research;
- economic research;
- implications of policy change for service quality;
- methods, technology and other tools.

Applicants are strongly encouraged to contact scientific staff prior to submitting an application.

This funding opportunity uses the NIH small grant programme (R03) grant mechanism and runs in parallel with several of identical scientific scope, PA-15-251, PA-15-253 and PA-15-250 which solicit applications under the NIH research project (R01), the NIH exploratory/developmental (R21) and the NIH planning (R34) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to US\$50,000 in direct costs per year. The maximum project period is two years.

Ref: PA-15-252 (reissue of PA-12-129).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 11 May 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-252.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276471>

Eligibility profile

Country of applicant institution: Any

Disciplines

Smoking & Tobacco; Social Services Delivery; Alcoholism; HIV/Aids; Quality of Care; Drug & Substance Abuse; Standards of Care; Health Economics; Access to Health Care

Contact Details

Tel: +1 301 443 4715

Email: djones1@nida.nih.gov



P ILOT AND FEASIBILITY CLINICAL TRIALS IN DIABETES, AND ENDOCRINE AND METABOLIC DISEASES (R21): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its pilot and feasibility clinical trials in diabetes, and endocrine and metabolic diseases (R21) funding opportunity announcement. This Aids-related announcement supports pilot and feasibility trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention or treatment of diabetes or selected endocrine and genetic metabolic diseases.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Foreign applications must reflect special opportunities, and must be applicable to US healthcare systems to be considered for funding

Application budgets are limited to a total of US\$275,000 in direct costs, with a maximum of US\$200,000 in direct costs per year. The maximum project period is two years.

Ref: PA-15-176 (reissue of PA-12-157).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May and are due by 5pm local time of

applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 07 Apr 15

Award type: Directed grants to institutions, research groups etc, Clinical trials

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-176.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#search=true&oppNum=PA-15-176>

Eligibility profile

Country of applicant institution: Any

Disciplines

Human Metabolism; Diabetes; Hormones & Endocrinology; Genetic Diseases; HIV/Aids

Contact Details

NIDDK

BG 2DEM Room 687

6707 Democracy Boulevard

Bethesda, MD 20892

Tel: +1 301 594 7733

Email: marteylk@mail.nih.gov

E XPLOATORY/DEVELOPMENTAL BIOENGINEERING RESEARCH GRANTS (R21): AIDS-RELATED

NIH: National Institute of Biomedical Imaging and Bioengineering

Description:

A total of six participating institutes of the National Institutes of Health invite

applications for their Aids-related exploratory/developmental bioengineering



research (R21) grants. The purpose of this Aids-related R21 funding opportunity announcement is to establish the feasibility of technologies, techniques or methods that: explore a unique multidisciplinary approach to a biomedical challenge, are high-risk but have high impact, and develop data that may lead to significant future research. EBRG applications may propose hypothesis-driven, discovery-driven, developmental, or design-directed research and are appropriate for evaluating unproven approaches for which there is minimal or no preliminary data.

Direct costs are limited to US\$275,000 over an R21 two-year period, with no more than US\$200,000 in direct costs allowed in any single year. Eligible organisations include US and foreign for-profit and non-profit organisations and public or private institutions.

Ref: PA-16-040 (replaces PA-12-284).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm applicant's local time, every 7 January, 7 May, 7 September until 8 January 2019.

Posted date: 23 Nov 15

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-040.html> n

Eligibility profile

Country of applicant institution: Any

Disciplines

Biomedical Engineering; HIV/ Aids; Bioengineering

Contact Details

Tel: +1 301 451 0707

Fax: kpeterso@mail.nih.gov

BIOENGINEERING RESEARCH GRANTS (R01): AIDS-RELATED

NIH: National Institute of Biomedical Imaging and Bioengineering

Description:

A total of 11 institutes and centres of the National Institutes of Health invite applications for their bioengineering research grants (R01): Aids-related. These aim to foster the development of an innovative technology, model, technique, design or method that has the potential for significant impact on biomedical research by infusing principles and concepts from the quantitative sciences. The purpose of this call is to encourage BRG applications that:

- apply a multidisciplinary approach to the solution of a biomedical problem;

- integrate, optimise, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational or clinical science and practice. Proposed BRG applications may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve



problems in biological, clinical or translational science.

This call seeks to encourage collaborations of quantitative and physical scientists with biomedical researchers to catalyse the development of innovative bioengineering approaches to the solution of important problems in biomedical research, clinical investigations and medical practice.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum award period is 5 years depending on the policy of each NIH Institute.

Ref: PAR-16-242 (replaces PAR-13-137).

Closing date: 07 Sep 16

Deadline information: Applications open 10 May 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 11 May 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-242.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Bioengineering; Biomedical Engineering; HIV/Aids

Contact Details

Email: +1 301 402 7469

BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R01): AIDS-RELATED NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the Office of Behavioral and Social Sciences Research invite applications for their Aids-related behavioural and integrative treatment development (R01) grants. The aim of this Aids-related programme is to encourage behavioural intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behaviour change, determine dose-response, optimise combinations and ascertain best sequencing of behavioural, combined, sequential or integrated behavioural and pharmacological drug abuse

treatment interventions, drug abuse treatment and adherence interventions for use in primary care, drug abuse treatment and adherence interventions that utilise technologies to boost affects and increase implementability, interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment, interventions to promote adherence to drug abuse treatment, HIV and addiction medication and interventions to treat chronic pain. Research of interest includes but is not limited to stage two and stage three efficacy research.



This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-16-074, which solicits applications under the R03 small grant programme mechanism, and PA-16-074, which solicits applications under the R34 planning grant programme.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-16-072 (replaces PA-13-077).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 11 Jan 16

Award type: Directed grants to institutions, research groups etc, Clinical trials

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-072.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Addiction; HIV/Aids; Chronic Pain; Behavioural Medicine; Drug & Substance Abuse

Contact Details

Tel: +1 301 443 3207

Email: aklinwm@mail.nih.gov

B BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R03): AIDS-RELATED NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the Office of Behavioral and Social Sciences Research invite applications for their Aids-related behavioural and integrative treatment development (R03) programme. The aim of this Aids-related programme is to encourage investigators to propose well-defined projects within the domain of behavioural or integrated interventions that can be completed within two years. Projects of interest fall within the research domain of behavioural or integrated interventions targeting:

- substance abuse;

- prevention of acquisition or transmission of HIV infection among individuals in drug abuse treatment;
- promotion of adherence to drug abuse treatment, HIV and addiction medications;
- chronic pain.

Specific examples include studies focusing on stage one intervention generation and stage one pilot or feasibility. Both should include the development of putative moderators, mediators and change mechanisms. Stage one studies to generate or refine drug abuse treatment or adherence interventions and stage one research to boost effects and



increase implementability of interventions with creative use of technology is also sought.

This funding opportunity announcement will use the NIH small research grant (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-16-072, which solicits applications under the R01 research project grant mechanism, and PA-16-073, which solicits applications under the R34 planning grant programme.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$100,000 over a two-year period, with no more than US\$50,000 in direct costs allowed in any single year.

Ref: PA-16-074 (replaces PAR-13-079).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2016 and are due by 5pm local

time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 11 Jan 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-074.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Behavioural Medicine; Chronic Pain; Drug & Substance Abuse; HIV/Aids; Addiction

Contact Details

Tel: +1 301 443 3207

Fax: aklinwm@mail.nih.gov

M ECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R21): AIDS-RELATED NIH: National Cancer Institute

Description:

A total of nine institutes and offices of the National Institutes of Health invite applications for their mechanisms, models, measurement and management in pain research (R21): Aids-related funding opportunity announcement. This Aids-related announcement aims to inform the scientific community of the pain research interests of the various institutes and centres at the NIH, and aims to stimulate and foster a wide range of basic, clinical and translational studies on pain as they relate to the missions of these institutes and centres. Research may address the following:

- molecular and cellular mechanisms of pain;
- genetics of pain;
- biobehavioural pain;
- models of pain;
- diagnosis and assessment of pain;
- pain management;
- epidemiology of pain;
- health disparities;
- translational pain research.



Research conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled or women investigators.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-188, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Applications budgets are limited to US\$275,000 in direct costs for a maximum period of two years. No more than US\$200,000 may be requested in any single year

Ref: PA-16-187 (replaces PA-13-119).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 15 Apr 16

Award type: Directed grants to institutions, research groups etc,

Networking/collaboration

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-187.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Osteoporosis & Other Bone Diseases; Health Disparities; Traumatology, Accidents & Injury; Behavioural Medicine; Diagnostic Sciences; Chemotherapy; Muscle Diseases; Cardiovascular Diseases; Oncology Nursing; Biochemistry & Molecular Biology; Geriatric Nursing; Molecular Genetics; Cell & Developmental Biology; Epidemiology; Addiction; Central Nervous System; HIV/ Aids; Pain Management; Chronic Pain

Contact Details

Tel: +1 240 276 7050

Fax: omaraa@mail.nih.gov

M MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R01): AIDS-RELATED

NIH: National Cancer Institute

Description:

A total of nine institutes and offices of the National Institutes of Health invite applications for their mechanisms, models, measurement and management in pain research (R01) Aids-related funding opportunity announcement. This Aids-related announcement aims to inform the scientific community of the pain research interests of the various institutes and centres at the NIH,

and aims to stimulate and foster a wide range of basic, clinical and translational studies on pain as they relate to the missions of these institutes and centres. Research may address the following:

- molecular and cellular mechanisms of pain;
- genetics of pain;



- biobehavioural pain;
- models of pain;
- diagnosis and assessment of pain;
- pain management;
- epidemiology of pain;
- health disparities;
- translational pain research.

Research conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled or women investigators.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-187, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Applications budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-16-188 (replaces PA-13-118).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 15 Apr 16

Award type: Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-188.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Health Disparities; Epidemiology; Chemotherapy; Traumatology, Accidents & Injury; Oncology Nursing; Osteoporosis & Other Bone Diseases; Diagnostic Sciences; Biochemistry & Molecular Biology; Behavioural Medicine; Cell & Developmental Biology; Muscle Diseases; Cardiovascular Diseases; Geriatric Nursing; Addiction; HIV/Aids; Pain Management; Chronic Pain

Contact Details

Tel: +1 240 276 7050

Email: omaraa@mail.nih.gov

R ESearch Project Grant (Parent R01): AIDS-RELATED

NIH: National Institutes of Health

Description:

A total of 23 institutes and offices of the National Institutes of Health invite applications for their research project grant (parent R01): Aids-related funding opportunity announcement. This Aids-related

announcement supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigators. The proposed project must be related to the stated programme interests of



one or more of the participating NIH institutes and centres based on their scientific missions.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-16-160 (replaces PA-13-302).

Closing date: 07 Sep 16

Deadline information: Applications open 5 May 2016 and are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 01 Apr 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-160.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Medicine & Health; HIV/ Aids

Contact Details

Tel: +1 301 402 7469

MOLECULAR GENETICS OF DRUG ADDICTION AND RELATED CO-MORBIDITIES (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for research into molecular genetics of drug addiction and related co-morbidities (R01) call. This Aids-related R01 funding opportunity announcement will support projects that identify or validate chromosomal loci and variations in genes that are associated with vulnerability to addiction and that inform the likelihood of responsiveness to treatment. Applications that propose to examine intermediate phenotypes or endophenotypes to assess the molecular genetics of drug addiction, addiction vulnerability or their associated co-morbidities and how they are related to drug addiction are especially encouraged. Also encouraged are genetic as well as

computational and large-scale genomic approaches.

Application budgets are not limited, but must reflect the needs of the project. The maximum period is five years. Domestic and foreign for-profit and non-profit organisations and private or public institutions are eligible to apply.

Ref: PA-14-025 (replaces PA-11-026).

Closing date: 07 Sep 16

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 12 Dec 13



Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-025.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-025>

Eligibility profile

Country of applicant institution: Any

Disciplines

Pharmacy & Pharmacology; Depression & Other Mood Disorders; Allied Health Professions; Public Health, Health Services & Primary Care; Biochemical Markers; Schizophrenia & Other Psychotic Disorders; Psychology; Disease Models; Biological Sciences; Primary Care; Population Studies, Medical; Biological Markers & Sensor Mechanisms; Genomics; Diagnostic Sciences; Drug & Substance Abuse; Molecular Genetics; Smoking & Tobacco; Mental Illness; Pharmacotherapy; Addiction; HIV/Aids

Contact Details

NIDA
6001 Executive Boulevard
Bethesda MD 20852
Tel: +1 301 445 1309
Email: mail@nih.gov

PRESCRIPTION DRUG ABUSE (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its prescription drug abuse (R01): Aids-related funding opportunity announcement. This Aids-related announcement aims to develop innovative research on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterise the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioural and pharmacological treatments. Studies on individual- and patient-level factors, prescriber factors, and health system factors are encouraged, as are studies on all classes of prescription drugs with high abuse liability, including analgesics, stimulants, sedative or hypnotics and anxiolytics. Researchers are

further encouraged to study the relationship between the prescription medication, the indication for which the medication was prescribed and the environmental and individual factors contributing to abuse.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-232, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.



Ref: PA-16-233 (replaces PA-13-015).

Closing date: 07 Sep 16

Deadline information: Applications open 10 May 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 11 May 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-233.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Pain Management; Neuroscience; Drug & Substance Abuse; HIV/Aids; Animal Models; Pharmaceutical Drugs

Contact Details

Tel: +1 301 402 7469

FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAS IN DRUG ADDICTION (R21): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related functional genetics, epigenetics and non-coding RNAs in drug addiction (R21) programme. This Aids-related R21 funding opportunity announcement encourages basic functional genomic research in two areas: functional validation to determine which candidate genes or variants have an authentic role in addictive processes, and detailed elucidation of the molecular pathways and processes modulated by candidate genes or variants, particularly for those genes with an unanticipated role in addiction.

This FOA will use the R21 exploratory/developmental research grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-014, which encourages applications under the R01 research project grant mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Applications budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Direct costs are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in any year.

Ref: PA-14-013 (reissue of PA-11-034).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 06 Dec 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000



Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-013.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-14-013>

Eligibility profile

Country of applicant institution: Any

Disciplines

Epigenetics; Psychology; Biological Markers & Sensor Mechanisms; Proteomics & Molecular Interactions; Biochemical Markers; Molecular Genetics; Neuroimaging; Diagnostic Sciences;

Disease Models; Ribonucleic Acid, RNA; Drug & Substance Abuse; Biological Sciences; Physiology; HIV/Aids; Pharmacokinetics; Primary Care; Neurotransmitters; Public Health, Health Services & Primary Care; Behavioural Medicine; Immunological & Bioassay Methods; Electrophysiology; Addiction; Genomics

Contact Details

NIDA

6001 Executive Boulevard

Bethesda, MD 20892

Tel: +1 301 435 1020

Email: satterleej@nida.nih.gov

INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R21): AIDS-RELATED NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its international research collaboration on drug abuse and addiction research (R01) research opportunity announcement. This Aids-related announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Special opportunities include access to unusual talent, resources, populations or environmental conditions in other countries that will speed scientific discovery. Projects must have relevance to the mission of NIDA and where feasible should address NIDA's scientific priority areas. Priority areas include: linkages between HIV/Aids and drug abuse; prevention, initiation and treatment of nicotine and tobacco use; the neuroscience of marijuana and cannabinoids; and the effect of

changes in laws and policies on marijuana and its impact.

This funding opportunity uses the NIH exploratory research project grant (R21) mechanism and runs in parallel with two of identical scientific scope, PA-15-141 and PA-15-142 which respectively solicit applications under the NIH small grant programme (R03) mechanism and the NIH research project grant (R01) mechanism.

Research must be conducted by US investigators in collaboration with non-US based investigators. Projects must include significant contributions of resources by each participant. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.



Application budgets are limited to US\$275,000 with a maximum of US\$200,000 in indirect costs per year. The maximum project period is two years.

Ref: PA-15-143 (reissue of PA-12-041).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 18 Mar 15

Award type: Directed grants to institutions, research groups etc, Networking/collaboration, Innovation grants

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-143.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275245>

Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism; Drug & Substance Abuse; HIV/ Aids; Smoking & Tobacco

Contact Details

National Institute on Drug Abuse
NSC BG Room 4274
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6480
Email: ipdirector@nida.nih.gov

I INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R03): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its international research collaboration on drug abuse and addiction research (R03) research opportunity announcement. This Aids-related announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Special opportunities include access to unusual talent, resources, populations or environmental conditions in other countries that will speed scientific discovery. Projects must have relevance to the mission of NIDA and where feasible should address NIDA's scientific priority areas. Priority areas include: linkages between HIV/Aids and drug abuse; prevention, initiation and treatment of nicotine and tobacco use; the neuroscience of

marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact.

This funding opportunity uses the NIH small grant programme (R03) mechanism and runs in parallel with two of identical scientific scope, PA-15-142 and PA-15-143 which respectively solicit applications under the NIH research project grant programme (R01) mechanism and the NIH exploratory/developmental grant (R21) mechanism.

Research must be conducted by US investigators in collaboration with non-US based investigators. Projects must include significant contributions of resources by each participant. US and foreign for-profit and



non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited US\$50,000 per year over a maximum project period of two years.

Ref: PA-15-141 (reissue of PA-12-042).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May and are due by 5 pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 18 Mar 15

Award type: Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-141.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275228>

Eligibility profile

Country of applicant institution: Any

Disciplines

Smoking & Tobacco; HIV/Aids; Alcoholism; Drug & Substance Abuse

Contact Details

National Institute on Drug Abuse
NSC BG Room 4274
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6480
Email: ipdirector@nida.nih.gov

SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R21)

NIH: National Institute on Drug Abuse

Description:

The NIH's National Institute on Drug Abuse invites applications for its drug abuse, risky decision making and HIV/Aids funding opportunity announcement.

This R21 call encourages applications to study cognitive, motivational or emotional mechanisms and brain neuroendocrine and reinforcement systems that relate to HIV-risk behaviours or treatment non-compliance. Interdisciplinary studies that incorporate approaches from psychology, economics, anthropology, sociology, decision sciences, neuroscience and computational modelling are encouraged.

The total project period for an application submitted in response to this funding opportunity announcement may not exceed two years. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Direct costs are limited to US\$275,000 over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

This FOA will use the NIH exploratory/developmental (R21) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-14-061, that encourages applications under the R01 and



PA-14-063, that encourages applications under the R03 mechanism.

PA-14-062 (reissue of PA-11-007).

Closing date: 07 Sep 16

Deadline information: Aids-related applications due every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 19 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-062.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Political Risk Factors & Analysis; Chemistry; Economic & Social Environment; Clinical Psychology; Public Health, Health Services & Primary Care; Neuropsychology; Physiology; Decision Science; Pharmacokinetics; Neuropharmacology; Diagnostic Sciences; Toxicology; Computer Science & Informatics; Gender Roles & Sexuality; Pharmacy & Pharmacology; Psychology; Social Work & Social Policy; Drug & Substance Abuse; HIV/Aids; Built Environment & Spatial Planning; Medical Sociology; Addiction; Sociology; Biological Sciences; Neurobiology

Contact Details

NIDA

6001 Executive Boulevard, Rm 3173

Bethesda, MD 20892-9593

Tel: +1 301 435 1318

Email: ylin1@nida.nih.gov

SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R03)

NIH: National Institute on Drug Abuse

Description:

The NIH's National Institute on Drug Abuse invites applications for its substance use and abuse, risky decision making and HIV/Aids funding opportunity announcement. This R03 program is intended to stimulate research that will increase understanding of the way people make decisions about engaging in behaviours that impact the risk of acquiring or transmitting HIV, or to adhere to treatments for HIV. Decision making processes may contribute to both substance use/abuse and other HIV acquisition or transmission risks.

This FOA encourages applications to study cognitive, motivational or emotional mechanisms and brain neuroendocrine and reinforcement systems that relate to HIV-risk

behaviours or treatment non-compliance. Interdisciplinary studies that incorporate approaches from psychology, economics, anthropology, sociology, decision sciences, neuroscience and computational modelling are encouraged.

This FOA for R03 applications is intended to support pilot and feasibility studies, small, self-contained research projects, development of research methodology, and development of new research technology that can be carried out in a short period of time with limited resources.



Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Budgets for direct costs of up to US\$50,000 per year and a project duration of up to two years may be requested for a maximum of US\$100,000 direct costs over a two-year project period.

This FOA will utilise the NIH small research grant (R03) mechanism and runs in parallel with FOAs of identical scientific scope, PA-14-061, that encourages applications under the R01 mechanism and PA-14-062 that encourages applications under the R21 mechanism. PA-14-063 (reissue of PA-11-008)

Closing date: 07 Sep 16

Deadline information: Standard applications due every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 19 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-063.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application->

[package.html#download=true&oppNum=PA-14-063](#)

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Pharmacokinetics; Neurobiology; Economic & Social Environment; Decision Science; Neuropharmacology; Diagnostic Sciences; Medical Sociology; Toxicology; Pharmacy & Pharmacology; Psychology; Physiology; Political Risk Factors & Analysis; Primary Care; Drug & Substance Abuse; Sociology; Gender Roles & Sexuality; Biological Sciences; Chemistry; Public Health, Health Services & Primary Care; Addiction; Social Work & Social Policy; Neuropsychology; Clinical Psychology

Contact Details

Division of Clinical Neurosciences and Behavior Research

NIDA

6001 Executive Boulevard, Rm 3173

Rockville, MD 20852-9555

Tel: +1 301 435 1318

Fax: +1 301 594 6043

Email: ylin1@nida.nih.gov

NEUROSCIENCE RESEARCH ON DRUG ABUSE (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites Aids-related applications for its neuroscience research on drug abuse (R01) grants. This Aids-related R01 funding opportunity announcement aims to understand the neurobiological mechanisms underlying drug abuse and addiction, with emphasis on changes that occur during chronic drug use,

withdrawal and relapse. In vivo and in vitro model systems, as well as human studies, are appropriate.

This FOA will use the R01 grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-337, which encourages applications under the R21



exploratory/developmental grants mechanism, and PA-13-336, which encourages applications under the R03 small grant programme mechanism. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. Public and private, non-profit and for-profit, and domestic and foreign organisations are eligible. PA-13-338 (replaces PA-10-268).

Closing date: 07 Sep 16

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 27 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-338.html>

Application

form:

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PA-13-338>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Cognitive & Behavioural Therapies; Biological Sciences; Diagnostic Sciences; Public Health, Health Services & Primary Care; Psychology; Drug & Substance Abuse; Pharmacy & Pharmacology; Social Work & Social Policy; Addiction; Physiology; Primary Care; Neuroscience; Allied Health Professions; Neurobiology; Behavioural Medicine

Contact Details

Division of Basic Neuroscience and Behavioral Research

NIDA

Neuroscience Center

6001 Executive Blvd, Rm 4282, MSC 9555

Bethesda, MD 20892-9555

Tel: +1 301 435 1317

Email: npilotte@nih.gov

NEUROSCIENCE RESEARCH ON DRUG ABUSE (R21): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its neuroscience research on drug abuse (R21) grants. This Aids-related R21 funding opportunity announcement aims to understand the neurobiological mechanisms underlying drug abuse and addiction, with emphasis on changes that occur during chronic drug use, withdrawal and relapse. In vivo and in vitro model systems, as well as human studies, are appropriate.

This FOA will use the NIH exploratory/developmental (R21) award mechanism and runs in parallel with FOAs of

identical scientific scope, PA-13-338, which encourages applications under the R01 research project grant mechanism, and PA-13-336, which encourages applications under the R03 small grant programme mechanism. Direct costs are limited to US\$275,000 over an R21 two-year period, with no more than US\$200,000 in any year. Public and private, non-profit and for-profit, and domestic and foreign organisations are eligible. PA-13-337 (replaces PA-10-269).

Closing date: 07 Sep 16



Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 27 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-337.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-337>

Eligibility profile

Country of applicant institution: Any

Disciplines

Neuroscience; Drug & Substance Abuse; Behavioural Medicine; Social Work & Social Policy; Physiology; Biological Sciences; Addiction; Pharmacy & Pharmacology; Public Health, Health Services & Primary Care; Allied Health Professions; Psychology; Diagnostic Sciences; Primary Care; Cognitive & Behavioural Therapies; HIV/Aids; Neurobiology

Contact Details

Division of Basic Neuroscience and Behavioral Research

NIDA

Neuroscience Center

6001 Executive Blvd, Rm 4282, MSC 9555

Bethesda, MD 20892-9555

Tel: +1 301 435 1317

Email: npilotte@nih.gov

NEUROSCIENCE RESEARCH ON DRUG ABUSE (R03): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites Aids-related applications for its neuroscience research on drug abuse (R03) grants. This Aids-related R03 funding opportunity announcement aims to understand the neurobiological mechanisms underlying drug abuse and addiction, with emphasis on changes that occur during chronic drug use, withdrawal and relapse. In vivo and in vitro model systems, as well as human studies, are appropriate.

This FOA will use the NIH small research grant (R03) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-337, which encourages applications under the R21

exploratory/developmental grant mechanism, and PA-13-338, which encourages applications under the R01 research project grant mechanism. Direct costs are worth a maximum of US\$100,000 over two years, with no more than US\$50,000 in any year. Public and private, non-profit and for-profit, and domestic and foreign organisations are eligible. PA-13-336 (replaces PA-10-270).

Closing date: 07 Sep 16

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 27 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000



Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-336.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-336>

Eligibility profile

Country of applicant institution: Any

Disciplines

Behavioural Medicine; Physiology; Diagnostic Sciences; Pharmacy & Pharmacology; Allied Health Professions; Public Health, Health Services & Primary Care; Primary Care;

Psychology; Drug & Substance Abuse; Cognitive & Behavioural Therapies; Social Work & Social Policy; Neurobiology; Neuroscience; HIV/Aids; Addiction; Biological Sciences

Contact Details

Division of Basic Neuroscience and Behavioral Research
NIDA
Neuroscience Center
6001 Executive Blvd, Rm 4282, MSC 9555
Bethesda, MD 20892-9555
Tel: +1 301 435 1317
Email: npilotte@nih.gov

DEVELOPMENT OF ASSAYS FOR HIGH-THROUGHPUT DRUG SCREENING FOR USE IN PROBE AND PRE-THERAPEUTIC DISCOVERY (R01): AIDS-RELATED

NIH: National Institute of Mental Health

Description:

Participating components of the National Institutes of Health invite applications for their Aids-related development of assays for high-throughput drug screening for use in probe and pre-therapeutic discover (R01). This Aids-related R01 funding opportunity announcement aims to stimulate research in the following areas:

- developing assays for specific biological targets and disease mechanisms to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets or as pre-therapeutic leads;
- establishing collaboration with screening centres that have the requisite expertise and experience needed in implementation of HTS assays for the discovery and

development of small molecule chemical probes.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is three years. Domestic and foreign for-profit and non-profit organisations and public and private institutions are eligible to apply. PAR-13-364 (replaces PA-10-213).

Closing date: 07 Sep 16

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 30 Sep 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-364.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-364>

Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care; Pharmacy & Pharmacology; Clinical Medicine; Nursing; Screening for Diseases; HIV/Aids; Pharmacotherapy;

Diagnostic Sciences; Public Health, Health Services & Primary Care; Blood Tests; Immunological & Bioassay Methods; Deoxyribonucleic Acid, DNA

Contact Details

NIDDK
6707 Democracy Boulevard
Bethesda MD 20892
Tel: +1 301 443 1421
Email: ili1@mail.nih.gov

DVELOPMENT OF ANIMAL MODELS AND RELATED BIOLOGICAL MATERIALS FOR RESEARCH (R21): AIDS-RELATED

NIH: Office of the Director

Description:

The NIH Office of the Director invites applications for its development of animal models and related biological materials for research programme (R21): Aids-related.

This Aids-related announcement solicits proposals to develop, characterise or improve animal models and related biological materials for human health and disease or to improve diagnosis and control of diseases that might interfere with animal use for biomedical research purposes. The objective of this FOA is to stimulate novel areas of investigation related to model systems, which must fall within the categorical interests of two or more institutions or centres of the NIH. Model systems include both mammalian and non-mammalian species, cell/tissue culture systems and integrative informatics models. Areas of interest include:

- new or significantly improved genetically modified animal models for human disease;

- development of novel tools for producing and improving animal models;
- characterisation of animal diseases;
- preservation of model systems;
- complementary approaches to the use of whole animals;
- informatics tools for mapping molecular interactive and functional networks;
- strategies to increase quality and reliability of the pre-clinical data using animal models;
- animal models to study the impact of microbiota, viruses, fungi and protozoa residing in animals or humans on human health and disease;
- animal models for investigating environmental factors on human health and disease;
- fundamental biology of animal models;
- development and refinement of animal models for newly emerging human pathogens.



Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$275,000 in direct costs over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

Ref: PA-16-141 (replaces PA-13-145).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 21 Mar 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-141.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Disease Models; Laboratory Animals;
HIV/Aids; Animal Models

Contact Details

Tel: +1 301 435 0749

Email: zous@mail.nih.gov



IDS-SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (R03)

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-science track award for research transition (R03) funding opportunity announcement. This announcement seeks to facilitate the entry of both newly independent and early-career investigators to the area of drug abuse research on HIV and Aids related to the following areas of interest:

- prevention of HIV acquisition and transmission;
- HIV treatment, including toward a cure research;
- co-morbidities, co-infections and complications;
- behavioural and social science research to advance treatment and prevention, and especially to address the continuum of care.

Applications are welcomed from all areas of HIV and Aids research that NIDA supports.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Projects may receive up to US\$100,000 per year for a maximum period of two years.

Ref: PA-15-290 (replaces PAR-12-282).

Closing date: 07 Sep 16

Deadline information: Applications open on 7 December 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.

Posted date: 10 Sep 15



Award type: Directed grants to institutions, research groups etc, Directed grants for individual investigators

Award amount max: \$200,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-290.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse; HIV/ Aids

Contact Details

Tel: +1 301 443 3207

Email: aklinwm@mail.nih.gov

BIOENGINEERING RESEARCH PARTNERSHIPS (U01): AIDS-RELATED

NIH: National Institute of Biomedical Imaging and Bioengineering

Description:

A total of 8 participating institutes and offices of the National Institutes of Health invite applications for their bioengineering research partnerships (U01) funding opportunity announcement. This Aids-related announcement aims to accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterised solutions that fulfil an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. This call focuses on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies and engage biomedical researchers or clinicians throughout the project. The goal of the programme is to support projects that can realise meaningful solutions within five to 10 years. In addition, other objectives may include establishing proof of concept, pre-commercial prototype production, licenser, release of software packages, designs or models, demonstrating the biological effectiveness of engineered constructs, elucidating the structural and functional relevance of biomolecules or tissues, first-in-

human testing, or starting the investigational device exemption or investigational new drug process. It is also of interest to encourage collaborations and partnerships among allied quantitative and biomedical disciplines.

This FOA will use the NIH research project (U01) co-operative agreements mechanism and runs in parallel with two FOAs of similar scientific scope, PAR-13-137, which solicits applications under the NIH research project (R01) grant mechanism and PA-16-040, which also solicits applications under the NIH exploratory or developmental (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-16-116 (replaces PAR-14-092).

Closing date: 07 Sep 16

Deadline information: Applications open 18 April 2016 and are due by 5pm local time of



applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 03 Mar 16

Award type: Directed grants to institutions, research groups etc,

Networking/collaboration

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-116.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Bioengineering; Biomolecular Modelling; HIV/Aids

Contact Details

Tel: +1 301 451 0707

Email: kpeterso@mail.nih.gov

BIOLOGY OF MANUAL THERAPIES (R01): AIDS-RELATED

NIH: National Center for Complementary and Integrative Health

Description:

The National Center for Complementary and Alternative Medicine invites Aids-related applications for its call on biology of manual therapies (R01). This Aids-related R01 funding opportunity announcement supports studies of the basic science and mechanisms of action underlying the neurophysiological, immunological, endocrinological or biomechanical consequences of manual therapies such as spinal manipulation, mobilisation and massage therapy.

This FOA uses the NIH research project grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-167, which solicits applications under the R21 mechanism.

Eligible institutions include domestic and foreign for-profit and non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PA-14-168 (replaces PA-10-209).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 31 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-168.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-168>

Eligibility profile

Country of applicant institution: Any

Disciplines

Aerospace Engineering & Avionics; Human Biological Sciences; Folk, Complementary & Alternative Medicine; Physiology;



Biomechanics; Clinical Medicine; Hormones & Endocrinology; Electrophysiology; Central Nervous System; Traumatology, Accidents & Injury; HIV/Aids; Diagnostic Sciences; Manufacturing & Industrial Engineering; Endocrine & Neuroendocrine Cancers; Therapy Evaluation; Mechanical Engineering; Growth & Growth Factors; Immunology

Contact Details

NCCAM
6707 Democracy Blvd, Suite 401
Bethesda, MD 20892
Tel: +1 301 594 3462
Fax: +1 301 401 1587
Email: patrap.khalsa@nih.gov

NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism and the Office of Dietary Supplements invite applications for their Aids-related nutrition and alcohol-related health outcomes (R01) grants. This Aids-related R01 funding opportunity announcement supports research to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this R01 funding opportunity announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-360 and PA-13-361, which use the R03 small grant programme and the R21 exploratory/developmental grant mechanisms, respectively. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-359 (replaces PA-10-239)

Closing date: 07 Sep 16

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2017

Posted date: 24 Sep 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-359.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-359>

Eligibility profile

Country of applicant institution: Any

Disciplines

Allied Health Professions; Epidemiology; General Practice & Family Health; HIV/Aids; Psychology; Preventive Medicine; Diagnostic Sciences; Nutrition & Dietetics; Disease Models; Alcoholism; Pathophysiology; Addiction; Primary Care; Cognitive Processes; Public Health, Health Services & Primary Care; Clinical Medicine

Contact Details



Division of Epidemiology and Prevention
Research
NIAAA
5635 Fishers Lane, Room 2081, MSC 9304

Bethesda, MD 20892-9304
Tel: +1 301 594 6231
Fax: +1 301 443 8614
Email: rbreslow@mail.nih.gov

NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R03): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism and the Office of Dietary Supplements invite applications for their Aids-related nutrition and alcohol-related health outcomes (R03) grants. This Aids-related R03 funding opportunity announcement supports research to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this R01 funding opportunity announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.

This FOA will use the small grant programme (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-359 and PA-13-361, which use the R01 research project grant and the R21 exploratory/developmental grant mechanisms, respectively. Budgets for direct costs of limited to US\$50,000 per year over a maximum two year project period. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-360 (replaces PA-10-240)

Closing date: 07 Sep 16

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017

Posted date: 24 Sep 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-360.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-360>

Eligibility profile

Country of applicant institution: Any

Disciplines

Allied Health Professions; Pathophysiology; Epidemiology; Disease Models; Clinical Medicine; General Practice & Family Health; Cognitive Processes; HIV/Aids; Psychology; Foetal Health & Prenatal Development; Preventive Medicine; Addiction; Primary Care; Nutrition & Dietetics; Alcoholism; Public Health, Health Services & Primary Care; Maternal Health

Contact Details

Division of Epidemiology and Prevention
Research
NIAAA
5635 Fishers Lane, Room 2081, MSC 9304
Bethesda, MD 20892-9304



Tel: +1 301 594 6231
Fax: +1 301 443 8614

Email: rbreslow@mail.nih.gov

NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism and the Office of Dietary Supplements invite applications for their Aids-related nutrition and alcohol-related health outcomes (R21) grants. This Aids-related R21 funding opportunity announcement supports research to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this R01 funding opportunity announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.

This FOA will use the exploratory/developmental research grant (R21) mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-359 and PA-13-360, which use the R01 research project grant and the R03 small grant programme mechanisms, respectively. Direct costs are limited to US\$275,000 over an R21 two-year period, with no more than US\$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-361 (replaces PA-10-241).

Closing date: 07 Sep 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017
Posted date: 24 Sep 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-361.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-361>

Eligibility profile

Country of applicant institution: Any

Disciplines

Addiction; HIV/Aids; Preventive Medicine; Primary Care; General Practice & Family Health; Psychology; Cognitive Processes; Alcoholism; Epidemiology; Clinical Medicine; Allied Health Professions; Nutrition & Dietetics; Maternal Health; Foetal Health & Prenatal Development; Public Health, Health Services & Primary Care; Disease Models; Pathophysiology

Contact Details

Division of Epidemiology and Prevention Research
NIAAA
5635 Fishers Lane, Room 2081, MSC 9304
Bethesda, MD 20892-9304
Tel: +1 301 594 6231
Fax: +1 301 443 8614
Email: rbreslow@mail.nih.gov



SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites research grant applications on screening and brief interventions to prevent or reduce alcohol use and its adverse consequences. This Aids-related R01 funding opportunity announcement encourages research on screening and brief interventions to prevent and reduce alcohol use and alcohol related harms among underage and young adult populations.

This FOA will utilise the NIH research project grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-15-294 and PA-15-296, that solicit applications under the small research grant (R21) and exploratory/developmental (R03) award mechanisms, respectively. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-15-295 (replaces PA-12-031).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September, until 8 May, 2018.

Posted date: 13 Jul 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-295.html>

Application form:

<http://apply.grants.gov/apply/GetGrantFromFedgrants?cfda=&opportunity=PA-07-406&competitionid>

Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism; HIV/Aids; Screening of Drugs & Agents

Contact Details

Tel: +1 301 402 9389

Fax: +1 301 443 8614

Email: shirleym@mail.nih.gov

SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites research grant applications on screening and brief interventions to

prevent or reduce alcohol use and its adverse consequences. This Aids-related R21 funding opportunity announcement is designed to



stimulate a developmentally grounded program of Aids-related research on screening and brief interventions to prevent or reduce underage drinking and hazardous young adult drinking.

This FOA will utilise the NIH exploratory/developmental grant (R21) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-15-95 and PA-15-296, that solicit applications under the R01 and R03 mechanisms, respectively. Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-15-294 (replaces PA-12-030).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September, until 8 May, 2018.

Posted date: 13 Jul 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-294.html>

Application form:

<http://apply.grants.gov/apply/GetGrantFromFedgrants?cfda=&opportunity=PA-07-407&competitionid>

Eligibility profile

Country of applicant institution: Any

Disciplines

Screening of Drugs & Agents; Alcoholism; HIV/Aids

Contact Details

Tel: +1 301 402 9389

Fax: +1 301 443 8614

Email: shirleym@mail.nih.gov

SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R03): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its screening and brief alcohol interventions in underage and young adult populations funding opportunity announcement. This Aids-related R03 funding announcement encourages research on screening and brief interventions to prevent and reduce alcohol use and alcohol related harms among underage and young adult populations.

This FOA will utilise the NIH small research grant (R03) award mechanism and runs in

parallel with an FOA of identical scientific scope, PA-15-294 and PA-15-295, that solicit applications under the R01 and R21 mechanisms, respectively. Budgets for direct costs are limited up to US\$50,000 per year for a project period of up to two years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-15-296.

Closing date: 07 Sep 16



Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 13 Jul 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-296.html>

Application form:

<http://apply.grants.gov/apply/GetGrantFromFedgrants?cfda=&opportunity=PA-07-408&competitionid=>

Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism; Screening of Drugs & Agents; HIV/Aids

Contact Details

Tel: +1 301 402 9389

Fax: +1 301 443 8614

Email: shirleym@mail.nih.gov

THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R01): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

A total of 10 institutes and offices of the National Institutes of Health invite applications for their health of sexual and gender minority populations (R01) funding opportunity announcement. This Aids-related announcement encourages research that describes the biological, clinical, behavioural and social processes that affect the health and development of sexual and gender minority populations and individuals, as well as their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that enhance the health and development of these populations. The research must focus on clearly defined health outcomes. The following types of research are prioritised:

- basic social and behavioural science studies addressing the processes involved as individuals discover,

uncover, address or adapt to their sexual orientation and claim or do not claim identity as SGM, and how these processes affect the mental and physical health of the individual;

- research leading to interventions to ameliorate health disparities in SGM populations;
- large-scale design, implementation and evaluation of preventive or treatment interventions addressing health issues in SGM populations;
- research on how family structures and processes-including both families of origin and families of choice-affect the health of SGM individuals and their family members, including whether and how being raised in a family headed by SGM individuals affects the health, development and wellbeing of children.



This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-262 and PA-15-263, which solicit applications under the NIH small grant programme (R03) grant mechanism and the NIH exploratory/developmental (R21) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the actual costs of the proposed project. The maximum project period is five years.

Ref: PA-15-261 (reissue of PA-12-111).

Closing date: 07 Sep 16

Deadline information: Applications open on 5 September 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018. Applicants requesting US\$500,000 or more in direct costs in any year must contact a research contact at least six weeks before submitting the application.

Posted date: 19 May 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-261.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276658>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Health of Minority Groups; Gender Roles & Sexuality; Lesbian, Gay, Bisexual & Transgender Studies

Contact Details

Eunice Kennedy Shriver NICHD
BG 6100 Room 8B05L
6100 Executive Boulevard
Rockville MD 20852
Tel: +1 301 435 6981
Email: newcomes@nih.gov



GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their gene-environment interplay in substance use disorders (R01) funding opportunity announcement.

This Aids-related announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors

in the genesis, course and outcomes of substance and alcohol use disorders. Collaborations to combine data and enhance power are strongly encouraged. Proposals are expected to focus on the interplay of genetics and environment.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.



This FOA uses the research project (R01) grant mechanism

and runs in parallel with two FOAs of identical scientific scope, PA-15-111, which solicits applications under the small grant programme (R03) and PA-15-112, which solicits applications under the exploratory/developmental (R21) grant mechanism.

Application budgets are not limited, but should reflect the needs of the project. The maximum project period is five years.

Ref: PA-15-110 (reissue of PA-11-235).

Closing date: 07 Sep 16

Deadline information: Applications open on 5 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Feb 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-110.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-15-110>

Eligibility profile

Country of applicant institution: Any

Disciplines

Medical Genetics; HIV/Aids; Drug & Substance Abuse; Alcoholism

Contact Details

NIDA

NSC BG Room 5150

6001 Executive Boulevard

Rockville MD 20852

Tel: +1 301 402 1908

Email: nw46w@nih.gov

GENETIC EPIDEMIOLOGY OF SUBSTANCE USE DISORDERS (R03): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their gene-environment interplay in substance use disorders (R03) funding opportunity announcement.

This Aids-related announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course and outcomes of substance and alcohol use disorders.

Collaborations to combine data and enhance power are strongly encouraged. Proposals are expected to focus on the interplay of genetics and environment.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

This FOA uses the small grant programme (R03) and runs in parallel with two FOAs of identical scientific scope, PA-15-110, which



solicits applications under the research project (R01) grant mechanism and PA-15-112, which solicits applications under the exploratory/developmental (R21) grant mechanism.

Direct costs are limited to US\$50,000 per year with a maximum project period of two years.

Ref: PA-15-111 (reissue of PA-11-237).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Feb 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-111.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-15-111>

Eligibility profile

Country of applicant institution: Any

Disciplines

Medical Genetics; Alcoholism; Drug & Substance Abuse; HIV/Aids

Contact Details

NIDA

NSC BG Room 5150

6001 Executive Boulevard

Rockville MD 20852

Tel: +1 301 402 1908

Email: nw46w@nih.gov

GENETIC EPIDEMIOLOGY OF SUBSTANCE USE DISORDERS (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their gene-environment interplay in substance use disorders (R21) funding opportunity announcement.

This Aids-related announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course and outcomes of substance and alcohol use disorders. Collaborations to combine data and enhance power are strongly encouraged. Proposals are

expected to focus on the interplay of genetics and environment.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

This FOA uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-110, which solicits applications under the research project (R01) grant mechanism and PA-15-111,



which solicits applications under the small grant programme (R03) mechanism.

Direct costs are limited to US\$275,000 over an R21 two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

Ref: PA-15-112 (reissue of PA-11-236).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Feb 15

Award type: Innovation grants, Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-112.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-15-112>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Drug & Substance Abuse; Alcoholism; Medical Genetics

Contact Details

NIDA

NSC BG Room 5150

6001 Executive Boulevard

Rockville MD 20852

Tel: +1 301 402 1908

Email: nw46w@nih.gov

NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH SMALL GRANT PROGRAMME FOR NEW INVESTIGATORS (R03): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research invites applications for its small grant programme for new investigators (R03): Aids-related. This Aids-related R03 funding opportunity announcement supports pilot and developmental research with the intention of facilitating subsequent submission of an Individual research project grant (R01) application.

Budgets for direct costs of up to US\$150,000 over a two-year period may be requested. Domestic and foreign for-profit and non-profit organisations and public or private

institutions are eligible to apply. PAR-13-348 (replaces PAR-10-275).

Closing date: 07 Sep 16

Deadline information: Submissions due by 5pm proposers's local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 12 Sep 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$150,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-348.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-PAR-13-348>

Eligibility profile

Country of applicant institution: Any

Disciplines

Oral Medicine; Diagnostic Sciences; Craniofacial Disorders; HIV/Aids; Dentistry; Oral & Maxillofacial Surgery; Dental Health & Hygiene

H **HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R21): AIDS-RELATED**

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research invites applications for health promotion among racial and ethnic minority males (R21): Aids-related. This Aids-related R21 funding opportunity announcement aims to stimulate and expand research in the health of minority men. Specifically, this initiative is intended to: enhance understanding of the numerous factors influencing the health promoting behaviours of racial and ethnic minority males and their sub populations across the life cycle; and solicit applications focusing on the development and testing of culturally and linguistically appropriate health-promoting interventions designed to reduce health disparities among racially and ethnically diverse males and their sub populations aged 21 and older.

This FOA will use the exploratory/developmental (R21) grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-328 that solicits applications under the R01 mechanism. Direct costs are limited to US\$275,000 over an R21 two-year period, with no more than US\$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-331 (replaces PA-10-237).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 15 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-331.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Nursing; Medicine & Health; Disadvantaged & Minority Groups; Urology; Public Health, Health Services & Primary Care; Health Promotion; Medical Sociology; Pharmaceutical Drugs; Health Systems, Risk Management; Population Studies, Medical; Sociology; Psychology; Diagnostic Sciences; Economic & Social Environment; HIV/Aids; Biomedical Engineering; Behavioural Medicine; Health Disparities



Contact Details

Office of Extramural Programs

NINR

6701 Democracy Blvd, Room 710, MSC 4870

Bethesda, MD 20892-4870

Tel: +1 301 402 6423

Email: cottonp@mail.nih.gov

HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R01): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research and the National Institute of Diabetes and Digestive and Kidney Diseases invite applications for health promotion among racial and ethnic minority males (R01): Aids-related. This Aids-related R01 funding opportunity announcement aims to stimulate and expand research in the health of minority men. Specifically, this initiative is intended to: enhance understanding of the numerous factors influencing the health promoting behaviours of racial and ethnic minority males and their sub populations across the life cycle; and solicit applications focusing on the development and testing of culturally and linguistically appropriate health-promoting interventions designed to reduce health disparities among racially and ethnically diverse males and their sub populations aged 21 and older.

This FOA will use the R01 research project grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-331, which solicits applications under the R21 mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-13-328 (replaces PA-10-236).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 15 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-328.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Medicine & Health; Psychology; Behavioural Medicine; Biomedical Engineering; Health Disparities; Public Health, Health Services & Primary Care; Nursing; Pharmaceutical Drugs; Sociology; Urology; Economic & Social Environment; Medical Sociology; Health Promotion; Population Studies, Medical; Diagnostic Sciences; Disadvantaged & Minority Groups; HIV/Aids

Contact Details

Office of Extramural Programs

NINR

6701 Democracy Blvd, Room 710, MSC 4870

Bethesda, MD 20892-4870



Tel: +1 301 402 6423

Email: cottonp@mail.nih.gov

EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its epidemiology and prevention in alcohol research programme. This aims to encourage the submission of investigator-initiated research grant applications to support research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms, and alcohol use disorders.

This funding opportunity announcement will utilise the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-188, which solicits applications under the 21 exploratory of developmental grant mechanism, and PA-14-189, which solicits applications under the R03 small grant programme mechanism.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-14-190.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on

every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 28 Apr 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-190.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Psychology; Biomedical Engineering; Diagnostic Sciences; Addiction; Economic & Social Environment; Public Health, Health Services & Primary Care; Sociology; Preventive Medicine; Population Studies, Medical; HIV/Aids; Epidemiology; Allied Health Professions; Behavioural Medicine; Alcoholism; Medical Sociology; Patient Care & Education

Contact Details

NIAAA

Building 5635FL, Room 2083

5635 Fishers Lane

Rockville MD 20852

Tel: +1 301 402 6328

Email: mscott@mail.nih.gov



E

PIDEMIOLGY AND PREVENTION IN ALCOHOL RESEARCH (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its epidemiology and prevention in alcohol research grants. The goal of this Aids-related funding opportunity is to encourage the submission of investigator-initiated research grant applications to support research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms, and alcohol use disorders. This mechanism will support investigation of novel scientific ideas or new model systems, tools or technologies that have the potential for significant impact on biomedical or biobehavioural research.

This funding opportunity announcement will utilise the NIH exploratory/developmental (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-190, which solicits applications under the R01 research project grant mechanism, and PA-14-189, which solicits applications under the R03 small grant programme mechanism.

Direct costs are limited to US\$275,000 over a maximum period of two years, with no more than US\$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-14-188 (replaces PA-11-018).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on

every 7 May, 7 September and 7 January until 8 September 2017.

Posted date: 28 Apr 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-188.html>

Application form:

<http://www.grants.gov/applicants/apply-for-grants.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Behavioural Medicine; Public Health, Health Services & Primary Care; Sociology; Medical Sociology; Allied Health Professions; HIV/Aids; Biomedical Engineering; Patient Care & Education; Alcoholism; Preventive Medicine; Epidemiology; Psychology; Economic & Social Environment; Addiction; Population Studies, Medical; Diagnostic Sciences

Contact Details

NIAAA

Building 5635FL, Room 2083

5635 Fishers Lane

Rockville MD 20852

+1 301 402 6328

Email: mscott@mail.nih.gov



I INTERNATIONAL RESEARCH COLLABORATION ON ALCOHOL AND ALCOHOLISM (U01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related international research collaboration on alcohol and alcoholism (U01) grants. The purpose of this Aids-related is to foster international collaborations between alcohol research investigators within the US and investigators located at non-US laboratories and performance sites, for the mutual advancement of the understanding of alcohol problems and of clinical and public health approaches to their solutions. The programme provides funds for research activities to be undertaken jointly between the US and a non-US laboratory that expands the research direction of both laboratories in a collaborative manner.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Grants are worth up to US\$250,000 per year for direct costs. The maximum project period is five years.

Ref: PAR-14-268 (replaces PAR-11-282).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 02 Jul 14

Award type: Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-268.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Psychology; Pathophysiology; Behavioural Medicine; Alcoholism; Social Problems; Primary Care; Sociology; Addiction; Epidemiology; Allied Health Professions; Public Health; HIV/Aids; Molecular Genetics; Public Health, Health Services & Primary Care; Diagnostic Sciences; Social Behaviour & Attitudes

Contact Details

NIAAA

5635 Fishers Lane, MSC 9304

Bethesda MD 20892-9304

Tel: +1 301 443 2594

Email: pmurray@mail.nih.gov

P ROGRAMME FOR EXTRAMURAL OR INTRAMURAL ALCOHOL RESEARCH COLLABORATIONS (U01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its

programme for extramural or intramural alcohol research collaborations (U01): Aids-



related. This Aids-related announcement encourages collaboration between alcohol researchers in the extramural community and those within the NIAAA intramural research programme. The objective of this call is to bring together the research expertise that, as a functioning collaborative unit, will address key alcohol-based research questions that would not otherwise be possible by the same individuals working towards similar goals in isolation. The goal of the research proposed by the collaborating investigators should address questions that advance the alcohol research field with respect to issues surrounding alcohol use disorders including dependence and the effects of alcohol on health.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Applicants may request direct costs of up to US\$250,000 per year. The maximum project period is five years.

Ref: PAR-16-214 (replaces PAR-13-133).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 26 Apr 16

Award type: Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: \$1,250,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-214.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/ Aids; Alcoholic Beverages; Alcoholism

Contact Details

Tel: +1 301 402 6966

Email: psilverm@mail.nih.gov

NLM EXPRESS RESEARCH GRANTS IN BIOMEDICAL INFORMATICS (R01): AIDS-RELATED NIH: National Library of Medicine

Description:

The National Library of Medicine invites applications for its Aids-related express research grants in biomedical informatics (R01). This Aids-related R01 funding opportunity aims to advance the sciences of biomedical informatics.

The scope of NLM's interest in the research domain of informatics is interdisciplinary, encompassing informatics problem areas in the application domains of health care, public health, basic biomedical research,

bioinformatics, biological modelling, translational research and health information management in disasters. NLM defines biomedical informatics as the science of optimal organisation, management, presentation and utilisation of information relevant to human health and biology. Informatics research produces concepts, tools and approaches that advance what is known in the field and have the capacity to improve human health.



Applicants may request funding over up to US\$250,000 per year for a period of four years.

Eligible applicants include domestic public and private non-profit and for-profit organisations. PAR-13-300 (PAR-11-208).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 02 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$1,000,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-300.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-13-300>

Eligibility profile

Country of applicant institution: Any

Disciplines

Health & Medical Informatics; Clinical Medicine; Bioinformatics; Administrative Big Data & Informatics; HIV/Aids; Business Big Data & Informatics; Libraries & Information Science; Informatics & Big Data; Health Systems; Translational Medicine; Computer Science & Informatics; Public Health; Public Health, Health Services & Primary Care

Contact Details

NLM Extramural Programmes
6705 Rockledge Drive
Rockledge 1, Suite 301
Bethesda, MD 20892
Tel: +1 301 594 4882
Email: simh@mail.nih.gov

EPIDEMIOLOGY OF DRUG ABUSE (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related epidemiology of drug abuse grants. These R01 grants support Aids-related projects that enhance understanding of the nature, extent, distribution, aetiology, comorbidities and consequences of drug use, abuse and addiction across individuals, families, communities and diverse population groups. Projects should aim to fill knowledge gaps related to changing patterns in drug use, associated factors and consequences in populations, including the following:

- individual, familial and environmental factors associated with drug use;
- interplay of factors that exacerbate or mitigate risk for drug initiation, addiction, desistence, recovery and relapse;
- co-occurring psychiatric conditions, behaviours and associated problems;
- indicators and mechanisms of risk, vulnerability and health disparities among and between subpopulations;
- developmental and life course trajectories related to the aetiology and natural history of drug use;



- need for, access to and utilisation of drug abuse prevention and treatment services and the social, community and organisational factors that influence intervention development, availability and effectiveness.
- public health impacts of the attitudes, availability, behaviours and products, resulting from the shifting marijuana policy environment.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This funding opportunity announcement utilises the NIH research project grant (R01) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-15-001 that encourages applications under the NIH exploratory or developmental (R21) and PA-15-002 that encourages applications under the NIH small research grant R03 mechanism.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-15-003 (replaces PA-11-230).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Oct 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-003.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-15-003>

Eligibility profile

Country of applicant institution: Any

Disciplines

Social Psychology; Public Health; Epidemiology; Pathogenesis; Addiction; Health Psychology; Social Aspects of Mental Health; Health Systems, Risk Management; Psychology; Sexual Risk Taking; Social Exclusion & Isolation; Public Health, Health Services & Primary Care; Compulsive Behaviour; Prognosis & Natural History of Disease; Social Work & Social Policy; Education; Poverty in Developing Countries; HIV/Aids; Equal Educational Opportunity; Primary Care; Drug & Substance Abuse

Contact Details

NIDA
6001 Executive Boulevard
Room 5213
Bethesda, MD 20892-9561
Tel: +1 301 443 6504
Email: lopezmar@nida.nih.gov

EPIDEMIOLOGY OF DRUG ABUSE (R21): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related epidemiology

of drug abuse grants. These Aids-related R21 grants support research projects that enhance



understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, abuse, and addiction across individuals, families, age groups, gender, communities, and diverse population groups. Projects should aim to fill knowledge gaps related to changing patterns in drug use, associated factors and consequences in populations, including, but not limited to:

- individual, familial, and environmental factors associated with drug use;
- interplay of factors that exacerbate or mitigate risk for drug initiation, addiction, desistence, recovery, and relapse;
- co-occurring psychiatric conditions, behaviours and associated problems;
- indicators and mechanisms of risk, vulnerability, and health disparities among and between sub-populations;
- developmental and life course trajectories related to the aetiology and natural history of drug use;
- need for, access to, and utilisation of drug abuse prevention and treatment services, and the social, community, and organisational factors that influence intervention development, availability, and effectiveness.
- public health impacts of the attitudes, availability, behaviours, and products, resulting from the shifting marijuana policy environment. This funding opportunity announcement will utilise the NIH exploratory/developmental (R21) award mechanism and runs in parallel with funding opportunity announcements of identical scientific scope, PA-15-001 that encourages applications under the NIH research project mechanism (R01) and PA-15-002 that encourages applications under the NIH small research grant R03 mechanism.

Direct costs are limited to US\$275,000 over an R21 two-year period, with no more than

US\$200,000 in direct costs allowed in any single year. Eligible applicants include both domestic and foreign public or private institutions as well as non-profit and for-profit organisations. PA-15-001 (replaces PA-11-231)

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Oct 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-001.html>

Application form:

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

Eligibility profile

Country of applicant institution: Any

Disciplines

Diagnostic Sciences; Epidemiology; Social Behaviour & Attitudes; Sociology; Behavioural Medicine; Economic & Social Environment; Youth & Adolescents; Health Disparities; Drug & Substance Abuse; Molecular Genetics; Child Development; Psychopathology; Medical Sociology; Population Studies, Medical; Public Health, Health Services & Primary Care; Social Problems; Psychology; HIV/Aids; Adolescent Paediatrics

Contact Details

DESPR

National Institute on Drug Abuse, NIH/DHHS

6001 Executive Boulevard, Room 5185, MSC 9589

Bethesda MD 20892-9589

Tel: +1 301 443 6504

Email: lopezmar@nida.nih.gov

EPIDEMIOLOGY OF DRUG ABUSE (R03): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related epidemiology of drug abuse grants. This Aids-related R03 funding opportunity announcement supports projects that enhance understanding of the nature, extent, distribution, aetiology, comorbidities and consequences of drug use, abuse and addiction across individuals, families, communities, and diverse population groups. Projects should aim to fill knowledge gaps related to changing patterns in drug use, associated factors and consequences in populations, including, but not limited to:

- individual, familial, and environmental factors associated with drug use;
- interplay of factors that exacerbate or mitigate risk for drug initiation, addiction, desistence, recovery, and relapse;
- co-occurring psychiatric conditions, behaviours and associated problems;
- indicators and mechanisms of risk, vulnerability, and health disparities among and between sub-populations;
- developmental and life course trajectories related to the aetiology and natural history of drug use;
- need for, access to, and utilisation of drug abuse prevention and treatment services, and the social, community, and organisational factors that influence intervention development, availability, and effectiveness.
- public health impacts of the attitudes, availability, behaviours, and products, resulting from the shifting marijuana policy environment.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. This funding opportunity announcement uses the NIH small research grant (R03) award

mechanism and runs in parallel with opportunities of identical scientific scope: PA-15-001, which solicits applications under the NIH exploratory and developmental (R21) mechanism, and PA-15-003, which solicits applications under the NIH research project grant (R01) mechanism.

Funding is worth up to US\$50,000 per year for a maximum project period of two years.

Ref: PA-15-002 (replaces PA-11-232).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Oct 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-002.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true?oppNum=PA-15-002>

Eligibility profile

Country of applicant institution: Any

Disciplines

Health Psychology; Social Psychology; Pathogenesis; Public Health, Health Services & Primary Care; Equal Educational Opportunity; Sexual Risk Taking; Public Health; Drug & Substance Abuse; Health Systems, Risk Management; Addiction; Epidemiology; Prognosis & Natural History of Disease; Poverty in Developing Countries;



Primary Care; Social Aspects of Mental Health; Social Exclusion & Isolation; Education; HIV/Aids; Psychology; Compulsive Behaviour; Social Work & Social Policy

Contact Details

DESPR

National Institute on Drug Abuse,
NIH/DHHS
6001 Executive Boulevard, Room 5185, MSC
9589
Bethesda, MD 20892-9589
Tel: +1 301 443 6504
Email: lopezmar@nida.nih.gov

SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R03): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related secondary analyses of existing alcohol epidemiology data (R03) grants. These R03 grants support Aids-related, investigator-initiated research projects that either analyse previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. The goal is to enhance understanding of patterns of alcohol consumption and the epidemiology of alcohol-related problems.

This funding opportunity announcement uses the small grant programme (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-338 that encourages applications under the research project grant (R01) mechanism and PA-14-336 that encourages applications under the exploratory/developmental (R21) mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Grants are worth up to US\$50,000 per year for direct costs over a maximum period of two years.

Ref: PA-14-337 (replaces PA-11-309).

Closing date: 07 Sep 16

Deadline information: Applications open on 24 September 2014 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September 2015 until 8 September 2017.

Posted date: 10 Sep 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-337.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-337>

Eligibility profile

Country of applicant institution: Any



Disciplines

Ethnic Groups; Pathogenesis; Social Work & Social Policy; Economic & Social Environment; Population Studies, Medical; Epidemiology; Allied Health Professions; HIV/Aids; Traumatology, Accidents & Injury; Primary Care; Data Analysis; Diagnostic Sciences; Alcoholism; Public Health, Health Services & Primary Care

Contact Details

NIAAA
6000 Executive Boulevard
Willco Building
Bethesda, MD 20892-7003
Tel: +1 301 443 0633
Email: zhaw@mail.nih.gov

S ECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R01): AIDS-RELATED NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related secondary analyses of existing alcohol epidemiology data (R01) grants. These R01 grants support Aids-related, investigator-initiated research projects that either analyse previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. The goal is to enhance understanding of patterns of alcohol consumption and the epidemiology of alcohol-related problems.

This funding opportunity announcement uses the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-337 that encourages applications under the small grant (R01) mechanism and PA-14-336 that encourages applications under the exploratory/developmental (R21) mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-338 (replaces PA-11-308).

Closing date: 07 Sep 16

Deadline information: Applications open on 24 September 2014 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September 2015 until 8 September 2017.

Posted date: 10 Sep 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-338.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PAR-14-338>

Eligibility profile

Country of applicant institution: Any



Disciplines

Alcoholism; Public Health, Health Services & Primary Care; Pathogenesis; HIV/Aids; Social Work & Social Policy; Data Analysis; Economic & Social Environment; Primary Care; Ethnic Groups; Population Studies, Medical; Allied Health Professions; Diagnostic Sciences; Traumatology, Accidents & Injury; Epidemiology

Contact Details

NIAAA
6000 Executive Boulevard
Willco Building
Bethesda, MD 20892-7003
Tel: +1 301 443 0633
Email: zhaw@mail.nih.gov

BEHAVIOURAL OR SOCIAL INTERVENTION CLINICAL PLANNING GRANT (R34): AIDS-RELATED *NIH: National Institute of Dental and Craniofacial Research*

Description:

The National Institute of Dental and Craniofacial Research invites applications for its Aids-related NIDCR behavioural or social intervention clinical planning grant (R34). These R34 Aids-related grants support activities that include:

- the development of the behavioural or social intervention manual and procedures for training interventionists;
- development of the clinical protocol that will guide a subsequent clinical trial;
- the tools for data management, participant safety and operational oversight;
- other activities to prepare for a subsequent clinical trial.

R34 applications preparing for a behavioural or social intervention study may involve human subjects as part of small-scale testing of the feasibility and acceptability of the interventions, measures, methods and training approaches.

Eligible applicants include domestic and foreign public or private institutions and non-profit or for-profit organisations.

Grants are worth up to US\$150,000 for a period of maximum of one year.

PAR-14-342 (replaces PAR-11-338)

Closing date: 07 Sep 16

Deadline information: Applications open on 21 October 2014 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 22 Sep 14

Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$150,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-342.html>

Application form:

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

Eligibility profile

Country of applicant institution: Any



Disciplines

Oral Medicine; Drug Design; Biochemical Markers; Biological Markers & Sensor Mechanisms; Dental Health & Hygiene; Diagnostic Sciences; Clinical Medicine; HIV/Aids; Dentistry; Clinical Chemistry

Contact Details

National Institute of Dental and Craniofacial Research
1DEM, Room 634, MSC 4878
6701 Democracy Boulevard
Bethesda, MD 20892-4878
Tel: +1 301 594 4814
Email: dclark2@nidcr.nih.gov

METHODOLOGY AND MEASUREMENT IN THE BEHAVIORAL AND SOCIAL SCIENCES (R01): AIDS-RELATED

NIH: Office of the Director

Description:

A total of 10 participating institutes and offices of the National Institutes of Health invite applications for their methodology and measurement in the behavioural and social sciences (R01): Aids-related funding opportunity announcement. This Aids-related announcement supports applications aimed at improving and developing methodology in the behavioural and social sciences through innovations in research designs, measurement, data collection and data analysis techniques. The purpose of this call is to advance the investigation of behavioural and social factors in health and disease and enhance the rigour and reproducibility of study results.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PAR-16-261, which solicits applications under the NIH exploratory or developmental (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed

project. The maximum project period is five years.

Ref: PAR-16-260 (replaces PAR-08-212).

Closing date: 07 Sep 16

Deadline information: Applications open 5 September 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2019.

Posted date: 17 May 16

Award type: Innovation grants, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-260.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Social Aspects of Mental Health; Behavioural Medicine; Research Methods in Sociology; Social Behaviour & Attitudes

**Contact Details**Email: deborah.young-hyman@nih.gov

Tel: +1 301 451 0724

R

RESEARCH TO ADVANCE VACCINE SAFETY (R01): AIDS-RELATED

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institutes of Allergy and Infectious Diseases, and the Centres for Disease Control invite applications for their research to advance vaccine safety (R01) funding opportunity announcement. This Aids-related announcement supports research that will contribute to the overall understanding of vaccine safety. Studies should address scientific areas potentially relevant to vaccine safety such as:

- physiological and immunological responses to vaccines and vaccine components;
- how genetic variations affect immune or physiological responses that may impact vaccine safety;
- identification of risk factors biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines;
- creation or evaluation of statistical methodologies for analysing data on vaccine safety, including data available from existing data sources such as passive reporting systems;
- the application of genomic or molecular technologies to improve knowledge of vaccine safety.

This funding opportunity will use the NIH research project grant (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-313, which encourages applications under the NIH

exploratory/developmental (R21) grant mechanism.

Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.

Budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-15-312 (replaces PA-12-037).

Closing date: 07 Sep 16

Deadline information: Applications open on 5 September, 2015 and are due by 5pm local time of applicant organisation every January 7, May 7, September 7 until 8 September, 2018.

Posted date: 29 Jul 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-312.html>

Application form:

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

Eligibility profile

Country of applicant institution: Any



Disciplines

Immunology; Immunisation Programmes & Vaccination; HIV/Aids

Contact Details

Tel: +1 240 627 3322

Email: bmulach@niaid.nih.gov

R ESearch TO ADVANCE VACCINE SAFETY (R21): AIDS-RELATED

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases, and Centres for Disease Control and Prevention invite applications for their research to advance vaccine safety (R21) funding opportunity announcement. This Aids-related announcement supports research that will contribute to the overall understanding of vaccine safety. Studies should address scientific areas potentially relevant to vaccine safety such as:

- physiological and immunological responses to vaccines and vaccine components;
- how genetic variations affect immune or physiological responses that may impact vaccine safety;
- identification of risk factors biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines;
- creation or evaluation of statistical methodologies for analysing data on vaccine safety, including data available from existing data sources such as passive reporting systems;
- the application of genomic or molecular technologies to improve knowledge of vaccine safety.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-312, which

solicits applications under the NIH research project grant (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Direct costs are limited to US\$275,000 over a two-year period, and no more than US\$200,000 may be requested in any year.

Ref: PA-15-313 (replaces PA-12-038)

Closing date: 07 Sep 16

Deadline information: Applications open on 16 September, 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.

Posted date: 29 Jul 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-313.html>

Application form:

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

Eligibility profile

Country of applicant institution: Any



Disciplines

Immunology; HIV/Aids; Immunisation
Programmes & Vaccination

Contact Details

Tel: +1 240 627 3322
Email: bmulach@niaid.nih.gov

P ILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN UROLOGIC DISORDERS (R21): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its Aids-related pilot and feasibility clinical research grants in urologic disorders (R21) funding opportunity announcement. This Aids-related announcement supports small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders research.

Studies should address important clinical and translational questions that are potentially of high clinical and public health impact.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-161, which also solicits applications under the R21 mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US\$275,000 in direct costs with a maximum of US\$200,00 in direct costs per year. The maximum project period is two years.

Ref: PAR-15-162 (reissue PAR-11-352).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 30 Mar 15

Award type: Directed grants to institutions, research groups etc, Innovation grants, Clinical trials

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-162.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275480>

Eligibility profile

Country of applicant institution: Any

Disciplines

Urology; HIV/Aids

Contact Details

NIDDK
BG 2DEM Room 627
6707 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 77717
Email: ziya.kirkali@nih.gov



S ECONDARY ANALYSES IN OBESITY, DIABETES, DIGESTIVE AND KIDNEY DISEASES (R21): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its secondary analyses in obesity, diabetes and digestive and kidney diseases (R21) funding opportunity announcement. This announcement supports the secondary analysis of existing data sets relevant to the following: diabetes and endocrine and metabolic diseases; genetic metabolic diseases; obesity, liver diseases; alimentary gastrointestinal tract diseases and nutrition; kidney, urologic and haematologic diseases. Innovative and high-risk applications with a likelihood for high impact are particularly encouraged.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US\$275,000 in direct costs, with up to US\$200,000 available for direct costs per year. The maximum project period is two years.

Ref: PA-15-169 (reissue of PA-12-125).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 02 Apr 15

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-169.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275615>

Eligibility profile

Country of applicant institution: Any

Disciplines

Diabetes; Gastroenterology; HIV/Aids; Hormones & Endocrinology; Nephrology & Kidneys; Metabolomics; Nutrition & Dietetics; Hepatology; Haematology; Obesity

Contact Details

NIDDK

BG 2DEM Room 659

6707 Democracy Boulevard

Bethesda MD 20817

Tel: +1 301 594 8879

Email: aynur.unalp-arida@nih.gov

P ILOT AND FEASIBILITY STUDIES IN PREPARATION FOR DRUG ABUSE PREVENTION TRIALS (R34): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse and the National institute on Alcohol Abuse and

Alcoholism invite applications for their pilot and feasibility studies in preparation for drug



and alcohol abuse prevention trials (R34) funding opportunity announcement. This Aids-related announcement supports pilot and feasibility testing of innovative new, revised or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings. It also supports pre-trial feasibility testing for prevention services and systems research. Of particular interest are prevention interventions targeting the healthcare system.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US\$450,000 in direct costs with up to US\$225,000 in direct costs per year.

The maximum project period is three years.

Ref: PA-15-177 (reissue of PA-12-171).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May and are due by 5pm local time of

applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 08 Apr 15

Award type: Directed grants to institutions, research groups etc, Clinical trials

Award amount max: \$450,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-177.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#search=true&oppNum=PA-15-177>

Eligibility profile

Country of applicant institution: Any

Disciplines

Preventive Medicine; Alcoholism; Drug & Substance Abuse; HIV/Aids

Contact Details

NIDA

NSC BG Room 5166

6001 Executive Boulevard

Rockville MD 20852

Tel: +1 301 443 8892

Email: lloydj2@nida.nih.gov

D RUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R21) AIDS-RELATED NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse invite applications for their drug discovery for nervous system disorders (R21) funding opportunity announcement. This Aids-related announcement aims to stimulate the discovery and preclinical testing of novel

compounds for the prevention and treatment of nervous system disorders. Projects aimed at the discovery of novel agents for ameliorating, modifying or correcting potential aberrations in brain signalling are encouraged. In addition, preference may be given to projects that explore novel approaches to identify



potential therapeutic agents and innovative therapeutic targets.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-16-041, which solicits applications under the (R01) grant mechanism. Application budgets are limited to US\$275,000 over two years, with no more than US\$200,000 in direct costs allowed in any single year.

Ref: PAR-16-042 (replaces PAR-13-049).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 May, 7 September and 7 January until 8 January 2019.

Posted date: 25 Nov 15

Award type: Innovation grants, Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-042.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Stroke & Cerebrovascular Disorders; Neuropharmacology; Central Nervous System; Movement Disorders; HIV/ Aids

Contact Details

Tel: +1 301 443 5288

Email: jdrisco1@mail.nih.gov

D RUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R01): AIDS-RELATED NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse invite applications for their drug discovery for nervous system disorders (R01) funding opportunity announcement. This Aids-related announcement aims to stimulate the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders. Projects aimed at the discovery of novel agents for ameliorating, modifying or correcting potential aberrations in brain signalling are encouraged. In addition, preference may be given to projects that explore novel approaches to identify potential therapeutic agents and innovative therapeutic targets.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

This funding opportunity uses the NIH R01 research project grant mechanism and runs in parallel with one of identical scientific scope, PAR-16-042, that solicits applications under the R21 grant mechanism.

Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-16-041 (replaces PAR-13-048).



Closing date: 07 Sep 16
 Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.
 Posted date: 25 Nov 15
 Award type: Innovation grants, Directed grants to institutions, research groups etc
 Award amount max: -
 Award budget total: -
 Website:
<http://grants.nih.gov/grants/guide/pa-files/PA-16-041.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Central Nervous System; Stroke & Cerebrovascular Disorders; HIV/Aids; Neuropharmacology; Movement Disorders

Contact Details

Tel: +1 301 443 5288

Email: jdrisco1@mail.nih.gov

BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R34): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the Office of Behavioral and Social Sciences Research invite applications for their Aids-related behavioural and integrative treatment development (R34) grants. The aim of this Aids-related programme is to encourage investigators to propose discrete well-defined projects within the domain of behavioural or integrated interventions that can be completed within three years. Projects of interest fall within the research domain of behavioural or integrated interventions targeting:

- substance abuse;
- prevention of acquisition or transmission of HIV infections among individuals in substance abuse treatment;
- promotion of adherence to substance abuse treatment, HIV and addiction medications;
- chronic pain.

Specific examples include studies focusing on stage one intervention generation and stage

one pilot or feasibility. Both should include the development of putative targets or moderators, mediators and change mechanisms. Stage one studies to generate or refine drug abuse treatment or adherence interventions and stage one research to boost effects and increase implementability of interventions with creative use of technology is also sought. The overarching goal is to encourage stage one research to produce maximally efficacious behavioural interventions to treat drug abuse, promote medication or treatment adherence and prevent HIV.

This funding opportunity announcement will use the R34 award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-16-074, which solicits applications under the R03 small grant mechanism, and PA-16-072, that solicits applications under the R01 research project grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.



Application budgets are limited to US\$450,000 over three years, with no more than US\$225,000 in direct costs allowed in any single year.

Ref: PA-16-073 (replaces PA-13-078).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 11 Jan 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-073.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Addiction; Chronic Pain; HIV/Aids; Drug & Substance Abuse; Behavioural Medicine

Contact Details

Tel: +1 301 443 3207

Email: aklinwm@mail.nih.gov

DEVELOPMENT AND CHARACTERISATION OF ANIMAL MODELS FOR AGEING RESEARCH (R01): AIDS-RELATED

NIH: National Institute on Aging

Description:

The National Institute on Aging invites Aids-related R01 applications for its development and characterisation of animal models for ageing research programme. The institute aims to promote Aids-related research under the R01 mechanism that develops, characterises, refines and enhances model systems for research on ageing. Studies that develop new model systems or refine existing models to maximise their value for ageing research will contribute to the understanding of normal changes in physiology and function with age and the onset, progression, therapeutics and prevention of age associated diseases. The objective of this programme is to enhance the biological resources and tools available to the research community for the study of biology of ageing.

This funding opportunity announcement will utilise the R01 award mechanism and runs in parallel with another FOA of identical scope,

PA-13-156 that solicits applications under the R21 mechanism. Application budgets are not limited, and the maximum project period is five years. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PA-13-155 (replaces PA-10-014).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation.

Deadlines on: 7 September 2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 25 Mar 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-155.html>



Application form:
<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-155>

Eligibility profile

Country of applicant institution: Any

Disciplines

Geriatrics & Gerontology; Animal Models;
 Biological Sciences; Biomolecular Modelling;
 Diagnostic Sciences; HIV/Aids; Human

Physiology; Cell Lines; Physiology;
 Biochemical Markers

Contact Details

Division of Aging Biology (DAB)
 National Institute on Aging
 7201 Wisconsin Avenue, GWY BG Room
 2C231
 Bethesda, MD 20892-9205
 Tel: +1 301 402 7749
 Email: mmurthy@mail.nih.gov

N IEI CLINICAL STUDY PLANNING GRANT PROGRAMME (R34): AIDS-RELATED NIH: National Eye Institute

Description:

The National Eye Institute invites applications for its clinical study planning grant programme (R34): Aids-related. This Aids-related announcement is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed manual of procedures. In addition, this programme is designed to:

- permit early peer review of the rationale for the proposed clinical trial or epidemiology study;
- support the development of other essential elements of the clinical study.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$150,000 in direct costs per year. The maximum period is two years.

Ref: PA-16-038 (replaces PAR-13-073).

Closing date: 07 Sep 16

Deadline information: Applications are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 19 Nov 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$300,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-038.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Epidemiology; Vision Science; Eye Diseases; Drug Design; Sensory Systems

Contact Details

Tel: +1 301 451 2020
 Email: everettd@mail.nih.gov



A CCELERATING THE PACE OF DRUG ABUSE RESEARCH USING EXISTING DATA (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute of Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the National Cancer Institute invite applications for their Aids-related accelerating the pace of drug abuse research using existing data (R01) programme. This Aids-related call supports the innovative analysis of existing social science, behavioural, administrative and neuroimaging data to study the etiology and epidemiology of drug-using behaviours and related disorders, prevention of drug use and HIV, and health service use.

Domestic and foreign public and private non-profit organisations and for-profit organisations may apply as well as domestic government institutions.

Direct costs are limited to US\$500,000 per year over a maximum period of five years.

Ref: PAR-16-234 (replaces PAR-13-080).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation

every 7 January, 7 May and 7 September until 8 May 2019. Deadlines on: 7 September 2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 11 May 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-234.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Addiction; HIV/Aids; Social Problems; Behavioural Medicine

Contact Details

Tel: +1 301 443 6504

Email: marsha.lopez@nih.gov

O BESITY POLICY EVALUATION RESEARCH (R01): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

A total of six institutes and offices of the National Institutes of Health invite applications for their obesity policy evaluation research (R01): Aids-related funding opportunity announcement. This Aids-related announcement encourages evaluations of large scale policies or programmes that are expected to influence

obesity-related behaviours or weight outcomes in an effort to prevent or reduce obesity. This FOA does not support the initiation and implementation of new programmes or policies; rather, it is intended to support evaluation of the effectiveness of programmes or policies that are being or will



be implemented regardless of NIH grant funding.

Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations.

Applications budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-16-165 (replaces PA-13-110).

Closing date: 07 Sep 16

Deadline information: Applications open 5 May 2016 and due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 05 Apr 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-165.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Nutrition & Dietetics; HIV/Aids; Sports & Exercise Studies; Dietary Guidelines; Food Consumption; Obesity

Contact Details

Tel: +1 301 594 4728

Email: hunterchristine@nidk.nih.gov

NIDCR SMALL RESEARCH GRANTS FOR DATA ANALYSIS AND STATISTICAL METHODOLOGY APPLIED TO GENOME-WIDE DATA (R03): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research invites proposals for its Aids-related small research grants for data analysis and statistical methodology applied to genome-wide data (R03). This Aids-related funding opportunity announcement will support meritorious research projects that involve statistical analysis of existing genome-wide data relevant to human dental, oral or craniofacial conditions or traits. This FOA supports statistical analysis of data derived from NIDCR-funded studies or of data derived from other sources. Experimental validation of new methods or statistical analyses may be proposed but the focus of the project should be on statistical methods development or analysis. Development of statistical methodology appropriate for analysing genome-wide data relevant to

human dental, oral or craniofacial conditions or traits may also be proposed.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions. Application budgets are limited to US\$200,000 over a maximum project period of two years and no more than US\$200,000 may be requested in any single year.

Ref: PAR-16-070 (replaces PAR-13-044).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 11 Jan 16



Award type: Directed grants to institutions, research groups etc

Award amount max: \$200,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-070.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Statistics; Dentistry; Craniofacial Disorders; Human Genome; HIV/Aids; Genomics; Data Analysis; Oral & Maxillofacial Surgery

Contact Details

Tel: +1 301 594 4846

Email: emily.harris@mail.nih.gov

EXTENDED DEADLINE: NINDS PHASE III INVESTIGATOR-INITIATED EFFICACY TRIALS (U01): AIDS-RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:

The National Institute of Neurological Disorders and Stroke has extended the expiration date for its NINDS phase III investigator-initiated efficacy clinical trials (U01): Aids-related funding opportunity announcement. The previous expiration date of 8 September 2016 has been extended to 8 January 2017. All other call information remain the same.

This Aids-related announcement supports investigator-initiated multi-site phase III randomised, controlled clinical trials which address research questions related to the mission and goals of NINDS. The clinical trials may evaluate an experimental intervention in comparison with a standard or control intervention, or compare two or more existing treatments. The programme supports drugs, biologics and devices, as well as surgical, behavioural and rehabilitation therapies. Trials should recruit study subjects from two or more geographically distinct enrolment sites, or centres.

Eligible organisations include domestic and foreign public and private non-profit

organisations and for-profit organisations and academic institutions.

Application budgets are not limited, but need to reflect the actual needs of the project. The maximum project period is five years. Ref: PAR-13-278 (replaces PAR-11-173).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 25 May 16

Award type: Clinical trials

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/notice-files/NOT-NS-16-028.html>

Eligibility profile

Country of applicant institution: Any

Disciplines



Biologics; Medical Devices; Pharmacy & Pharmacology; Behavioural Medicine; Surgery & Intensive Care

Contact Details

Tel: +1 301 496 0870

Email: gilbertp@ninds.nih.gov

EXTENDED DEADLINE: NINDS EXPLORATORY CLINICAL TRIALS (R01) - AIDS-RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:

The National Institute of Neurological Disorders and Stroke has extended the expiration date for its NINDS exploratory clinical trials (R01): Aids-related funding opportunity announcement. The previous expiration date of 8 May 2016 has been extended to 8 January 2017. All other call information remains the same.

This announcement supports exploratory clinical trials that address research questions related to the mission and goals of NINDS. The clinical trials may evaluate drugs, biologics, devices, or surgical, behavioural or rehabilitation therapies.

Public and private non-profit organisations and for-profit organisations worldwide may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-13-281 (replaces PAR-10-199).

Closing date: 07 Sep 16

Deadline information: Application due by 5pm local time of applicant organisation every 7 January 7 May and 7 September until 8 January 2017.

Posted date: 26 May 16

Award type: Clinical trials

Website:

<http://grants.nih.gov/grants/guide/notice-files/NOT-NS-16-029.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Pharmacy & Pharmacology; HIV/Aids; Biologics; Medical Devices; Behavioural Medicine

Contact Details

Tel: +1 301 496 0870

Email: gilbertp@ninds.nih.gov

COLLABORATIVE CLINICAL VISION RESEARCH PROJECT GRANT (U10): AIDS-RELATED

NIH: National Eye Institute

Description:

The National Eye Institute invites Aids-related applications for its collaborative clinical vision research project grant (U10).

This Aids-related U10 funding opportunity announcement supports investigator-initiated clinical vision research projects, including



multi-centre clinical trials and other complex or high-risk clinical vision research studies.

This funding opportunity announcement will use the U10 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-097, PAR-14-098, PAR-14-099 and PAR-14-100, each of which invites applications under the UG1 mechanism.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-096 (replaces PAR-10-207).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of the organisation, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 13 Feb 14

Award type: Research centres, Directed grants to institutions, research groups etc, Clinical trials

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-10-207.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do>

Eligibility profile

Country of applicant institution: Any

Disciplines

Epidemiology; Diagnostic Sciences;
Optometry; Drug Design; Eye Diseases;
Vision Science; Sensory Systems; HIV/ Aids

Contact Details

NEI

5635 Fishers Lane

Bethesda, MD 20892-9300

Tel: +1 301 451 2020

Email: everettd@mail.nih.gov

FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAs IN DRUG ADDICTION (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related functional genetics, epigenetics and non-coding RNAs in drug addiction (R01) programme. This Aids-related R01 funding opportunity announcement encourages basic functional genomic research in two areas: functional validation to determine which candidate genes or variants have an authentic role in addictive processes, and detailed elucidation of the molecular pathways and processes modulated by candidate genes or variants,

particularly for those genes with an unanticipated role in addiction.

This FOA will use the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-013, which encourages applications under the R21 exploratory/developmental grant mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.



Applications budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PA-14-014 (reissue of PA-11-033).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 06 Dec 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-014.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-14-014>

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse; Molecular Genetics; Disease Models; Psychology; Addiction; Electrophysiology; Genomics; Ribonucleic Acid, RNA; Proteomics & Molecular Interactions; HIV/Aids; Physiology; Neurotransmitters; Epigenetics; Neuroimaging; Primary Care; Behavioural Medicine; Biochemical Markers; Public Health, Health Services & Primary Care; Diagnostic Sciences; Biological Markers & Sensor Mechanisms; Pharmacokinetics; Biological Sciences; Immunological & Bioassay Methods

Contact Details

NIDA

6001 Executive Boulevard

Bethesda, MD 20892

Tel: +1 301 435 1020

Email: satterleej@nida.nih.gov

GRAND OPPORTUNITY IN MEDICATIONS DEVELOPMENT FOR SUBSTANCE-USE DISORDERS (U01): AIDS RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its its-related grand opportunity in medications development for substance-use disorders (U01). This Aids-related U01 funding opportunity announcement will support a diverse array of preclinical and clinical projects to accelerate the development of medication for the treatment of substance-use disorders. The goal is to fund medication studies that will have a high impact and quickly yield the necessary results to advance medications closer to approval by the US Food and Drug Administration. The aim is to enable critical

medications development studies that would not be possible using traditional means.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

The NIH intends to commit US\$10 million to fund two to three awards in fiscal year 2013. Application budgets are limited to US\$5m a year over a three-year period. PAR-13-270

Closing date: 07 Sep 16



Deadline information: Applications due by 5pm local time of applicant organisation.

Deadlines on: 7 May 2014, 7 September 2014, 7 May 2015, 7 September 2015, 7 May 2016, 7 September 2016.

Posted date: 12 Jul 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$15,000,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-270.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-270>

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug Design; HIV/Aids; Public Health, Health Services & Primary Care; Diagnostic Sciences; Clinical Pharmacy & Pharmacology; Human Biological Sciences; Pharmaceutical Drugs; Drug & Substance Abuse; Pharmacy & Pharmacology; Clinical Medicine; Primary Care

Contact Details

Division of Pharmacotherapies and Medical Consequences of Drug Abuse
NIDA
NIH
9000 Rockville Pike
Bethesda, MD 20892
Tel: +1 301 443 8639
Email: imontoya@mail.nih.gov

FAMILY AND INTERPERSONAL RELATIONSHIPS IN AN AGEING CONTEXT (R01): AIDS-RELATED NIH: National Institute on Aging

Description:

The National Institute on Aging invites applications for its family and interpersonal relationships in an ageing context (R01) grants. This Aids-related R01 funding opportunity announcement encourages innovative, hypothesis-driven research that can expand understanding of the role and impact of families and interpersonal relationships on health and well-being in midlife and older age. This FOA encourages research that takes a life span perspective, including studies which focus on early life influences on later life outcomes and on processes in midlife that impact subsequent trajectories of health and function. NIA is particularly interested in research that can inform the design of interventions that target the maintenance and improvement of ageing-relevant outcomes for the following: satisfying, high quality intimate relationships, compliance and adherence to healthy

behaviours; adaptive caregiving relationships, shared decision-making and economic security.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants requesting US\$500,000 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The maximum project period is five years.

Ref: PA-15-042 (reissue of PA-11-128).

Closing date: 07 Sep 16

Deadline information: Applications open on 5 January 2015 and are due by 5pm local time



of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 21 Nov 14

Award type: Innovation grants, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-042.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-15-042>

Eligibility profile

Country of applicant institution: Any

Disciplines

Psychology of Ageing; HIV/Aids; Geriatrics & Gerontology

Contact Details

National Institute on Aging
NIH

GWY BG Room 533

7201 Wisconsin Avenue

Bethesda MD 20814

Tel: +1 301 402 4156

Email: melissa.gerald@nih.gov

PREDICTIVE MULTISCALE MODELS FOR BIOMEDICAL, BIOLOGICAL, BEHAVIORAL, ENVIRONMENTAL AND CLINICAL RESEARCH (INTERAGENCY U01): AIDS-RELATED

NIH: National Institute of Biomedical Imaging and Bioengineering

Description:

A total of 23 participating institutes and centres of the National Institutes of Health, the US Army Research Office, the Department of Energy, the US Food and Drug Administration, the National Aeronautics and Space Administration, the National Science Foundation and the Office of Naval Research invite applications for their predictive multi scale models for biomedical, biological, behavioural, environmental and clinical research (interagency U01) grants. This Aids-related funding opportunity aims to support the development of multi scale models to accelerate biological, biomedical, behavioural, environmental and clinical research. This FOA supports the development of non-standard modelling methods and experimental approaches to facilitate multi scale modelling and active participation in community-driven activities through the Multiscale Modeling Consortium.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Direct costs are limited to US\$500,000 per year and the maximum project period is five years.

Ref: PAR-15-085 (Reissue of PAR-11-203)

Closing date: 07 Sep 16

Deadline information: Applications due by 5 pm local applicant's time every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 09 Jan 15

Award type: Innovation grants, Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: \$2,500,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-085.html>

Application form:

<http://www.grants.gov/web/grants/applicant>



[s/download-application-package.html#download=true?oppNum=PA-R-15-085](https://www.nih.gov/grants/apply/download-application-package.html#download=true?oppNum=PA-R-15-085)

Eligibility profile

Country of applicant institution: Any

Disciplines

Computer Simulation & Modelling; Medical Models, Mathematical; Disease Models;

Computational Biology; Biomolecular Modelling; HIV/Aids; Data Analysis

Contact Details

NIBIB
BG 2 Dem Room 200
6707 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 451 4778
Email: grace.peng@nih.gov

S PATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R01) AIDS-RELATED NIH: National Cancer Institute

Description:

The National Cancer Institute and the National Institute of Environmental Health Sciences invite applications for their Aids-related spatial uncertainty: data, modeling and communication (R01) grants. This Aids-related R01 funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualise the nature and consequences of spatial uncertainty.

This FOA uses the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-009 and PA-15-011, that solicit applications under the exploratory and developmental grant (R21) and the small grant award (R03) mechanisms, respectively. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-15-010 (replaces PA-11-238).

Closing date: 07 Sep 16

Deadline information: Applications by 5pm local time of applicant organisation every, 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 13 Oct 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-010.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-15-010>

Eligibility profile

Country of applicant institution: Any

Disciplines

Preventive Medicine; Prognosis & Natural History of Disease; Clinical Medicine; Health & Medical Informatics; HIV/Aids; Disease Control; Public Health, Health Services & Primary Care; Health Systems, Risk



Management; Social Work & Social Policy; Population Studies, Medical; Blood Tests; Demography; Computer Science & Informatics; Diagnostic Sciences; Libraries & Information Science; Informatics & Big Data; Epidemiology; Bioinformatics; Primary Care

Contact Details

NCI
6116 Executive Boulevard, Room 504
Bethesda, MD 20852
Tel: +1 240 276 6851
Email: li.zhu@nih.gov

S PATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R21) AIDS-RELATED

NIH: National Cancer Institute

Description:

The National Cancer Institute and the National Institute of Environmental Health Sciences invite applications for their Aids-related spatial uncertainty: data, modeling and communication (R21) grants. This Aids-related R21 funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualise the nature and consequences of spatial uncertainty.

This FOA uses the NIH exploratory and developmental grant (R21) mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-010 and PA-15-011, that solicit applications under the research project grant (R01) award and the small grant (R03) award mechanisms, respectively. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Funding is worth up to US\$275,000 over a maximum two-year project period.

Ref: PA-15-009 (replaces PA-11-239).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation,

every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 13 Oct 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-009.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-15-009>

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine; Health Systems, Risk Management; Blood Tests; Health & Medical Informatics; Informatics & Big Data; Bioinformatics; Demography; Disease Control; Computer Science & Informatics; Diagnostic Sciences; Population Studies, Medical; Epidemiology; Prognosis & Natural History of Disease; Primary Care; Libraries & Information Science; Social Work & Social Policy; HIV/Aids; Public Health, Health Services & Primary Care; Preventive Medicine



Contact Details

NCI
6116 Executive Boulevard, Room 504

Bethesda, MD 20852
Tel: +1 240 276 6851
Email: li.zhu@nih.gov

S PATIAL UNCERTAINTY: DATA, MODELLING AND COMMUNICATION (R03) AIDS-RELATED NIH: National Cancer Institute

Description:

The National Cancer Institute and the National Institute of Environmental Health Sciences invite applications for their Aids-related spatial uncertainty: data, modelling and communication (R03) grants. This Aids-related R03 funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualise the nature and consequences of spatial uncertainty.

This FOA uses the NIH small grant (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-009 and PA-15-010, that solicit applications under the exploratory and developmental grant (R21) and the research project grant (R01) award mechanisms, respectively. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Funding is worth up to US\$50,000 per year over a maximum two-year project period.

Ref: PA-15-011 (replaces PA-11-240).

Closing date: 07 Sep 16
Deadline information: Applications due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September annually until 8 January 2018.
Posted date: 13 Oct 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-011.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-15-011>

Eligibility profile

Country of applicant institution: Any

Disciplines

Health & Medical Informatics; Preventive Medicine; Libraries & Information Science; Prognosis & Natural History of Disease; Epidemiology; Primary Care; Demography; Disease Control; HIV/Aids; Public Health, Health Services & Primary Care; Computer Science & Informatics; Population Studies, Medical; Informatics & Big Data; Health Systems, Risk Management; Bioinformatics; Social Work & Social Policy

Contact Details

NCI
6116 Executive Boulevard, Room 504
Bethesda, MD 20852
Tel: +1 240 276 6851
Email: li.zhu@nih.gov



MECHANISTIC STUDIES OF PAIN AND ALCOHOL DEPENDENCE (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their Aids-related mechanistic studies of pain and alcohol dependence (R01) research project grant. This Aids-related R01 funding opportunity announcement supports research in the mechanistic studies on the relationship between excessive alcohol drinking, alcohol dependence and pain with the aim of understanding genetic, pharmacological and learning mechanisms underlying the association between the propensity to drink alcohol excessively and pain responses. Application budgets are not limited, but need to reflect the actual needs of the project. The maximum project period is five years. Applicants requesting US\$500,000 or more in direct costs in any year, excluding consortium facilities and administrative costs, must contact NIH programme staff at least six weeks before submitting the application.

Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.

Ref: PA-15-026 (replaces PA-11-267).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation

every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 13 Nov 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://www.grants.nih.gov/grants/guide/pa-files/PA-15-026.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-15-0267>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Pain Management; Chronic Pain; Alcoholism

Contact Details

NIAAA

BG 5635FL RM 2052

5635 Fishers Ln

Rockville, MD 20852

Tel: +1 301 443 1192

Email: regunathans@mail.nih.gov

TARGETED BASIC BEHAVIOURAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R01)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for

their targeted basic behavioural and social science and intervention development for HIV prevention and care (R01) grants. This R01



funding opportunity announcement aims to provide a global outline of areas for innovative, targeted basic behavioural and social science research and intervention development research to reduce the number of new HIV infections and improve the overall health of those living with HIV and encourage research grant applications in these areas.

This FOA encourages research designed to:

- conduct basic behavioural and social science research that is needed to advance the development of HIV prevention and care interventions;
- translate and operationalise the findings from these basic studies to develop interventions and assess their feasibility;
- conduct tests of the efficacy of HIV prevention and care interventions.

This FOA uses the NIH research (R01) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-128, that encourages applications under the NIH exploratory/developmental (R21) grant mechanism. Application budgets are not limited but need to reflect the actual needs of the project. The total project period may not exceed five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.

Ref: PA-14-127 (replaces PA-11-275).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-127.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=P A-14-127>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Psychology; Behavioural Medicine; Health Counselling; Public Health, Health Services & Primary Care; Health Systems; Biomedical Engineering; Pharmaceutical Drugs; Clinical Medicine; Primary Care; Social Work & Social Policy; Preventive Medicine; Diagnostic Sciences

Contact Details

NIMH
NSC BG
Room 6118
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 433 6100
Email: ebrouwer@mail.nih.gov



TARGETED BASIC BEHAVIOURAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R21)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their targeted basic behavioural and social science and intervention development for HIV prevention and care (R21) grants. This R21 funding opportunity announcement aims to provide a global outline of areas for innovative, targeted basic behavioural and social science research and intervention development research to reduce the number of new HIV infections and improve the overall health of those living with HIV and encourage research grant applications in these areas.

This FOA encourages research designed to:

- conduct basic behavioural and social science research that is needed to advance the development of HIV prevention and care interventions;
- translate and operationalise the findings from these basic studies to develop interventions and assess their feasibility;
- conduct tests of the efficacy of HIV prevention and care interventions.

This FOA uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-127, that encourages applications under the NIH research project (R01) grant mechanism. Direct costs are limited to US\$275,000 over a two year project period, with no more than US\$200,000 allowed in any single year. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.

Ref: PA-14-128 (replaces PA-11-277).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-128.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-128>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Public Health, Health Services & Primary Care; Biomedical Engineering; Clinical Medicine; Preventive Medicine; Social Work & Social Policy; Psychology; Health Systems; Pharmaceutical Drugs; Behavioural Medicine; Primary Care; Diagnostic Sciences; Health Counselling

Contact Details

NIMH
NSC BG
Room 6118
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 433 6100
Email: ebrouwer@mail.nih.gov



SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIOURAL AND SOCIAL SCIENCES

(R01): AIDS-RELATED

NIH: Office of the Director

Description:

A total of 11 participating institutes of the National Institutes for Health invite applications for their systems science and health in the behavioural and social sciences (R01) grants. This Aids-related R01 funding opportunity announcement seeks to increase the breadth and scope of topics that can be addressed with systems science methodologies. This FOA calls for research projects that are applied or basic in nature, including methodological and measurement development, have a human behavioural or social science focus and employ methodologies suited to addressing the complexity inherent in behavioural and social phenomena, referred to as systems science methodologies. Additionally, this FOA seeks to promote interdisciplinary collaboration among health researchers and experts in computational approaches to further the development of modelling- and simulation-based systems science methodologies and their application to important public health challenges. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity announcement uses the NIH research project R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-15-047 that solicits applications under the exploratory/developmental research grant award (R21) mechanism. Application budgets are not limited but need to reflect actual needs of the proposed project. Applicants requesting US\$500,000 or more in direct costs in any year must contact NIH programme staff at least six

weeks before submitting the application. The maximum project period is five years.

Ref: PAR-15-048 (Reissue of PAR-11-314).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 24 Nov 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-048.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PAR-15-048>

Eligibility profile

Country of applicant institution: Any

Disciplines

Social Problems; HIV/Aids; Social Sciences; Research Methods in Sociology

Contact Details

NCI
BG 9609 Room 3E602
9609 Medical Centre DR
Rockville, MD 20850
Tel: +1 301 402 1146
Email: wireley@mail.nih.gov



SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIOURAL AND SOCIAL SCIENCES

(R21): AIDS-RELATED

NIH: Office of the Director

Description:

A total of 11 participating institutes of the National Institutes for Health invite applications for their systems science and health in the behavioural and social sciences (R21) grants. This Aids-related R21 funding opportunity announcement seeks to increase the breadth and scope of topics that can be addressed with systems science methodologies. This FOA calls for research projects that are applied or basic in nature, including methodological and measurement development, have a human behavioural or social science focus and employ methodologies suited to addressing the complexity inherent in behavioural and social phenomena, referred to as systems science methodologies. Additionally, this FOA seeks to promote interdisciplinary collaboration among health researchers and experts in computational approaches to further the development of modelling- and simulation-based systems science methodologies and their application to important public health challenges. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. This funding opportunity announcement uses the NIH exploratory/developmental R21 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-15-048 that solicits applications under the research project grant award (R01) mechanism. Application budgets are limited to US\$275,000 over the two-year R21 period, with no more than US\$200,000 in any year. The maximum project period is two years.

Ref: PAR-15-047 (Reissue of PAR-11-315).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 24 Nov 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-047.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PAR-15-047>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Social Sciences; Research Methods in Sociology; Social Problems

Contact Details

NCI

BG 9609 Room 3E602

9609 Medical Centre DR

Rockville MD 20850

Tel: +1 301 402 1146

Email: wireley@mail.nih.gov



BUILDING GENETICS AND GENOMIC KNOWLEDGE ABOUT DENTAL, ORAL AND CRANIOFACIAL DISEASES AND DISORDERS (R01): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research invites applications for its building a genetic and genomic knowledge base in dental, oral and craniofacial diseases and disorders (R01) grants. This Aids-related R01 funding opportunity announcement encourages research into dental, oral, and craniofacial diseases and disorders for which there is evidence for genetic heritability but for which there is no strong understanding of the genetics or genomics of the disease or disorder.

Research areas may include identification of promising areas of the genome, and characterisation and elucidation of the functions of genetic variants that affect disease risk in humans. The goal is to drive development of effective diagnostic, therapeutic, and preventive approaches. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

The maximum project period is five years.

Ref: PA-14-347 (replaces PA-11-317).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 23 Sep 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-347.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-347>

Eligibility profile

Country of applicant institution: Any

Disciplines

Medical Genetics; Special Needs Dentistry; Diagnostic Sciences; Public Health, Health Services & Primary Care; Genomics; Genetics & Systems Biology; Allied Health Professions; Genetic Diseases; Primary Care; Dentistry; Clinical Medicine; Craniofacial Disorders; Medicine & Health; Population & Ecological Genetics; Quantitative Genetics; Human Genome; Cancer Genetics; Preventive Medicine; Biological Sciences; Oral Medicine; Preventive Dentistry; HIV/Aids

Contact Details

NIDCR

Public Information and Liaison Branch

45 Center Drive, MSC 6400

Bethesda, MD 20892-6400

Tel: +1 301 594 4846

Email: emily.harris@nih.gov



TARGETED BASIC BEHAVIOURAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R01)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their targeted basic behavioural and social science and intervention development for HIV prevention and care (R01) grants. This R01 funding opportunity announcement aims to provide a global outline of areas for innovative, targeted basic behavioural and social science research and intervention development research to reduce the number of new HIV infections and improve the overall health of those living with HIV and encourage research grant applications in these areas.

This FOA encourages research designed to:

- conduct basic behavioural and social science research that is needed to advance the development of HIV prevention and care interventions;
- translate and operationalise the findings from these basic studies to develop interventions and assess their feasibility;
- conduct tests of the efficacy of HIV prevention and care interventions.

This FOA uses the NIH research (R01) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-128, that encourages applications under the NIH exploratory/developmental (R21) grant mechanism. Application budgets are not limited but need to reflect the actual needs of the project. The total project period may not exceed five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.

Ref: PA-14-127 (replaces PA-11-275).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-127.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=P A-14-127>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Psychology; Behavioural Medicine; Health Counselling; Public Health, Health Services & Primary Care; Health Systems; Biomedical Engineering; Pharmaceutical Drugs; Clinical Medicine; Primary Care; Social Work & Social Policy; Preventive Medicine; Diagnostic Sciences

Contact Details

NIMH
NSC BG
Room 6118
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 433 6100
Email: ebrouwer@mail.nih.gov



TARGETED BASIC BEHAVIOURAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R21)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their targeted basic behavioural and social science and intervention development for HIV prevention and care (R21) grants. This R21 funding opportunity announcement aims to provide a global outline of areas for innovative, targeted basic behavioural and social science research and intervention development research to reduce the number of new HIV infections and improve the overall health of those living with HIV and encourage research grant applications in these areas.

This FOA encourages research designed to:

- conduct basic behavioural and social science research that is needed to advance the development of HIV prevention and care interventions;
- translate and operationalise the findings from these basic studies to develop interventions and assess their feasibility;
- conduct tests of the efficacy of HIV prevention and care interventions.

This FOA uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-127, that encourages applications under the NIH research project (R01) grant mechanism. Direct costs are limited to US\$275,000 over a two year project period, with no more than US\$200,000 allowed in any single year. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.

Ref: PA-14-128 (replaces PA-11-277).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-128.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=P A-14-128>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Public Health, Health Services & Primary Care; Biomedical Engineering; Clinical Medicine; Preventive Medicine; Social Work & Social Policy; Psychology; Health Systems; Pharmaceutical Drugs; Behavioural Medicine; Primary Care; Diagnostic Sciences; Health Counselling

Contact Details

NIMH
NSC BG
Room 6118
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 433 6100
Email: ebrouwer@mail.nih.gov



SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIOURAL AND SOCIAL SCIENCES (R01): AIDS-RELATED

NIH: Office of the Director

Description:

A total of 11 participating institutes of the National Institutes for Health invite applications for their systems science and health in the behavioural and social sciences (R01) grants. This Aids-related R01 funding opportunity announcement seeks to increase the breadth and scope of topics that can be addressed with systems science methodologies. This FOA calls for research projects that are applied or basic in nature, including methodological and measurement development, have a human behavioural or social science focus and employ methodologies suited to addressing the complexity inherent in behavioural and social phenomena, referred to as systems science methodologies. Additionally, this FOA seeks to promote interdisciplinary collaboration among health researchers and experts in computational approaches to further the development of modelling- and simulation-based systems science methodologies and their application to important public health challenges. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity announcement uses the NIH research project R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-15-047 that solicits applications under the exploratory/developmental research grant award (R21) mechanism. Application budgets are not limited but need to reflect actual needs of the proposed project. Applicants requesting US\$500,000 or more in direct costs in any year must contact NIH programme staff at least six

weeks before submitting the application. The maximum project period is five years.

Ref: PAR-15-048 (Reissue of PAR-11-314).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 24 Nov 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-048.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PAR-15-048>

Eligibility profile

Country of applicant institution: Any

Disciplines

Social Problems; HIV/Aids; Social Sciences; Research Methods in Sociology

Contact Details

NCI

BG 9609 Room 3E602

9609 Medical Centre DR

Rockville, MD 20850

Tel: +1 301 402 1146

Email: wireley@mail.nih.gov



SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIOURAL AND SOCIAL SCIENCES

(R21): AIDS-RELATED

NIH: Office of the Director

Description:

A total of 11 participating institutes of the National Institutes for Health invite applications for their systems science and health in the behavioural and social sciences (R21) grants. This Aids-related R21 funding opportunity announcement seeks to increase the breadth and scope of topics that can be addressed with systems science methodologies. This FOA calls for research projects that are applied or basic in nature, including methodological and measurement development, have a human behavioural or social science focus and employ methodologies suited to addressing the complexity inherent in behavioural and social phenomena, referred to as systems science methodologies. Additionally, this FOA seeks to promote interdisciplinary collaboration among health researchers and experts in computational approaches to further the development of modelling- and simulation-based systems science methodologies and their application to important public health challenges. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. This funding opportunity announcement uses the NIH exploratory/developmental R21 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-15-048 that solicits applications under the research project grant award (R01) mechanism. Application budgets are limited to US\$275,000 over the two-year R21 period, with no more than US\$200,000 in any year. The maximum project period is two years.

Ref: PAR-15-047 (Reissue of PAR-11-315)

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 24 Nov 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-15-047.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PAR-15-047>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Social Sciences; Research Methods in Sociology; Social Problems

Contact Details

NCI
BG 9609 Room 3E602
9609 Medical Centre DR
Rockville MD 20850
Tel: +1 301 402 1146
Email: wireley@mail.nih.gov



BUILDING GENETICS AND GENOMIC KNOWLEDGE ABOUT DENTAL, ORAL AND CRANIOFACIAL DISEASES AND DISORDERS (R01): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research invites applications for its building a genetic and genomic knowledge base in dental, oral and craniofacial diseases and disorders (R01) grants. This Aids-related R01 funding opportunity announcement encourages research into dental, oral, and craniofacial diseases and disorders for which there is evidence for genetic heritability but for which there is no strong understanding of the genetics or genomics of the disease or disorder.

Research areas may include identification of promising areas of the genome, and characterisation and elucidation of the functions of genetic variants that affect disease risk in humans. The goal is to drive development of effective diagnostic, therapeutic, and preventive approaches. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

The maximum project period is five years.

Ref: PA-14-347 (replaces PA-11-317).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 23 Sep 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-347.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-347>

Eligibility profile

Country of applicant institution: Any

Disciplines

Medical Genetics; Special Needs Dentistry; Diagnostic Sciences; Public Health, Health Services & Primary Care; Genomics; Genetics & Systems Biology; Allied Health Professions; Genetic Diseases; Primary Care; Dentistry; Clinical Medicine; Craniofacial Disorders; Medicine & Health; Population & Ecological Genetics; Quantitative Genetics; Human Genome; Cancer Genetics; Preventive Medicine; Biological Sciences; Oral Medicine; Preventive Dentistry; HIV/Aids

Contact Details

NIDCR

Public Information and Liaison Branch

45 Center Drive, MSC 6400

Bethesda, MD 20892-6400

Tel: +1 301 594 4846

Email: emily.harris@nih.gov



HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIOURS IN CHILDREN AND ADOLESCENTS (R01): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

A total of two institutes and offices of the NIH invite applications for their Aids-related healthy habits: timing for developing sustainable healthy behaviours in children and adolescents (R01) grants. This R01 funding opportunity announcement encourages applications that employ innovative research to identify mechanisms of influence and promote positive sustainable health behaviour in children and youth up to the age of 21. Applications to promote positive health behaviour should target social and cultural factors, including schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Topics to be addressed in this announcement include:

- effective, sustainable processes for influencing young people to make healthy behaviour choices;
- identification of the appropriate stage of influence for learning sustainable lifelong health behaviours;
- the role of technology and new media in promoting healthy behaviour;
- identification of factors that support healthy behaviour development in vulnerable populations, identification of barriers to healthy behaviours;
- identification of mechanisms and mediators that are common to the development of a range of habitual health behaviours.

Given the many factors involved in developing sustainable health behaviours, applications from multidisciplinary teams are strongly encouraged. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited, but need to reflect actual needs of the

proposed project. The maximum project period is five years.

Ref: PA-14-177 (Reissue of PA-11-327).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of the application organisation on every 7 May, 7 September and 7 January until 8 May 2017.

Posted date: 22 Apr 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-177.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Education; Social Work & Social Policy; Health Education; Health Promotion; Dentistry; Psychology; Maternal Health; Social Programmes; Health Psychology; Child Development; Public Health; Primary Care; Communication & Media Studies; Media Studies; Computer, Internet & Mobile Gaming; Group Dynamics & Collective Behaviour; Mental Health; Food Science; Child Protection & Welfare; Social Problems; Communication Studies; Medical Education; Social Psychology; Public Health, Health Services & Primary Care; Social Aspects of Mental Health; Popular Culture; Adolescent Paediatrics; Malnutrition; HIV/Aids; Sociology; Children's Literature; Behavioural Medicine; Social Behaviour & Attitudes

Contact Details



Tel: +1 301 594 6908

Email: mary.roary@nih.gov

HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIOURS IN CHILDREN AND ADOLESCENTS (R21): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

A total of two institutes and offices of the NIH invite applications for their Aids-related healthy habits: timing for developing sustainable healthy behaviours in children and adolescents (R21) grants. This AIDS-related R21 funding opportunity announcement encourages applications that employ innovative research to identify mechanisms of influence and promote positive sustainable health behaviour in children and youth up to the age of 21. Applications to promote positive health behaviour should target social and cultural factors, including schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Topics to be addressed in this announcement include:

- effective, sustainable processes for influencing young people to make healthy behaviour choices;
- identification of the appropriate stage of influence for learning sustainable lifelong health behaviours;
- the role of technology and new media in promoting healthy behaviour;
- identification of factors that support healthy behaviour development in vulnerable populations, identification of barriers to healthy behaviours;
- identification of mechanisms and mediators that are common to the development of a range of habitual health behaviours.

Given the many factors involved in developing sustainable health behaviours, applications from multidisciplinary teams are

strongly encouraged. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-176 (Reissue of PA-11-329).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of the application organisation every 16 February, 16 June and 16 October until 8 May 2017.

Posted date: 22 Apr 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-176.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Health Psychology; Popular Culture; Communication Studies; Social Problems; Malnutrition; Media Studies; Medical Education; Sociology; Mental Health; Health Promotion; Maternal Health; Social Programmes; Social Psychology; Education; Computer, Internet & Mobile Gaming; Behavioural Medicine; Public Health, Health Services & Primary Care; Health Education; Social Aspects of Mental Health; Primary



Care; Children's Literature; Child Development; Dentistry; Psychology; Communication & Media Studies; Food Science; Child Protection & Welfare; Social Work & Social Policy; HIV/Aids; Group Dynamics & Collective Behaviour; Public

Health; Adolescent Paediatrics; Social Behaviour & Attitudes

Contact Details

Tel: +1 301 594 6908
Email: mary.roary@nih.gov



ALCOHOL IMPAIRMENT OF IMMUNE FUNCTION, HOST DEFENSE AND TISSUE HOMEOSTASIS (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its alcohol impairment of immune function, host defense and tissue homeostasis (R01) funding opportunity announcement. This Aids-related announcement invites applications from researchers with broad expertise to study the consequences of alcohol consumption on immune function, with the goal of improving the outcome of patients who abuse alcohol.

This FOA also aims to attract research applications that utilise comprehensive approaches and cutting edge technology to address mechanistic questions about alcohol's effect on human health. In view of the complexity of the interactions within the immune system and among immune, neural and endocrine networks, systems approaches are encouraged.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is five years.

Ref: PA-15-159 (reissue of PA-12-025).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 27 Mar 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-159.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275459>

Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism; Immunology

Contact Details

NIAID
BG 5635FL Room 2021
5635 Fishers Lane
Rockville MD 20852



Tel: +1 301 443 8744

Email: jungma@mail.nih.gov

HIGH THROUGHPUT SCREENING TO DISCOVER CHEMICAL PROBES (R01): AIDS-RELATED

NIH: National Institute of Mental Health

Description:

A total of 11 components of the National Institutes of Health invites applications for their solicitation of high throughput screening to discover chemical probes (R01) grants. This Aids-related R01 funding opportunity announcement encourages investigators to form collaborations with an established academic, non-profit or commercial high throughput screening facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, NIH wishes to stimulate research in:

- discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH institutes;
- discovery or validation of novel, biological targets that will inform studies of disease mechanisms.

Emphasis will be placed on assays that provide new insight into important disease targets and processes.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed three years.

Ref: PAR-14-284 (replaces PAR-12-058).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 September, 7 January and 7 July until 8 September 2017.

Posted date: 18 Jul 14

Award type: Directed grants to institutions, research groups etc,
Networking/collaboration

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-284.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PAR-14-284>

Eligibility profile

Country of applicant institution: Any

Disciplines

Translational Medicine; Disease Models; Pharmacy & Pharmacology; Nursing; Clinical Medicine; Physiology; Human Biological Sciences; Chemistry; Public Health, Health Services & Primary Care; Immunological & Bioassay Methods; Dentistry; Allied Health Professions; Diagnostic Sciences; Medicinal Chemistry; HIV/Aids; Primary Care; Medicine & Health; Screening for Diseases; Molecular Probes

Contact Details

National Institute of Mental Health



Division of Neuroscience and Basic Behavior
Science
6001 Executive Boulevard, Room 7175, MSC
9641

Bethesda, MD 20892-9641
Tel: +1 301 443 6102
Email: yyao@mail.nih.gov

THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R03): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

A total of eight institutes and offices of the National Institutes of Health invite applications for their health of sexual and gender minority populations (R03) funding opportunity announcement. This Aids-related announcement encourages research that describes the biological, clinical, behavioural and social processes that affect the health and development of sexual and gender minority populations and individuals, as well as their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that enhance the health and development of these populations. The research must focus on clearly defined health outcomes. The following types of research are prioritised:

- basic social and behavioural science studies addressing the processes involved as individuals discover, uncover, address or adapt to their sexual orientation and claim or do not claim identity as SGM, and how these processes affect the mental and physical health of the individual;
- research leading to interventions to ameliorate health disparities in SGM populations;
- large-scale design, implementation and evaluation of preventive or treatment interventions addressing health issues in SGM populations;
- research on how family structures and processes-including both families of

origin and families of choice-affect the health of SGM individuals and their family members, including whether and how being raised in a family headed by SGM individuals affects the health, development and well-being of children.

This funding opportunity uses the NIH small grant programme (R03) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-261 and PA-15-263, which solicit applications under the NIH research project (R01) grant mechanism and the NIH research project (R01) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to US\$100,000 over a two-year project period, with no more than US\$50,000 in direct costs allowed in any year.

Ref: PA-15-262 (reissue of PA-12-112).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 19 May 15

Award type: Directed grants to institutions, research groups etc



Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-262.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#search=true&oppNum=PA-15-262> m

Eligibility profile

Country of applicant institution: Any

Contact Details

Health of Minority Groups; Lesbian, Gay, Bisexual & Transgender Studies; Gender Roles & Sexuality; HIV/Aids

Contact Details

Eunice Kennedy Shriver NICHD
BG 6100 Room 8B05L
6100 Executive Boulevard
Rockville MD 20852
Tel: +1 301 435 6981
Email: newcomes@mail.nih.gov

THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R21): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

A total of nine institutes and offices of the National Institutes of Health invite applications for their health of sexual and gender minority populations (R21) funding opportunity announcement. This Aids-related announcement encourages research that describes the biological, clinical, behavioural and social processes that affect the health and development of sexual and gender minority populations and individuals, as well as their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that enhance the health and development of these populations. The research must focus on clearly defined health outcomes. The following types of research are prioritised:

- basic social and behavioural science studies addressing the processes involved as individuals discover, uncover, address or adapt to their sexual orientation and claim or do not claim identity as SGM, and how these

processes affect the mental and physical health of the individual;

- research leading to interventions to ameliorate health disparities in SGM populations;
- large-scale design, implementation and evaluation of preventive or treatment interventions addressing health issues in SGM populations;
- research on how family structures and processes-including both families of origin and families of choice-affect the health of SGM individuals and their family members, including whether and how being raised in a family headed by SGM individuals affects the health, development and wellbeing of children.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-261 and PA-15-262, which solicit applications under the NIH research project (R01) grant mechanism



and the NIH small grant programme (R03) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in direct costs allowed in any year.

Ref: PA-15-263 (reissue of PA-12-113).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 September 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 19 May 15

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-263.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276657>

Eligibility profile

Country of applicant institution: Any

Disciplines

Gender Roles & Sexuality; Lesbian, Gay, Bisexual & Transgender Studies; HIV/Aids; Health of Minority Groups

Contact Details

Eunice Kennedy Shriver NICHD
BG 6100 Room 8B05L
6100 Executive Boulevard
Rockville MD 20852
Tel: +1 301 435 6981
Email: newcomes@mail.nih.gov

P ILOT HEALTH SERVICES AND ECONOMIC RESEARCH ON THE TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R34): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their pilot health services and economic research on the treatment of drug, alcohol and tobacco abuse (R34) funding opportunity announcement. This Aids-related announcement encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials into the quality, effectiveness, affordability and utilisation of drug, tobacco or alcohol use disorder treatments.

This funding opportunity uses the NIH planning (R34) grant mechanism and runs in

parallel with several of identical scientific scope, PA-15-251, PA-15-252 and PA-15-253 which solicit applications under the NIH research project (R01), the NIH small grant programme (R03) and the NIH exploratory/developmental (R21) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US\$450,000 in direct costs with up to US\$225,000 in direct costs per year.



The maximum project period is three years.

Ref: PA-15-250 (Reissue of PA-12-130).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 11 May 15

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$450,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-250.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276467>

Eligibility profile

Country of applicant institution: Any

Disciplines

Smoking & Tobacco; Drug & Substance Abuse; HIV/Aids; Access to Health Care; Social Services Delivery

Contact Details

Tel: +1 301 443 4715

Email: duffys@nida.nih.gov

DEVELOPMENT AND TESTING OF NOVEL INTERVENTIONS TO IMPROVE HIV PREVENTION, CARE, AND PROGRAMME IMPLEMENTATION (R34)

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse, the National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their development and testing of novel interventions to improve HIV prevention, care and programme implementation (R34) funding opportunity announcement. This announcement supports pilot or feasibility studies of new or adapted interventions to prevent HIV infection among populations where substance use may be a contributing factor; pilot or feasibility studies of new or adapted interventions to improve the care of HIV infection among populations where substance use is prevalent, including interventions that integrate treatment for substance use disorders and HIV infection; or pilot or feasibility studies to increase the scale, uptake, delivery or quality of HIV prevention or care interventions with established evidence of efficacy. Both primary and

secondary prevention will be supported. The full range of substance use will be considered including problematic episodic use and substance use disorders, as well as a full range of substances and modes of administration. The most important consideration is that substance use may affect transmission directly as in the case of injection drug use or may affect transmission risk behaviour. Domestic and overseas populations will be considered, with particular attention to populations with disproportionate burden of HIV infection and those where HIV infection or drug use are emergent.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Direct costs are limited to US\$450,000 over a three-year period, with no more than



US\$225,000 direct costs allowed in any single year.

Ref: PA-15-268 (reissue of PA-12-231).

Closing date: 07 Sep 16

Deadline information: Applications open on 7 August and are due by 5pm local time of applicant organisation on every 7 January, 7 September and 7 May until 8 May 2018.

Posted date: 29 May 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$450,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-268.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276883>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/ Aids; Drug & Substance Abuse

Contact Details

Tel: +1 301 443 1923

Email: jenkinsri@mail.nih.gov

PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS: EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R01): AIDS-RELATED

NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its Aids-related physical activity and weight control interventions among cancer survivors: effects on biomarkers of prognosis and survival (R01) funding opportunity announcement. This Aids-related announcement encourages transdisciplinary and translational research that will identify specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control, on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin or glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Biomarkers may include but are not limited to intervention-

induced changes in sex hormones, insulin-like growth factors or their binding proteins, leptin and other adipokines, immunologic or inflammatory factors, oxidative stress and DNA damage or repair capacity, angiogenesis, or prostaglandins. Research topics of interest include, but are not limited to:

- clinical studies to determine the optimal type and intensity of intervention for different subgroups of cancer survivors;
- studies with animal model components.

This FOA uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PAR-16-123, which utilises the NIH exploratory or developmental grant (R21) mechanism.



Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-16-122 (replaces PA-15-311).

Closing date: 07 Sep 16
Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.
Posted date: 10 Mar 16
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-122.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Obesity; Cancer Studies & Oncology; Diagnostic Sciences; Human Metabolism; Cancer Cell Biology; HIV/Aids

Contact Details

Tel: +1 240 276 6782
 Fax: +1 301 594 5070
 Email: pernafm@mail.nih.gov

PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS - EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R21): AIDS-RELATED

NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R21): Aids-related funding opportunity announcement. This Aids-related announcement encourages transdisciplinary and translational research that will identify specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin or glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies

where available. Biomarkers may include but are not limited to intervention-induced changes in sex hormones, insulin-like growth factors or their binding proteins, leptin and other adipokines, immunologic or inflammatory factors, oxidative stress and DNA damage or repair capacity, angiogenesis, or prostaglandins. Research topics of interest include:

- clinical studies to determine the optimal type and intensity of intervention for different subgroups of cancer survivors;
- studies with animal model components.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.



This FOA uses the NIH exploratory or developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-122, which solicits applications under the NIH research project grant (R01) mechanism.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in direct costs allowed in any year.

Ref: PAR-16-123.

Closing date: 07 Sep 16
Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.
Posted date: 10 Mar 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-123.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Obesity; Cancer Studies & Oncology; Cancer Cell Biology; Human Metabolism; HIV/ Aids

Contact Details

Tel: +1 240 276 6782

Email: pernafm@mail.nih.gov

C LINICAL DEVELOPMENT OF MINIMALLY INVASIVE BIOASSAYS TO SUPPORT OUTPATIENT CLINICAL TRIALS OF THERAPEUTICS FOR SUBSTANCE USE DISORDERS (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related clinical development of minimally invasive bioassays to support outpatient clinical trials of therapeutics for substance use disorders (R21) grants. This Aids-related funding opportunity announcement solicits proposals that seek to develop non-invasive methods to support outpatient clinical trials of pharmacotherapies for substance use disorders. Clinical trials evaluating the efficacy of medications to treat substance use disorders are limited by two major issues: an uncertainty in assessing the level of a subjects adherence to the trial medication regimen and an inability to accurately and quantitatively monitor the frequency and level of a subject's illicit drug exposure. This FOA encourages the development of systems that address at least

one of these issues. The announcement has two main aims:

- to encourage the development of systems that will improve estimations of level adherence to the medication regime in a manner that is non- or minimally invasive and can be conducted at point of care;
- to encourage the development of systems that can accurately assess the quantity and frequency of consumption of abused drug during an outpatient clinical trial.

This FOA will utilise the NIH exploratory and developmental grant (R21) mechanism and runs in parallel with one of identical scientific scope, PA-16-076, that solicits applications



under the research project (R01) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$275,000 over a two-year period with no more than US\$200,000 in either year.

Ref: PA-16-075 (replaces PAR-12-239).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.

Posted date: 11 Jan 16

Award type: Directed grants to institutions, research groups etc, Clinical trials

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-075.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Medical Devices; Drug Design; HIV/Aids; Immunological & Bioassay Methods; Drug & Substance Abuse; Pharmacotherapy

Contact Details

Tel: +1 301 443 8039

Email: aidan.hampson@nih.gov

ETHICAL ISSUES IN RESEARCH ON HIV/AIDS AND ITS CO-MORBIDITIES (R21)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Disease, the National Cancer Institute and the National Institute of Mental Health invite applications for the ethical issues in research on HIV/Aids and its co-morbidities (R21) funding opportunity announcement. This supports projects that address ethical issues relevant to research on HIV and associated co-morbidities, including research with populations living with, or at high risk of, HIV acquisition.

Projects may include conceptual work in bioethics or empirical work gathering and analysing relevant ethical issues in research, or a combination of the two. Empirical projects may include quantitative or qualitative methods in data collection, and

bioethics projects should focus on at least one of the following goals:

- development of the empirical knowledge base for human subjects protection and ethical standards in HIV/Aids research;
- development of conceptual bioethics approaches to advance scholarship on difficult ethical challenges in HIV/Aids research;
- supporting the integration of bioethics work with ongoing research in HIV/Aids.

This announcement uses the R21 exploratory or developmental grant mechanism and runs in parallel with an opportunity of a similar scientific scope, PAR-15-274, which solicits



applications under the R01 research project grant mechanism.

Applicants may be from US and foreign for-profit and non-profit organisations or public and private organisations.

Each award covers direct costs of up to US\$275,000 over a maximum period of two years. The maximum award budget for direct costs for any single year is US\$200,000.

Ref: PAR-15-275 (replaces PAR-12-243).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on deadline dates until 9 January 2018.

Posted date: 09 Jun 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-15-275.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do>

Eligibility profile

Country of applicant institution: Any

Disciplines

Research Ethics & Misconduct; HIV/Aids; Bioethics & Neuroethics; Patient Care & Education

Contact Details

Tel: +1 240 627 3210

Email: dawsonl@niaid.nih.gov

ETHICAL ISSUES IN RESEARCH ON HIV/AIDS AND ITS CO-MORBIDITIES (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Disease, the National Cancer Institute and the National Institute of Mental Health invite applications for the ethical issues in research on HIV/Aids and its co-morbidities (R01) funding opportunity announcement. This supports projects that address ethical issues relevant to research on HIV and associated co-morbidities, including research with populations living with, or at high risk of, HIV acquisition.

Projects may include conceptual work in bioethics or empirical work gathering and analysing relevant ethical issues in research, or a combination of the two. Empirical projects may include quantitative or qualitative methods in data collection, and

bioethics projects should focus on at least one of the following goals:

- development of the empirical knowledge base for human subjects protection and ethical standards in HIV/Aids research;
- development of conceptual bioethics approaches to advance scholarship on difficult ethical challenges in HIV/Aids research;
- supporting the integration of bioethics work with ongoing research in HIV/Aids.

This announcement uses the R01 research project grant mechanism and runs in parallel with an opportunity of a similar scientific



scope, PAR-15-275, which solicits applications under the R21 exploratory or developmental grant mechanism.

Applicants may be from US and foreign for-profit and non-profit organisations or public and private organisations.

Application budgets must reflect the actual needs of the proposed project. The maximum award period is five years.

Ref: PAR-15-274 (replaces PAR-12-244).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on deadline dates until 9 January 2018.

Deadlines on: 7 January 2016, 7 September 2016, 7 January 2017, 7 September 2017, 8 January 2018.

Posted date: 09 Jun 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA15-274.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do>

Eligibility profile

Country of applicant institution: Any

Disciplines

Bioethics & Neuroethics; Patient Care & Education; HIV/Aids; Research Ethics & Misconduct

Contact Details

Tel: +1 240 627 3210

Email: dawsonl@niaid.nih.gov

L LYMPHATICS IN HEALTH AND DISEASE IN THE DIGESTIVE SYSTEM, KIDNEY AND URINARY TRACT (R01): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

The National Institute of Diabetes and Kidney Diseases invites applications for its lymphatics in health and disease in the digestive system, kidney and urinary tract (R01): Aids-related. This R01 funding opportunity announcement supports research into aspects of lymphatic vessel physiology, development and pathophysiology related to health and diseases of digestive system, kidney and urinary tract organs. Studies to understand the factors that control local lymphatic vessel functional anatomy and physiology and development during health or disease in these organs and systems, and the mechanisms by which alterations of lymphatic vessel function affect organ

function, are of interest. Studies with a major focus on immune mechanisms are not encouraged. This FOA will use the R01 research project grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

Application budgets are limited to US\$250,000 in direct costs per year. The maximum project period is five years. Ref: PAR-15-306 (replaces PAR-12-259).

Closing date: 07 Sep 16



Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2015.

Posted date: 27 Jul 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$1,250,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-306.html>

Application form:

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

Eligibility profile

Country of applicant institution: Any

Disciplines

Lymphatic System; Gastroenterology; HIV/Aids; Urology; Nephrology & Kidneys

Contact Details

NIDDK

BG 2Dem Room 661

6707 Democracy Boulevard

Bethesda, MD 20817

Tel: +1 301 402 0671

Email: carringj@mail.nih.gov

E XAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R01) AIDS-RELATED

NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its examination of survivorship care planning efficacy and impact (R01) Aids-related funding opportunity announcement. This Aids-related announcement aims to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy, with the goal to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors. Specifically, this call aims to stimulate research that will:

- develop and test metrics for evaluating the impact of survivorship care planning;
- evaluate the impact of survivorship care planning on cancer survivors morbidity, self-management and adherence to care recommendations, utilisation of follow-up care;

- evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organisations implementing the care planning;
- identify models and processes of care that promote effective survivorship care planning.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-011, which solicits applications under the NIH exploratory or developmental (R21) grant mechanism.

US and foreign for-profit and non-profit organisations, and public or private institutions may apply.

Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years.



Ref: PA-16-012 (replaces PA-12-275).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 26 Oct 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-012.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Quality of Care; Life Expectancy & Quality of Life; Rehabilitation Engineering; Cancer Studies & Oncology; HIV/Aids; Emotional Rehabilitation

Contact Details

Tel: +1 240 276 6947

Email: taplins@mail.nih.gov



ADVANCING ERYTHROID CELL BIOLOGY (R01): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

The National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood, Institute invite applications for their Aids-related advancing erythroid cell biology (R01) grants. This Aids-related R01 funding opportunity announcement supports research efforts towards a complete description of the molecular and cellular components of erythropoiesis and how these components function to achieve normal erythropoiesis. Research should identify fundamental mechanisms of haematologic development and cell differentiation. The programme aims to:

- use the erythroid cell system to test hypotheses regarding coordination of gene expression and interaction of proteins during haematologic development and differentiation;
- elucidate structure-function relationships in normal and diseased

erythroid blood cell states that will inform biology of other cell types.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Ref: PA-16-039 (replaces PA-13-034).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm applicant's local time every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 23 Nov 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-039.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PA-16-039>

Protein Synthesis, Modification & Turnover;
Medical Genetics; HIV/Aids; Epigenetics;
Haematology; Cell & Developmental Biology

Eligibility profile

Country of applicant institution: Any

Contact Details

Tel: +1 301 594 7726

Email: terry.bishop@nih.gov

Disciplines

D ISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R03): AIDS-RELATED

NIH: National Institute of Mental Health

Description:

A total of 13 offices and institutes of the National Institutes of Health invite applications for their dissemination and implementation research in health (R03): Aids-related funding opportunity announcement. This Aids-related announcement supports research that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures and strategies to disseminate and implement evidence-based health behaviour change interventions, evidence-based prevention, early detection, diagnostic, treatment and management, and quality of life improvement services into public health, clinical practice, and community settings. The R03 grant mechanism supports:

- pilot or feasibility studies;
- secondary analysis of existing data;
- small, self-contained research projects;
- development of research methodology;
- development of new research technology.

This FOA uses the NIH small grant (R03) programme mechanism, and runs in parallel with two FOAs of identical scientific scope, PAR-16-238, which solicits applications under

the NIH research project (R01) grant mechanism and PAR-16-238, which solicits applications under the NIH exploratory or developmental (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to \$50,000 in direct costs per year for a maximum period of two years.

Ref: PAR-16-237 (replaces PAR-13-056).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 11 May 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-237.html>



Eligibility profile

Country of applicant institution: Any

Disciplines

Medical & Diagnostic Tests; Public Health;
Preventive Medicine; Health Promotion;
Health Systems

Contact Details

Tel: +1 240 276 5090

Email: dchamber@mail.nih.gov

R ESearch Education Programme for Clinical Researchers and Clinicians (R25): AIDS-RELATED NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related research education programme for clinical researchers and clinicians (R25) grants. This Aids-related funding opportunity announcement supports educational activities that complement and enhance the training of a workforce to meet the nation's biomedical, behavioural and clinical research needs. The announcement is intended to support research education activities that enhance the knowledge of substance abuse and addiction research. The programme is intended for those in clinically focused careers or those training for careers as clinicians or service providers, clinical researchers or optimally a combination of the two. This mechanism may not be used for support of non-research-related clinical training.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US\$350,000 in direct costs allowed in any single year. The maximum project period is five years.

Ref: PAR-16-224 (replaces PAR-13-084).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation.

Deadlines on: 7 September 2016, 7

September 2017, 7 September 2018.

Posted date: 06 May 16

Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc

Award amount max: \$1,750,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-224.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Medical Education; Drug & Substance Abuse; Addiction; HIV/ Aids

Contact Details

Tel: +1 301 402 1533

Fax: +1 301 443 6814

Email: bsims@nida.nih.gov



REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R21): AIDS-RELATED

NIH: National Institute on Aging

Description:

The National Institute on Aging invites R21 Aids-related applications for its regional and international differences in health and longevity at older ages grants.

Aids-related applications are sought from organisations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both across industrialised nations and across geographical areas in the United States.

This FOA will utilise the R21 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

The combined budget for direct costs may not exceed US\$275,000 over two years. no more than US\$200,000 per year may be requested.

PA-13-124.

Closing date: 07 Sep 16

Deadline information: Applications due 5pm local time of the application organisation on every 7 January, 7 May and 7 September annually until 8 September 2016.

Posted date: 22 Feb 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-124.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Psychology; Population Studies, Medical; Primary Care; Health Disparities; HIV/Aids; Geriatrics & Gerontology; Psychology of Ageing; Social Work & Social Policy; International Health; Social & Income Inequality; Public Health, Health Services & Primary Care; Life Expectancy & Quality of Life

Contact Details

Tel: +1 301 496 3138

Email: patmiosg@nia.nih.gov

REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R03): AIDS-RELATED

NIH: National Institute on Aging

Description:

The National Institute on Aging invites R03 Aids-related applications for its regional and international differences in health and longevity at older ages grants.

Aids-related applications are sought from organisations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both across



industrialised nations and across geographical areas in the United States.

This FOA will utilise the R03 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

The combined budget for direct costs may not exceed US\$100,000 over two years. no more than US\$50,000 per year may be requested.

PA-13-123.

Closing date: 07 Sep 16

Deadline information: Applications due 5pm local time of the application organisation on every 7 January, 7 May and 7 September annually until 8 September 2016.

Posted date: 22 Feb 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-123.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Public Health, Health Services & Primary Care; Psychology of Ageing; Psychology; Health Disparities; Geriatrics & Gerontology; HIV/Aids; Population Studies, Medical; Social & Income Inequality; Life Expectancy & Quality of Life; Primary Care; Social Work & Social Policy; International Health

Contact Details

Tel: +1 301 496 3138

Email: patmiosg@nia.nih.gov

REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R01): AIDS-RELATED NIH: National Institute on Aging

Description:

The National Institute on Aging invites R01 Aids-related applications for its regional and international differences in health and longevity at older ages grants.

Aids-related applications are sought from organisations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both across industrialised nations and across geographical areas in the United States.

This FOA will utilise the R01 award mechanism. Domestic and foreign public and

private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited but must reflect the actual needs of the proposed project. Funding is available for up to five years. PA-13-125.

Closing date: 07 Sep 16

Deadline information: Applications due 5pm proposer's local time, 7 January, 7 May and 7 September annually until 8 September 2016.

Posted date: 22 Feb 13

Award type: Directed grants to institutions, research groups etc



Award amount max: -

Award budget total: -

Website:

http://grants.nih.gov/grants/guide/pa-files/PA-13-125.html#_Section_IV_Application_1

Eligibility profile

Country of applicant institution: Any

Disciplines

Social & Income Inequality; Public Health, Health Services & Primary Care; Geriatrics & Gerontology; International Health; Life Expectancy & Quality of Life; Population Studies, Medical; Social Work & Social Policy; HIV/Aids; Primary Care; Psychology of Ageing; Health Disparities; Psychology

Contact Details

Tel: +1 301 496 3138

Email: patmiosg@nia.nih.gov

THE EFFECTS OF MODULATING CHRONIC LOW GRADE INFLAMMATION ON GERIATRIC CONDITIONS - SECONDARY DATA OR BIOSPECIMEN ANALYSES AND ANCILLARY STUDIES IN ONGOING OR COMPLETED CLINICAL TRIALS (R01) AIDS-RELATED

NIH: National Institute on Aging

Description:

The National Institute on Aging invites Aids-related R01 proposals on the effects of modulating chronic low grade inflammation on geriatric conditions - secondary data or biospecimen analyses and ancillary studies in ongoing or completed clinical trials.

This Aids-related R01 opportunity supports ancillary studies and secondary analyses of data or biospecimens from ongoing or completed studies of the effects of inflammation or anti-inflammatory agents on geriatric conditions, such as functional decline, mobility disability, fatigue, falls, cognitive decline and dementia, and chronic pain.

Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited but must reflect the actual needs of the proposed

project. Funding is available for up to five years.

PA-13-221.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time.

Posted date: 08 May 13

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-221.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Diagnostic Sciences; Blood Tests; HIV/Aids; Pharmacotherapy; Neurology; Primary Care; Alzheimer's Disease & Senile Dementia;



Inflammation; Public Health, Health Services & Primary Care; Clinical Medicine; Care for Disabled People; Chronic Fatigue Syndrome; Geriatrics & Gerontology; Pharmacy & Pharmacology

Contact Details

Tel: +1 301 435 3046

Email: radzisz@mail.nih.gov

R ESearch TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R03): AIDS-RELATED

NIH: National Institute on Aging

Description:

A total of six institutes of the NIH invite applications for grants for research to characterise and reduce stigma to improve health. This Aids-related R03 funding opportunity announcement encourages research grant applications to characterise the role of stigma in health, life course development, and ageing, both in the US and globally, and to test interventions to prevent or reduce the impact of stigma at the individual, community, healthcare system, and policy levels. The goal is to promote research addressing the health-related aspects of stigma, including the aetiology and perpetuation of it; its impact on physical and mental health, well-being, life course development, and ageing; its influence on health behaviours and on use, access to, and quality of received healthcare services; its contribution to health disparities affecting vulnerable demographic groups; and intervention strategies to reduce health-related stigma or the negative health and life course developmental impacts of stigma.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

This funding opportunity uses the R03 small grant programme mechanism and runs in parallel with two of identical scientific scope, PA-13-246, which solicits applications under

the NIH exploratory/developmental grant mechanism, and PA-13-248, which uses the R03 research project grant mechanism.

The combined budget for direct costs over the two-year maximum period may not exceed US\$100,000. No more than US\$50,000 in direct costs may be requested in any single year. PA-13-247.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September, 2016.

Posted date: 17 Jun 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$50,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-247.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Economic & Social Environment; Behavioural Medicine; Social Services Delivery; Public Health, Health Services & Primary Care; Primary Care; Psychology of Ageing; Medical



Sociology; Sociology; Health Systems, Administration; Social Work & Social Policy; Health Disparities; Health Education; Mental Health; Psychology; HIV/Aids; Geriatrics & Gerontology; Education; Allied Health Professions

Contact Details

NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: +1 301 402 4156
Email: nielsenli@nia.nih.gov

R ESearch TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R21): AIDS-RELATED NIH: National Institute on Aging

Description:

A total of six institutes of the NIH invite applications for grants for research to characterise and reduce stigma to improve health. This Aids-related R21 funding opportunity announcement encourages research grant applications to characterise the role of stigma in health, life course development, and ageing, both in the US and globally, and to test interventions to prevent or reduce the impact of stigma at the individual, community, healthcare system, and policy levels. The goal is to promote research addressing the health-related aspects of stigma, including the aetiology and perpetuation of it; its impact on physical and mental health, well-being, life course development, and ageing; its influence on health behaviours and on use, access to, and quality of received healthcare services; its contribution to health disparities affecting vulnerable demographic groups; and intervention strategies to reduce health-related stigma or the negative health and life course developmental impacts of stigma.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

This funding opportunity uses the R21 exploratory/developmental research grant mechanism, and runs in parallel with two of identical scope, PA-13-248, which solicits applications under the R01 research project grant mechanism, and PA-13-247, which uses the R03 small grant mechanism.

The combined budget for direct costs over the two-year maximum period may not exceed US\$275,000. No more than US\$200,000 in direct costs may be requested in any single year. PA-13-246.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September, 2016.

Posted date: 17 Jun 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-246.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-HG-13-013>



Eligibility profile

Country of applicant institution: Any

Health Disparities; Health Systems, Administration; Social Services Delivery; Social Work & Social Policy

Disciplines

Psychology of Ageing; Education; Psychology; Public Health, Health Services & Primary Care; Allied Health Professions; Sociology; Behavioural Medicine; Primary Care; Medical Sociology; HIV/Aids; Mental Health; Economic & Social Environment; Health Education; Geriatrics & Gerontology;

Contact Details

NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: +1 301 402 4156
Email: nielsenli@nia.nih.gov

R RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R01): AIDS-RELATED NIH: National Institute on Aging

Description:

A total of six institutes of the NIH invite applications for grants for research to characterise and reduce stigma to improve health. This Aids-related R01 funding opportunity announcement encourages research grant applications to characterise the role of stigma in health, life course development, and ageing, both in the US and globally, and to test interventions to prevent or reduce the impact of stigma at the individual, community, healthcare system, and policy levels. The goal is to promote research addressing the health-related aspects of stigma, including the aetiology and perpetuation of it; its impact on physical and mental health, well-being, life course development, and ageing; its influence on health behaviours and on use, access to, and quality of received healthcare services; its contribution to health disparities affecting vulnerable demographic groups; and intervention strategies to reduce health-related stigma or the negative health and life course developmental impacts of stigma.

Applications may be submitted by foreign or domestic for-profit and non-profit

organisations and public and private organisations.

This funding opportunity uses the NIH exploratory/developmental (R01) research project grant mechanism and runs in parallel with two of identical scientific scope, PA-13-246, which solicits applications under the NIH exploratory/developmental grant mechanism, and PA-13-247, which utilises the R03 small grant programme mechanism.

Application budgets are not limited, but need to reflect the actual needs of the proposed project. The scope of the project should determine the project period; the maximum period is five years. PA-13-248.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September, 2016.

Posted date: 17 Jun 13

Award type: Directed grants to institutions, research groups etc



Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-247.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Economic & Social Environment; Education; Sociology; Social Work & Social Policy; Geriatrics & Gerontology; Behavioural Medicine; Health Education; Allied Health

Professions; HIV/Aids; Primary Care; Psychology of Ageing; Mental Health; Medical Sociology; Psychology; Health Systems, Administration; Public Health, Health Services & Primary Care; Health Disparities; Social Services Delivery

Contact Details

NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: +1 301 402 4156
Email: nielsenli@nia.nih.gov

S ECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute of Alcohol Abuse and Alcoholism invites applications for its Aids-related secondary analyses of alcohol and chronic disease (R21) grants. This Aids-related R21 funding opportunity announcement aims to support secondary analyses of alcohol related to chronic disease aetiology and epidemiology. The goal of this programme is to facilitate cost-effective exploratory or novel studies that break new ground or extend previous discoveries towards new directions or applications.

This funding opportunity announcement will use the NIH exploratory/development research grant (R21) mechanism and runs in parallel with two FOA of identical scientific scope, PA-13-261, which solicits applications under the R03 small grant programme mechanism, and PA-13-260, which solicits applications under the R01 research project grant mechanism.

Direct costs are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in any year. Domestic and foreign for-profit and nonprofit organisations and public or private institutions may apply. PA-13-251

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 09 Jul 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-251.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-251>



Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care; Pathogenesis; HIV/Aids;
Chronic Care; Epidemiology; Clinical
Medicine; Alcoholism; Public Health, Health
Services & Primary Care

Contact Details

NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 594 6231
Email: rbreslow@mail.nih.gov

S ECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R03): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute of Alcohol Abuse and Alcoholism invites applications for its Aids-related secondary analyses of alcohol and chronic disease (R03) grants. This Aids-related R03 funding opportunity announcement aims to support secondary analyses of alcohol related to chronic disease aetiology and epidemiology. The goal of this programme is to facilitate innovative yet cost-effective research using previously collected data.

This funding opportunity announcement will use the NIH small grant programme (R03) mechanism and runs in parallel with two FOA of identical scientific scope, PA-13-260, which solicits applications under the R01 research project grant mechanism, and PA-13-251, which solicits applications under the R21 exploratory/developmental research grant mechanism.

Direct costs are limited to US\$100,000 over a two-year project period, with no more than US\$50,000 in any year. Domestic and foreign for-profit and nonprofit organisations and public or private institutions may apply. PA-13-261.

Closing date: 07 Sep 16

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 09 Jul 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-261.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-261>

Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care; Public Health, Health Services & Primary Care; Pathogenesis; Chronic Care; Clinical Medicine; Epidemiology; Alcoholism; HIV/Aids

Contact Details

NIAAA
5635 Fishers Lane



Rockville, MD 20852
Tel: +1 301 594 6231

Email: rbreslow@mail.nih.gov

IMPPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING-RELATED BEHAVIOURS AND PREVENTION RESEARCH (R21): AIDS-RELATED

— NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related implications of new digital media use for underage drinking, drinking-related behaviours and prevention research (R21) grants. This Aids-related R21 funding opportunity announcement aims to investigate whether, and how, heaving involvement in new digital media use, particularly social media and social networking sites, may influence adolescent alcohol use and drinking patterns, as well as drinking-related problems. The FOA also encourages studies exploring the ways new digital media may be use as platforms for preventative interventions aimed at underage drinking and related problems.

This funding opportunity announcement will use the NIH exploratory/development research grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-262, which solicits applications under the R01 research project grant mechanism.

Direct costs are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in any year. Domestic and foreign for-profit and non-profit organisations and public or private institutions may apply. PA-13-263.

Closing date: 07 Sep 16

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 09 Jul 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-263.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-263>

Eligibility profile

Country of applicant institution: Any

Disciplines

Social Behaviour & Attitudes; Sociology; Public Health, Health Services & Primary Care; Primary Care; Communication & Media Studies; Alcoholism; Business & Management Studies; Communication Studies; Social Networks & Social Media; Networking Protocols; HIV/Aids; Media Studies

Contact Details

NIAAA

5635 Fishers Lane

Rockville, MD 20852

Tel: +1 301 443 8820

Email: rfreeman@mail.nih.gov



S ECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute of Alcohol Abuse and Alcoholism invites applications for its Aids-related secondary analyses of alcohol and chronic disease (R01) grants. This Aids-related R01 funding opportunity announcement aims to support secondary analyses of alcohol related to chronic disease aetiology and epidemiology. The goal of this programme is to facilitate innovative yet cost-effective research using previously collected data.

This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with two FOA of identical scientific scope, PA-13-261, which solicits applications under the R03 small grant programme mechanism and PA-13-251, which solicits applications under the R21 exploratory/developmental research grant mechanism.

Direct costs are not limited, but must reflect the needs of the project. The maximum project period is five years. Domestic and foreign for-profit and nonprofit organisations and public or private institutions may apply. PA-13-260.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 09 Jul 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-260.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-260>

Eligibility profile

Country of applicant institution: Any

Disciplines

Chronic Care; Pathogenesis; Epidemiology; HIV/Aids; Alcoholism; Public Health, Health Services & Primary Care; Clinical Medicine; Primary Care

Contact Details

NIAAA

5635 Fishers Lane

Rockville, MD 20852

Tel: +1 301 594 6231

Email: rbreslow@mail.nih.gov

I MPPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING-RELATED BEHAVIOURS AND PREVENTION RESEARCH (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related implications of new digital media use

for underage drinking, drinking-related behaviours and prevention research (R01) grants. This Aids-related R01 funding



opportunity announcement aims to investigate whether, and how, heaving involvement in new digital media use, particularly social media and social networking sites, may influence adolescent alcohol use and drinking patterns, as well as drinking-related problems. The FOA also encourages studies exploring the ways new digital media may be use as platforms for preventative interventions aimed at underage drinking and related problems.

This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-263, which solicits applications under the R21 exploratory/developmental research grant mechanism.

Direct costs are not limited, but must reflect the needs of the project. The maximum project period is five years. Domestic and foreign for-profit and nonprofit organisations and public or private institutions may apply. PA-13-262.

Closing date: 07 Sep 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 09 Jul 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-262.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-262>

Eligibility profile

Country of applicant institution: Any

Disciplines

Communication & Media Studies; Media Studies; Networking Protocols; Public Health, Health Services & Primary Care; Social Networks & Social Media; Primary Care; Sociology; Social Behaviour & Attitudes; Alcoholism; Communication Studies; Business & Management Studies; HIV/Aids

Contact Details

NIAAA
 5635 Fishers Lane
 Rockville, MD 20852
 Tel: +1 301 443 8820
 Email: rfreeman@mail.nih.gov

SYNERGISING OMIC AND SYMPTOM SCIENCE (R01): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research invites applications for its Aids-related synergising omic and symptom science (R01) grants. This Aids-related R01 funding opportunity announcement aims to promote integration of diverse information from molecular and biological processes with patient-reported outcomes.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PA-13-264.

Closing date: 07 Sep 16



Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 10 Jul 13

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-264.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-264>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biological Sciences; HIV/Aids; Genomics; Carbohydrates; Medical Effectiveness & Patient Outcomes; Pharmacogenomics; Proteomics & Molecular Interactions; Pharmacy & Pharmacology; Diagnostic Sciences; Epigenetics

Contact Details

NINR

6701 Democracy Boulevard

Bethesda, MD 20817

Tel: + 301 496 9623

Email: mardens@mail.nih.gov

SYSTEMIC AMYLOIDOSIS: BASIC, TRANSLATIONAL AND CLINICAL RESEARCH (R01): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

The National Institute of Diabetes and Digestive and Kidney Disease, the National Cancer Institute and the National Institute on Aging invite applications for their Aids-related systemic amyloidosis: basic, translational and clinical research (R01) grants. This Aids-related R01 funding opportunity announcement will support basic and clinical research projects that advance understanding of pathogenic mechanisms underlying systemic amyloidosis, develop improved techniques for the clinical detection and diagnosis of systemic amyloid diseases, develop novel cellular and in vivo models to identify candidate therapeutic agents with, and evaluate the clinical efficacy of novel therapies designed to prevent, arrest and reverse the morbid and lethal progression of these diseases.

Eligible applicants include domestic and foreign for-profit or non-profit organisations

and public or private institutions. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. PA-13-286.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 29 Jul 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-286.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-286>



Eligibility profile

Country of applicant institution: Any

Disciplines

Biological Sciences; Medical & Diagnostic Tests; HIV/Aids; Chemistry; Protein Synthesis, Modification & Turnover; Pharmacotherapy; Primary Care; Diagnostic Sciences; Structural Biology; Public Health, Health Services & Primary Care; Cell Physiology & Metabolism; Protein

Trafficking; Pharmacy & Pharmacology; Nursing; Clinical Medicine; Pathogenesis; Non-Communicable Diseases; Biological Macromolecules, Physical Characteristics

Contact Details

NIDDK
6707 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 594 6007
Email: rasoolyr@mail.nih.gov

B BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R21): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The National Institute of Child Health and Human Development invites applications for Aids-related its biomarkers: bridging paediatric and adult therapeutics (R21) grants. This Aids-related R21 funding opportunity announcement invites applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to paediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy. Projects supported will be confined to those biomarkers that correlate with a clinical observation, have been extensively studied in adults, and for which there is solid evidence that they have paediatric applications. Discovery of new biomarkers for use in new drug development or in preclinical studies are not part of this FOA.

This funding opportunity announcement will use the NIH exploratory/developmental research grant award (R21) mechanism and runs in parallel with two FOAs of identical scientific scope: PAR-13-299, which solicits applications under the small grants

programme (R03) mechanism and PAR-13-296, which solicits applications under the research project grant (R01) mechanism.

Direct costs are limited to US\$275,000 over two years, with no more than US\$200,000 in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-295 (replaces PAR-11-324).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 02 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-295.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-295>



Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine; Medical Instrumentation; Biochemical Markers; Biological Markers & Sensor Mechanisms; Diagnostic Sciences; Drug Design; Medical & Diagnostic Tests; Paediatrics; HIV/Aids

Contact Details

Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard, Room 4A01C, MSC 7510
Bethesda, MD 20892
Tel: +1 301 496 5589
Email: gg65m@nih.gov

B BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R03): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The National Institute of Child Health and Human Development invites applications for its Aids-related biomarkers: bridging paediatric and adult therapeutics (R03) grants. This Aids-related R03 funding opportunity announcement invites applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to paediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy. Projects supported will be confined to those biomarkers that correlate with a clinical observation, have been extensively studied in adults, and for which there is solid evidence that they have paediatric applications. Discovery of new biomarkers for use in new drug development or in preclinical studies are not part of this FOA.

This funding opportunity announcement will use the NIH small grants programme (R03) mechanism and runs in parallel with two FOAs of identical scientific scope: PA-13-296, which solicits applications under the research project grants (R01) mechanism and PA-13-295, which solicits applications under the

exploratory/developmental grant (R21) mechanism. Applicants may request up to US\$50,000 per year in direct costs for a maximum of two years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-299 (replaces PAR-11-323).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 02 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-299.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-299>



Eligibility profile

Country of applicant institution: Any

Disciplines

Drug Design; Biochemical Markers; Biological Markers & Sensor Mechanisms; Medical Instrumentation; Paediatrics; HIV/Aids; Diagnostic Sciences; Clinical Medicine; Medical & Diagnostic Tests

Contact Details

Obstetric and Paediatric Pharmacology and Therapeutics Branch
 NICHD
 6100 Executive Boulevard, Room 4A01C, MSC 7510
 Bethesda, MD 20892
 Tel: +1 301 496 5589
 Email: gg65m@nih.gov

THE ROLE OF THE CYTOSKELETON IN CELLULAR AGEING (R21/R33): AIDS-RELATED

NIH: National Institute on Aging

Description:

The National Institute on Aging invites applications for its Aids-related role of the cytoskeleton in cellular ageing (R21/R33) grants. This Aids-related R21/R33 funding opportunity announcement aims to stimulate the development of innovative research strategies to increase understanding of the molecular and cellular changes in the cytoskeleton that occur during the ageing process. Applications considering the effect of age on factors such as cytoskeleton structure and function, the impact of the cytoskeleton on intracellular organelle interactions, and the signalling or regulatory molecules controlling cellular architecture are encouraged. There is also interest in studying the role of the cytoskeleton in nuclear-cytoplasmic communications and in spatio-temporal relationships during the ageing process and in age-related diseases.

The total project period for the combined R21/R33 application submitted in response to this FOA may not exceed five years and total direct costs are limited to \$1.18 million. The R21 phase may not exceed two years or \$275,000 in direct costs. The R33 phase may not exceed three years or \$900,000 in direct costs.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-301.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 02 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$1,175,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-301.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-301>

Eligibility profile

Country of applicant institution: Any

Disciplines

Cell & Developmental Biology; HIV/Aids; Biological Sciences; Biochemistry & Molecular



Biology; Geriatrics & Gerontology; Diagnostic Sciences; Cell Physiology & Metabolism

7201 Wisconsin Avenue
Bethesda, MD 20814
Tel: +1 301 496 6428
Email: jvelazqu@mail.nih.gov

Contact Details

NIA

B IOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R01): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The National Institute of Child Health and Human Development invites applications for its Aids-related biomarkers: bridging paediatric and adult therapeutics (R01) grants. This Aids-related R01 funding opportunity announcement invites applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to paediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy. Projects supported will be confined to those biomarkers that correlate with a clinical observation, have been extensively studied in adults, and for which there is solid evidence that they have paediatric applications. Discovery of new biomarkers for use in new drug development or in preclinical studies are not part of this FOA.

This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with two FOAs of identical scientific scope: PAR-13-299, which solicits applications under small grants programme (R03) mechanism and PAR-13-295, which solicits applications under the exploratory/developmental grant (R21) programme. Application budgets are not limited, but must reflect actual needs of the project. The project period is a maximum of five years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-296 (replaces PAR-11-322).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 September 2016. Deadlines on: 7 September 2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 02 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-296.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-296>

Eligibility profile

Country of applicant institution: Any

Disciplines

Diagnostic Sciences; HIV/Aids; Paediatrics; Clinical Medicine; Biochemical Markers; Medical Instrumentation; Biological Markers



& Sensor Mechanisms; Drug Design; Medical
& Diagnostic Tests

Contact Details

Obstetric and Paediatric Pharmacology and
Therapeutics Branch
NICHD

6100 Executive Boulevard, Room 4A01C, MSC
7510

Bethesda, MD 20892

Tel: +1 301 496 5589

Email: gg65m@nih.gov

BEHAVIOURAL AND SOCIAL SCIENCE RESEARCH ON UNDERSTANDING AND REDUCING HEALTH DISPARITIES (R21): AIDS-RELATED

NIH: Office of the Director

Description:

Participating institutes and centres of the National Institutes of Health invite applications for Aids-related behavioural and social science research on understanding and reducing health disparities (R21) grants. This R21 funding opportunity announcement supports behavioural and social science research on the causes and solutions to health and disabilities disparities in the US population. Emphasis is placed on research in and among three broad areas of action:

- public policy;
- healthcare;
- disease and disability prevention.

Particular attention is given to reducing health gaps among groups. Proposals that use an interdisciplinary approach, investigate multiple levels of analysis, incorporate a life-course perspective, or employ innovative methods such as system science or community-based participatory research are particularly encouraged.

This FOA will utilise the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PAR13-292, which solicits applications under the R01 mechanism. Direct costs are limited to US\$275,000 over an R21 two year period, with

no more than US\$200,000 in direct costs allowed in any single year.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-288 (replaces PAR-10-137).

Closing date: 07 Sep 16

Deadline information: Deadlines by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 05 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-288.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Health Systems Policy; Primary Care; Behavioural Medicine; HIV/Aids; Preventive Medicine; Health Disparities; Care for Disabled People; Population Studies, Medical;



Allied Health Professions; Medical Sociology; Public Health, Health Services & Primary Care; Clinical Medicine; Economic & Social Environment; Sociology; Psychology; Social Work & Social Policy; Public Health; Rural Health; Disadvantaged & Minority Groups; Health Systems

Contact Details

OBSSR
31 Center Drive
Building 31, Room B1C19
Bethesda, MD 20892-2027
Tel: +1 301 451 4286
Email: michael.spittel@mail.nih.gov

BEHAVIOURAL AND SOCIAL SCIENCE RESEARCH ON UNDERSTANDING AND REDUCING HEALTH DISPARITIES (R01): AIDS-RELATED *NIH: Office of the Director*

Description:

Participating institutes and centres of the National Institutes of Health invite applications for Aids-related behavioural and social science research on understanding and reducing health disparities (R01) grants. This Aids-related R01 funding opportunity announcement supports behavioural and social science research on the causes and solutions to health and disabilities disparities in the US population. Emphasis is placed on research in and among three broad areas of action:

- public policy;
- healthcare;
- disease and disability prevention.

Particular attention is given to reducing health gaps among groups. Proposals that use an interdisciplinary approach, investigate multiple levels of analysis, incorporate a life-course perspective, or employ innovative methods such as system science or community-based participatory research are particularly encouraged.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-288, which solicits applications under the R21 mechanism. Projects may last up to five years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-292 (replaces PAR-10-136).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 05 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-292.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-292>

Eligibility profile

Country of applicant institution: Any

Disciplines

Social Work & Social Policy; Sociology; Medical Sociology; Economic & Social Environment; Psychology; Health Systems; Rural Health; HIV/Aids; Health Systems



Policy; Population Studies, Medical; Health Disparities; Behavioural Medicine; Clinical Medicine; Public Health; Care for Disabled People; Public Health, Health Services & Primary Care; Preventive Medicine; Disadvantaged & Minority Groups; Primary Care; Allied Health Professions

Contact Details

OBSSR
31 Center Drive
Building 31, Room B1C19
Bethesda, MD 20892-2027
Tel: +1 301 451 4286
Email: michael.spittel@mail.nih.gov

GUT MICROBIOTA-DERIVED FACTORS IN THE INTEGRATED PHYSIOLOGY AND PATHOPHYSIOLOGY OF DISEASES WITHIN NIDDK'S MISSION (R01): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

The National Institute of Diabetes and Kidney Diseases invites applications for its Aids-related gut microbiota-derived factors in the integrated physiology and pathophysiology of diseases within NIDDK's mission (R01) grants. This Aids-related R01 funding opportunity announcement supports research to define interactions between the host and the gut microbiota that regulate normal physiology and pathopathology of diseases within NIDDK's mission. The goal is to discover specific human gut microbiota-derived factors that affect or are affected by host physiology, homeostasis and disease pathophysiology. Projects will also define the specific factors and pathway microbiota-derived factors use to affect host processes within the gut or distant organ sites.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. PAR-13-293.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 05 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-293.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-293>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/ Aids; Biological Sciences; Gastroenterology; Waste Recycling, Reduction & Recovery; Diagnostic Sciences; Microbial Ecology

Contact Details

Division of Digestive Diseases and Nutrition
NIDDK
6707 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 451 3759
Email: greymj@mail.nih.gov



AUDACIOUS GOALS INITIATIVE HIGH PRIORITY RESEARCH AREA – INTERSECTION OF AGEING AND BIOLOGICAL MECHANISMS OF EYE DISEASE (R01): AIDS-RELATED

NIH: National Eye Institute

Description:

The National Eye Institute and the National Institute on Aging invites applications for its audacious goals initiative high priority research area: intersection of ageing and biological mechanisms of eye disease (R01): Aids-related grants. This Aids-related R01 funding opportunity announcement aims to improve understanding of the intersection between ageing and the biological mechanism of eye disease. The following research areas are of interest:

- understanding how the biology of ageing contributes to disease;
- valuating how the failure of homeostatic processes causes or allows the transition from aging to early disease;
- defining the biological staging of disease to understand pathophysiology, identify biomarkers and explore therapy;
- distinguishing normal ocular changes associated with aging from pathophysiologic changes;
- investigate the diverse cellular, molecular, genetic, and neural circuitry mechanisms underlying age-related changes in the eye;
- ascertain the impact of age-related changes in the eye on the progression of visual function as well as associated brain or behavioral functions for the aged and the utility of such changes as early biomarkers for pathological processes for the aged;
- identify and evaluate interventions that will modify age-related changes to alter the course of pathological development.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PA-13-332.

Closing date: 07 Sep 16

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 15 Aug 13

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-332.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-332>

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine; Diagnostic Sciences; Biochemical Markers; Pathophysiology; Geriatrics & Gerontology; Eye Diseases; Biological Markers & Sensor Mechanisms; HIV/Aids

Contact Details

NEI
5635 Fishers Lane
Rockville MD, 20852
Tel: +1 301 451 2020
Email: mckiegeo@nei.nih.gov

S **TRATEGIC ALLIANCES FOR MEDICATIONS DEVELOPMENT TO TREAT SUBSTANCE USE DISORDERS (R01): AIDS-RELATED**

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its strategic alliances for medications development to treat substance use disorders (R01). The purpose of this Aids-related R01 funding opportunity announcement is to support research that advances compounds towards US Food and Drug Administration approval by leveraging NIDA funds with the strengths and resources of outside organisations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

Application budgets for direct costs may be up to \$3 million per year, but need to reflect the actual needs of the proposed project. The maximum period of support is three years. PAR-13-334 (Reissue of PAS-12-122).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation. Deadlines on: 7 May 2014, 7 September 2014, 7 May 2015, 7 September 2015, 7 May 2016, 7 September 2016.

Posted date: 20 Aug 13

Award type: Directed grants to institutions, research groups etc, Academic-Industry links, Clinical trials, Networking/collaboration

Award amount max: \$6,000,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-334.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-334>

Eligibility profile

Country of applicant institution: Any

Disciplines

Blood Tests; Clinical Medicine; Drug Design; Primary Care; Pharmaceutical Drugs; Diagnostic Sciences; Pharmacy & Pharmacology; Public Health, Health Services & Primary Care; Drug & Substance Abuse; Methods of Drug Delivery; HIV/Aids

Contact Details

Division of Pharmacotherapies and Medical Consequences of Drug Abuse

NIDA

6001 Executive Boulevard

Bethesda, MD 20892-9561

Tel: +1 301 443 8096

Email: jb168r@nih.gov





M MECHANISMS OF ALCOHOL AND STIMULANT CO-ADDICTION (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their Aids-related mechanisms of alcohol and stimulant co-addiction (R21) grants. This Aids-related R21 funding opportunity announcement promotes research on neurobiological and behavioural mechanisms that might explain how alcohol and stimulants interact at genetic, epigenetic, cellular, neurocircuitry and behavioural levels to promote co-addiction.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PAR-13-339, which solicits applications under the R01 research project grant mechanism. Direct costs are limited to US\$275,000 over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-340.

Closing date: 07 Sep 16

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 29 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-340.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-340>

Eligibility profile

Country of applicant institution: Any

Disciplines

Addiction; Behavioural Medicine; Psychology; Public Health, Health Services & Primary Care; Drug & Substance Abuse; Biological Sciences; Neurobiology; Diagnostic Sciences; Primary Care; HIV/Aids; Alcoholism

Contact Details

NIAAA

6000 Executive Boulevard

Bethesda, MD 20892-7003

Tel: +1 301 443 7600

Email: igrakalic@mail.nih.gov

M MECHANISMS OF ALCOHOL AND STIMULANT CO-ADDICTION (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their Aids-

related mechanisms of alcohol and stimulant co-addiction (R01) grants. This Aids-related R01 funding opportunity announcement



promotes research on neurobiological and behavioural mechanisms that might explain how alcohol and stimulants interact at genetic, epigenetic, cellular, neurocircuitry and behavioural levels to promote co-addiction.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PAR-13-340, which solicits applications under the R21 exploratory/developmental grant mechanism. Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-339.

Closing date: 07 Sep 16

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 29 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-339.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-339>

Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism; Drug & Substance Abuse; HIV/Aids; Public Health, Health Services & Primary Care; Behavioural Medicine; Psychology; Addiction; Biological Sciences; Neurobiology; Diagnostic Sciences; Primary Care

Contact Details

NIAAA

6000 Executive Boulevard

Bethesda, MD 20892-7003

Tel: +1 301 443 7600

Email: igrakalic@mail.nih.gov

EXPLOATORY/DEVELOPMENTAL CLINICAL RESEARCH GRANTS IN OBESITY (R21): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

The National Institute of Diabetes and Digestive and Kidney Diseases, the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and the Office of Dietary Supplements invite applications for their exploratory/developmental clinical research grants in obesity (R21) funding opportunity announcement. This Aids-related announcement supports exploratory and developmental clinical studies that accelerate the development of effective interventions for

prevention or treatment of overweight or obesity in adults and children. Exploratory epidemiological research with a goal of informing translational and clinical research may also be supported.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US\$275,000 in direct costs with up to



US\$200,00 in direct costs per year. The maximum project period is two years.

Ref: PA-15-163 (reissue of PA-12-179).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 30 Mar 15

Award type: Directed grants to institutions, research groups etc, Clinical trials, Innovation grants

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-163.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Obesity

Contact Details

NIDDK

BG 2DEM Room 673

6707 Democracy Boulevard

Bethesda MD 20817

+1 301 451 8354

Email: kuczmarskir@mail.nih.gov

DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R03): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The National Institute of Child Health and the Office of Rare Diseases invite applications for the development of appropriate formulations and paediatric drug delivery systems (R03): Aids-related grants. This Aids-related R03 funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Development and testing of novel paediatric drug delivery systems is also part of this initiative. This FOA also encourages development of novel drug delivery systems in the paediatric population. Investigators are encouraged to explore approaches and concepts new to the area of paediatric formulation development, testing and use of newly developed techniques superior to the ones currently used in the field.

This funding opportunity announcement will use the NIH research project R03 grant mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-325, which solicits applications under the research project grant (R01) mechanism and PAR-13-326, which solicits applications under the exploratory/developmental research grant award (R21) mechanism.

Application budgets are limited to US\$100,000 over a two-year project period, with no more than US\$50,000 in direct costs per year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-344 (replaces PAR-11-302).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7



May and 7 September until 8 September 2016.

Posted date: 05 Sep 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-344.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-344>

Eligibility profile

Country of applicant institution: Any

Disciplines

Paediatrics; Allied Health Professions; Drug Design; Methods of Drug Delivery; Pharmacy & Pharmacology; Clinical Medicine; Diagnostic Sciences

Contact Details

NICHHD

Obstetric and Paediatric Pharmacology and Therapeutics Branch

6100 Executive Boulevard, Room 4A01C, MSC 7510

Bethesda, MD 20852

Tel: +1 301 496 5589

Email: gg65m@nih.gov

DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R21): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The National Institute of Child Health and the National Institute on Deafness and Other Communication Disorders invite applications for the development of appropriate formulations and paediatric drug delivery systems (R21): Aids-related grants. This Aids-related R21 funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Development and testing of novel paediatric drug delivery systems is also part of this initiative.

This funding opportunity announcement will use the NIH research project R21 grant mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-325, which solicits applications under the research project grant (R01) mechanism and PAR-13-344, which solicits applications under the small grant award (R03) mechanism.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in direct costs per year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-326 (replaces PAR-11-303)

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 05 Sep 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-326.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-326>

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine; Diagnostic Sciences; Drug Design; Allied Health Professions; Paediatrics;

Pharmacy & Pharmacology; Methods of Drug Delivery

Contact Details

NICHHD
Obstetric and Paediatric Pharmacology and Therapeutics Branch
6100 Executive Boulevard, Room 4A01C, MSC 7510
Bethesda, MD 20852
Tel: +1 301 496 5589
Email: gg65m@nih.gov

DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R01): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The National Institute of Child Health and the National Institute on Deafness and Other Communication Disorders invite applications for the development of appropriate formulations and paediatric drug delivery systems (R01): Aids-related grants. This Aids-related R01 funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Development and testing of novel paediatric drug delivery systems is also part of this initiative.

This funding opportunity announcement will use the NIH research project R01 grant mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-344, which solicits applications under the small grant (R03) mechanism and PAR-13-326, which solicits applications under the exploratory/developmental research grant award (R21) mechanism.

Application budgets are not limited, but should reflect the actual needs of the project.

The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-325 (replaces PAR-11-301).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 05 Sep 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-325.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-325>

Eligibility profile

Country of applicant institution: Any



Disciplines

Paediatrics; Clinical Medicine; Methods of Drug Delivery; Pharmacy & Pharmacology; Allied Health Professions; Drug Design; Diagnostic Sciences

Contact Details

NICHD

Obstetric and Paediatric Pharmacology and Therapeutics Branch

6100 Executive Boulevard, Room 4A01C, MSC 7510

Bethesda, MD 20852

Tel: +1 301 496 5589

Email: gg65m@nih.gov

EARLY-CAREER AWARD IN CHEMISTRY OF DRUG ABUSE AND ADDICTION (R21/R33): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related early-career award in chemistry of drug abuse and addiction (R21/R33). This Aids-related R21/R33 funding opportunity announcement seeks to facilitate the entry of new-to-NIH investigators into basic chemistry research applied to drug abuse and addiction.

Direct costs are limited to US\$250,000 over a R21 two-year period, with a maximum of US\$200,000 allowed in any single year. The R33 award phase will be limited to US\$250,000 in direct costs per year. The total project period for an application submitted in response to this funding opportunity may not exceed four years. Awards will support milestone driven exploratory/feasibility proof of concept studies (R21 phase, up to two years), with possible rapid transition to expedited development (R33 phase, up to three years, depending upon the requested period for the R21 phase). Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PAR-13-350 (replaces PAS-10-274).

Closing date: 07 Sep 16

Deadline information: Submissions due by 5pm proposers's local time, every 7 January,

7 May and 7 September until 8 September 2016.

Posted date: 12 Sep 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$1,000,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-350.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-350>

Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care; Psychology; Drug & Substance Abuse; Alcoholism; Clinical Chemistry; Public Health, Health Services & Primary Care; Biological Sciences; Neurobiology; Addiction; HIV/Aids

Contact Details

Division of Basic Neuroscience and Behavioral Research

NIDA

6001 Executive Boulevard



Bethesda, MD 20892-9555
Tel: +1 301 443 9800

Email: boughk@mail.nih.gov



ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R03): AIDS-RELATED

NIH: National Institute on Aging

Description:

The National Institute on Aging and the the National Center for Complementary and Alternative Medicine invite applications for their grants for advancing the science of geriatric palliative care. This Aids-related R03 funding opportunity announcement encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasises studies in a variety of settings including ambulatory care, hospitals, assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programmes. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.

This FOA uses the R03 small grant programme mechanism and runs in parallel with two of identical scientific scope: PA-13-354, which solicits applications under the R01 research project grant mechanism, and PA-13-355, which solicits applications under the R21 exploratory/developmental grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit

organisations and public and private organisations.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The total project period may not exceed two years; direct costs are limited to US\$50,000 per year. PA-13-356.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation.

Deadlines on: 7 September 2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 20 Sep 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-356.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Social Work & Social Policy; Geriatrics & Gerontology; Palliative Nursing; Nursing; Primary Care; Public Health, Health Services & Primary Care; Pharmaceutical Drugs; Health Counselling; Geriatric Nursing; Hospice & Palliative Care; Health Systems; HIV/Aids; Pain Management; Clinical Medicine; Chronic Pain; Hospitalisation;



Clinical Pharmacy & Pharmacology; Blood Tests; Pharmacy & Pharmacology

Contact Details

NIA

7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: +1 301 496 6761
Email: basil.eldadah@nih.gov

A ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R21): AIDS-RELATED

NIH: National Institute on Aging

Description:

The National Institute on Aging and the the National Center for Complementary and Alternative Medicine invite applications for their grants for advancing the science of geriatric palliative care. This Aids-related R21 funding opportunity announcement encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasises studies in a variety of settings including ambulatory care, hospitals, assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programmes. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with two of identical scientific scope: PA-13-356, which solicits applications under the R03 small grant programme mechanism, and PA-13-354,

which solicits applications under the R01 research project grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The total project period may not exceed two years; the combined budget for direct costs over this period may not exceed US\$275,000. No more than US\$200,000 may be requested in any single year. PA-13-355.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation.

Deadlines on: 7 September 2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 20 Sep 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-355.html>

Eligibility profile

Country of applicant institution: Any



Disciplines

Geriatrics & Gerontology; Nursing; Pain Management; Health Counselling; Pharmacy & Pharmacology; Public Health, Health Services & Primary Care; HIV/Aids; Hospitalisation; Geriatric Nursing; Health Systems; Pharmaceutical Drugs; Clinical Pharmacy & Pharmacology; Primary Care; Blood Tests; Chronic Pain; Hospice &

Palliative Care; Clinical Medicine; Palliative Nursing; Social Work & Social Policy

Contact Details

NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: +1 301 496 6761
Email: basil.eldadah@nih.gov

A DVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R01): AIDS-RELATED NIH: National Institute on Aging

Description:

The National Institute on Aging and the the National Center for Complementary and Alternative Medicine invite applications for their grants for advancing the science of geriatric palliative care. This Aids-related R01 funding opportunity announcement encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasises studies in a variety of settings including ambulatory care, hospitals, assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programmes. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.

This FOA uses the R01 research project grant mechanism and runs in parallel with two of

identical scientific scope: PA-13-356, which solicits applications under the R03 small grant programme mechanism, and PA-13-355, which solicits applications under the R21 exploratory/developmental grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years. PA-13-354.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation.

Deadlines on: 7 September 2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 20 Sep 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-13-354.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-354>

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Pharmacy & Pharmacology; Health Systems; Chronic Pain; Pharmacy & Pharmacology; Geriatric Nursing; Nursing; Clinical Medicine; HIV/Aids; Public Health,

Health Services & Primary Care; Social Work & Social Policy; Health Counselling; Blood Tests; Pharmaceutical Drugs; Geriatrics & Gerontology; Palliative Nursing; Primary Care; Hospitalisation; Pain Management; Hospice & Palliative Care

Contact Details

NIA

7201 Wisconsin Avenue

Suite 2C231 MSC 9205

Bethesda, MD 20892-9205

Tel: +1 301 496 6761

Email: basil.eldadah@nih.gov

**MODELLING SOCIAL BEHAVIOUR (R01): AIDS-RELATED**

NIH: National Institute of General Medical Sciences

Description:

A total of 10 institutes and offices of the National Institutes of Health invites applications for their Aids-related modelling social behaviour (R01) call. This Aids-related R01 funding opportunity announcement aims to develop and test innovative theories and computational, mathematical or engineering approaches to deepen understanding of complex social behaviour. This research will examine phenomena at multiple scales to address the emergence of collective behaviours that arise from individual elements or parts of a system working together.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. Transdisciplinary teams are encouraged, including at minimum researchers with expertise in the behavioural or social sciences as well as those in computational and systems modelling.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years for new and early-stage investigators, and four years for established investigators.

Ref: PAR-13-374.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm, local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 18 Oct 13

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-13-374.html>

Eligibility profile

Country of applicant institution: Any



Disciplines

Social Behaviour & Attitudes; Computer Simulation & Modelling; Computer Science & Informatics; HIV/Aids; Sociology

Contact Details

NIGMS
45 Center Drive
Bethesda, MD 20814
Tel: +1 301 594 2987
Email: marcusst@mail.nih.gov

NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (COLLABORATIVE R01): AIDS-RELATED

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health invites applications for its new computational methods for understanding the functional role of DNA variants that are associated with mental disorders (collaborative R01): Aids-related grants. The aim of this collaborative R01 funding opportunity announcement is to support Aids-related development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex aetiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness. This should take into account the added complexities and nuances of brain diseases, and ultimately inform the identification and validation of potential targets for novel treatment development.

This FOA is suitable when two or more sites are needed to complete the study. Each site must have its own programme director or principal investigator. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

MIMH will invest US\$3 million in fiscal year 2015 to fund this and a companion FOA. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is three years.

Ref: PAR-13-391.

Closing date: 07 Sep 16

Deadline information: Deadlines 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 14 Nov 13

Award type: Directed grants to institutions, research groups etc,
Networking/collaboration

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-391.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PAR-13-391>

Eligibility profile

Country of applicant institution: Any



Disciplines

Pathogenesis; Computer Science & Informatics; Diagnostic Sciences; Mental Health; Telemedicine; Bioinformatics; Psychology; Structural Biology; Human Genome; Health & Medical Informatics; Systematics; Deoxyribonucleic Acid, DNA; Biostatistics; Mental Illness

Contact Details

NIMH
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6653
Email: anjene.addington@nih.gov

NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (R01): AIDS-RELATED

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health invites applications for its new computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01): Aids-related grants. The aim of this R01 funding opportunity announcement is to support Aids-related development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex aetiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness. This should take into account the added complexities and nuances of brain diseases, and ultimately inform the identification and validation of potential targets for novel treatment development.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

MIMH will invest US\$3 million in fiscal year 2015 to fund this and a companion FOA. Application budgets are not limited, but must

reflect the needs of the project. The maximum project period is three years.

Ref: PAR-13-391.

Closing date: 07 Sep 16

Deadline information: Deadlines 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 14 Nov 13

Award type: Directed grants to institutions, research groups etc,
Networking/collaboration

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-392.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PAR-13-392>

Eligibility profile

Country of applicant institution: Any



Disciplines

Mental Illness; Psychology; Biostatistics; Telemedicine; Pathogenesis; Systematics; Mental Health; Health & Medical Informatics; HIV/Aids; Structural Biology; Computer Science & Informatics; Diagnostic Sciences; Deoxyribonucleic Acid, DNA; Bioinformatics; Human Genome

Contact Details

NIMH
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6653
Email: anjene.addington@nih.gov

PUBLIC HEALTH IMPACT OF THE CHANGING POLICY/LEGAL ENVIRONMENT FOR MARIJUANA (R01): AIDS-RELATED NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related public health impact of the changing policy/legal environment for marijuana (R01) grants. This Aids-related R01 funding opportunity announcement encourages research on the impact of changing marijuana policies and laws on public health outcomes. This includes:

- marijuana exposure among children, adolescents and adults;
- other licit and illicit drug use;
- education and professional achievement;
- social development;
- risky behaviours;
- mental health;
- HIV.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

NIH will invites US\$3 million in fiscal year 2014 to fund six to ten awards. Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is three years.

Ref: PAS-14-020.

Closing date: 07 Sep 16

Deadline information: Submissions due by 5pm proposers's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 09 Dec 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAS-14-020.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Addiction; Drug & Substance Abuse; Social Behaviour & Attitudes; Pharmacokinetics; Medical Effectiveness & Patient Outcomes; Cognitive & Behavioural Therapies; Primary Care; Health Systems Policy; Public Health; Mental Health; Child Development; Sociology; Social Work & Social Policy; Clinical Medicine; Educational Evaluation & Assessment; Behavioural Medicine;



Psychology; Public Health, Health Services & Primary Care; Diagnostic Sciences; HIV/ Aids; Blood Tests; Education

Contact Details

NIDA
6001 Executive Boulevard
Rockville, MD 20852
Tel: +1 301 443 6504
Email: lopezmar@mail.nih.gov

NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R21): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites Aids-related applications for its grants on neuroimmune signalling and function in substance abuse disorders (R21). This Aids-related R21 funding opportunity announcement aims to examine the molecular, cellular, circuit and behavioural responses to neuroimmune signalling within the central nervous system. Research should pertain to the initiation, escalation and maintenance of the neurological consequences resulting from substance use disorders and to abstinence, withdrawal and relapse. The goal is to determine the extent to which neuroimmune responses contribute to or protect against the risk and consequences of SUDs.

This FOA will use the R21 exploratory/developmental research grant mechanism, and runs in parallel with an FOA of identical scientific scope, PA-14-084, which encourages applications under the R01 research project grant mechanism.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in any year.

Ref: PAR-14-083.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposers's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 05 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-083.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-083>

Eligibility profile

Country of applicant institution: Any

Disciplines

Public Health, Health Services & Primary Care; Primary Care; Cell & Developmental Biology; Pathology; Neuroscience; Biological Sciences; Behavioural Medicine; Psychology; Ethology & Comparative Psychology; HIV/Aids; Diagnostic Sciences; Drug & Substance Abuse; Biochemistry & Molecular Biology; Cytopathology



Contact Details

NIDA

6001 Executive Boulevard

Bethesda, MD 20892-9561

Tel: +1 301 443 3205

Email: rsorensen@mail.nih.gov

NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R01): AIDS-RELATED NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites Aids-related applications for its grants on neuroimmune signalling and function in substance abuse disorders (R01). This Aids-related R01 funding opportunity announcement aims to examine the molecular, cellular, circuit and behavioural responses to neuroimmune signalling within the central nervous system. Research should pertain to the initiation, escalation and maintenance of the neurological consequences resulting from substance use disorders and to abstinence, withdrawal and relapse. The goal is to determine the extent to which neuroimmune responses contribute to or protect against the risk and consequences of SUDs.

This FOA will use the R01 research project grant mechanism, and runs in parallel with an FOA of identical scientific scope, PA-14-083, which encourages applications under the R21 exploratory/developmental research grant mechanism.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-084.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 05 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-084.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-14-084>

Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care; Cell & Developmental Biology; Neuroscience; HIV/Aids; Cytopathology; Biological Sciences; Psychology; Drug & Substance Abuse; Ethology & Comparative Psychology; Public Health, Health Services & Primary Care; Pathology; Behavioural Medicine; Biochemistry & Molecular Biology; Diagnostic Sciences

Contact Details

NIDA

6001 Executive Boulevard



Bethesda, MD 20892-9561
Tel: +1 301 443 3205

Email: rsorensen@mail.nih.gov

SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R03): AIDS-RELATED NIH: National Institute on Drug Abuse

Description:

The NIH's National Institute on Drug Abuse invites Aids-related applications for its substance use and abuse, risky decision making and HIV/Aids funding opportunity announcement. This R03 program is intended to stimulate Aids-related research that will increase understanding of the way people make decisions about engaging in behaviours that impact the risk of acquiring or transmitting HIV, or to adhere to treatments for HIV. Decision making processes may contribute to both substance use/abuse and other HIV acquisition or transmission risks.

This FOA encourages applications to study cognitive, motivational or emotional mechanisms and brain neuroendocrine and reinforcement systems that relate to HIV-risk behaviours or treatment non-compliance. Interdisciplinary studies that incorporate approaches from psychology, economics, anthropology, sociology, decision sciences, neuroscience and computational modelling are encouraged.

This FOA for R03 applications is intended to support pilot and feasibility studies, small, self-contained research projects, development of research methodology, and development of new research technology that can be carried out in a short period of time with limited resources.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Budgets for direct costs of up to US\$50,000 per year and a project duration of up to two years may be requested for a maximum of US\$100,000 direct costs over a two-year project period.

This FOA will utilise the NIH small research grant (R03) mechanism and runs in parallel with FOAs of identical scientific scope, PA-14-061, that encourages applications under the R01 mechanisms and PA-14-062 that encourages applications under the R21 mechanism. PA-14-063 (reissue of PA-11-008)

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 19 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-063.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-063>

Eligibility profile

Country of applicant institution: Any



Disciplines

Physiology; HIV/Aids; Pharmacokinetics; Clinical Psychology; Pharmacy & Pharmacology; Social Work & Social Policy; Public Health, Health Services & Primary Care; Addiction; Sociology; Economic & Social Environment; Political Risk Factors & Analysis; Neuropsychology; Chemistry; Drug & Substance Abuse; Gender Roles & Sexuality; Diagnostic Sciences; Decision Science; Medical Sociology; Neurobiology;

Psychology; Biological Sciences; Toxicology; Neuropharmacology

Contact Details

Division of Clinical Neurosciences and Behavior Research
NIDA
6001 Executive Boulevard, Rm 3173
Rockville, MD 20852-9555
Tel: +1 301 435 1318
Fax: +1 301 594 6043
Email: ylin1@nida.nih.gov

SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R01): AIDS-RELATED NIH: National Institute on Drug Abuse

Description:

The NIH's National Institute on Drug Abuse invites applications for its drug abuse, risky decision making and HIV/Aids funding opportunity announcement. This Aids-related R01 funding opportunity announcement intends to stimulate model driven research that will increase understanding of the way people make decisions about engaging in behaviours that impact the risk of acquiring or transmitting HIV, or to adhere to treatments for HIV. Decision making processes may contribute to both substance use and abuse and other HIV acquisition or transmission risks.

This announcement encourages applications to study cognitive, motivational or emotional mechanisms and brain neuroendocrine and reinforcement systems that relate to HIV-risk behaviors or treatment non-compliance. Interdisciplinary studies that incorporate approaches from psychology, economics, anthropology, sociology, decision sciences, neuroscience and computational modelling are encouraged.

The total project period for an application submitted in response to this funding opportunity announcement may not exceed five years. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. This FOA utilises the NIH R01 research project grant award mechanism and runs in parallel with FOAs of identical scientific scope, PA-14-062, that solicits applications under the R21 mechanism and PA-14-063 that solicits applications under the R03 mechanism.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum funding period is five years.

Ref: PA-14-061 (reissue of PA-11-006)

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 19 Feb 14



Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-061.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-061>

Eligibility profile

Country of applicant institution: Any

Disciplines

Public Health, Health Services & Primary Care; Addiction; Gender Roles & Sexuality; Chemistry; Biological Sciences; Sociology;

Psychology; Computer Science & Informatics; Political Risk Factors & Analysis; Toxicology; Pharmacokinetics; Computer Simulation & Modelling; Pharmacy & Pharmacology; Social Work & Social Policy; Drug & Substance Abuse; Neurobiology; Decision Science; Economic & Social Environment; Physiology; Diagnostic Sciences; Clinical Psychology; Neuropharmacology; Medical Sociology; HIV/Aids

Contact Details

Division of Clinical Neurosciences and Behavior Research
NIDA

6001 Executive Boulevard, Rm 3173
Rockville, MD 20852-9555

Email: +1 301 435 1318

Fax: +1 301 594 6043

Email: ylin1@nida.nih.gov

ERADICATION OF HIV-1 FROM CENTRAL NERVOUS SYSTEM RESERVOIRS (R01)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health, the National Institute of Allergy and Infectious Disease, the National Institute on Drug Abuse and the National Institute of Neurological Disorders and Stroke invite research applications for their eradication of HIV infection of central nervous system reservoirs (R01) grants. This R01 programme announcement aims to address the problem of HIV-1 persistence focused solely on the CNS of persons treated with highly active anti-retroviral therapy. This FOA will support research in the following areas:

- basic research to identify and characterise persistent HIV-1 in CNS derived cells such as macrophages, microglia or astrocytes in the setting

of suppressive anti-retroviral therapy, with or without substance use;

- basic research to determine the mechanisms involved in the temporal establishment, maintenance and resurgence of persistent HIV-1 in the CNS in relationship to the timing of antiretroviral therapy;
- development of physiologically relevant animal models and CNS-based cellular assays that recapitulate HIV-1 persistence and latency in the presence of effective HAART including effects of chronic substance use;
- assessment of current and emerging eradication approaches on whether or how well they have successfully



reactivated persistent HIV from CNS-derived cells such as macrophages, microglia and astrocytes;

- assessment of CNS toxicity and adverse impacts of current and emerging eradication strategies.

Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PA-14-095.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 12 Feb 14

Award type: Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-095.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-14-095>

Eligibility profile

Country of applicant institution: Any

Disciplines

Central Nervous System; Neuropsychology; Infectious Diseases; Neurobiology; Preventive Medicine; General Practice & Family Health; Cellular Interactions; HIV/Aids; Neuroimaging; Medical & Diagnostic Tests; Psychology; Nucleus & Organelles; Pathogenesis; Primary Care; Proteomics & Molecular Interactions; Antivirals; Virology; Human Biological Sciences; Neurology; Biological Sciences; Clinical Medicine; Diagnostic Sciences; Public Health, Health Services & Primary Care; Infection Agents & Pathogens; Physiology; Molecular Genetics

Contact Details

NIMH
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 443 6100
Email: jjeymoha@mail.nih.gov



CLINICAL VISION RESEARCH: RESOURCE CENTRE GRANT (UG1): AIDS-RELATED

NIH: National Eye Institute

Description:

The National Eye Institute invites Aids-related applications for its clinical vision research: resource centre grant (UG1). This Aids-related UG1 funding opportunity

announcement supports single component resource centres to provide imaging, laboratory or other requisite services for a



multi-centre clinical trial or other complex or high-risk clinical vision research study.

This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-098, PAR-14-099 and PAR-14-100, each of which invites applications under the UG1 mechanism.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-097.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 13 Feb 14

Award type: Research centres, Directed grants to institutions, research groups etc, Clinical trials

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-097.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do>

Eligibility profile

Country of applicant institution: Any

Disciplines

Sensory Systems; Diagnostic Sciences; Optometry; Drug Design; Vision Science; Eye Diseases; HIV/ Aids; Epidemiology

Contact Details

NEI

5635 Fishers Lane

Bethesda, MD 20892-9300

Tel: +1 301 451 2020

Email: everettd@mail.nih.gov

CLINICAL VISION RESEARCH: CHAIR'S GRANT (UG1): AIDS-RELATED

NIH: National Eye Institute

Description:

The National Eye Institute invites Aids-related applications for its clinical vision research: chair's grant (UG1). This Aids-related UG1 funding opportunity announcement supports the scientific rationale, study aims and significance of the research project.

This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope,

PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-097, PAR-14-099 and PAR-14-100, each of which invites applications under the UG1 mechanism.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.



Ref: PAR-14-098.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 13 Feb 14

Award type: Clinical trials, Directed grants to institutions, research groups etc, Research centres

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-098.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do>

Eligibility profile

Country of applicant institution: Any

Disciplines

Optometry; Epidemiology; Diagnostic Sciences; Sensory Systems; Vision Science; HIV/Aids; Drug Design; Eye Diseases

Contact Details

NEI

5635 Fishers Lane

Bethesda, MD 20892-9300

Tel: +1 301 451 2020

Email: everettd@mail.nih.gov

C CLINICAL VISION RESEARCH: CLINICAL CENTRE GRANT (UG1): AIDS-RELATED

NIH: National Eye Institute

Description:

The National Eye Institute invites Aids-related applications for its clinical vision research: clinical centre grant (UG1). This Aids-related UG1 funding opportunity announcement supports the organisation and operations of the clinical centre responsible for recruitment and retention of study participants and implementation of the study protocol.

This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-097, PAR-14-098 and PAR-14-100, each of which invites applications under the UG1 mechanism.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-099.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 13 Feb 14

Award type: Research centres, Directed grants to institutions, research groups etc, Clinical trials

Award amount max: -

Award budget total: -

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-099.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do>

Eligibility profile

Country of applicant institution: Any

Disciplines

Epidemiology; Diagnostic Sciences; HIV/Aids; Optometry; Vision Science; Eye Diseases; Sensory Systems; Drug Design

Contact Details

NEI
5635 Fishers Lane
Bethesda, MD 20892-9300
Tel: +1 301 451 2020
Email: everettd@mail.nih.gov



CLINICAL VISION RESEARCH: COORDINATING CENTRE GRANT (UG1): AIDS-RELATED

NIH: National Eye Institute

Description:

The National Eye Institute invites Aids-related applications for its clinical vision research: coordinating centre grant (UG1). This Aids-related UG1 funding opportunity announcement supports the provision of details of the coordinating centre's responsibilities and operations.

This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-097, PAR-14-098 and PAR-14-099, each of which invites applications under the UG1 mechanism.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-100.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 13 Feb 14

Award type: Directed grants to institutions, research groups etc, Clinical trials, Research centres

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-100.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug Design; HIV/Aids; Diagnostic Sciences; Eye Diseases; Vision Science; Optometry; Sensory Systems; Epidemiology



Contact Details

NEI
5635 Fishers Lane

Bethesda, MD 20892-9300
Tel: +1 301 451 2020
Email: everettd@mail.nih.gov

SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R03): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related call on synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R03). This Aids-related R03 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies.

This FOA uses the R03 small grant programme grant mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-14-105 and PAR-14-106 which use the R21 exploratory/developmental and R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum two year project period may not exceed US\$100,000. No more than US\$50,000 in direct costs may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.

Ref: PAR-14-014.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 21 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-104.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-104>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; General Practice & Family Health; Diagnostic Sciences; Drug Design; Public Health, Health Services & Primary Care; Psychology; Chemistry; Drug & Substance Abuse; Pharmacokinetics; Primary Care; Behavioural Medicine; Clinical Medicine; Methods of Drug Delivery.

Contact Details

Tel: +1 301 435 1304
Email: rrapaka@nida.nih.gov



SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R21): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related call on synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R21). This Aids-related R21 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-104 and PA-14-106 which use the R03 small grant and R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum two year project period may not exceed US\$275,000. No more than US\$200,000 may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.

Ref: PA-14-105.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 21 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-105.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-105>

Eligibility profile

Country of applicant institution: Any

Disciplines

Pharmacokinetics; Primary Care; Public Health, Health Services & Primary Care; General Practice & Family Health; Drug Design; HIV/Aids; Chemistry; Methods of Drug Delivery; Drug & Substance Abuse; Behavioural Medicine; Psychology; Clinical Medicine; Diagnostic Sciences

Contact Details

Tel: +1 301 435 1304

Email: rrapaka@nida.nih.gov

SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related call on

synthetic psychoactive drugs and strategic approaches to counteract their deleterious



effects (R01). This Aids-related R01 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies.

This FOA uses the R01 research project grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-105 and PA-14-106 which use the R21 exploratory/developmental and R03 small grant mechanisms respectively.

Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.

Ref: PA-14-106.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 21 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-106.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-106>

Eligibility profile

Country of applicant institution: Any

Disciplines

Diagnostic Sciences; General Practice & Family Health; Drug Design; Primary Care; Drug & Substance Abuse; Public Health, Health Services & Primary Care; HIV/Aids; Methods of Drug Delivery; Behavioural Medicine; Pharmacokinetics; Clinical Medicine; Chemistry; Psychology

Contact Details

Tel: +1 301 435 1304

Email: rrapaka@nida.nih.gov

FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R01): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research invites applications for its Aids-related call on family-centred self-management of chronic conditions (R01). This Aids-related R01 funding opportunity announcement seeks to build on the science of family-centred self-management in chronic conditions.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-113, which uses the R21 exploratory/developmental research grant mechanism.

Foreign or US for-profit and non-profit organisations and public and private organisations may apply.



Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-14-112.

Closing date: 07 Sep 16
Deadline information: Applications due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 25 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-112.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Social Programmes; Social Work & Social Policy; HIV/Aids; Public Health, Health Services & Primary Care; Chronic Care; Primary Care; Community Health Services

Contact Details

Tel: +1 301 594 5970

Email: hussk@mail.nih.gov

FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R21): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research invites applications for its Aids-related call on family-centred self-management of chronic conditions (R21). This Aids-related R21 funding opportunity announcement seeks to build on the science of family-centred self-management in chronic conditions.

This FOA uses the R21 exploratory/developmental research grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-112, which uses the R01 research project grant mechanism.

Foreign or US for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-14-113.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 25 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-113.html>



Eligibility profile

Country of applicant institution: Any

Disciplines

Social Programmes; Social Work & Social Policy; HIV/Aids; Chronic Care; Public

Health, Health Services & Primary Care; Primary Care; Community Health Services

Contact Details

Tel: +1 301 594 5970

Email: hussk@mail.nih.gov



ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its alcohol-induced effects on tissue injury and repair (R21) grants. This Aids-related R21 funding opportunity announcement supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. The NIAAA is especially interested in integrative research that elucidates alcohol's effects on complex mechanisms of injury and repair that are either common or specific to each organ system. The call also encourages the study of alcohol's effect on stem cells, embryonic development and regeneration, as well as the studies on molecular and cellular actions of moderate alcohol consumption.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-123, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US\$275,000 over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

Ref:PA-14-124.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-124.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-124>

Eligibility profile

Country of applicant institution: Any

Disciplines

Pathophysiology; Regenerative Medicine; Diagnostic Sciences; Stem Cell; Stem Cell Genomics; Cytopathology; Biological Sciences; Traumatology, Accidents & Injury;



Embryonic Stem Cells; HIV/Aids; Pathology; Alcoholism; Cellular Interactions; Stem Cell Therapy; Foetal Health & Prenatal Development; Induced Pluripotent Stem Cells

Contact Details

Tel: +1 301 443 7351

Email: duntyw@mail.nih.gov

ADVANCING STRUCTURAL LEVEL INTERVENTIONS THROUGH ENHANCED UNDERSTANDING OF SOCIAL DETERMINANTS IN HIV PREVENTION AND CARE (R21)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute of Allergy and Infectious Disease invite applications for their advancing structural level interventions through enhanced understanding of social determinants in HIV prevention and care (R21) grants. This R21 funding opportunity announcement aims to understand and address social determinants associated with the prevention and treatment of HIV. This FOA supports two research endeavours:

- characterising the social determinants that are most relevant to HIV prevention and treatment outcomes, particularly in association with inequities in HIV risk or outcomes;
- developing and testing structural interventions aimed at reducing the negative impact or maximising positive aspects of social determinants.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-133, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US\$275,000 over a two-year period, with no more than

US\$200,000 in direct costs allowed in any single year.

Ref: PA-14-134.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm, local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-134.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-134>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biomedical Engineering; HIV/Aids; Primary Care; Public Health, Health Services & Primary Care; Diagnostic Sciences; Health Disparities; Preventive Medicine



Contact Details

NIMH
NSC BG RM 6117
6001 Executive Blvd

Rockville MD 20852
Tel: +1 301 443 8962
Email: grossmanc@mail.nih.gov

IMPROVING DELIVERY OF HIV PREVENTION AND TREATMENT THROUGH IMPLEMENTATION SCIENCE AND TRANSLATIONAL RESEARCH (R21)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their improving delivery of HIV prevention and treatment through implementation science and translational research (R21) grant. This R21 funding opportunity announcement encourages research designed to increase the public health impact of efficacious HIV/Aids-related interventions for prevention and treatment.

The goals of this scientific agenda are to learn how best to deliver interventions more efficiently and effectively in real-world communities and clinics, to more readily transfer interventions from one setting or population to another, and to make better informed choices for combination intervention packages.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-131, which solicits applications under the R01 research project grant mechanism.

Direct costs are limited to US\$275,000 over a two year project period, with no more than US\$200,000 allowed in any single year. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.

Ref: PA-14-129.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-129.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-129>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; General Practice & Family Health; Primary Care; Pharmaceutical Drugs; Health Counselling; Public Health; Psychology; Diagnostic Sciences; Preventive Medicine; Clinical Medicine; Social Work & Social Policy; Population Studies, Medical; Public Health, Health Services & Primary Care; Biomedical Engineering



Contact Details

NIMH
NSC BG
Room 6106

6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 1613
Email: cgordon1@mail.nih.gov

S TRENGTHENING ADHERENCE TO ANTIRETROVIRAL-BASED HIV TREATMENT AND PREVENTION (R21) NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their strengthening adherence to antiretroviral-based HIV treatment and prevention (R21) grant. This R21 funding opportunity announcement supports research to understand and promote adherence to antiretroviral regimens for HIV treatment and prevention. Studies addressing pre-exposure prophylaxis and antiretroviral therapy are the foci of this FOA. The emphasis is on the development of feasible interventions to improve and sustain PrEP or ART adherence, which could be rapidly implemented to improve HIV treatment and prevention outcomes.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-126, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US\$275,000 over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

Ref: PA-14-125.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm, local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-125.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-125>

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine; Virology; General Practice & Family Health; Preventive Medicine; HIV/Aids; Public Health, Health Services & Primary Care; Diagnostic Sciences; Primary Care; Antivirals

Contact Details

NIMH
NSC BG



Room 6116
6001 Executive Boulevard
Rockville MD 20852

Tel: +1 301 443 6802
Email: stirrattm@mail.nih.gov



ACCCELERATING IMPROVEMENTS IN THE HIV CARE CONTINUUM (R21)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their strengthening adherence to antiretroviral-based HIV treatment and prevention (R21) grant. This R21 funding opportunity announcement supports innovative studies to address gaps in HIV care continuum research. Research should focus on less-studies aspects of entering and remaining in HIV care.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-132, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US\$275,000 over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

Ref: PA-14-130.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm, local time of applicant organisation,

every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-130.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-130>

Eligibility profile

Country of applicant institution: Any

Disciplines

Standards of Care; Access to Health Care; Diagnostic Sciences; HIV/Aids; Quality of Care; Primary Care; Public Health, Health Services & Primary Care; Health Systems, Consumer Choice; Clinical Medicine; Blood Tests

Contact Details

Tel: +1 301 443 1613

Email: cgordon1@mail.nih.gov





ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its alcohol-induced effects on tissue injury and repair (R01) grants. This Aids-related R01 funding opportunity announcement supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. The NIAAA is especially interested in integrative research that elucidates alcohol's effects on complex mechanisms of injury and repair that are either common or specific to each organ system. The call also encourages the study of alcohol's effect on stem cells, embryonic development and regeneration, as well as the studies on molecular and cellular actions of moderate alcohol consumption.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-124, which solicits applications under the R21 exploratory/developmental grant mechanism. US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Ref: PA-14-123.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation,

every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-123.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-123>

Eligibility profile

Country of applicant institution: Any

Disciplines

Traumatology, Accidents & Injury; Diagnostic Sciences; Induced Pluripotent Stem Cells; Cellular Interactions; Stem Cell Therapy; Pathology; Regenerative Medicine; Alcoholism; Cytopathology; Biological Sciences; Stem Cell; Pathophysiology; HIV/Aids; Embryonic Stem Cells; Stem Cell Genomics; Foetal Health & Prenatal Development

Contact Details

Tel: +1 301 443 7351

Email: duntyw@mail.nih.gov

ADVANCING STRUCTURAL LEVEL INTERVENTIONS THROUGH ENHANCED UNDERSTANDING OF SOCIAL DETERMINANTS IN HIV PREVENTION AND CARE (R01)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute of Allergy and

Infectious Disease invite applications for their advancing structural level interventions



through enhanced understanding of social determinants in HIV prevention and care (R01) grants. This R01 funding opportunity announcement aims to understand and address social determinants associated with the prevention and treatment of HIV. This FOA supports two research endeavours:

- characterising the social determinants that are most relevant to HIV prevention and treatment outcomes, particularly in association with inequities in HIV risk or outcomes;
- developing and testing structural interventions aimed at reducing the negative impact or maximising positive aspects of social determinants.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-134, which solicits applications under the R21 exploratory/developmental grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Ref: PA-14-133.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm, local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-133.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-133>

Eligibility profile

Country of applicant institution: Any

Disciplines

Preventive Medicine; Primary Care; Diagnostic Sciences; Public Health, Health Services & Primary Care; Biomedical Engineering; Health Disparities; HIV/Aids

Contact Details

NIMH
NSC BG RM 6117
6001 Executive Blvd
Rockville MD 20852
Tel: +1 301 443 8962
Email: grossmanc@mail.nih.gov

IMPROVING DELIVERY OF HIV PREVENTION AND TREATMENT THROUGH IMPLEMENTATION SCIENCE AND TRANSLATIONAL RESEARCH (R01)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their improving delivery of HIV prevention

and treatment through implementation science and translational research (R01) grant. This R01 funding opportunity announcement encourages research designed to increase the



public health impact of efficacious HIV/Aids-related interventions for prevention and treatment.

The goals of this scientific agenda are to learn how best to deliver interventions more efficiently and effectively in real-world communities and clinics, to more readily transfer interventions from one setting or population to another, and to make better informed choices for combination intervention packages.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-129, which solicits applications under the R21 exploratory/developmental grant mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.

Ref: PA-14-131.

Closing date: 07 Sep 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-131.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-131>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biomedical Engineering; General Practice & Family Health; Clinical Medicine; HIV/Aids; Population Studies, Medical; Psychology; Public Health; Diagnostic Sciences; Health Counselling; Primary Care; Public Health, Health Services & Primary Care; Pharmaceutical Drugs; Preventive Medicine; Social Work & Social Policy

Contact Details

NIMH
 NSC BG
 Room 6106
 6001 Executive Boulevard
 Rockville MD 20852
 Tel: +1 301 443 1613
 Email: cgordon1@mail.nih.gov

S TRENGTHENING ADHERENCE TO ANTIRETROVIRAL-BASED HIV TREATMENT AND PREVENTION (R01) NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their strengthening adherence to antiretroviral-based HIV treatment and

prevention (R01) grant. This R01 funding opportunity announcement supports research to understand and promote adherence to antiretroviral regimens for HIV treatment and prevention. Studies addressing pre-exposure



prophylaxis and antiretroviral therapy are the foci of this FOA. The emphasis is on the development of feasible interventions to improve and sustain PrEP or ART adherence, which could be rapidly implemented to improve HIV treatment and prevention outcomes.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-125, which solicits applications under the R21 exploratory/developmental grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Ref: PA-14-126.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm, local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-126.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-126>

Eligibility profile

Country of applicant institution: Any

Disciplines

Public Health, Health Services & Primary Care; General Practice & Family Health; Diagnostic Sciences; Clinical Medicine; Primary Care; Antivirals; Preventive Medicine; HIV/Aids; Virology

Contact Details

NIMH
NSC BG
Room 6116
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6802
Email: stirrattm@mail.nih.gov



ACCELERATING IMPROVEMENTS IN THE HIV CARE CONTINUUM (R01)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their strengthening adherence to antiretroviral-based HIV treatment and prevention (R01) grant. This R01 funding opportunity announcement supports innovative studies to address gaps in HIV care continuum research. Research should

focus on less-studied aspects of entering and remaining in HIV care.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-130, which solicits applications under the R21 exploratory/developmental grant mechanism.



US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Ref: PA-14-132.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-132.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-132>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Primary Care; Health Systems; Consumer Choice; Diagnostic Sciences; Quality of Care; Clinical Medicine; Access to Health Care; Public Health, Health Services & Primary Care; Standards of Care; Blood Tests

Contact Details

Tel: +1 301 443 1613

Email: cgordon1@mail.nih.gov

PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R34): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related grants on the prevention and treatment of substance using populations with or at risk for hepatitis C virus (R34). This Aids-related R34 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. This FOA supports the initial development of a clinical trial or research project focused on HCV for at-risk substance using populations, including those with or at risk for HIV.

This FOA uses the R34 planning grant mechanism, and runs in parallel with two

FOAs of identical scientific scope, PA-14-136 and PA-14-137, which use the R21 exploratory/developmental grant mechanism and the R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum three year project period may not exceed US\$450,000. No more than US\$225,000 may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.

Ref: PA-14-135.



Closing date: 07 Sep 16
 Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.
 Posted date: 04 Mar 14
 Award type: Directed grants to institutions, research groups etc
 Award amount max: \$450,000
 Award budget total: -
 Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-135.html>

Application form:
<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-135>

Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care; Infection Agents & Pathogens; General Practice & Family Health; Drug & Substance Abuse; Public Health, Health Services & Primary Care; Diagnostic Sciences; HIV/Aids; Drug Design; Infectious Diseases; Preventive Medicine; Hepatology

Contact Details

NIDA
 6001 Executive Boulevard
 Bethesda, MD 20892
 Tel: +1 301 443 3207
 Email: aklinwm@nida.nih.gov

PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R21): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related grants on the prevention and treatment of substance using populations with or at risk for hepatitis C virus (R21). This Aids-related R21 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. This FOA supports the initial development of a clinical trial or research project focused on HCV for at-risk substance using populations, including those with or at risk for HIV.

This FOA uses the R21 exploratory/developmental grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-135 and PA-14-137, which use the R34 planning grant

mechanism and the R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum two year project period may not exceed US\$275,000. No more than US\$200,000 may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.

Ref: PA-14-136.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 04 Mar 14



Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-136.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-136>

Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care; Public Health, Health Services & Primary Care; General Practice & Family Health; Drug & Substance Abuse; Preventive Medicine; Hepatology; Infection Agents & Pathogens; Diagnostic Sciences; HIV/Aids; Drug Design; Infectious Diseases

Contact Details

NIDA

6001 Executive Boulevard

Bethesda, MD 20892

Tel: +1 301 443 3207

Email: aklinwm@nida.nih.gov

NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its grants on neuroimmune mechanisms of alcohol-related disorders (R21). This Aids-related R21 funding opportunity announcement seeks studies to address the role of neuroimmune modulation in response to and in the neuroadaptation of the brain to acute and chronic alcohol exposure, and alcohol dependence and withdrawal. The goal is to achieve fundamental insights of neuroimmune mechanisms underlying brain functional and behavioural changes induced by alcohol.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-139 which uses the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US\$275,000 over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

Ref: PA-14-138.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 04 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-138.html>



Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-138>

Eligibility profile

Country of applicant institution: Any

Disciplines

Neurology; Clinical Medicine; HIV/Aids; Immunology; Biological Sciences; Behavioural

Medicine; Neuroscience; Neuropsychology; Neuroendocrinology; Psychology; Neurobiology; Alcoholism; Endocrine & Neuroendocrine Cancers; Diagnostic Sciences; Ethology & Comparative Psychology

Contact Details

NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 443 1678
Email: changhai.cui@nih.gov

PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related grants on the prevention and treatment of substance using populations with or at risk for hepatitis C virus (R01). This Aids-related R01 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. This FOA supports the initial development of a clinical trial or research project focused on HCV for at-risk substance using populations, including those with or at risk for HIV.

This FOA uses the R01 research project grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-135 and PA-14-136, which use the R34 planning grant mechanism and the R21 exploratory/developmental grant mechanisms respectively.

Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.

Ref: PA-14-137.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 04 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-137.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-137>

Eligibility profile



Country of applicant institution: Any

Disciplines

Public Health, Health Services & Primary Care; Drug Design; General Practice & Family Health; Infectious Diseases; Hepatology; Drug & Substance Abuse; HIV/Aids; Preventive Medicine; Diagnostic Sciences; Infection Agents & Pathogens; Primary Care

Contact Details

NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 443 3207
Email: aklinwm@nida.nih.gov

NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its grants on neuroimmune mechanisms of alcohol-related disorders (R01). This Aids-related R01 funding opportunity announcement seeks studies to address the role of neuroimmune modulation in response to and in the neuroadaptation of the brain to acute and chronic alcohol exposure, and alcohol dependence and withdrawal. The goal is to achieve fundamental insights of neuroimmune mechanisms underlying brain functional and behavioural changes induced by alcohol.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-138, which uses the R21 exploratory/developmental grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Ref: PA-14-139 (re-issue of PA-11-064).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 04 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-139.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-139>

Eligibility profile

Country of applicant institution: Any

Disciplines

Neuroscience; Alcoholism; Behavioural Medicine; Immunology; Neurobiology; Diagnostic Sciences; Psychology; Ethology &



Comparative Psychology; Neuropsychology;
Neuroendocrinology; Biological Sciences;
HIV/Aids; Clinical Medicine; Neurology;
Endocrine & Neuroendocrine Cancers

NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 443 1678
Email: changhai.cui@nih.gov

Contact Details

COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R21): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research invites Aids-related applications for its community partnerships to advance research (R21). This Aids-related R21 funding opportunity announcement encourages researchers to partner with communities using community engaged research methodologies that will enhance relationships leading to better interventions and positive health outcomes.

This funding opportunity announcement will use the NIH R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-142, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in any year.

Ref: PAR-14-141.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 05 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-141.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-141>

Eligibility profile

Country of applicant institution: Any

Disciplines

Medical Research of Selected Fields; Pharmaceutical Drugs; HIV/Aids; Clinical Medicine; Primary Care; Medical Effectiveness & Patient Outcomes; Public Health, Health Services & Primary Care; Biomedical Engineering; Translational Medicine; Nursing

Contact Details

NINR
National Institutes of Health
31 Center Drive, Room 5B10
Bethesda MD 20892-2178



Tel: +1 301 594 5971

Email: mccloskd@mail.nih.gov

COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R01): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research invites Aids-related applications for its community partnerships to advance research (R01). This Aids-related R01 funding opportunity announcement encourages researchers to partner with communities using community engaged research methodologies that will enhance relationships leading to better interventions and positive health outcomes.

This funding opportunity announcement will use the NIH R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-141, which solicits applications under the R21 exploratory/developmental research grant award mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-142.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 05 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-142.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-142>

Eligibility profile

Country of applicant institution: Any

Disciplines

Translational Medicine; Medical Research of Selected Fields; Clinical Medicine; Nursing; HIV/Aids; Primary Care; Medical Effectiveness & Patient Outcomes; Biomedical Engineering; Pharmaceutical Drugs; Public Health, Health Services & Primary Care

Contact Details

NINR

National Institutes of Health

31 Center Drive, Room 5B10

Bethesda MD 20892-2178

Tel: +1 301 594 5971

Email: mccloskd@mail.nih.gov



ESTABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R21): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research invites Aids-related applications for its grants on establishing behavioural and social measures for causal pathway research in dental, oral and craniofacial health (R21). This Aids-related R21 funding opportunity announcement aims to establish measures of specific behavioural or social phenomena to test causal hypotheses about behavioural and social contributors to dental, oral or craniofacial diseases. This announcement encourages the development and testing of two types of measures:

- measures of the health behaviours, social interactions, community characteristics, built environments, targeted by behavioural or social interventions to improve oral health;
- measures of the hypothesised moderators and mediators of a behavioural or social intervention's effect.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-143, which uses the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions may apply.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in any year.

Ref: PAR-14-144.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 06 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-144.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PAR-14-144>

Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care; Dentistry; Restorative Dentistry; Oral & Maxillofacial Surgery; Dental Health & Hygiene; Paediatric Dentistry; Craniofacial Disorders; Medical Education; Oral Medicine; Preventive Dentistry; Behavioural Medicine; Special Needs Dentistry; HIV/Aids; Public Health, Health Services & Primary Care; Psychology

Contact Details

NIDCR

6701 Democracy Boulevard
Bethesda, MD 20817

Tel: +1 301 451 3888

Email: riddleme@mail.nih.gov



ESTABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R01): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research invites Aids-related applications for its grants on establishing behavioural and social measures for causal pathway research in dental, oral and craniofacial health (R01). This Aids-related R01 funding opportunity announcement aims to establish measures of specific behavioural or social phenomena to test causal hypotheses about behavioural and social contributors to dental, oral or craniofacial diseases. This announcement encourages the development and testing of two types of measures:

- measures of the health behaviours, social interactions, community characteristics, built environments, targeted by behavioural or social interventions to improve oral health;
- measures of the hypothesised moderators and mediators of a behavioural or social intervention's effect.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-144, which uses the R21 exploratory/developmental grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-143.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 06 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-143.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PAR-14-144>

Eligibility profile

Country of applicant institution: Any

Disciplines

Psychology; Preventive Dentistry; HIV/Aids; Medical Education; Behavioural Medicine; Oral & Maxillofacial Surgery; Restorative Dentistry; Dentistry; Oral Medicine; Craniofacial Disorders; Public Health, Health Services & Primary Care; Paediatric Dentistry; Dental Health & Hygiene; Special Needs Dentistry; Primary Care

Contact Details

NIDCR

6701 Democracy Boulevard

Bethesda, MD 20817

Tel: +1 301 451 3888

Email: riddleme@mail.nih.gov



EARLY STAGE DEVELOPMENT OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01): AIDS-RELATED

NIH: National Institute of General Medical Sciences

Description:

A total of 12 institutes and offices of the National Institutes of Health invite applications for their Aids-related grants on early stage development of technologies in biomedical computing, informatics and big data science (R01). This Aids-related R01 funding opportunity announcement aims to promote a broad base of research and development of technologies in biomedical computing, informatics and big data science that will support rapid progress in areas of scientific opportunity in biomedical research. Applications should develop enabling technologies that could apply to the interests of most NIH institutes and centres and range from basic biomedicine and including research to all relevant organ systems and diseases.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. Application budgets may not exceed US\$300,000 direct costs per year, over a maximum project period of three years. Ref: PA-14-155.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 17 Mar 14

Award type: Directed grants to institutions, research groups etc, Prototypes and demonstrations

Award amount max: \$900,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-155.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-155>

Eligibility profile

Country of applicant institution: Any

Disciplines

Research Management; Computer Science & Informatics; Bioinformatics; Health & Medical Informatics; Innovation & Technology Management; Diagnostic Sciences; Biotechnology; Informatics & Big Data; Biological Sciences; HIV/Aids; Engineering Standards & Specifications; Therapy Evaluation; Disease Control; Biomolecular Modelling

Contact Details

NIGMS

45 Center Drive

Bethesda, MD 20814

Tel: +1 301 451 6446

Email: lysterp@mail.nih.gov

EXTENDED DEVELOPMENT, HARDENING AND DISSEMINATION OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01): AIDS-RELATED

NIH: National Institute of General Medical Sciences

**Description:**

A total of 12 institutes and offices of the National Institutes of Health invite applications for their Aids-related grants on extended development, hardening and dissemination of technologies in biomedical computing, informatics and big data science (R01). This Aids-related R01 funding opportunity announcement supports the extended development, maintenance, testing, evaluation, hardening and dissemination of existing biomedical software. The scheme aims to promote a broad base of research and development of technologies in biomedical computing, informatics and big data science that will support rapid progress in areas of scientific opportunity in biomedical research. Applications should develop enabling technologies that could apply to the interests of most NIH institutes and centres and range from basic biomedicine and including research to all relevant organ systems and diseases.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-14-156.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 17 Mar 14

Award type: Technology innovation/development, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-156.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-156>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biotechnology; Health & Medical Informatics; HIV/Aids; Computer Science & Informatics; Research Management; Engineering Standards & Specifications; Bioinformatics; Innovation & Technology Management; Biomolecular Modelling; Therapy Evaluation; Diagnostic Sciences; Biological Sciences; Informatics & Big Data; Disease Control

Contact Details

NIGMS

45 Center Drive

Bethesda, MD 20814

Tel: +1 301 451 6446

Email: lysterp@mail.nih.gov

T RANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R21): AIDS-RELATED

NIH: National Institute on Aging

Description:

The National Institute on Aging and the National Institute of Biomedical Imaging and

Bioengineering invite applications for their Aids-related call on translational research to



help older adults maintain their health and independence in the community (R21). This Aids-related R21 funding opportunity announcement supports translational research collaborations between academic research centres and community-based organisations with expertise in serving or engaging older adults to develop tools, techniques, programmes or policies to respond to the needs of the ageing population.

This FOA uses the R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-161, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in any year.

Ref: PAR-14-159 (replaces PAR-11-124).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 21 Mar 14

Award type: Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: £275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-159.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true?oppNum=PA-14-159>

Eligibility profile

Country of applicant institution: Any

Disciplines

Geriatrics & Gerontology; Home Health Care Services; HIV/Aids; Social Programmes; Psychology of Ageing; Social Work & Social Policy; Public Health, Health Services & Primary Care; Accessibility for Disabled People; Primary Care; Psychology; Access to Health Care; Health Systems Policy

Contact Details

NIA

7201 Wisconsin Avenue

Bethesda, MD 20814

Tel: +1 301 402 4156

Email: kingjo@nia.nih.gov

T RANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R01): AIDS-RELATED

NIH: National Institute on Aging

Description:

The National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering invite applications for their Aids-related call on translational research to help older adults maintain their health and independence in the community (R01). This

Aids-related R01 funding opportunity announcement supports translational research collaborations between academic research centres and community-based organisations with expertise in serving or engaging older adults to develop tools, techniques,



programmes or policies to respond to the needs of the ageing population.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-159, which solicits applications under the R21 exploratory/developmental research grant award mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-161 (replaces PAR-11-123).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 21 Mar 14

Award type: Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-161.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-14-161>

Eligibility profile

Country of applicant institution: Any

Disciplines

Psychology of Ageing; Accessibility for Disabled People; HIV/Aids; Psychology; Health Systems Policy; Primary Care; Home Health Care Services; Public Health, Health Services & Primary Care; Access to Health Care; Social Work & Social Policy; Geriatrics & Gerontology; Social Programmes

Contact Details

NIA

7201 Wisconsin Avenue

Bethesda, MD 20814

Tel: +1 301 402 4156

Email: kingjo@nia.nih.gov

EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R21): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related call on the effects of cannabis use and cannabinoids on the developing brain (R21). This Aids-related R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through

young adulthood in animal models and humans.

This FOA uses the R21 exploratory/developmental grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-163 and PA-14-164, which use the R01 research project grant mechanism and the R03 small research grant mechanism respectively.



US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in any year.

Ref: PA-14-162.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 27 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-162.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application->

[package.html#download=true?oppNum=PA-14-162](http://grants.nih.gov/grants/guide/pa-files/PA-14-162.html#download=true?oppNum=PA-14-162)

Eligibility profile

Country of applicant institution: Any

Disciplines

Pharmacokinetics; Cognitive Processes; Drug & Substance Abuse; Neuroscience; Neurology; Psychology; Primary Care; Diagnostic Sciences; HIV/Aids; Public Health, Health Services & Primary Care; Central Nervous System

Contact Details

NIDA

6001 Executive Boulevard

Bethesda, MD 20892

Tel: +1 301 435 4649

Email: wudy@mail.nih.gov

EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R03): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related call on the effects of cannabis use and cannabinoids on the developing brain (R03). This Aids-related R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans.

This FOA uses the R03 small research grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-162 and PA-14-163, which use the R21

exploratory/developmental grant mechanism and the R01 research project grant mechanism respectively.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US\$100,000 over a two-year project period, with no more than US\$50,000 in any year.

Ref: PA-14-164.

Closing date: 07 Sep 16



Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 27 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-164.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true?oppNum=PA-14-164>

Eligibility profile

Country of applicant institution: Any

Disciplines

Central Nervous System; Cognitive Processes; Psychology; Pharmacokinetics; HIV/Aids; Neuroscience; Public Health, Health Services & Primary Care; Diagnostic Sciences; Neurology; Primary Care; Drug & Substance Abuse

Contact Details

NIDA

6001 Executive Boulevard

Bethesda, MD 20892

Tel: +1 301 435 4649

Email: wudy@mail.nih.gov

EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R01): AIDS-RELATED NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related call on the effects of cannabis use and cannabinoids on the developing brain (R01). This Aids-related R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans.

This FOA uses the R01 research project grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-162 and PA-14-164, which use the R21 exploratory/developmental grant mechanism and the R03 small research grant mechanism respectively.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PA-14-163.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 27 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-163.html>

**Application form:**

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-14-163>

Eligibility profile

Country of applicant institution: Any

Disciplines

Diagnostic Sciences; Psychology; Drug & Substance Abuse; HIV/Aids; Neuroscience;

Neurology; Cognitive Processes; Central Nervous System; Primary Care; Public Health, Health Services & Primary Care; Pharmacokinetics

Contact Details

NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 435 4649
Email: wudy@mail.nih.gov

CLINICAL TRIAL PLANNING GRANT FOR INTERVENTIONS AND SERVICES TO IMPROVE TREATMENT AND PREVENTION OF HIV/AIDS (R34)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their clinical trial planning grant for interventions and services to improve treatment and prevention of HIV/Aids. This R34 funding opportunity supports efforts to prevent acquisition and transmission of HIV infection, or to improve treatment and care for persons who are HIV infected, or both. Priority areas and potential research topics include:

- research to develop and test the feasibility and acceptability of integrated prevention and/or treatment strategies to improve clinical outcomes within target populations;
- novel approaches to maximise HIV testing, linkage to care, retention, and durable viral suppression;
- behavioural or service interventions that initiate, sustain, and restore adherence to recommended HIV care or regimens;

- studies that elucidate information about barriers and needs of populations who have difficulty engaging in and sustaining treatment and prevention care;
- interventions that promote effective utilisation of health services;
- acceptability or feasibility studies that inform drug development or that complement an ongoing efficacy or effectiveness trial of an experimental strategy or intervention;
- challenges and the implementation of multiple prevention methods;
- approaches that sustain engagement in care among people living with HIV and other serious co-morbidities or co-infections.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Direct costs are limited to US\$450,000 over the project period, with no more than US\$225,000 available in any single year. The maximum project period is three years.



Ref: PA-14-179.

Closing date: 07 Sep 16
Deadline information: Applications due by 5pm proposer's local time every 7 May, 7 September and 7 January until 8 January 2017.

Posted date: 23 Apr 14
Award type: Directed grants to institutions, research groups etc

Award amount max: \$450,000

Award budget total: -

Website:

http://grants.nih.gov/grants/guide/pa-files/PA-14-179.html#_Section_VII_Agency

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Public Health; Biomedical Engineering; Diagnostic Sciences; Blood Tests; Preventive Medicine; Public Health, Health Services & Primary Care; Patient Care & Education; Pharmaceutical Drugs; Clinical Medicine

Contact Details

NIH: National Institutes of Health
 6701 Rockledge Drive, Room 1040 - MSC 7710
 Bethesda, MD 20892-7710
 Tel: +1 301 451 7324
 Fax: +1 301 480 8443
 Email: elizabeth.flanagan@nih.gov

MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R21): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

A total of two institutes and offices of the NIH invite Aids-related applications for their mHealth tools to promote effective patient-provider communication, adherence to treatment and self management of chronic diseases in underserved populations R21 grants. The purpose of this R21 Aids-related funding opportunity announcement is to stimulate research utilising mobile health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations.

This funding opportunity announcement will utilise the NIH research project grant R21 mechanism and runs in parallel with another FOA of identical scientific scope: PA-14-180

that solicits applications under the research project grant (R01) funding mechanism. The combined budget for direct costs for the two year project period may not exceed US\$275,000 and no more than US\$200,000 may be requested in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-14-181 (Reissue of PA-11-332).

Closing date: 07 Sep 16
Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 23 Apr 14
Award type: Directed grants to institutions, research groups etc



Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-181.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Assistive Technology; Medical & Diagnostic Tests; Patient Care & Education; Primary

Care; Public Health, Health Services & Primary Care; Social Work & Social Policy; Clinical Medicine; 5G, Wireless & Mobile Networks; Health Economics; Chronic Care; Rural Health; HIV/Aids; Social Programmes; Pharmaceutical Drugs; Computer Science & Informatics

Contact Details

Tel: +1 301 594 5971

Email: mccloskd@mail.nih.gov

MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R01) AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

A total of two institutes and offices of the NIH invite applications for their Aids-related mHealth tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R01) grants. The purpose of this Aids-related R01 funding opportunity announcement is to stimulate research utilising mobile health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations.

This funding opportunity announcement will utilise the NIH research project grant R01 mechanism and runs in parallel with another FOA of identical scientific scope: PA-14-181 that solicits applications under the exploratory/developmental grant (R21) funding mechanism. Application budgets are not limited, but need to reflect actual needs of the proposed project. The total project period is a maximum of five years. Domestic and foreign for-profit and non-profit organisations

and public or private institutions are eligible to apply.

Ref: PA-14-180 (Reissue of PA-11-330).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 23 Apr 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-180.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Pharmaceutical Drugs; Primary Care; Medical & Diagnostic Tests; Information Systems;



Clinical Medicine; Electrical & Electronic Engineering; Screening for Diseases; Health Economics; Chronic Care; HIV/Aids; 5G, Wireless & Mobile Networks; Patient Care & Education; Computer Science & Informatics;

Public Health, Health Services & Primary Care; Assistive Technology; Rural Health

Contact Details

Tel: +1 301 594 5971
Email: mccloskd@mail.nih.gov

EXPLOATORY CLINICAL TRIALS OF MIND AND BODY INTERVENTIONS FOR NCCAM HIGH PRIORITY RESEARCH TOPICS (R34) AIDS-RELATED

NIH: National Center for Complementary and Integrative Health

Description:

The National Center for Complementary and Alternative Medicine (NCCAM) invites Aids-related applications for its exploratory clinical trials of mind and body interventions for NCCAM high priority research topics (R34). The goal of this R34 Aids-related funding opportunity is to support early phase clinical trials of mind and body approaches for conditions that have been identified by NCCAM as high priority research topics.

Priority areas include:

- the mind and body or integrated approach, including spinal manipulation, mobilisation, massage, tai chi, qi gong, yoga, acupuncture, hypnosis, guided imagery, light therapy, breathing activity, progressive relaxation, meditation, biofeedback, or mindfulness techniques;
- symptom management for chronic pain syndromes, reduction of prescription drug use or abuse in patients with chronic pain, medication adherence, post-traumatic stress, traumatic brain injury, sleep disorders or disturbances, anxiety, depression, promotion of psychological resilience, weight loss and weight loss maintenance, smoking cessation and promotion of healthy eating and physical activity.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Proposals may request up to \$450,000 over a maximum of three years.

Ref: PA-14-182.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm applicant's local time. Deadlines on: 7 September 2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 23 Apr 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$450,000

Award budget total: -

Website:

http://grants.nih.gov/grants/guide/pa-files/PA-14-182.html#_Section_III_Eligibility

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse; Anxiety Disorders; Exercise Physiology; Experimental Psychology; Clinical Medicine; Pharmacy & Pharmacology; Psychology; Post Traumatic



Stress Disorder; Health Counselling; Chronic Pain; Sports & Exercise Studies; Stress, Psychological; Smoking & Tobacco; Clinical Pharmacy & Pharmacology; Psychobiology; Traumatology, Accidents & Injury; Nutrition & Dietetics; HIV/Aids; Chronic Care; Cognitive & Behavioural Therapies; Social Work & Social Policy; Folk, Complementary & Alternative Medicine; Health Promotion; Mental Health; Allied Health Professions; Public Health, Health Services & Primary

Care; Pharmaceutical Drugs; Stress, Biological; Addiction; Depression & Other Mood Disorders; Sports Psychology; Sleep & Sleep Disorders; Diagnostic Sciences; Pain Management

Contact Details

Tel: +1 301 402 1272

Email: weberwj@mail.nih.gov

UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related unconventional roles of ethanol metabolising enzymes, metabolites and cofactors in health and disease (R01) funding opportunity announcement. This Aids-related announcement provides support for integrated, innovative research on the novel and unconventional contributions of ethanol metabolising pathways, their metabolites, cofactors and interactions with synergising biological pathways in the development of alcohol-induced diseases and end organ injuries.

The aim is to generate data that leads to breakthroughs in identification and understanding of key cellular and molecular components in the initiation, progression and maintenance of the diverse medical disorders caused by excessive or long term alcohol consumption. The generated knowledge should enable clinicians to improve disease outcomes and consequently, public health. Research areas include the following: ethanol and NAD⁺; ethanol and acetate; ethanol and SAM; ethanol and zinc; endogenous substrates and functions of alcohol

metabolising pathways – regulation of growth, development and disease.

This announcement uses the R01 research project grant mechanism and runs in parallel with one of identical scientific scope, PA-15-057, which encourages applications under the R21 exploratory or developmental grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years. Ref: PA-15-058 (reissue of PA-14-198).

Closing date: 07 Sep 16

Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 09 Dec 14

Award type: Networking/collaboration, Innovation grants, Directed grants to institutions, research groups etc

Award amount max: -



Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-058.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-15-058>

Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholic Beverages; Alcoholism; HIV/ Aids; Cell Physiology & Metabolism; Addiction; Hepatology

Contact Details

NIAAA
Building 5635FL, Room 2119
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 443 2193
Email: orosza@mail.nih.gov

N K CELLS TO INDUCE IMMUNOLOGICAL MEMORY TO PREVENT HIV INFECTION (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites application for its natural killer cells to induce immunological memory to prevent HIV infection (R01) grants. The purpose of this R01 funding opportunity is to support multidisciplinary, hypothesis-driven research on NK cells, leading to the discovery of pathways relevant for early immune responses and immune regulation impacting the potential protective immunity to be induced by HIV vaccination. Secondary objectives include the development of novel technologies to allow for more definitive studies of human immune monitoring in the context of vaccine clinical trials and the recruitment of innate immunologists to the HIV vaccine field.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-217

Closing date: 07 Sep 16

Deadline information: Deadlines every 7 September, 7 January and 7 May until 8 January 2017.

Posted date: 13 May 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-217.html>

Application form:

<http://www.grants.gov/applicants/apply-for-grants.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Virology; Immunology; Clinical Medicine; HIV/ Aids; Immunisation Programmes & Vaccination;

**Contact Details**

Tel: +1 240 627 3038

Email: cesar.boggiano@nih.gov

Diagnostic Sciences

F^C RECEPTOR AND ANTIBODY EFFECTOR FUNCTION IN HIV VACCINE DISCOVERY (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites application for its Fc Receptor and antibody effector function in HIV vaccine discovery (R01) grants. The purpose of this R01 funding opportunity is to stimulate and support investigator driven collaborative research to probe how vaccine elicited antibodies protect against viral acquisition via Fc receptor mediated mechanisms and also benchmark functional profiles of vaccines that protect against viral infections to inform advancement of HIV vaccine candidates. Areas of interest include, but are not limited to:

- identification of Fc receptor binding profiles that correlate with protective antibody responses;
- use of animal models to understand mechanisms of antibody dependent protective immune responses to broadly neutralising antibodies and or candidate vaccines in vivo;
- examination of adjuvants in both modulating Fc receptor binding profiles and in their influence on immune effector function and/or antibody effector function;
- investigations of antibody glycosylation and Fc receptor-mediated activity and function;
- passive administration studies of BNABs and or non-neutralising antibodies in pre-clinical animal models to understand Fc-related mechanisms of immune protection;

- examination of Fc Receptor binding and effector function of vaccine-elicited IgA antibodies.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-218.

Closing date: 07 Sep 16

Deadline information: Deadlines every 7 September, 7 January and 7 May until 8 January 2017.

Posted date: 13 May 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-218.html>

Application form:

<http://www.grants.gov/applicants/apply-for-grants.html>

Eligibility profile

Country of applicant institution: Any



Disciplines

Immunology; Virology; Genetics & Systems Biology; Clinical Medicine; Medical Genetics; HIV/Aids; Immunisation Programmes & Vaccination; Diagnostic Sciences

Contact Details

Tel: +1 240 627 3031
Email: thandi.onami@nih.gov

HIV VACCINE VECTOR-HOST INTERACTIONS: UNDERSTANDING THE BIOLOGY AND IMMUNOLOGY (R21)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites application for its HIV vaccine vector-host interactions: understanding the biology and immunology (R21) grants. The purpose of this R21 funding opportunity is to support increased understanding of the biology and immunology of natural viral infections and HIV vaccine vectors. This initiative is intended to advance understanding of the following:

- the biology and immune response to live attenuated or replication-defective viral vectors developed from adenoviridae, poxviridae, adeno-associated viruses and herpesviridae families in humans and non-human primates;
- the development of animal models that could better evaluate the potential for increased HIV acquisition following vaccination.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US\$275,000 over an R21 two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

Ref: PA-14-214.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm, local time of applicant organisation, on every 7 September, 7 January and 7 May until 8 January 2017.

Posted date: 14 May 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-214.html>

Application form:

<http://www.grants.gov/applicants/apply-for-grants.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine; Immunisation Programmes & Vaccination; Immunology; Genetics & Systems Biology; Medical Genetics; Virology; HIV/Aids; Diagnostic Sciences

Contact Details

NIAID
Office of Communications and Public Liaison
Building 31, Room 7A-50



31 Center Drive MSC 2520
Bethesda, MD 20892-2520
Tel: +1 301 435 3749

Fax: +1 301 402 0120
Email: mpensiero@niaid.nih.gov

HIV VACCINE VECTOR-HOST INTERACTIONS: UNDERSTANDING THE BIOLOGY AND IMMUNOLOGY (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites application for its HIV vaccine vector-host interactions: understanding the biology and immunology (R21) grants. The purpose of this R01 funding opportunity is to support increased understanding of the biology and immunology of natural viral infections and HIV vaccine vectors. This initiative is intended to advance understanding of the following:

- the biology and immune response to live attenuated or replication-defective viral vectors developed from adenoviridae, poxviridae, adeno-associated viruses and herpesviridae families in humans and non-human primates;
- the development of animal models that could better evaluate the potential for increased HIV acquisition following vaccination.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-215

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm, local time of applicant institution, on every 7 September, 7 January and 7 May until 8 January 2017.

Posted date: 14 May 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-215.html>

Application form:

<http://www.grants.gov/applicants/apply-for-grants.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine; Medical Genetics; Genetics & Systems Biology; Diagnostic Sciences; Immunology; HIV/Aids; Immunisation Programmes & Vaccination; Virology

Contact Details

NIAID

Office of Communications and Public Liaison
Building 31, Room 7A-50

31 Center Drive MSC 2520

Bethesda, MD 20892-2520

Tel: +1 301 435 3749

Email: mpensiero@niaid.nih.gov



CLINICAL EVALUATION OF ADJUNCTS TO OPIOID THERAPIES FOR THE TREATMENT OF CHRONIC PAIN (R01) AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse and the National Center for Complementary and Alternative Medicine invite applications for their clinical evaluation of adjuncts to opioid therapies for the treatment of chronic pain (R01) Aids-related grants. The purpose of this R01 Aids-related funding opportunity is to support meritorious clinical studies that seek to characterise opioid and pharmaceutical adjunct combinations that safely improve analgesia in chronic pain patients. As a secondary objective, this opportunity aims to disseminate the results of these studies as widely as possible to the healthcare providers who regularly prescribe opioids to the patient population. This will ensure that standard clinical practices are influenced by the findings of the proposed studies. In the population proposed to be studied, the subjects should be etiologically homogenous and symptomatically well-defined. Examples of such chronic pain populations in which opioids are often prescribed include patients with radicular cervical pain, metastatic bone pain or peripheral neuropathies. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period is three years.

Ref: PAR-14-225

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation

every 7 January, 7 May and 7 September until 8 September 2017

Posted date: 16 May 14

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-225.html>

Application form:

<http://www.grants.gov/applicants/apply-for-grants.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Opiates; Pharmacy & Pharmacology; Molecular Genetics; Drug & Substance Abuse; General Practice & Family Health; HIV/Aids; Neurobiology; Chronic Pain; Cognitive & Behavioural Therapies; Pain Management; Epidemiology; Mental Health; Public Health, Health Services & Primary Care; Preventive Medicine; Physiology; Neuroscience; Biological Sciences; Diagnostic Sciences; Primary Care

Contact Details

NIDA

6001 Executive Boulevard

Room 5213

Bethesda, MD 20892-9561

Tel: +1 301 443 8039

Email: aidan.hampson@nih.gov



ADVANCING RESEARCH IN VOICE DISORDERS (R21) AIDS-RELATED

NIH: National Institute on Deafness and other Communication Disorders

Description:

The National Institute on Deafness and Other Communication Disorders invites applications for its advancing research in voice disorders (R21) Aids-related grants. The purpose of this R21 Aids-related funding opportunity is to focus on advancing the scientific knowledge of the human larynx and human voice production in health and disease and optimal ways to prevent, evaluate, diagnose and clinically manage voice disorders. This is to support the development of novel ideas, technologies, or methodologies at an early stage of development which have the potential to break new ground or extend toward new directions or applications. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. The combined budget for direct costs for the two year project period may not exceed US\$275,000. No more than US\$200,000 may be requested in any single year. The total project period may not exceed two years.

Ref: PA-14-235.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 22 May 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-235.html>

Application form:

<http://www.grants.gov/applicants/apply-for-grants.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Speech Pathology & Disorders; Public Health, Health Services & Primary Care; HIV/Aids; Physiology; Clinical Medicine; Prosthetic & Orthotic Devices; Primary Care; Allied Health Professions; Speech & Language Therapy

Contact Details

NIDCD

Division of Extramural Research
Executive Plaza South, Room 400C
6120 Executive Boulevard, MSC 7180
Rockville, MD 20892-7180

Tel: +1 301 496 5061

Email: shekiml@nidcd.nih.gov



ADVANCING RESEARCH IN VOICE DISORDERS (R01) AIDS-RELATED

NIH: National Institute on Deafness and other Communication Disorders

Description:

The National Institute on Deafness and Other Communication Disorders invites

applications for its advancing research in voice disorders (R01) Aids-related grants. The



purpose of this R01 Aids-related funding opportunity is to focus on advancing the scientific knowledge of the human larynx and human voice production in health and disease and optimal ways to prevent, evaluate, diagnose and clinically manage voice disorders. Furthermore it encourages a range of research inclusive of basic, clinical, and translational. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-236

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 22 May 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-236.html>

Application form:

<http://www.grants.gov/applicants/apply-for-grants.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/ Aids; Allied Health Professions; Primary Care; Speech Pathology & Disorders; Speech & Language Therapy; Physiology; Public Health, Health Services & Primary Care; Prosthetic & Orthotic Devices; Clinical Medicine

Contact Details

NIDCD

Division of Extramural Research
Executive Plaza South, Room 400C
6120 Executive Boulevard, MSC 7180
Rockville, MD 20892-7180

Tel: +1 301 496 5061

Email: shekiml@nidcd.nih.gov

BASIC RESEARCH ON HIV PERSISTENCE (R21): AIDS-RELATED

NIH: National Institutes of Health

Description:

The National Institute of Mental Health invites applications for its basic research on HIV persistence (R21) Aids-related. This Aids-related R21 announcement will support basic research in aspects of the persistence of HIV or Simian immunodeficiency virus infection in individuals or animals receiving highly active anti-retroviral therapy. It is expected that applications will involve at least one of the following areas of study: cellular, structural or systems biology, host or viral genetics, immunology, or virology. The

emphasis of this initiative is on the development of new ideas and approaches in HIV-1 persistence including model and assay development that may directly inform future studies on the design of therapeutic strategies to achieve long term remission without treatment or a complete eradication of residual virus and complete cure for HIV infection and AIDS.

Higher education institutions, non-profits other than institutions of higher education,



for-profit organisations, governments and foreign institutions are eligible to apply.

Approximately eight awards are available, worth up to US\$275,000 each for two years.

Ref: PAR-14-428.

Closing date: 07 Sep 16

Deadline information: Application are due by 5pm local time of applicant organisation, every 7 September, 7 January and 7 May until 8 January 2017.

Posted date: 05 Jun 14

Award type: Networking/collaboration, Innovation grants, Directed grants to institutions, research groups etc

Award budget total: \$2,000,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-248.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application->

[package.html#download=true&oppNum=PAR-14-248](#)

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine; Biological Sciences; Cytopathology; Blood Tests; Diagnostic Sciences; Primary Care; Public Health, Health Services & Primary Care; Pathology; Virology; Animal Models; HIV/Aids; Immunology; Infection Agents & Pathogens; Infectious Diseases

Contact Details

National Institute of Allergy and Infectious Diseases (NIAID)

Tel: +1 301 496 5332

Email: salzwedelk@niaid.nih.gov

MULTIDISCIPLINARY STUDIES OF HIV AND VIRAL HEPATITIS CO-INFECTION (R21)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites applications for its multidisciplinary studies of HIV and viral hepatitis co-infection (R21) grant. The purpose of this R21 funding opportunity is to fill gaps in our understanding of the pathogenic interactions between HIV and hepatitis viruses, co-morbidities associated with HIV/hepatitis virus co-infection, and the effectiveness of interferon-free direct-acting antiviral drug regimens to treat HIV and HCV co-infection.

Research should focus on HIV-infected adults, pregnant or postpartum women, adolescents, children, infants and sub-populations at

highest risk for HBV or HCV co-infection. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than US\$200,000 may be requested in any single year.

Ref: PAR-14-254.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 11 Jun 14



Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-254.html>

Application form:

<http://www.grants.gov/applicants/apply-for-grants.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Infectious Diseases; Primary Care; Diagnostic Sciences; Clinical Medicine; Hepatology; Infection Agents & Pathogens; Public Health, Health Services & Primary Care; Virology; Blood Tests; HIV/Aids; Disease Control

Contact Details

NIH NIAID

Office of Communications and Public Liaison

Building 31, Room 7A-50

31 Center Drive MSC 2520

Bethesda, MD 20892-2520

Tel: +1 240 627 3094

Fax: +1 301 402 0120

Email: sbrobst@mail.nih.gov

MULTIDISCIPLINARY STUDIES OF HIV AND VIRAL HEPATITIS CO-INFECTION (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites applications for its multidisciplinary studies of HIV and viral hepatitis co-infection (R01) grant. The purpose of this R01 funding opportunity is to fill gaps in our understanding of the pathogenic interactions between HIV and hepatitis viruses, co-morbidities associated with HIV and hepatitis virus co-infection, and the effectiveness of interferon-free direct-acting antiviral drug regimens to treat HIV or HCV co-infection. Research should focus on HIV-infected adults, pregnant or postpartum women, adolescents, children, infants and sub-populations at highest risk for HBV or HCV co-infection. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-255.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 11 Jun 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-255.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Blood Tests; Diagnostic Sciences; Hepatology; Infection Agents & Pathogens; Infectious Diseases; Virology; Primary Care; Public Health, Health Services & Primary Care; HIV/Aids; Disease Control; Clinical Medicine



Contact Details

NIH NIAID

Office of Communications and Public Liaison
Building 31, Room 7A-50

31 Center Drive MSC 2520

Bethesda, MD 20892-2520

Tel: +1 240 627 3094

Email: sbrobst@mail.nih.gov

NINDS CREATE BIO DISCOVERY TRACK: OPTIMISATION IN PREPARATION FOR DEVELOPMENT OF BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (U01): AIDS-RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:

The National Institute of Neurological Disorders and Stroke invites applications for its cooperative research to enable and advance translational enterprises for biotechnology products and biologics discovery track: optimisation in preparation for development of biotechnology products and biologics (U01) grants. The purpose of this Aids-related U01 funding opportunity announcement is the discovery of therapeutic biotechnology products and biologics for disorders that fall under the NINDS mission. This FOA supports the optimisation of therapeutic leads showing convincing proof-of-concept. At the end of the funding period, projects that successfully advance through support from this programme will have identified an optimised candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy or target engagement, and other favourable properties that are consistent with the desired clinical application, and will be ready for entry into the CREATE bio development track for further development to enable filing for an investigational new drug. The NINDS CREATE bio programme is dedicated to biotechnology product and biologics- based therapies, which broadly include modalities such as peptides, proteins, oligonucleotides, gene therapies and cell therapies.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application

budgets are not limited but must reflect the actual needs of the proposed project. Budgets will normally remain under US\$500,000 in direct costs in any given year. The project period is typically three years and may not exceed four years.

Ref: PAR-14-286.

Closing date: 07 Sep 16

Deadline information: Applications open on 21 September and are due by 5pm local time of applicant organisation on 7 January 2015 and every 7 May and 7 September until 8 May 2017.

Posted date: 21 Jul 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-286.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PAR-14-286>

Eligibility profile

Country of applicant institution: Any

Disciplines



Clinical Pharmacy & Pharmacology; Primary Care; Diagnostic Sciences; Biological Sciences; Chemistry; Public Health, Health Services & Primary Care; Neurology; Cell Physiology & Metabolism; Blood Tests; HIV/Aids; Clinical Medicine; Protein Synthesis, Modification & Turnover; Neuropharmacology; Gene Therapy; Neurobiology; Pharmacotherapy; Pharmacokinetics; Toxicology; Pharmacy &

Pharmacology; Drug Design; Methods of Drug Delivery

Contact Details

NIH/NINDS
Neuroscience Center, Room 2106
6001 Executive Blvd MSC
Bethesda MD 20892
Tel: +1 301 496 1779
Email: createnquiries@mail.nih.gov

NINDS CREATE BIO DEVELOPMENT TRACK: PRECLINICAL AND EARLY-PHASE CLINICAL DEVELOPMENT FOR BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (UH2/UH3): AIDS-RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:

The National Institute of Neurological Disorders and Stroke invites applications for its NINDS cooperative research to enable and advance translational enterprises for biotechnology products and biologics development track: preclinical and early-phase clinical development for biotechnology products and biologics (UH2/UH3) grants. The purpose of this Aids-related UH2/UH3 funding opportunity announcement is the development of therapeutic biotechnology products and biologics for disorders that fall under the NINDS mission. An identified candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy or target engagement, and other favourable properties that are consistent with the desired clinical application, is required for entry to the CREATE bio development track. The FOA supports investigational new drug-enabling studies for the candidate and early-phase clinical trials. At the end of the funding period, a successful project should have an IND application submitted to the US Food and Drug Administration, at a minimum. The NINDS CREATE bio programme is dedicated to biotechnology product and biologics-based therapies, which broadly include modalities such as peptides, proteins, oligonucleotides, gene therapies and cell therapies.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Applications should rarely exceed US\$1million in direct costs per year during the UH2 phase and US\$1.5million in direct costs per year during the UH3 phase. The proposed project period for the UH2 phase may not exceed two years and the UH3 phase may not exceed four and a half years. The total duration of UH2 and UH3 phases may not exceed five years.

Ref: PAR-14-288.

Closing date: 07 Sep 16

Deadline information: Applications open on 21 September and are due by 5pm local time of applicant organisation on 7 January 2015 and every 7 May and 7 September until 8 May 2017.

Posted date: 21 Jul 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-288.html>

**Application form:**

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=P AR-14-288>

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug Design; Neuropharmacology; Pharmacotherapy; Cell Physiology & Metabolism; HIV/Aids; Methods of Drug Delivery; Diagnostic Sciences; Clinical Pharmacy & Pharmacology; Primary Care;

Blood Tests; Gene Therapy; Public Health, Health Services & Primary Care; Neurobiology; Chemistry; Protein Synthesis, Modification & Turnover; Clinical Medicine; Toxicology; Biological Sciences; Neurology; Pharmacokinetics; Pharmacy & Pharmacology

Contact Details

NIH/NINDS

Neuroscience Center, Room 2106

6001 Executive Blvd MSC

Bethesda MD 20892

Tel: +1 301 496 1779

Email: createnquiries@mail.nih.gov

B LUEPRINT NEUROTHERAPEUTICS NETWORK: SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT FOR DISORDERS OF THE NERVOUS SYSTEM (UH2/UH3): AIDS-RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:

A total of nine participating institutes and centres of the National Institutes of Health invite applications for their Blueprint neurotherapeutics network: small molecule drug discovery and development for disorders of the nervous system (UH2/UH3) grants. The purpose of this Aids-related UH2/UH3 funding opportunity announcement is to help neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organisations that specialise in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under good manufacturing practices, and phase I clinical testing.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The combined duration of the UH2 and UH3 award cannot exceed five years.

Ref: PAR-14-293.

Closing date: 07 Sep 16

Deadline information: Applications open on 21 September and are due by 5pm local time of applicant organisation on 7 January 2015 and every 7 May and 7 September until 8 May 2017.

Posted date: 23 Jul 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-293.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=P-AR-14-293>

Eligibility profile

Country of applicant institution: Any

Disciplines

Toxicology; Clinical Medicine; Gene Therapy; Chemistry; Neuropharmacology; Diagnostic Sciences; Biological Sciences; Public Health,

Health Services & Primary Care; Clinical Pharmacy & Pharmacology; Central Nervous System; Primary Care; Neurobiology; Protein Synthesis, Modification & Turnover; Cell Physiology & Metabolism; Drug Design; Methods of Drug Delivery; Pharmacotherapy; Neurology; Pharmacy & Pharmacology; Pharmacokinetics; HIV/Aids

Contact Details

NIH: NINDS

Division of Extramural Research
6001 Executive Boulevard Suite 3309
Bethesda, MD 20892- 9531
Tel: +1 301 496 1779
Email: farkasr@ninds.nih.gov

ARTS-BASED APPROACHES IN PALLIATIVE CARE FOR SYMPTOM MANAGEMENT (R01): AIDS-RELATED

NIH: National Center for Complementary and Integrative Health

Description:

A total of four participating institutes and centres of the National Institutes of Health invite applications for their arts-based approaches in palliative care for symptom management (R01) grants. The purpose of this Aids-related R01 funding opportunity announcement is to foster research on the potential for arts-based approaches to enhance palliative care for individuals living with multiple symptoms related to serious chronic or terminal illness. This FOA is intended to support mechanistic clinical studies to provide an evidence base for the use of the arts in palliative care for symptom management. The objective is to understand the biological, physiological, neurological, psychological, or sociological mechanisms by which the arts exert their effects on symptom management during and throughout the palliative care continuum. The term “arts” refers not only to artistic activities, but also to creative activities, such as literature, rituals, oral histories and storytelling.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Applicants may request up to US\$300,000 in direct costs per year. The maximum project period is three years.

Closing date: 07 Sep 16

Deadline information: Applications open on 5 September and are due by 5pm local time of applicant organisation every 7 September, 7 January and 7 May until 8 September 2017.

Posted date: 25 Jul 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$900,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-294.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application->



[package.html#download=true&oppNum=PAR-14-294](#)

Eligibility profile

Country of applicant institution: Any

Disciplines

Health Systems, Administration; HIV/Aids; Psychology; Death & Mortality; Music Therapy; Hospice & Palliative Care; Oral History; Social Work & Social Policy; Art Therapies; Palliative Nursing; Clinical Medicine; Primary Care; Public Health,

Health Services & Primary Care; Performing Arts; Theatre Studies; Allied Health Professions; Nursing; Visual Arts; Literature, Drama; Paediatrics; Customs & Traditions; Art & Design: History, Practice & Theory

Contact Details

NIH: National Center for Complementary and Alternative Medicine
31 Center Drive, MSC 2182
Bethesda, MD 20892-2182
Tel: +1 301 443 8374
Email: lee.alekel@nih.gov

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R03) AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The National Institutes of Health invites applications for their patient safety in the context of perinatal, neonatal and paediatric care programme. This Aids-related R03 funding opportunity announcement encourages collaborative research projects related to patient safety in the context of perinatal, neonatal and paediatric care both in routine hospital settings and in the intensive care units. Proposals may address:

- the epidemiology of errors and adverse events in neonatal and paediatric care hospital units;
- medication errors;
- diagnostic errors;
- procedure-related errors;
- human factor and fatigue;
- promotion of a safety culture;
- other working conditions and systems issues;
- risk reduction and disclosure practices.

Eligibility is unrestricted. This funding opportunity uses the NIH small grant (R03) mechanism and runs in parallel with one of identical scientific scope, PA-14-312, which solicits applications under the NIH research project grant (R01) mechanism.

Funding is worth up to US\$50,000 per year for a maximum project period of two years.

Ref: PA-14-313 (replaces PAR-11-226).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 September 2014 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 07 Aug 14

Award type: Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-14-313.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-313>

Eligibility profile

Country of applicant institution: Any

Disciplines

Health Systems, Risk Management; HIV/Aids; Standards of Care; Psychology; Maternal Health; Clinical Decision-making & Analysis; Paediatric Nursing; Health Psychology; Blood Tests; Nursing; Quality of Care; Diagnostic Sciences; Neonatal Disorders; Public Health & Medical Law; Allied Health Professions; Pregnancy & Birth;

Clinical Medicine; Medical & Diagnostic Tests; Health & Medical Informatics; Paediatrics; Law; Public Health, Health Services & Primary Care; Hospitalisation; Health Professions & Workforce; Medical Effectiveness & Patient Outcomes; Primary Care; Safety & Accident Investigation; Business & Management Studies; Telemedicine; Medical Research of Selected Fields; Patient Care & Education

Contact Details**NIH**

Pregnancy and Perinatology Branch
Eunice Kennedy Shriver National Institute of Child and Human Development
6100 Executive Blvd, 4B03D
Bethesda MD 20892
Tel: +1 301 435 6873
Fax: +1 301 496 3790
Email: kosomari@mail.nih.gov

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL, AND PAEDIATRIC CARE (R21): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The National Institute of Child Health and Human Development invites applications for its patient safety in the context of perinatal, neonatal, and paediatric care (R21) grants. The purpose of this Aids-related R21 funding opportunity announcement is to encourage a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and paediatric care both in routine hospital settings and in the intensive care units. The FOA welcomes applications related to the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems,

and institutional levels to help reduce and eliminate medical errors.

It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness.

This FOA will utilise the R21 mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-14-312 that encourages applications under the R01 research grant programme mechanism and PAR-14-313 that encourages applications under the R03 small grant programme mechanism. Domestic and foreign for-profit and non-profit organisations



and public or private institutions are eligible to apply.

Application budgets are limited to direct costs of up \$275,000 over a two-year project period and no more than \$200,000 may be requested in any one year.

Ref: PA-14-311 (replaces PAR-11-227).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 07 Aug 14

Award type: Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-311.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application->

[package.html#download=true&oppNum=P A-14-311](#)

Eligibility profile

Country of applicant institution: Any

Disciplines

Epidemiology; Obstetrics & Gynaecology; Paediatrics; Clinical Medicine; Public Health, Health Services & Primary Care; Primary Care; Patient Care & Education; HIV/Aids; Women's Health; Neonatal Disorders; General Practice & Family Health; Paediatric Nursing; Quality of Care; Maternal Health; Midwifery; Pregnancy & Birth; Nursing

Contact Details

NIH: National Institute of Child Health and Human Development
Building 31, Room 2A32
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 435 6873
Email: kosomari@mail.nih.gov

MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R21): AIDS-RELATED NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health invites applications for its molecular and cellular substrates of complex brain disorders (R21) grants. This Aids-related funding opportunity announcement uses the R21 mechanism to encourage new research activities directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. By using the R21 activity code, this funding opportunity seeks to foster the

introduction of novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential to advance research at the interface between cellular and molecular mechanisms and that address gaps in understanding the biological mechanisms behind putative disease associated processes with the goal of accelerating progress in emerging research areas relevant to complex brain disorders.



This FOA uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-309 that encourages applications under the NIH research project (R01) grant mechanism. Direct costs are limited to US\$275,000 over a two year period, with no more than US\$200,000 in direct costs in any one year. The total project period may not exceed two years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PAR-14-310 (replaces PAR-11-300).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 07 Aug 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-310.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application>

[package.html#download=true&oppNum=PAR-14-310](#)

Eligibility profile

Country of applicant institution: Any

Disciplines

Diagnostic Sciences; Central Nervous System; Biological Sciences; Neuroendocrinology; Electrophysiology; HIV/Aids; Public Health, Health Services & Primary Care; Psychology; Neuropharmacology; Cognitive Processes; Mental Illness; Allied Health Professions; Pharmacy & Pharmacology; Neuroscience; Neuroanatomy; Cell & Developmental Biology; Nucleus & Organelles; Neurobiology; Clinical Medicine; Primary Care; Muscle Diseases; Intellectual Disabilities; Neurology; Biochemistry & Molecular Biology; Endocrine & Neuroendocrine Cancers

Contact Details

NIMH
6001 Executive Blvd
Room 8184 MSC 9663
Bethesda, Maryland 20892
Tel: +1 301 443 5288
Email: casanuma@mail.nih.gov

MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R01): AIDS-RELATED NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health invites applications for its molecular and cellular substrates of complex brain disorders (R01) grants. This Aids-related R01 funding opportunity announcement encourages research grant applications directed toward the discovery of the impact of alterations

associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. This FOA seeks to encourage innovative leads at the interface between cellular and molecular mechanisms, and that address gaps in understanding the biological mechanisms



behind putative disease and associated processes with the goal of accelerating progress in emerging research areas relevant to complex brain disorders. Proposals should be hypothesis-driven and propose discovery-based studies with an emphasis on exploring neurobiological mechanisms at the molecular, cellular and circuit levels.

This FOA uses the NIH research project (R01) grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-310 that encourages applications under the NIH exploratory/developmental (R21) grant mechanism. Application budgets are not limited but must reflect the actual needs of the proposed project. The total project period may not exceed five years. Applicants that request US\$500,000 or more in direct costs in any year must contact the NIH six weeks prior to applying.

US and foreign for-profit and non-profit organisations, higher education institutions and public and private organisations may apply.

Ref: PAR-14-309 (replaces PAR-11-299).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 07 Aug 14

Award type: Directed grants to institutions, research groups etc

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-309.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PAR-14-309>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Psychology; Allied Health Professions; Central Nervous System; Neuroanatomy; Cell & Developmental Biology; Intellectual Disabilities; Pharmacy & Pharmacology; Neurology; Cognitive Processes; Endocrine & Neuroendocrine Cancers; Neuroscience; Biochemistry & Molecular Biology; Nucleus & Organelles; Biological Sciences; Diagnostic Sciences; Primary Care; Mental Illness; Public Health, Health Services & Primary Care; Muscle Diseases; Clinical Medicine; Electrophysiology; Neurobiology; Neuropharmacology; Neuroendocrinology

Contact Details

NIMH
6001 Executive Blvd
Room 8184 MSC 9663
Bethesda, Maryland 20892
Tel: +1 301 443 5288
Email: casanuma@mail.nih.gov

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R01) AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The National Institutes of Health invites applications for their patient safety in the context of perinatal, neonatal and paediatric

care programme. This Aids-related R01 funding opportunity announcement encourages collaborative research projects



related to patient safety in the context of perinatal, neonatal and paediatric care both in routine hospital settings and in the intensive care units. Proposals may address:

- the epidemiology of errors and adverse events in neonatal and paediatric care hospital units;
- medication errors;
- diagnostic errors;
- procedure-related errors;
- human factor and fatigue;
- promotion of a safety culture;
- other working conditions and systems issues;
- risk reduction and disclosure practices.

Eligibility is unrestricted. This funding opportunity uses the NIH research project grant (R01) mechanism and runs in parallel with one of identical scientific scope, PA-14-313, which solicits applications under the NIH small grant (R03) mechanism.

Applicants requesting US\$500,000 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The total project period may not exceed five years.

Ref: NIH PA-14-312 (replaces PAR-11-225).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm proposer's local time every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 07 Aug 14

Award type: Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-312.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-312>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Health & Medical Informatics; Health Psychology; Standards of Care; Medical Research of Selected Fields; Primary Care; Law; Hospitalisation; Paediatric Nursing; Maternal Health; Quality of Care; Diagnostic Sciences; Safety & Accident Investigation; Nursing; Allied Health Professions; Public Health & Medical Law; Psychology; Blood Tests; Clinical Medicine; Medical Effectiveness & Patient Outcomes; Business & Management Studies; Pregnancy & Birth; Telemedicine; Patient Care & Education; Health Systems, Risk Management; Health Professions & Workforce; Clinical Decision-making & Analysis; Neonatal Disorders; Medical & Diagnostic Tests; Public Health, Health Services & Primary Care; Paediatrics

Contact Details

NIH

Pregnancy and Perinatology Branch
Eunice Kennedy Shriver National Institute of Child and Human Development
6100 Executive Blvd, 4B03D
Bethesda MD 20892
Tel: +1 301 435 6873
Fax: +1 301 496 3790
Email: kosomari@mail.nih.gov



S ECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related secondary analyses of existing alcohol epidemiology data (R21) grants. These R21 grants support Aids-related, investigator-initiated research projects that either analyse previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. The goal is to enhance understanding of patterns of alcohol consumption and the epidemiology of alcohol-related problems.

This funding opportunity announcement uses the NIH exploratory/developmental research grant (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-338 that encourages applications under the research project grant (R01) mechanism and PA-14-337 that encourages applications under the small grant programme (R03) mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Grants are worth up to US\$275,000 in direct costs over a maximum period of two years. No more than US\$200,000 may be requested in any single year.

Ref: PA-14-336.

Closing date: 07 Sep 16

Deadline information: Applications open on 24 September 2014 and are due by 5pm local time of applicant organisation on every 7

January, 7 May and 7 September 2015 until 8 September 2017. Deadlines on: 7 September 2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 10 Sep 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-337.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-336>

Eligibility profile

Country of applicant institution: Any

Disciplines

Pathogenesis; Traumatology, Accidents & Injury; Psychology; Clinical Medicine; Social Problems; Chronic Care; Alcoholism; Primary Care; Addiction; Allied Health Professions; Public Health, Health Services & Primary Care; Epidemiology; Education; Economic & Social Environment

Contact Details

NIAAA
6000 Executive Boulevard
Willco Building
Bethesda, MD 20892-7003
Tel: +1 301 443 0633
Email: zhaw@mail.nih.gov



S

ELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R21): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

A total of three participating institutes and centres of the National Institutes of Health invite applications for their Aids-related self-management for health in chronic conditions (R21) grants. These Aids-related R21 grants support research in self-management focused across conditions. Projects should address the Institute of Medicine's recommendation for crosscutting, coordinated public health actions for living well with chronic illness, by describing an initiative that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses or conditions.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This FOA will use the NIH exploratory and developmental grant (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-344 that encourages applications under the research project grant(R01) mechanism and PA-14-345 that encourages applications under the academic research enhancement award (R15) mechanism.

The combined budget for direct costs for the two-year project period may not exceed US\$275,000. No more than US\$200,000 in direct costs may be requested in any single year. The maximum project period is two years.

Ref: PA-14-343.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation on every 7

January, 7 May and 7 September until 8 January 2018.

Posted date: 22 Sep 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-343.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-343>

Eligibility profile

Country of applicant institution: Any

Disciplines

Telemedicine; General Practice & Family Health; Access to Health Care; Clinical Medicine; Clinical Decision-making & Analysis; Home Health Care Services; Primary Care; HIV/Aids; Social Work & Social Policy; Chronic Care; Economic & Social Environment; Libraries & Information Science; Medical Effectiveness & Patient Outcomes; Health Systems; Public Health, Health Services & Primary Care; Quality of Care; Health Systems Policy; Disease Control; Health & Medical Informatics; Standards of Care

Contact Details

NINR
NIH
31 Center Drive, Room 5B10
Bethesda MD 20892-2178
Tel: +1 301 594 5970
Email: hussk@mail.nih.gov



N **IDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY PLANNING GRANT (R34): AIDS-RELATED** NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research invites applications for its NIDCR clinical trial or biomarker clinical validation study planning grant (R34) Aids-related call. This R34 Aids-related call for funding supports activities to develop a draft clinical protocol, the clinical investigators brochure, tools for data and quality management, safety and operational oversight plans, recruitment and retention strategies, a study team and other essential documents.

US and foreign for-profit and non-profit organisations and public and private organisations may apply. This funding opportunity uses the NIH planning grant (R34) mechanism and runs in parallel with two opportunities of identical scientific scope, PAR-14-342, which solicits applications under the same mechanism (R34) and PAR-11-339, which solicits applications under the NIH research project cooperative agreement (U01) mechanism.

Direct costs may not exceed US\$150,000 over a period of one year.

Ref: PAR-14-346 (replaces PAR-11-338).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm applicant's local time. Deadlines on: 7

September 2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 22 Sep 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$150,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-346.html>

Application form:

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

Eligibility profile

Country of applicant institution: Any

Disciplines

Diagnostic Sciences; Drug Design; Oral Medicine; Craniofacial Disorders; Dental Health & Hygiene; Biochemical Markers; Clinical Medicine; HIV/Aids; Biological Markers & Sensor Mechanisms; Dentistry

Contact Details

NIH NIDCR

Public Information and Liaison Branch

45 Center Drive, MSC 6400

Bethesda MD 20892-6400

Tel: +1 301 435 7908

Email: jatkinso@mail.nih.gov

S **ELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R01): AIDS-RELATED** NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research, the National Institute on Ageing and the

National Institute on Deafness and Other Communication Disorders invites



applications for its Aids-related self-management for health in chronic conditions grants. These R01 AIDS-related grants support activities that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses and conditions.

Eligible applicants include domestic and foreign public or private institutions and non-profit or for-profit organisations.

The maximum project period is five years.

PA-14-344

Closing date: 07 Sep 16

Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May, 7 September until 8 January 2018.

Posted date: 22 Sep 14

Award type: Directed grants to institutions, research groups etc, Clinical trials

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-344.html>

Application form:

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

Eligibility profile

Country of applicant institution: Any

Disciplines

Sociology; Public Health; HIV/Aids; Social Work & Social Policy; Chronic Fatigue Syndrome; Combustion & Fuel Engineering; Public Health, Health Services & Primary Care; Avionics; Allied Health Professions; Clinical Medicine; Business & Management Studies; Chronic Care; Health Counselling; Primary Care; Assistive Technology; Employment & Unemployment Studies

Contact Details

National Institute of Nursing Research
31 Center Drive, Room 5B10
Bethesda MD 20892-2178
Tel: +1 301 594 5970
Email: hussk@mail.nih.gov

STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R21): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its Aids-related studies in neonatal resuscitation (R21) grants. These Aids-related R21 grants support collaborative research projects on a wide range of topics related to neonatal resuscitation.

Projects should help develop strategies to deliver highest quality of healthcare to

newborn infants and children with utmost safety and effectiveness. Projects may relate to the epidemiology of various domains of medical errors and consequent patient harm, assessing the factors at various levels that contribute to such errors, and intervention strategies at individual, systems and institutional-levels to help reduce and eliminate medical errors.



Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This Aids-related funding opportunity uses the R21 exploratory and developmental grant mechanism, and runs in parallel with two opportunities of identical scientific scope: PA-14-351, which solicits applications under the R03 small grant programme mechanism, and PA-14-350, which solicits applications under the R01 research project grant mechanism.

Application budgets are limited to US\$275,000 over a maximum of two years, and no more than US\$200,000 may be requested in a single year.

Ref: PA-14-349 (replaces PAR-11-224).

Closing date: 07 Sep 16

Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant institution on every 7 May, 7 September and 7 January until 8 January 2018.

Posted date: 29 Sep 14

Award type: Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-350.html>

Application form:

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

Eligibility profile

Country of applicant institution: Any

Disciplines

Obstetrics & Gynaecology; HIV/Aids; Allied Health Professions; Foetal Health & Prenatal Development; Respiratory Medicine; Cardiology; Clinical Medicine; Neonatal Disorders; Paediatrics

Contact Details

NIH: National Institute of Child Health and Human Development
Building 31, Room 2A32
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 435 6873
Email: kosomari@mail.nih.gov

S TUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R03): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its Aids-related studies in neonatal resuscitation (R03) grants. These Aids-related R03 grants support collaborative research projects on a wide range of topics related to neonatal resuscitation.

Projects should help develop strategies to deliver highest quality of healthcare to newborn infants and children with utmost safety and effectiveness. Projects may relate to the epidemiology of various domains of medical errors and consequent patient harm, assessing the factors at various levels that contribute to such errors, and intervention strategies at individual, systems and



institutional-levels to help reduce and eliminate medical errors.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This Aids-related funding opportunity utilises the R03 mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-350 that encourages applications under the R01 research project grant mechanism and PA-14-349 that encourages applications under the R21 exploratory or developmental grant mechanism.

Application budgets are limited to US\$50,000 in direct costs per year over a maximum period of two years.

Ref: PA-14-351 (replaces PAR-11-223).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 29 Sep 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-351.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-351>

Eligibility profile

Country of applicant institution: Any

Disciplines

Neonatal Disorders; Respiratory Medicine; Foetal Health & Prenatal Development; Obstetrics & Gynaecology; Clinical Medicine; Paediatrics; HIV/Aids; Cardiology; Allied Health Professions

Contact Details

NICHHD
Building 31, Room 2A32
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 435 6873
Email: kosomari@mail.nih.gov

STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R01): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its Aids-related studies in neonatal resuscitation (R01) grants. These Aids-related R01 grants support collaborative research projects on a wide range of topics related to neonatal resuscitation.

Projects should help develop strategies to deliver highest quality of healthcare to newborn infants and children with utmost safety and effectiveness. Projects may relate to the epidemiology of various domains of medical errors and consequent patient harm, assessing the factors at various levels that contribute to such errors, and intervention



strategies at individual, systems and institutional-levels to help reduce and eliminate medical errors.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This Aids-related funding opportunity uses the R01 research project mechanism, and runs in parallel with two opportunities of identical scientific scope: PA-14-35, which solicits applications under the R03 small grant programme mechanism, and PA-14-349, which solicits applications under the R21 exploratory and developmental grant mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The total project period may not exceed five years.

Ref: PA-14-350 (replaces PAR-11-222).

Closing date: 07 Sep 16

Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 29 Sep 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-350.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-350>

Eligibility profile

Country of applicant institution: Any

Disciplines

Respiratory Medicine; Paediatrics; Foetal Health & Prenatal Development; Obstetrics & Gynaecology; Cardiology; HIV/Aids; Neonatal Disorders; Allied Health Professions; Clinical Medicine

Contact Details

NIH: National Institute of Child Health and Human Development
Building 31, Room 2A32
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 435 6873
Email: kosomari@mail.nih.gov

BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R21): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research and the National Institute of Biomedical Imaging and Bioengineering invite applications for their biology of the temporomandibular joint in health and disease (R21): Aids-related grants. This R21 Aids-related funding opportunity

encourages research that advances understanding of the temporomandibular joint in health and disease, and aims to stimulate research focused on the biology of joint function and the tissues that make up the joint. Focus areas include:



- bone;
- muscle;
- cartilaginous and ligamentous tissues;
- vascularisation and innervation;
- models;
- measurement of joint health, disease and functions.

This Aids-related funding opportunity uses the NIH research project (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-14-358, which solicits applications under the NIH exploratory and developmental grant (R01) mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Funding is worth up to US\$275,000 over two years, and projects may request no more than US\$200,000 per year.

Ref: PA-14-359.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Oct 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-359.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-14-359>

Eligibility profile

Country of applicant institution: Any

Disciplines

Musculoskeletal System; Clinical Medicine; Muscle Diseases; Orthopaedic Surgery; Physiology; Bone Cancers; Connective Tissue; Osteoporosis & Other Bone Diseases; HIV/Aids; Diagnostic Sciences; Movement Disorders; Cardiology; Disease Models; Human Biological Sciences; Primary Care; Human Physiology; Public Health, Health Services & Primary Care

Contact Details

NIH: National Institute of Dental and Craniofacial Research
Public Information and Liaison Branch
45 Center Drive, MSC 6400
Bethesda MD 20892-6400
Tel: +1 301 594 9898
Email: jasonwan@mail.nih.gov

BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R01): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research and the National Institute of Biomedical Imaging and Bioengineering invite applications for their biology of the temporomandibular joint in

health and disease (R01): Aids-related grants. This Aids-related R01 funding opportunity encourages research that advances understanding of the temporomandibular joint in health and disease, and aims to



stimulate research focused on the biology of joint function and the tissues that make up the joint. Focus areas include:

- bone;
- muscle;
- cartilaginous and ligamentous tissues;
- vascularisation and innervation;
- models;
- measurement of joint health, disease and functions.

This Aids-related funding opportunity uses the NIH exploratory and developmental grant (R01) mechanism and runs in parallel with one of identical scientific scope, PA-14-359, which solicits applications under the NIH research project (R21) grant mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Budgets are not limited but must reflect the actual needs of the proposed project. The scope of the project should define its duration.

Ref: PA-14-358.

Closing date: 07 Sep 16

Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Oct 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-358.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-14-358>

Eligibility profile

Country of applicant institution: Any

Disciplines

Diagnostic Sciences; Primary Care; Disease Models; Musculoskeletal System; Movement Disorders; Orthopaedic Surgery; Human Physiology; Osteoporosis & Other Bone Diseases; Cardiology; Muscle Diseases; Bone Cancers; Clinical Medicine; Connective Tissue; Physiology; Human Biological Sciences; HIV/Aids; Public Health, Health Services & Primary Care

Contact Details

NIH: National Institute of Dental and Craniofacial Research
Public Information and Liaison Branch
45 Center Drive, MSC 6400
Bethesda MD 20892-6400
Tel: +1 301 594 9898
Email: jasonwan@mail.nih.gov

B IOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R21): AIDS-RELATED

NIH: National Institutes of Health

Description:

The National Institutes of Health, under the National Institute of Nursing Research and the National Institute on Aging, invite

applications for their Aids-related biobehavioural and technological interventions to attenuate cognitive decline in



individuals with cognitive impairment or dementia grants. These Aids-related R21 grants aim to stimulate clinical research focused on biobehavioural or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment, or disease or age-related cognitive decline. Particular interest is on the following:

- interventions that can be implemented in community settings by the affected individual, informal caregivers or others in the community;
- research to inform the development of the type of interventions identified above;
- research that examines underlying mechanisms and biomarkers associated with response to interventions.

This funding opportunity uses the R21 exploratory or developmental grant mechanism that seeks to foster the introduction of novel scientific ideas, model systems, tools, agents, targets and technologies that have the potential to substantially advance biomedical research. The opportunity runs in parallel with two opportunities of identical scientific scope; PA-15-017, which solicits applications under the R01 research project grant mechanism, and PA-15-016, which solicits applications under the R15 academic research enhancement award mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

Grants cover direct costs up to a maximum of US\$275,000 over a period of up to two years.

Ref: PA-15-015.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 15 Oct 14

Award type: Directed grants to institutions, research groups etc,

Networking/collaboration

Award amount max: \$275,000

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-015.html>

Application form:

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

Eligibility profile

Country of applicant institution: Any

Disciplines

Public Health, Health Services & Primary Care; General Practice & Family Health; Clinical Medicine; Alzheimer's Disease & Senile Dementia; Neuroscience; Health Economics; Primary Care; Psychology; Neurology; Medical Effectiveness & Patient Outcomes; Cognitive Processes; Diagnostic Sciences; HIV/Aids

Contact Details

NINR

Building 1DEM

Suite 713A

6701 Democracy Boulevard

Bethesda, MD 20817

Tel: +1 301 594 5968

Email: tullyla@mail.nih.gov



BIOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R01): AIDS-RELATED

NIH: National Institutes of Health

Description:

The National Institutes of Health, under the National Institute of Nursing Research and the National Institute on Aging, invite applications for their Aids-related biobehavioural and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia grants. These Aids-related R01 grants aim to stimulate clinical research focused on biobehavioural or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment, or disease or age-related cognitive decline. Particular interest is on the following:

- interventions that can be implemented in community settings by the affected individual, informal caregivers or others in the community;
- research to inform the development of the type of interventions identified above;
- research that examines underlying mechanisms and biomarkers associated with response to interventions.

This funding opportunity uses the R01 research project grant mechanism and runs in parallel with two opportunities of identical scientific scope; PA-15-016, which solicits applications under the R15 academic research enhancement award mechanism, and PA-15-015, which solicits applications under the R21 exploratory or developmental award mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

Grants are awarded for a maximum project period of five years.

Ref: PA-15-017.

Closing date: 07 Sep 16

Deadline information: Applications requesting US\$500,000 or more in direct costs per year should contact NIH staff at least six weeks before applying.

Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018. Deadlines on: 7 September 2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 15 Oct 14

Award type: Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-017.html>

Application form:

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine; Health Economics; Diagnostic Sciences; General Practice & Family Health; Cognitive Processes; Public Health, Health Services & Primary Care; Primary Care; HIV/Aids; Psychology; Neurology; Alzheimer's Disease & Senile Dementia; Medical Effectiveness & Patient Outcomes; Neuroscience



Contact Details

NINR
Building 1DEM
Suite 713A

6701 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 594 5968
Email: tullyla@mail.nih.gov

The National Institute of Neurological Disorders and Stroke, the National Institute on Aging, the National Institute on Drug Abuse and the National Institute of Mental Health invite applications for their Aids-related promoting research in basic neuroscience (R01) grants. These Aids-related R01 grants aim to stimulate research addressing fundamental questions in basic neuroscience.

Projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the structure and/or function of the normal nervous system. Grants are not intended to stimulate research that is explicitly disease-related.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAS-15-029.

Closing date: 07 Sep 16
Deadline information: Applications requesting US\$500,000 or more in direct costs per year should contact NIH staff at least six weeks before applying.
Applications are invited between 5 January

and 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018. Deadlines on: 7 September 2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 05 Nov 14

Award type: Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAS-15-029.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Neuroanatomy; Stroke & Cerebrovascular Disorders; Diagnostic Sciences; Pharmacy & Pharmacology; Public Health, Health Services & Primary Care; Psychology; Neuropsychology; Muscle Diseases; Neuroscience; Clinical Medicine; Primary Care; HIV/Aids; Electrophysiology; Neuroendocrinology; Endocrine & Neuroendocrine Cancers; Neurobiology; Neuropharmacology; Neurology; Neurosurgery; Biological Sciences; Neurotransmitters; Neuroimaging

Contact Details

Tel: +1 301 496 5745
Email: rr260c@nih.gov



D IABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R21): AIDS-RELATED

NIH: National Institute on Aging

Description:

The National Institute on Aging invites applications for its diabetes and cardiovascular disease in older adults (R21) grants. These Aids-related R21 grants encourage basic, clinical and epidemiological outcomes research on the impact of age on the development of, diagnosis and management of diabetes and cardiovascular disease complications in older persons or animal models. Research supported by this initiative is expected to elucidate the role of ageing mechanisms that underlie the increased vulnerability of older adults to DM and its CVD complications and to provide evidence-based guidance to improve more appropriate diagnostic criteria, risk stratification and intervention recommendations to prevent the onset, or improve short- and long-term outcomes, of DM and CVD in older persons.

This funding opportunity uses the R21 exploratory and developmental research grant mechanism and runs in parallel with two of identical scientific scope, PA-15-037, which solicits applications under the R01 research project grant mechanism and PA-15-039, which solicits applications under the R03 small grant programme mechanism. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$275,000 for direct costs over a maximum project period of two years. No more than US\$200,000 may be requested in any single year.

Ref: PA-15-038.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 20 Nov 14

Award type: Innovation grants, Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-038.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-15-038>

Eligibility profile

Country of applicant institution: Any

Disciplines

Cardiovascular Diseases; Diabetes; HIV/ Aids; Geriatrics & Gerontology

Contact Details

GWY BG Room 3C307
7201 Wisconsin Avenue
Bethesda MD 20814
Tel: +1 301 496 6761
Email: susan.zieman@nih.gov



D **IABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R03): AIDS-RELATED**

NIH: National Institute on Aging

Description:

The National Institute on Aging invites applications for its diabetes and cardiovascular disease in older adults (R03) grants. These Aids-related R03 grants encourage basic, clinical and epidemiological outcomes research on the impact of age on the development of, diagnosis and management of diabetes and cardiovascular disease complications in older persons or animal models. Research supported by this initiative is expected to elucidate the role of ageing mechanisms that underlie the increased vulnerability of older adults to DM and its CVD complications and to provide evidence-based guidance to improve more appropriate diagnostic criteria, risk stratification and intervention recommendations to prevent the onset, or improve short- and long-term outcomes, of DM and CVD in older persons.

This funding opportunity uses the R03 small grant programme mechanism and runs in parallel with two of identical scientific scope, PA-15-037, which solicits applications under the R01 research project grant mechanism and PA-15-038, which solicits applications under the R21 exploratory and developmental research grant mechanism. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Application budgets are limited to US\$100,000 for direct costs over a maximum project period of two years. No more than US\$50,000 may be requested in any single year.

Ref: PA-15-039.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 20 Nov 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-039.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-15-039>

Eligibility profile

Country of applicant institution: Any

Disciplines

Diabetes; HIV/Aids; Geriatrics & Gerontology; Cardiovascular Diseases

Contact Details

GWY BG Room 3C307
7201 Wisconsin Avenue
Bethesda MD 20814
Tel: +1 301 496 6761
Email: susan.zieman@nih.gov



D **IABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R01): AIDS-RELATED**

NIH: National Institute on Aging

Description:

The National Institute on Aging invites applications for its diabetes and cardiovascular disease in older adults (R01) grants. These Aids-related R01 grants encourage basic, clinical and epidemiological outcomes research on the impact of age on the development of, diagnosis and management of diabetes and cardiovascular disease complications in older persons or animal models. Research supported by this initiative is expected to elucidate the role of ageing mechanisms that underlie the increased vulnerability of older adults to DM and its CVD complications and to provide evidence-based guidance to improve more appropriate diagnostic criteria, risk stratification and intervention recommendations to prevent the onset, or improve short- and long-term outcomes, of DM and CVD in older persons.

This funding opportunity uses the R01 research project grant mechanism and runs in parallel with two of identical scientific scope, PA-15-038, which solicits applications under the R21 exploratory and developmental grant mechanism and PA-15-039, which solicits applications under the R03 small grant programme mechanism. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-15-037.

Closing date: 07 Sep 16

Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 05 Jan 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-037.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-15-037>

Eligibility profile

Country of applicant institution: Any

Disciplines

Diabetes; Cardiovascular Diseases; HIV/ Aids; Geriatrics & Gerontology

Contact Details

GWY BG Room 3C307
7201 Wisconsin Avenue
Bethesda MD 20814
Tel: +1 301 496 6761
Email: susan.zieman@nih.gov



UNDERACTIVE BLADDER IN AGEING (R03): AIDS-RELATED

NIH: National Institute on Aging

Description:

The National Institute on Aging invites applications for its underactive bladder in ageing (R03) grants. This Aids-related R03 funding opportunity announcement invites applications that propose basic, clinical or translational research on underactive bladder and its consequences in ageing and in older persons. Applications should focus on the:

- biology, aetiology and pathophysiology of UAB in animal models and older adults;
- translation of basic or clinical research into clinical practice and health decision-making;
- diagnosis, prevention, management and clinical outcomes of UAB in older adults;
- epidemiology and risk factors for the development of UAB with advancing age.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. This FOA uses the NIH small grant (R03) mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-049 that solicits applications under the research project grant award (R01) mechanism and PA-15-051 that solicits applications under the exploratory/developmental (R21) mechanism. Application budgets are limited to US\$100,000 over the two-year R03 period, with no more than US\$50,000 in any year. The maximum project period is two years.

Ref: PA-15-050.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 25 Nov 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-050.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-15-050>

Eligibility profile

Country of applicant institution: Any

Disciplines

Incontinence; Geriatrics & Gerontology; Urology; HIV/Aids

Contact Details

NIA

GWY BG Room 3C307

7201 Wisconsin Avenue

Bethesda MD 20814

Tel: +1 301 496 6761

Email: saliveme@mail.nih.gov



UNDERACTIVE BLADDER IN AGEING (R21): AIDS-RELATED

NIH: National Institute on Aging

Description:

The National Institute on Aging invites applications for its underactive bladder in ageing (R21) grants. This Aids-related funding opportunity announcement invites applications that propose basic, clinical or translational research on underactive bladder and its consequences in ageing and in older persons. Applications should focus on the:

- biology, aetiology and pathophysiology of UAB in animal models and older adults;
- translation of basic or clinical research into clinical practice and health decision-making;
- diagnosis, prevention, management and clinical outcomes of UAB in older adults;
- epidemiology and risk factors for the development of UAB with advancing age.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. This FOA uses the NIH exploratory/developmental R21 grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-049 that solicits applications under the research project grant award (R01) mechanism and PA-15-050 that solicits applications under the small grant programme (R03) mechanism.

Application budgets are limited to US\$275,000 over the two-year R21 period, with no more than US\$200,000 in any year.

Ref: PA-15-051.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 25 Nov 14

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-051.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-15-051>

Eligibility profile

Country of applicant institution: Any

Disciplines

Incontinence; Urology; HIV/Aids; Geriatrics & Gerontology

Contact Details

NIA
GWY BG Room 3C307
7201 Wisconsin Avenue
Bethesda MD 20814
Tel: +1 301 496 6761
Email: saliveme@mail.nih.gov



UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related unconventional roles of ethanol metabolising enzymes, metabolites and cofactors in health and disease (R21) funding opportunity announcement. This Aids-related announcement provides support for integrated, innovative research on the novel and unconventional contributions of ethanol metabolising pathways, their metabolites, cofactors and interactions with synergising biological pathways in the development of alcohol-induced diseases and end organ injuries.

The aim is to generate data that leads to breakthroughs in identification and understanding of key cellular and molecular components in the initiation, progression and maintenance of the diverse medical disorders caused by excessive or long term alcohol consumption. The generated knowledge should enable clinicians to improve disease outcomes and consequently, public health. Research areas include the following: ethanol and NAD⁺; ethanol and acetate; ethanol and SAM; ethanol and zinc; endogenous substrates and functions of alcohol metabolising pathways – regulation of growth, development and disease.

This announcement uses the R21 exploratory or developmental research grant mechanism and runs in parallel with one of identical scientific scope, PA-15-058, which encourages applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Grants cover direct costs up to a maximum of US\$275,000 over a maximum period of two

years. No more than US\$200,000 may be requested in any single year.

Ref: PA-15-057 (reissue of PA-12-234).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 09 Dec 14

Award type: Innovation grants, Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-057.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-15-057>

Eligibility profile

Country of applicant institution: Any

Disciplines

Addiction; Alcoholism; HIV/Aids; Alcoholic Beverages; Cell Physiology & Metabolism; Hepatology

Contact Details

NIAAA

Building 5635FL, Room 2119

5635 Fishers Lane

Rockville, MD 20852

Tel: +1 301 443 2193

Email: orosza@mail.nih.gov

Description:

The National Institute of Dental and Craniofacial Research invites applications for its Aids-related clinical trial or biomarker validation study cooperative agreement (U01) funding opportunity announcement. This Aids-related announcement supports investigator-initiated phase I, II, III or IV clinical trials, stage one to four behavioural or social intervention trials or biomarker validation studies that require prospective collection of clinical outcomes and clinical specimens through the funding mechanism. Eligible clinical trials may focus on the following:

- chemotherapeutic, pharmacologic or other interventions to prevent or treat periodontal diseases and various types of dental caries;
- testing new dental materials for restoration of carious lesions;
- testing non-opiate methods of reducing postoperative pain and swelling after dental surgery;
- preventing or treatment of HIV/Aids, its associated oral complications, coinfections or malignancies, and dental diseases caused by bacteria, fungi or viruses;
- testing therapies to prevent or treat oral candidiasis, oral herpes virus infections and other pathogens with oral targets that commonly occur in those with congenital or acquired immune dysfunction;
- testing treatments for oral mucositis and other oral manifestations of systemic diseases;
- comparing therapies for oral diseases in medically complex patients;
- preventing or managing salivary dysfunction;
- testing treatments for temporomandibular dysfunction and other orofacial pain conditions;

- validation of biomarkers of oral or dental diseases through prospective collection of biospecimens and data on clinical outcomes;
- testing the efficacy or effectiveness and mechanisms of action of behavioural or social interventions to improve dental, oral or craniofacial health;
- adapting behavioural or social principles, methods or interventions from other areas of health to be applied and tested in dental, oral or craniofacial health, or in the dental setting;
- developing and testing algorithms for tailoring or targeting behavioural or social interventions for individuals, groups, communities or settings in which further testing is justified.

This announcement uses the NIH research (U01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PAR-14-342 and PAR-14-346, both of which solicit applications under the NIH planning grant (R34) mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the needs of the project. The maximum project period is five years.

Ref: PAR-15-059 (reissue of PAR-11-339).

Closing date: 07 Sep 16

Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018. Deadlines on: 7 September 2016, 7 January 2017, 7 May 2017, and repeated annually.



Posted date: 09 Dec 14

Award type: Directed grants to institutions,
research groups etc,
Networking/collaboration, Clinical trials

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-059.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=P-AR-15-059>

Eligibility profile

Country of applicant institution: Any

Disciplines

Preventive Medicine; Dentistry; HIV/Aids;
Infection Agents & Pathogens; Pain
Management; Biochemical Markers

Contact Details

NIDCR

Building 1DEM, Room 634

6701 Democracy Boulevard

Bethesda, MD 20817

Tel: +1 301 435 7908

Email: jatkinso@mail.nih.gov

BUILDING ON HIGH IMPACT BASIC NEUROBIOLOGY THROUGH ASSAY DEVELOPMENT: ADVANCING TOOLS FOR THERAPEUTIC DISCOVERY (R01): AIDS-RELATED

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health, the National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their Aids-related building on high impact basic neurobiology through assay development: advancing tools for therapeutic discovery (R01) grants.

This Aids-related announcement encourages research to develop novel, robust assays to reveal changes in neuronal and glial function. The goal is to adapt state-of-the-art measures of basic cellular processes or molecular events that are key mediators of nervous system function with the intent to probe mechanisms or perturbations in an unbiased and efficient manner.

US and foreign for-profit and non-profit organisations and public and private institutions are eligible to apply. Application budgets are not limited but need to reflect the

actual needs of the proposed project. Applicants requesting US\$500,00 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The maximum project period is four years.

Ref: PAR-15-066 (reissue of PAR-11-319).

Closing date: 07 Sep 16

Deadline information: Applications open on 23 January and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 11 Dec 14

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-066.html>

**Application form:**

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=P-AR-15-066>

Eligibility profile

Country of applicant institution: Any

Disciplines

Cellular Interactions; Neurobiology;
HIV/Aids

Contact Details

NSC BG Room 7189
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 5288
Email: jdrisco1@mail.nih.gov

INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): ASSAY DEVELOPMENT AND THERAPEUTIC AGENT IDENTIFICATION AND CHARACTERISATION TO SUPPORT THERAPEUTIC DISCOVERY (R21/R33): AIDS- RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:

The National Institute of Neurological Disorders and Stroke invites applications for its innovation grants to nurture initial translational efforts (IGNITE): assay development and therapeutic agent identification and characterisation to support therapeutic discovery (R21/R33) funding opportunity announcement. This Aids-related announcement encourages research to develop in vitro or ex vivo assays and conduct iterative screening efforts to identify and characterise potential therapeutic agents for neurological disorders. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity uses the NIH phased innovation award (R21/R33) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-071, which also solicits applications under the NIH phased innovation award (R21/R33) grant mechanism.

Application budgets are limited to US\$750,000 over the maximum combined project period of three years, with a maximum of US\$250,000 for the R21 phase and US\$500,000 for the R33 phase. The R21 and R33 cannot be awarded in the same fiscal year.

Ref: PAR-15-070.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 15 Dec 14

Award type: Innovation grants, Directed grants to institutions, research groups etc
Award amount max: \$750,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-071.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application->



[package.html#download=true&oppNum=PAR-15-070](#)

Eligibility profile

Country of applicant institution: Any

Disciplines

Neurology; HIV/Aids

Contact Details

NSC BG Room 2106
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 496 1779
Email: amir.tamiz@nih.gov

INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): PHARMACODYNAMICS AND IN VIVO EFFICACY STUDIES FOR SMALL MOLECULES AND BIOLOGICS/BIOTECHNOLOGY PRODUCTS (R21/R33): AIDS-RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:

The National Institute of Neurological Disorders and Stroke invites applications for its innovation grants to nurture initial translational efforts (IGNITE): pharmacodynamics and in vivo efficacy studies for small molecules and biologics/biotechnology products (R21/R33) funding opportunity announcement. This Aids-related announcement provides funding to conduct pharmacodynamics, pharmacokinetics and in vivo efficacy studies to demonstrate that proposed therapeutic agents have sufficient biological activity to warrant further development to treat neurological disorders. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity uses the NIH phased innovation award(R21/R33) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-070, which also solicits applications under the NIH phased innovation award (R21/R33) grant mechanism.

Application budgets are limited to US\$750,000 over the maximum combined project period of three years, with a maximum of US\$250,000 for the R21 phase and US\$500,000 for the R33 phase. The R21 and R33 cannot be awarded in the same fiscal year.

Ref: PAR-15-071.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 15 Dec 14

Award type: Innovation grants, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-071.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PAR-15-071>



Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Neurology

Contact Details

NSC BG Room 2106
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 496 1779
Email: amir.tamiz@nih.gov

ACADEMIC-INDUSTRIAL PARTNERSHIPS FOR TRANSLATION OF TECHNOLOGIES FOR CANCER DIAGNOSIS AND TREATMENT (R01): AIDS-RELATED

NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its Aids-related academic-industrial partnerships for translation of technologies for cancer diagnosis and treatment (R01) funding opportunity announcement. This Aids-related announcement enables academic and industrial investigators to form research partnerships and work together to accelerate the translation of technologies, methods, assays or devices, systems for preclinical or clinical molecular diagnosis or in vitro imaging designed to solve a targeted cancer problem.

The proposed systems may include molecular diagnosis, molecular imaging or related research resources. Clinical trials that test functionality, and optimise and validate the performance of the proposed translational work may also be funded.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the needs of the project. The maximum funding period is five years.

Ref: PAR-15-075.

Closing date: 07 Sep 16

Deadline information: Applications open on 6 February and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 17 Dec 14

Award type: Academic-Industry links, Directed grants to institutions, research groups etc, Clinical trials, Research calls for business, Networking/collaboration

Award amount max: -

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-075.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true?oppNum=PAR-15-075>

Eligibility profile

Country of applicant institution: Any

Disciplines

Oncology Nursing; Chemotherapy;
Radiotherapy; Cancer Immunology;
HIV/Aids; Molecularly Targeted Therapy;
Cancer Diagnosis



Contact Details

NCI
Building 9609 Room 3W424
9609 Medical Center Drive

Rockville, MD 20850
Tel: +1 240 276 5714
Email: ossandom@mail.nih.gov

PREVENTION RESEARCH IN MID-LIFE ADULTS (R21): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute on Nursing Research and the National Institute on Ageing invite applications for their prevention research in mid-life adults (R21) funding opportunity announcement. This Aids-related announcement encourages research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimise health and wellness as individuals age and prevent illness and disability in later years. This FOA particularly encourages interventions that can be delivered in multiple settings. Studies in disparate groups, such as African American, Native American and Hispanic populations who have a greater prevalence of illness related to multiple chronic conditions, are especially needed. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-098, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The combined application budget is limited to US\$275,000 in direct costs over a two year period. No more than US\$200,000 may be requested in any single year.

Ref: PA-15-097.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 23 Jan 15

Award type: Clinical trials, Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-097.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=P A-15-097>

Eligibility profile

Country of applicant institution: Any

Disciplines

Geriatric Nursing; HIV/Aids; Preventive Medicine; Geriatrics & Gerontology; Health of Minority Groups

Contact Details

NINR
BG 1Dem Room 717
6701 Democracy Boulevard



Bethesda MD 20817
Tel: +1 301 594 2154

Email: mary.roary@nih.gov

PREVENTION RESEARCH IN MID-LIFE ADULTS (R01): AIDS RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute on Nursing Research and the National Institute on Ageing invite applications for their prevention research in mid-life adults (R01) funding opportunity announcement. This Aids-related announcement encourages research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimise health and wellness as individuals age and prevent illness and disability in later years. This FOA particularly encourages interventions that can be delivered in multiple settings. Studies in disparate groups, such as African American, Native American and Hispanic populations who have a greater prevalence of illness related to multiple chronic conditions, are especially needed. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-097, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. Applicants requesting US\$500,000 or more in direct costs in any year (excluding consortium F&A) must contact NIH program staff at least six weeks before submitting the application.

Ref: PA-15-098

Closing date: 07 Sep 16

Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 23 Jan 15

Award type: Clinical trials, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-098.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-15-098>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Geriatrics & Gerontology; Preventive Medicine; Geriatric Nursing; Health of Minority Groups

Contact Details

NINR
BG 1Dem Room 717
6701 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 2154
Email: mary.roary@nih.gov

REDUCTIONS IN ILLICIT DRUG USE AND FUNCTIONAL OUTCOMES (R21/R33): AIDS-RELATED NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its reductions in illicit drug use and functional outcomes (R21/R33) funding opportunity announcement. This Aids-related announcement encourages research that determines whether reductions in illicit drug use are associated with positive changes in health-related and other functional outcomes in individuals with substance use disorders. Functional outcomes include, for example, reductions in morbidity, mortality, criminal justice involvement and overall healthcare expenditures.

This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by possible transition to expanded research support (R33 phase). The transition to the R33 phase will be determined by NIH programme evaluation of successful achievement of the milestones set for the R21 phase.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The R21 phase may request up to two years of support for a maximum of US\$275,000 in direct costs, with no more than US\$200,000 requested in any single year. The R33 phase may request up to three years of support for a maximum of US\$500,000 in direct costs per year, although requests for more than US\$500,000 per year may also be considered.

Ref: PA-15-099.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 26 Jan 15

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-099.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-15-099>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Health Promotion; Drug & Substance Abuse; Smoking & Tobacco; Alcoholism

Contact Details

NSC BG Room 4131
6001 Executive Boulevard
Rockville MD 20852
Email: imontoya@mail.nih.gov

MATERNAL NUTRITION AND PRE-PREGNANCY OBESITY: EFFECTS ON MOTHERS, INFANTS AND CHILDREN (R01): AIDS-RELATED NIH: National Institute of Nursing Research

**Description:**

The National Institute of Nursing Research and Office of Dietary Supplements invite applications for their maternal nutrition and pre-pregnancy obesity: effects on mothers, infants and children (R01) funding opportunity announcement. This Aids-related announcement encourages projects to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited, but need to reflect actual needs of the proposed project. Applicants requesting US\$500,000 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The maximum project period is five years.

Ref: PA-15-100 (replaces PA-12-061).

Closing date: 07 Sep 16

Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 28 Jan 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-100.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true?oppNum=PA-15-100>

Eligibility profile

Country of applicant institution: Any

Disciplines

Obesity; HIV/Aids; Foetal Health & Prenatal Development; Pregnancy & Birth; Maternal Health; Reproduction & Fertility

Contact Details

NINR

Building 1Dem, Room 718

6701 Democracy Boulevard

Bethesda MD 20817

Tel: +1 301 594 5976

Email: hardylr@mail.nih.gov

R OLE OF EXOSOMES IN HIV PATHOGENESIS (R21)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases, together with the National Institute of Mental Health, invites applications for its role of exosomes in HIV pathogenesis (R21) funding opportunity announcement. This announcement encourages new research on the potential role of exosomes in cell-to-cell communication

relevant to HIV transmission, innate or adaptive immune responses to HIV or HIV pathogenesis. Studies looking at the function of exosomes in acute infection, or in chronic infection in individuals on fully suppressive antiretroviral regimens are encouraged.



US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The maximum budget for direct costs for the two-year project period is US\$275,000. No more than US\$200,000 may be requested in any single year.

The maximum project period is two years.

Ref: PA-15-107.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 02 Feb 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-107.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-15-107>

Eligibility profile

Country of applicant institution: Any

Disciplines

Pathogenesis; HIV/ Aids

Contact Details

BG 5601Floor Room 9G38

5601 Fishers Lane

Rockville MD 20852

Tel: +1 240 627 3869

Email: elizabeth.stansell@nih.gov

EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R03): AIDS-RELATED

NIH: National Cancer Institute

Description:

The National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Environmental Health Sciences invite applications for their Aids-related early-life factors and cancer development in later life (R03) funding opportunity announcement. This Aids-related announcement stimulates research focused on the role of early-life factors in cancer development in later life. A better understanding is sought in the following areas:

- early-life factors that are associated with later cancer development, with

early-life including maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and adult years;

- how early-life factors mediate biological processes relevant to carcinogenesis;
- whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

This announcement uses the R03 small grant programme mechanism, which supports pilot or feasibility studies, secondary analysis of



existing data, small and self-contained research projects, the development of research methodology or the development of new research technology. The announcement also runs on parallel with two announcements of identical scientific scope; PA-15-126, which uses the R01 research project grant mechanism, and PA-15-125, which uses the R21 exploratory or developmental research grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. The principal investigator should attend an NCI-sponsored two-day meeting, generally held every second year in the Washington DC area.

Awards are worth up to US\$100,000 each in direct costs over a maximum period of two years.

Ref: PA-15-124.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018. Posted date: 27 Feb 15

Award type: Research calls for business, Networking/collaboration, Innovation grants, Directed grants to institutions, research groups etc, Academic-Industry links, Technology innovation/development
Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-124.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=274816>

Eligibility profile

Country of applicant institution: Any

Disciplines

Cancer Studies & Oncology; HIV/Aids

Contact Details

NCI
Building 9609
Room 4E548
9609 Medical Center Drive
Rockville MD 20850
Tel: +1 240 276 6941
Email: mahabir@mail.nih.gov

EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R21): AIDS-RELATED

NIH: National Cancer Institute

Description:

The National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Environmental Health Sciences invite applications for their Aids-related early-life factors and cancer development in later life (R21) funding opportunity announcement. This Aids-related announcement stimulates research focused on

the role of early-life factors in cancer development in later life. A better understanding is sought in the following areas:

- early-life factors that are associated with later cancer development, with early-life including maternal-paternal, in utero, birth and infancy, puberty



and adolescence, and teenage and adult years;

- how early-life factors mediate biological processes relevant to carcinogenesis;
- whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

This announcement uses the R21 exploratory or developmental grant mechanism and runs on parallel with two announcements of identical scientific scope; PA-15-126, which uses the R01 research project grant mechanism, and PA-15-124, which uses the R03 small grant programme mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. The principal investigator should attend an NCI-sponsored two-day meeting, generally held every second year in the Washington DC area.

Awards are worth up to US\$275,000 each in direct costs over a maximum period of two years.

Ref: PA-15-125.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 27 Feb 15

Award type: Directed grants to institutions, research groups etc, Academic-Industry links, Networking/collaboration, Research calls for business

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-125.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=274785>

Eligibility profile

Country of applicant institution: Any

Disciplines

Cancer Studies & Oncology; HIV/Aids

Contact Details

NCI

Building 9609

Room 4E548

9609 Medical Center Drive

Rockville MD 20850

Tel: +1 240 276 6941

Email: mahabir@mail.nih.gov



ADVANCING TRANSLATIONAL AND CLINICAL PROBIOTIC OR PREBIOTIC AND HUMAN MICROBIOME RESEARCH (R01): AIDS-RELATED

NIH: National Cancer Institute

Description:

The National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Drug Abuse, the National Center for Complementary and

Integrative Health and the Office of Dietary Supplements invite applications for their Aids-related advancing translational and clinical probiotic or prebiotic and human microbiome research (R01) funding



opportunity announcement. This Aids-related announcement supports interdisciplinary collaborations across scientific disciplines engaged in microbiome and probiotic or prebiotic research.

The aim is to accelerate translational and clinical phase I and II a/b safety and efficacy studies for substantial measurable functional benefits of probiotic or prebiotic components or their combinations, and to understand the underlying mechanisms of their actions and variability in responses to these interventions.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets must reflect the actual needs of the proposed projects. The maximum project period is five years.

Ref: PA-15-127.

Closing date: 07 Sep 16

Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 27 Feb 15

Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants, Academic-Industry links,

Research calls for business, Networking/collaboration

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-127.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#search=true&oppNum=PA-15-127>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Medical Genetics; Microbial Genomics; Microbial Ecology; Population & Ecological Genetics

Contact Details

NCI

Building 9606

Room 5E568

9609 Medical Center Drive

Rockville MD 20850

Tel: +1 240 276 7118

Email: gabriela.riscuta@nih.gov

EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R01): AIDS-RELATED NIH: National Cancer Institute

Description:

The National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Environmental Health Sciences invite applications for their Aids-related early-life factors and cancer development in later life (R01) funding

opportunity announcement. This Aids-related announcement stimulates research focused on the role of early-life factors in cancer development in later life. A better understanding is sought in the following areas:



- early-life factors that are associated with later cancer development, with early-life including maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and adult years;
- how early-life factors mediate biological processes relevant to carcinogenesis;
- whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

This announcement uses the R01 research project grant mechanism and runs on parallel with two announcements of identical scientific scope; PA-15-125, which uses the R21 exploratory or developmental grant mechanism, and PA-15-124, which uses the R03 small grant programme mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. The principal investigator should attend an NCI-sponsored two-day meeting, generally held every second year in the Washington DC area.

Application budgets need to reflect the actual needs of the proposed projects. The maximum project period is five years.

Ref: PA-15-126.

Closing date: 07 Sep 16

Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 27 Feb 15

Award type: Networking/collaboration, Research calls for business, Directed grants to institutions, research groups etc, Academic-Industry links

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-126.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=274784>

Eligibility profile

Country of applicant institution: Any

Disciplines

Cancer Studies & Oncology; HIV/Aids

Contact Details

NCI

Building 9609

Room 4E548

9609 Medical Center Drive

Rockville MD 20850

Tel: +1 240 276 6941

Email: mahabir@mail.nih.gov

FUNCTIONAL WELLNESS IN HIV - MAXIMISING THE TREATMENT CASCADE (R21) AIDS-RELATED

NIH: National Institutes of Health

Description:

The National Institute of Nursing Research and the Office of Behavioral and Social Sciences Research invite applications for their aids-related functional wellness in HIV - maximising the treatment cascade (R21)

funding opportunity announcement. This aids-related announcement encourages the development of HIV interventions that target opportunities to improve the delivery of healthcare across the continuum of care for



persons infected with HIV. Projects should include strategies and interventions that aim to:

- improve functional wellness and increase quality of life in HIV positive individuals;
- determine barriers and facilitators to entering and maintaining HIV care;
- validate the construct of functional wellness;
- develop and test methods to improve entrance and continuance in HIV care.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-133, which solicits applications under the NIH research project (R01) grant mechanism.

The combined budget for direct costs over the two-year project period may not exceed US\$275,000, with no more than US\$200,000 requested in any single year. The maximum project period is two years.

Ref: PA-15-134.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May 2015 and are due by 5pm local time of applicant organisation every 7 May, 7 September and 7 January until 8 May 2018.

Posted date: 06 Mar 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-134.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#search=true&oppNum=PA-15-134>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Life Expectancy & Quality of Life; Quality of Care

Contact Details

Tel: +1 301 594 5976

Email: lynda.hardy@nih.gov

FUNCTIONAL WELLNESS IN HIV – MAXIMISING THE TREATMENT CASCADE (R01) AIDS-RELATED

NIH: National Institutes of Health

Description:

The National Institute of Nursing Research and the Office of Behavioral and Social Sciences Research invite applications for their aids-related functional wellness in HIV – maximising the treatment cascade (R01) funding opportunity announcement. This aids-related announcement encourages the

development of HIV interventions that target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV. Projects should include strategies and interventions that aim to:



- improve functional wellness and increase quality of life in HIV positive individuals;
- determine barriers and facilitators to entering and maintaining HIV care;
- validate the construct of functional wellness;
- develop and test methods to improve entrance and continuance in HIV care.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-134, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

Application budgets are not limited but must reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-15-133.

Closing date: 07 Sep 16

Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 7 May, 7 September and 7 January until 8 May 2018.

Posted date: 06 Mar 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-133.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#search=true&oppNum=PA-15-133>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Life Expectancy & Quality of Life; Quality of Care

Contact Details

Tel: +1 301 594 5976

Email: lynda.hardy@nih.gov

P ILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN KIDNEY DISEASES (R21): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its Aids-related pilot and feasibility clinical research grants in kidney diseases (R21) funding opportunity announcement. This Aids-related announcement supports small scale or pilot and feasibility clinical and translational research studies, including epidemiological

studies or clinical trials related to kidney diseases research.

Studies should address important clinical and translational questions that are potentially of high clinical and public health impact.

This funding opportunity uses the NIH exploratory/developmental (R21) grant



mechanism and runs in parallel with one of identical scientific scope, PAR-15-162, which also solicits applications under the R21 mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US\$275,000 in direct costs with a maximum of US\$200,00 in direct costs per year. The maximum project period is two years.

Ref: PAR-15-161 (reissue PAR-11-352).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 30 Mar 15

Award type: Directed grants to institutions, research groups etc, Clinical trials, Innovation grants

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-15-161.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#search=true&oppNum=PAR-15-161>

Eligibility profile

Country of applicant institution: Any

Disciplines

Nephrology & Kidneys; HIV/Aids

Contact Details

BG 2DEM Room 633
6707 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 7717
Email: mm726k@nih.gov

IMPROVING DIET AND PHYSICAL ACTIVITY ASSESSMENT (R21): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

A total of seven participating institutes and centres of the National Institutes of Health invite applications for their diet and physical activity assessment methodology (R21) funding opportunity announcement. This Aids-related announcement supports innovative research to enhance the quality of measurements of dietary intake and physical activity.

This FOA uses the NIH exploratory/developmental grant (R21) award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-15-

170, which solicits applications under the NIH research project grant (R01) award mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US\$275,000 in direct costs, with up to US\$200,000 available for direct costs per year. The maximum project period is two years.

PAR-15-171 (reissue of PAR-12-197).



Closing date: 07 Sep 16

Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation on 7 January and 7 September 2016, 7 May 2017, and 7 January and 7 September 2018.

Posted date: 02 Apr 15

Award type: Innovation grants, Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-15-171.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#search=true&oppNum=PAR-15-171>

Eligibility profile

Country of applicant institution: Any

Disciplines

Nutrition & Dietetics; Behavioural Medicine; Obesity; HIV/Aids

Contact Details

NIDDK

BG 2DEM Room 681

6707 Democracy Boulevard

BETHESDA MD 20817

Tel: +1 301 594 4578

Email: evansmary@niddk.nih.gov

D IET AND PHYSICAL ACTIVITY ASSESSMENT METHODOLOGY (R01): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

A total of five institutes and offices of the National Institutes of Health invite applications for their diet and physical activity assessment methodology (R01): Aids-related funding opportunity announcement. This Aid-related announcement aims to enhance the quality of measurements of dietary intake and physical activity. Applications submitted are encouraged to include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods or modelling to improve assessment and to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behaviour through pattern analysis; or integrated measurement

of diet and physical activity along with the environmental context of such behaviours. Specifically, this call is intended to support innovative research focused on assessments of dietary and physical activity patterns and the settings in which such behaviours occur, not on the determinants of these behaviours, studies of the causal association between environment and behaviour, or interventions designed to modify or improve behaviours related to dietary intake or physical activity or sedentary behaviour.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-171, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.



Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-16-167 (replaces PAR-15-170).

Closing date: 07 Sep 16

Deadline information: Applications open 5 May 2016 and due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 07 Apr 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-167.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Exercise Physiology; Nutrition & Dietetics

Contact Details

Tel: +1 301 594 4578

Email: evansmary@niddk.nih.gov

IMMUNE SYSTEM PLASTICITY IN THE PATHOGENESIS AND TREATMENT OF COMPLEX DENTAL, ORAL, AND CRANIOFACIAL DISEASES (R21) - AIDS RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research invites applications for its immune system plasticity in the pathogenesis and treatment of complex dental, oral, and craniofacial diseases (R21) funding opportunity announcement. This Aids-related announcement supports contemporary, systematic research to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral and craniofacial diseases as well as to develop novel tools and technologies to treat and prevent disease based on precise modulation of the immune system. Plasticity, for the purposes of this initiative, is defined as the ability of the immune system to undergo changes in both characteristics and functions in response to the environment.

Clinical trials are not supported.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-192, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US\$275,000 in direct costs with up to US\$200,000 in direct costs per year.

The maximum project period is two years.

Ref: PAR-15-193.

Closing date: 07 Sep 16



Deadline information: Applications open on 16 September 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.

Posted date: 29 Apr 15

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-15-193.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276222>

Eligibility profile

Country of applicant institution: Any

Disciplines

Dental Health & Hygiene; Oral Medicine; Restorative Dentistry; Endodontics; Preventive Dentistry; HIV/Aids; Dental Therapeutics & Pharmacology; Periodontics; Craniofacial Disorders

Contact Details

BG 1DEM Room 620
6701 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 9718
Email: amanda.melillo@mail.nih.gov

IMMUNE SYSTEM PLASTICITY IN THE PATHOGENESIS AND TREATMENT OF COMPLEX DENTAL, ORAL, AND CRANIOFACIAL DISEASES (R01) - AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research invites applications for its immune system plasticity in the pathogenesis and treatment of complex dental, oral and craniofacial diseases (R21) funding opportunity announcement. This Aids-related announcement supports contemporary, systematic research to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral and craniofacial diseases as well as to develop novel tools and technologies to treat and prevent disease based on precise modulation of the immune system. Plasticity, for the purposes of this initiative, is defined as the ability of the immune system to undergo changes in both characteristics and functions in response to the environment.

Clinical trials are not supported.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-193, which solicits applications under the NIH exploratory/developmental (R21) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the actual needs of the proposed project.

The maximum project period is five years.

Ref: PAR-15-192.

Closing date: 07 Sep 16



Deadline information: Applications open on 5 September 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018. Applicants requesting US\$500,000 or more in direct costs in any year must contact a scientific contact at least six weeks before submitting the application. **Deadlines on:** 7 January 2016, 7 May 2016, 7 September 2016.

Posted date: 29 Apr 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-192.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276220>

Eligibility profile

Country of applicant institution: Any

Disciplines

Endodontics; Oral Medicine; Preventive Dentistry; Dental Therapeutics & Pharmacology; Dental Health & Hygiene; Periodontics; Craniofacial Disorders; HIV/Aids; Restorative Dentistry

Contact Details

BG 1DEM Room 620
6701 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 9718
Email: amanda.melillo@mail.nih.gov

DEVELOPING THE THERAPEUTIC POTENTIAL OF THE ENDOCANNABINOID SYSTEM FOR PAIN TREATMENT (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

A total of seven institutes and centres of the National Institutes of Health invite applications for their developing the therapeutic potential of the endocannabinoid system for pain treatment (R01) funding opportunity announcement. This Aids-related announcement supports projects that seek to elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain. Applications should consider the following points:

- if plant-derived cannabis material is proposed it should be well justified, with a statement on where the material or compounds will be obtained, and the stats of a schedule one license should be noted;

- explicit sex or gender analyses of effects are highly encouraged;
- role of cannabinoids in the modulation of HIV pain is also encouraged.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is four years.

Ref: PA-15-188.

Closing date: 07 Sep 16

Deadline information: Applications are accepted between 5 September 2015 and 5pm



local time of applicant organisation on every 7 May, 7 September and 7 January until 8 September 2018.

Posted date: 29 Apr 15

Award type: Research calls for business, Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-188.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276193>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Chronic Pain; Pain Management

Contact Details

Tel: +1 301 435 1313

Email: dthomas1@nida.nih.gov

STUDIES AT PERIVIALE GESTATION (R03) - AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its studies at periviable gestation (R03) funding opportunity announcement. This Aids-related announcement supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. The scope of this FOA includes the following areas:

- knowledge gaps in obstetrical care practices at periviable gestations;
- knowledge gaps in neonatal care at periviable gestations;
- research needs concerning family counseling.

This funding opportunity uses the NIH small grant programme (R03) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-198, which solicits applications under the NIH exploratory or developmental (R21) grant mechanism and PA-15-200, which solicits

applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US\$100,000 in direct costs with up to US\$50,000 in direct costs per year.

The maximum project period is two years.

Ref: PA-15-199.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September, until 8 September 2018.

Posted date: 05 May 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-15-199.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276312>

Eligibility profile

Country of applicant institution: Any

Disciplines

Obstetrics & Gynaecology; Family & Relationships Counselling; HIV/Aids; Foetal Health & Prenatal Development; Pregnancy & Birth

Contact Details

NICHD

BG 6100 RM 4B03B

6100 Executive Boulevard

Rockville MD 20852

Tel: +1 301 435 7909

Email: higginsr@mail.nih.gov

S **TUDIES AT PERIVIALE GESTATION (R21) - AIDS-RELATED**

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its studies at periviable gestation (R21) funding opportunity announcement. This Aids-related announcement supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. The scope of this FOA includes the following areas:

- knowledge gaps in obstetrical care practices at periviable gestations;
- knowledge gaps in neonatal care at periviable gestations;
- research needs concerning family counseling.

This funding opportunity uses the NIH exploratory or developmental (R21) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-199, which solicits applications under the NIH small grant programme (R03) grant mechanism and PA-15-200, which solicits applications under the NIH research project ((R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US\$275,000 in direct costs with up to US\$200,000 in direct costs per year.

The maximum project period is two years.

Ref: PA-15-198.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September, until 8 September 2018.

Posted date: 05 May 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-198.html>

**Application form:**

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276320>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Foetal Health & Prenatal Development; Family & Relationships

Counselling; Pregnancy & Birth; Obstetrics & Gynaecology

Contact Details

NICHHD
BG 6100 RM 4B03B
6100 Executive Boulevard
Rockville MD 20852
Tel: +1 301 435 7909
Tel: higginsr@mail.nih.gov

STUDIES AT PERIVIALE GESTATION (R01) - AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its studies at periviable gestation (R01) funding opportunity announcement. This Aids-related announcement supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. The scope of this FOA includes the following areas:

- knowledge gaps in obstetrical care practices at periviable gestations;
- knowledge gaps in neonatal care at periviable gestations;
- research needs concerning family counseling.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-198, which solicits applications under the NIH exploratory or developmental (R21) grant mechanism and PA-15-199, which solicits applications under the NIH small grant programme (R03) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-15-200.

Closing date: 07 Sep 16

Deadline information: Applications open on 5 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September, until 8 September 2018. Applicants requesting US\$500,000 or more in direct costs in any year must contact a scientific contact at least six weeks before submitting the application.

Posted date: 05 May 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-200.html>

**Application form:**

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276313>

Eligibility profile

Country of applicant institution: Any

Disciplines

Pregnancy & Birth; Obstetrics & Gynaecology;
HIV/Aids; Family & Relationships

Counselling; Foetal Health & Prenatal Development

Contact Details

NICHD
BG 6100 RM 4B03B
6100 Executive Boulevard
Rockville MD 20852
Tel: +1 301 435 7909
Email: higginsr@mail.nih.gov

HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R03) – AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its human studies to evaluate promising medications to treat alcohol use disorder (R03) funding opportunity announcement. This Aids-related announcement encourages applications that use human laboratory paradigms or clinical trials to evaluate the safety and efficacy of novel or repurposed compounds, that bind to new targets, for treatment of alcohol use disorder or AUD with a comorbid post-traumatic stress disorder.

This funding opportunity uses the NIH small grant programme (R03) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-256 and PA-15-254, which solicit applications under the NIH research project (R01) grant mechanism and the NIH exploratory/developmental (R21) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US\$100,000 in direct costs with up to US\$50,000 in direct costs per year.

The maximum project period is two years.

Ref: PA-15-255.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 14 May 15

Award type: Clinical trials, Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-255.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#search=true&oppNum=PA-15-255>



Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism; Post Traumatic Stress Disorder;
HIV/Aids

Contact Details

BG 5635FL Room 2041
5635 Fishers Lane
Rockville MD 20852
Tel: +1 301 443 0636
Email: rlitten@mail.nih.gov

HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R21) – AIDS-RELATED NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its human studies to evaluate promising medications to treat alcohol use disorder (R21) funding opportunity announcement. This Aids-related announcement encourages applications that use human laboratory paradigms or clinical trials to evaluate the safety and efficacy of novel or repurposed compounds, that bind to new targets, for treatment of alcohol use disorder or AUD with a comorbid post-traumatic stress disorder.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-255 and PA-15-256, which solicit applications under the NIH small grant programme (R03) grant mechanism and the NIH research project (R01) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US\$275,000 in direct costs with up to US\$200,000 in direct costs per year.

The maximum project period is two years.

Ref: PA-15-254.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 14 May 15

Award type: Innovation grants, Directed grants to institutions, research groups etc, Clinical trials

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-254.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276516>

Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism; Post Traumatic Stress Disorder;
HIV/Aids

Contact Details



BG 5635FL Room 2041
5635 Fishers Lane
Rockville MD 20852

Tel: +1 301 443 0636
Email: rlitten@mail.nih.gov

HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R01) – AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its human studies to evaluate promising medications to treat alcohol use disorder (R03) funding opportunity announcement. This Aids-related announcement encourages applications that use human laboratory paradigms or clinical trials to evaluate the safety and efficacy of novel or repurposed compounds, that bind to new targets, for treatment of alcohol use disorder or AUD with a comorbid post-traumatic stress disorder.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-255 and PA-15-254, which solicit applications under the NIH small grant programme (R03) grant mechanism and the NIH exploratory/developmental (R21) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the actual costs of the proposed project.

The maximum project period is five years.

Ref: PA-15-256.

Closing date: 07 Sep 16

Deadline information: Applications open on 5 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Applicants requesting US\$500,000 or more in direct costs in any year must contact scientific contact at least six weeks before submitting the application.

Posted date: 14 May 15

Award type: Clinical trials, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://www.grants.nih.gov/grants/guide/pa-files/PA-15-256.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276559>

Eligibility profile

Country of applicant institution: Any

Disciplines

Post Traumatic Stress Disorder; Alcoholism; HIV/ Aids

Contact Details

BG 5635FL Room 2041
5635 Fishers Lane
Rockville MD 20852
Tel: +1 301 443 0636
Email: rlitten@mail.nih.gov



FAST-TRACK DEVELOPMENT OF MEDICATIONS TO TREAT CANNABIS USE DISORDERS (UG3/UH3) – AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its fast-track development of medications to treat cannabis use disorders (UG3/UH3) funding opportunity announcement. This Aids-related announcement aims to accelerate the discovery and development of medications to treat cannabis use disorders. Studies should focus on the following topics:

- new chemical entities;
- already-marketed pharmacotherapies
- biologics, for example immunotherapies such as vaccines and antibodies, enzymes and gene therapies;
- combinations of medication or new delivery devices and technologies.

The UG3/UH3 phase innovation awards cooperative agreement involves two phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the two-year period. The UH3 is to provide funding for three years to a project that successfully completed the milestones set in the UG3. Investigators responding to this FOA must address both UG3 and UH3 phases.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget of US\$3 million for fiscal year 2016 funds three awards. Application budgets are limited to US\$1m in direct costs per year. The maximum project period is two

years for the UG3 phase and three years for the UH3 phase.

Ref: PAR-15-267.

Closing date: 07 Sep 16

Deadline information: Applications open on 28 June and are due by 5pm local time of applicant organisation on 7 September 2015, 7 May and 7 September 2016, 7 May and 7 September 2017 and 7 May 2018.

Posted date: 28 May 15

Award type: Academic-Industry links, Directed grants to institutions, research groups etc

Award amount max: \$1,000,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-267.html>

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276828>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Methods of Drug Delivery; Drug & Substance Abuse; Drug Design

Contact Details

NSC BG Room 4131
6001 Executive Boulevard
Rockville MD 20852
Tel; +1 301 443 8639
Email: imontoya@mail.nih.gov



EXPLOITING RNA AS A TARGET FOR HIV INTERVENTIONS (R21)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Disease and the National Institute of Mental Health invite applications for their exploiting RNA as a target for HIV infections (R21) funding opportunity announcement. This aims to investigate the role of viral and cellular non-coding RNAs in the regulation of HIV replication, pathogenesis, latency, immunity and gene expression, exploit lncRNAs for the development of novel HIV interventions, and exploit advances in RNA structural biology to identify novel targets for HIV intervention and functional cure.

Applicants may be from US and foreign for-profit and non-profit organisations or public and private organisations.

Each award covers direct costs of up to US\$275,000 over a maximum project period of two years. No more than US\$200,000 may be requested in any single year.

Ref: PA-15-272.

Closing date: 07 Sep 16

Deadline information: Applications open on 7 August 2015 and are due by 5pm local time

of applicant organisation on every 7 September, 7 January and 7 May until 8 May 2018.

Posted date: 08 Jun 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-272.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do>

Eligibility profile

Country of applicant institution: Any

Disciplines

Pharmacy & Pharmacology; Immunology; HIV/Aids; Ribonucleic Acid, RNA

Contact Details

Tel: +1 240 627 3209

Email: brigitte.sanders@nih.gov

HARNESSING BIG DATA TO HALT HIV (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases, the National Cancer Institute, the National Institute on Drug Abuse and the National Institute of Mental Health invite applications for their harnessing

big data to halt HIV (R01) funding opportunity announcement. This promotes research that transforms understanding of HIV transmission, the HIV care continuum and HIV comorbidities using big data science.



Projects should identify gaps in rare, unseen and otherwise undiscovered biomedical, behavioural, social patterns and other social determinants that shed light on HIV acquisition, transmission and long-term control as in the HIV treatment continuum. Approaches should include projects to assemble big data sources, conduct robust and reproducible analyses, and create meaningful visualisation of big data.

Applicants may be from US and foreign for-profit and non-profit organisations or public and private organisations.

Application budgets must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-15-273.

Closing date: 07 Sep 16

Deadline information: Applications open on 7 August 2015 and are due by 5pm local time of applicant organisation on every 7

September, 7 January and 7 May until 8 May 2018.

Posted date: 08 Jun 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-273.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do>

Eligibility profile

Country of applicant institution: Any

Disciplines

Telemedicine; HIV/Aids; Health & Medical Informatics; Bioinformatics

Contact Details

Tel: +1 240 627 3214

Email: rm434n@nih.gov

B IOENGINEERING RESEARCH PARTNERSHIP – NON- OR MINIMALLY-INVASIVE METHODS TO MEASURE BIOCHEMICAL SUBSTANCES DURING NEONATAL AND PERINATAL PATIENT CARE AND RESEARCH (R01): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications, under the bioengineering research partnership, for its Aids-related non- or minimally-invasive methods to measure biochemical substances during neonatal and perinatal patient care and research (R01) funding opportunity announcement. Funding enables bioengineering and biomedical scientists to collaborate in developing non- and minimally-invasive methods for measuring

biochemical substances in connection with the care of perinatal patient populations.

The developed methods should test analytes and physiological variables, and may include serum electrolytes, liver function tests, renal functions, biomarkers of infection and inflammation, metabolic by-products of drugs, concentrations of drugs used in clinical care or research and physiological variables affected by cardiopulmonary and metabolic systems. Sources for developing the noted



monitoring could include trans-epidermal, transcutaneous using nano-sized electrodes, saliva and other fluids.

This announcement solicits applications under the R01 research project grant mechanism and runs in parallel with an opportunity of an identical scientific scope, RFA-HD-16-028, which solicits applications from US-based applicants using the R41 small business technology transfer grant mechanism for phase I projects.

Applicants may be from US and foreign for-profit and non-profit organisations or public and private organisations.

Application budgets must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-15-285.

Closing date: 07 Sep 16

Deadline information: Applications open on 5 September 2015 and are due by 5pm local time of applicant organisation on every 7 September, 7 January and 7 May until 8 January 2018. Deadlines on: 7 September

2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 23 Jun 15

Award type: Networking/collaboration, Directed grants to institutions, research groups etc, Directed grants for individual investigators

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-285.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do>

Eligibility profile

Country of applicant institution: Any

Disciplines

Maternal Health; Foetal Health & Prenatal Development; Pregnancy & Birth; Screening of Drugs & Agents; Drug & Substance Abuse

Contact Details

Tel: +1 301 402 1872

Email: rajut@mail.nih.gov

END-OF-LIFE AND PALLIATIVE NEEDS OF ADOLESCENTS AND YOUNG ADULTS WITH SERIOUS ILLNESSES (R21): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research, the National Cancer institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Office of Research on Women's Health invite applications for their end-of-life and palliative needs of adolescents and young adults with serious illnesses (R21) Aids-related funding opportunity announcement. This Aids-related announcement aims to foster research on the unique perspectives, needs, wishes and

decision-making processes of adolescents and young adults with serious, advanced illnesses. This also supports research focused on specific end-of-life and palliative care models that support the physical, psychological, spiritual and social needs of AYA with serious illness as well as their families and caregivers. The objective is to encourage clinical studies aimed at:

- increasing this knowledge base;



- the development of AYA-appropriate measurement tools;
- the design, testing and evaluation of AYA-specific EOLPC models of care and interventions that positively impact health related quality of life for AYA with serious illness and their family and caregivers.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-324, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit, non-profit and public and private organisations may apply.

Application budgets may not exceed US\$275,000 over the maximum project period of two years. No more than US\$200,000 may be requested in any single year.

Ref: PA-15-325.

Closing date: 07 Sep 16

Deadline information: Applications are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January, 2019.

Posted date: 10 Aug 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-325.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Palliative Nursing; Youth & Adolescents; Hospice & Palliative Care; HIV/Aids; Child & Adolescent Psychiatry; Adolescent Paediatrics

Contact Details

Tel: +1 301 594 8911

Email: lynn.adams@nih.gov

END-OF-LIFE AND PALLIATIVE NEEDS OF ADOLESCENTS AND YOUNG ADULTS WITH SERIOUS ILLNESSES (R01) AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research, the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Office of Research on Women's Health invite applications for their end-of-life and palliative needs of adolescents and young adults with serious illnesses (R01) funding opportunity announcement. This Aids-related announcement aims to foster research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses.

Funding also supports research focused on specific end-of-life or palliative care models that support the physical, psychological, spiritual and social needs of AYA with serious illness as well as their families and caregivers. The objective is to encourage clinical studies aimed at:

- increasing this knowledge base;
- developing AYA-appropriate measurement tools;
- designing, testing and evaluating of AYA-specific EOLPC models of care



and interventions that positively impact health-related quality of life for AYA with serious illness, and their family and caregivers. This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-325, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit, non-profit and public and private organisations may apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-15-324.

Closing date: 07 Sep 16

Deadline information: Applications open on 5 January 2016 and are due by 5pm local time

of applicant organisation every 7 September, 7 January and 7 May until 8 January 2019.

Posted date: 10 Aug 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-324.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Adolescent Paediatrics; Youth & Adolescents; Child & Adolescent Psychiatry

Contact Details

Tel: +1 301 594 8911

Email: lynn.adams@nih.gov

ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS (R21)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their ethical, legal and policy issues in HIV research with key populations (R21) funding opportunity announcement. This encourages applications to analyse and address ethical, legal or policy challenges to specific to work with populations that experience high risk of HIV acquisition due to certain behaviours and risk exposures. Projects should focus on ethical, legal or policy challenges in relation to research studies or programme implementation for HIV or associated co-

morbidities affecting one or more of the following key populations:

- men who have sex with men;
- people who inject drugs;
- people in prisons and other closed settings;
- sex workers;
- transgender people;
- adolescent girls and young women at high risk of HIV acquisition or who are living with HIV. Empirical and conceptual research projects addressing these topics are encouraged. This funding opportunity



uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scope, PAR-15-328, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are limited to US\$275,000 for the maximum project period of two years. No more than US\$200,000 may be requested in any single year.

Ref: PAR-15-327

Closing date: 07 Sep 16

Deadline information: Applications open on 7 December, 2015 and are due 7 January and 7 September, 2016 and 2017 and on 8 January and 7 September, 2018 by 5pm local time of applicant organisation until 8 September, 2018. Deadlines on: 7 January 2016, 7

September 2016, 7 January 2017, 7 September 2017, 8 January 2018, 7 September 2018.

Posted date: 11 Aug 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-327.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Health Systems Policy; HIV/Aids; Lesbian, Gay, Bisexual & Transgender Studies; Medical & Health Ethics; Legal Ethics; Prostitution; Women's Health

Contact Details

Tel: +1 240 627 3210

Email: dawsonl@niaid.nih.gov

ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS (R21) AIDS-RELATED

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their ethical, legal and policy issues in HIV research with key populations (R21) funding opportunity announcement. This Aids-related announcement encourages applications to analyse and address ethical, legal or policy challenges to specific to work with populations that experience high risk of HIV acquisition due to certain behaviours and risk exposures. Projects should be focused on ethical, legal or policy challenges in relation to research studies or programme implantation

for HIV or associated co-morbidities affecting one or more of the following key populations:

- men who have sex with men
- people who inject drugs;
- people in prisons and other closed settings;
- sex workers;
- transgender people;
- adolescent girls and young women at high risk of HIV acquisition or who are living with HIV. Empirical and conceptual research projects addressing these topics are encouraged. This funding opportunity



uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scope, PAR-15-328, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are limited to US\$275,000 for the maximum project period of two years. No more than US\$200,000 may be requested in any single year.

Ref: PAR-15-327

Closing date: 07 Sep 16

Deadline information: Applications open on 7 December, 2015 and are due 7 January and 7 September, 2016 and 2017 and on 08 January and 7 September, 2018 by 5pm local time of applicant organisation until 8 September, 2018. Deadlines on: 7 January 2016, 7 September 2016, 7 January 2017, 7

September 2017, 8 January 2018, 7 September 2018.

Posted date: 11 Aug 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-327.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Lesbian, Gay, Bisexual & Transgender Studies; Health Systems Policy; Medical & Health Ethics; Prostitution; HIV/Aids; Legal Ethics; Women's Health

Contact Details

Tel: +1 240 627 3210

Email: dawsonl@niaid.nih.gov

ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their ethical, legal and policy issues in HIV research with key populations (R01) funding opportunity announcement. This encourages applications to analyse and address ethical, legal or policy challenges to specific to work with populations that experience high risk of HIV acquisition due to certain behaviours and risk exposures. Projects should focus on ethical, legal or policy challenges in relation to research studies or programme implantation

for HIV or associated co-morbidities affecting one or more of the following key populations:

- men who have sex with men;
- people who inject drugs;
- people in prisons and other closed settings;
- sex workers;
- transgender people;
- adolescent girls and young women at high risk of HIV acquisition or who are living with HIV.



Empirical and conceptual research projects addressing these topics are encouraged. This funding opportunity uses the NIH exploratory/developmental (R01) grant mechanism and runs in parallel with one of identical scope, PAR-15-327, which solicits applications under the NIH research project (R21) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-15-328

Closing date: 07 Sep 16

Deadline information: Applications open on 7 December, 2015 and are due 7 January and 7 September, 2016 and 2017 and on 8 January and 7 September, 2018 by 5pm local time of applicant organisation until 9 September, 2018. Deadlines on: 7 January 2016, 7

September 2016, 7 January 2017, 7 September 2017, 8 January 2018, 7 September 2018.

Posted date: 11 Aug 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-328.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Legal Ethics; Medical & Health Ethics; Lesbian, Gay, Bisexual & Transgender Studies; Women's Health; Prostitution; Health Systems Policy; HIV/Aids

Contact Details

Tel: +1 240 627 3210

Email: dawsonl@niaid.nih.gov

ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS (R01) AIDS-RELATED

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their ethical, legal and policy issues in HIV research with key populations (R01) funding opportunity announcement. This Aids-related announcement encourages applications to analyse and address ethical, legal or policy challenges to specific to work with populations that experience high risk of HIV acquisition due to certain behaviours and risk exposures. Projects should focus on ethical, legal or policy challenges in relation to

research studies or programme implantation for HIV or associated co-morbidities affecting one or more of the following key populations:

- men who have sex with men;
- people who inject drugs;
- people in prisons and other closed settings;
- sex workers;
- transgender people;
- adolescent girls and young women at high risk of HIV acquisition or who are living with HIV. Empirical and



conceptual research projects addressing these topics are encouraged. This funding opportunity uses the NIH exploratory/developmental (R01) grant mechanism and runs in parallel with one of identical scope, PAR-15-327, which solicits applications under the NIH research project (R21) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-15-328

Closing date: 07 Sep 16

Deadline information: Applications open on 7 December, 2015 and are due 7 January and 7 September, 2016, 2017 and on 8 January and 7 September, 2018 by 5pm local time of applicant organisation until 9 September.

Deadlines on: 7 January 2016, 7 September 2016, 7 January 2017, 7 September 2017, 8 January 2018, 7 September 2018.

Posted date: 11 Aug 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-328.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Health Systems Policy; Medical & Health Ethics; Legal Ethics; Prostitution; HIV/Aids; Lesbian, Gay, Bisexual & Transgender Studies; Women's Health

Contact Details

Tel: +1 240 627 3210

Email: dawsonl@niaid.nih.gov

S MALL RESEARCH GRANTS FOR ORAL HEALTH DATA ANALYSIS AND STATISTICAL METHODOLOGY DEVELOPMENT AIDS-RELATED (R03)

NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research invites applications for its small research grants for oral health data analysis and statistical methodology development (R03) funding opportunity announcement. This Aids-related announcement supports research projects that involve secondary data analyses of existing oral or craniofacial database resources, or aims to develop needed statistical methodology for analysing oral and craniofacial data using existing oral or

craniofacial databases. This R03 grant mechanism supports research specifically limited in time and amount for studies in categorical programme areas.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Projects may receive up to US\$100,000 per year for a maximum period of two years.



Ref: PAR-15-344 (replaces PAR-12-120).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.

Posted date: 10 Sep 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$200,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-344.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Data Analysis; Oral Medicine

Contact Details

Tel: +1 301 594 4876

Email: dena.fischer@nih.gov

R ESearch on the Mechanisms and Behavioural Outcomes of Multisensory Processing (R01) AIDS-Related NIH: National Institutes of Health

Description:

A total of eleven institutes and offices of the National Institutes of Health invite applications for their research on the mechanisms and behavioural outcomes of multisensory processing (R01) funding opportunity announcement. This Aids-related announcement supports basic, behavioural and clinical research projects examining the interactions between neural systems such as cognitive, affective or motor processes and multiple sensory modalities. Innovative studies, using animal or human subjects examining two or more senses for the elucidation of mechanisms and behavioural outcomes of multisensory processing, are encouraged. The initiative supports the use of diverse methodologies including basic biochemical, molecular, cellular, genetic approaches, neuroimaging and neurophysiological analyses, experimental psychophysics, “real world” settings, immersive virtual technology and animal models.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants requesting US\$500,000 or more in direct costs in any year must contact a scientific research contact at least six weeks before submitting the application. The maximum project period is five years.

Ref: PA-15-347.

Closing date: 07 Sep 16

Deadline information: Applications open on 5 January 2016 and due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019. Deadlines on: 7 September 2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 18 Sep 15

Award type: Clinical trials, Directed grants to institutions, research groups etc



Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-347.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Sensory Perception; Central Nervous System; Sensory Systems; Animal Neurobiology

Contact Details

Tel: +1 301 496 9350

Email: wagsterm@nia.nih.gov

PERSONALISED STRATEGIES TO MANAGE SYMPTOMS OF CHRONIC ILLNESS (R21) AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research invites applications for its personalised strategies to manage symptoms of chronic illness (R21) Aids-related funding opportunity announcement. This Aids-related announcement aims to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life in persons with chronic illness through increasing knowledge of the biological mechanisms of symptoms and promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms. The research objectives are to:

- examine complex adaptive symptoms related to biobehavioural and environmental interactions that underlie symptom evolution to include change over time;
- identify and validate novel biomarkers and other patient risk factors to assess individual susceptibility to physical, cognitive and affective symptoms and serve as surrogate endpoints for evaluating clinical benefit of targeted interventions;

- develop computer-simulated dynamic models that result in strategies to address individual heterogeneity related symptoms, clusters and patterns;
- develop and test targeted scalable interventions to prevent and mitigate symptoms and clusters to include examination of omics and genetic factors that predict response to interventions;
- examine large databases and electronic health records to discover new biologic, clinical, psychosocial, behavioural and economic factors related to symptom burden and health-related quality of life experienced by persons with chronic illness and new patterns and trends that may translate to targeted interventions.

This funding opportunity uses the NIH exploratory and developmental research (R21) grant mechanism and runs in parallel with two of identical scientific scope, PA-16-007 and PA-16-006, which solicits applications under the NIH research (R01) project grant mechanism and the NIH academic research (R15) enhancement award.



US and foreign for-profit and non-profit organisations and public and private organisations may apply. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

Application budgets are limited to US\$275,000 for a maximum project period of two years. No more than US\$200,000 may be requested in any single year.

Ref: PA-16-008.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2016 and are due by 5pm local time of applicant organisation every 7 May, 7 September and 7 January until 8 January 2019. Deadlines on: 7 September 2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 19 Oct 15

Award type: Clinical trials, Innovation grants, Directed grants for individual investigators, Networking/collaboration

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-008.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biochemical Markers; Life Expectancy & Quality of Life; HIV/Aids; Intensive Care & Life Support; Innovation & Technology Management; Genomics

Contact Details

Tel: +1 301 594 5968

Email: tullyla@mail.nih.gov

PERSONALISED STRATEGIES TO MANAGE SYMPTOMS OF CHRONIC ILLNESS (R01) AIDS-RELATED NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research invites applications for its personalised strategies to manage symptoms of chronic illness (R01) Aids-related funding opportunity announcement. This Aids-related announcement aims to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life in persons with chronic illness through increasing knowledge of the biological mechanisms of symptoms and promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms. The research objectives are to:

- examine complex adaptive symptoms related to biobehavioural and environmental interactions that underlie symptom evolution to include change over time;
- identify and validate novel biomarkers and other patient risk factors to assess individual susceptibility to physical, cognitive and affective symptoms and serve as surrogate endpoints for evaluating clinical benefit of targeted interventions;
- develop computer-simulated dynamic models that result in strategies to address individual heterogeneity



related symptoms, clusters and patterns;

- develop and test targeted scalable interventions to prevent and mitigate symptoms and clusters to include examination of omics and genetic factors that predict response to interventions;
- examine large databases and electronic health records to discover new biologic, clinical, psychosocial, behavioural and economic factors related to symptom burden and health-related quality of life experienced by persons with chronic illness and new patterns and trends that may translate to targeted interventions.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two of identical scientific scope, PA-16-008 and PA-16-006, which solicits applications under the NIH exploratory and developmental (R21) grant mechanism and the NIH academic research (R15) enhancement award.

US and foreign for-profit and non-profit organisations and public and private organisations may apply. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

Application budgets are not limited but need to reflect the actual needs of the proposed

project. The maximum project period is five years.

Ref: PA-16-007.

Closing date: 07 Sep 16

Deadline information: Applications open on 5 January 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Deadlines on: 7 September 2016, 7 January 2017, 7 May 2017, and repeated annually.

Posted date: 19 Oct 15

Award type: Directed grants to institutions, research groups etc, Clinical trials, Innovation grants, Networking/collaboration

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-007.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Intensive Care & Life Support; Genomics; Biochemical Markers; Innovation & Technology Management; Life Expectancy & Quality of Life

Contact Details

Tel: +1 301 594 5968

Email: tullyla@mail.nih.gov

E XAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R21) AIDS-RELATED NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its examination of survivorship care planning efficacy and

impact (R21) Aids-related funding opportunity announcement. This Aids-related announcement aims to stimulate research



evaluating the effect of care planning on self-management of late effects of cancer therapy, with the goal to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors. Specifically, this call aims to stimulate research that will:

- develop and test metrics for evaluating the impact of survivorship care planning;
- evaluate the impact of survivorship care planning on cancer survivors morbidity, self-management and adherence to care recommendations, utilisation of follow-up care;
- evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organisations implementing the care planning;
- identify models and processes of care that promote effective survivorship care planning.

This funding opportunity uses the NIH exploratory and developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-012, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets are limited to US\$275,000 per year for a maximum project period of two years. No more than US\$200,000 may be requested in any single year.

Ref: PA-16-011 (replaces PA-12-274).

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 26 Oct 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-011.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Emotional Rehabilitation; Quality of Care; HIV/Aids; Life Expectancy & Quality of Life; Rehabilitation Engineering; Cancer Studies & Oncology

Contact Details

Tel: +1 240 276 6947

Email: taplins@mail.nih.gov

H IV AND AIDS HIGH PRIORITY DRUG ABUSE RESEARCH (R01)

NIH: National Institute on Drug Abuse

Description:

The National Insitute on Drug Abuse invites applications for its HIV and Aids high priority drug abuse research (R01) funding opportunity announcement. This

announcement aims to stimulate high priority research relevant to drug abuse and HIV and Aids. Populations of interest include urban and non-urban drug users, including those



transitioning to injection drug use and populations where HIV is heavily concentrated such as men who have sex with men, especially men of young age from minority groups.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

NIDA intends to fund up to 34 awards and has set aside US\$18 million for fiscal years 2016 to 2019. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAS-16-018.

Closing date: 07 Sep 16
Deadline information: Applications open on 7 December 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.

Posted date: 28 Oct 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: \$18,000,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAS-16-018.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse; Disadvantaged & Minority Groups; Health of Minority Groups; Lesbian, Gay, Bisexual & Transgender Studies; HIV/Aids

Contact Details

Tel: +1 301 443 2261

Email: kahanas@mail.nih.gov

INNOVATIVE QUESTIONS IN SYMPTOM SCIENCE AND GENOMICS (R21): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research invites applications for its innovative questions in symptom science and genomics (R21) Aids-related funding opportunity announcement. This Aids-related announcement seeks to optimise innovation, insight and cutting edge conceptual and technological breakthroughs by catalysing research that emanates from the identified questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived.

This funding opportunity uses the NIH exploratory or developmental research grant (R21) mechanism and runs in parallel with two of identical scientific scope, PA-16-024 and PA-16-022, which solicit applications under the NIH research project grant (R01) mechanism and the NIH academic research enhancement award (R15) mechanism, respectively.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.



Application budgets are limited to US\$275,000 and no more than US\$200,000 may be requested in any single year. The maximum project period is two years.

Ref: PA-16-023.

Closing date: 07 Sep 16

Deadline information: Applications open on 16 January 2016 and due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 02 Nov 15

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-023.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Nursing; Genomics; Diagnostic Sciences

Contact Details

Tel: +1 301 594 5968

Email: tullyla@mail.nih.gov

I INNOVATIVE QUESTIONS IN SYMPTOM SCIENCE AND GENOMICS (R01): AIDSRELATED

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research invites applications for its innovative questions in symptom science and genomics (R01) Aids-related funding opportunity announcement. This Aids-related announcement seeks to optimise innovation, insight and cutting edge conceptual and technological breakthroughs by catalysing research that emanates from the identified questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived.

This funding opportunity uses the NIH research project grant (R21) mechanism and runs in parallel with two of identical scientific scope, PA-16-023 and PA-16-022, which solicit applications under the NIH exploratory or developmental grant (R01) mechanism and the NIH academic research enhancement award (R15) mechanism, respectively.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-16-024.

Closing date: 07 Sep 16

Deadline information: Applications open on 5 January 2016 and due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 02 Nov 15

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: -

Award budget total: -

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-16-024.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Nursing; Diagnostic Sciences; Genomics

Contact Details

Tel: +1 301 594 5968

Email: tullyla@mail.nih.gov



INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS - DEVELOPMENT AND VALIDATION OF MODEL SYSTEMS AND PHARMACODYNAMIC MARKERS TO FACILITATE THE DISCOVERY OF NEUROTHERAPEUTICS (R21/R33): AIDS- RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:

The National Institute of Neurological Disorders and Stroke and the National Institute on Drug Abuse invite applications for their innovation grants to nurture initial translational efforts: development and validation of model systems and pharmacodynamic markers to facilitate the discovery of neurotherapeutics (R21/R33) funding opportunity announcement. This Aids-related announcement aims to develop and validate animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, testing paradigms and endpoints that will be utilised to facilitate the development of neurotherapeutics. Applications that have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings are sought after.

This funding opportunity uses the NIH phased innovation (R21/R33) award mechanism and runs in parallel with two of identical scientific scope, PAR-15-070 and PAR-15-071, which solicit applications under the same mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions

NINDS intends to commit up to US\$750,000 per year to fund nine awards in fiscal years 2016 to 2018. Direct costs are limited to US\$250,000 per year regardless of grant phase. The project period is limited to three years, with no more than two years in either phase.

Ref: RFA-NS-16-013.

Closing date: 07 Sep 16

Deadline information: Applications are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.



Posted date: 04 Nov 15

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$750,000

Award budget total: \$2,250,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-16-013.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biological Systems Analysis & Modelling; HIV/Aids; Neurology; Animal Models

Contact Details

Tel: +1 301 496 1779

Email: mary.pelleymounter@mail.nih.gov

A PPLYING METABOLOMICS TO DRIVE BIOMARKER DISCOVERY IN SYMPTOM SCIENCE (R21): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research and the National Center for Complementary and Integrative Health invite applications for their applying metabolomics to drive biomarker discovery in symptom science (R21) funding opportunity announcement. This Aids-related announcement encourages applications on biomarker discovery that utilise metabolomics approaches to advance the understanding, assessment and management of symptoms. Research objectives include:

- identification of biomarkers of symptoms, including fatigue, impaired sleep, pain, nausea, dyspnea and cognitive impairment using metabolomic approaches;
- application of metabolite profiling and biomarker discovery tools to discriminate symptomatic from asymptomatic individuals, differing symptoms and varying symptoms experienced by individuals with similar conditions or illnesses;
- influence of particular metabolite profiles in combination with genetic

variants on symptom risk, management and response to treatment;

- assessment of biomarkers as gleaned from metabolomic approaches to facilitate personalised health strategies for symptom management.

This funding opportunity announcement focuses on both preclinical and clinical research.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-030, which solicits applications under the NIH research project (R01) grant mechanism

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

The combined budget for direct costs excluding consortia facilities and administration costs for the maximum two



year project period is US\$275,000. No more than US\$200,000 in direct costs may be requested in any single year.

Ref: PA-16-029.

Closing date: 07 Sep 16

Deadline information: Applications are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 04 Nov 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-029.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/ Aids; Metabolomics; Biological Markers & Sensor Mechanisms; Diagnostic Sciences

Contact Details

Tel: +1 301 594 2775

Email: matocham@mail.nih.gov

APPLYING METABOLOMICS TO DRIVE BIOMARKER DISCOVERY IN SYMPTOM SCIENCE (R01): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research and the National Center for Complementary and Integrative Health invite applications for their applying metabolomics to drive biomarker discovery in symptom science (R01) funding opportunity announcement. This Aids-related announcement encourages applications on biomarker discovery that utilise metabolomics approaches to advance the understanding, assessment and management of symptoms. Research objectives include:

- identification of biomarkers of symptoms, including fatigue, impaired sleep, pain, nausea, dyspnea and cognitive impairment using metabolomic approaches;
- application of metabolite profiling and biomarker discovery tools to discriminate symptomatic from asymptomatic individuals, differing

symptoms and varying symptoms experienced by individuals with similar conditions or illnesses;

- influence of particular metabolite profiles in combination with genetic variants on symptom risk, management and response to treatment;
- assessment of biomarkers as gleaned from metabolomic approaches to facilitate personalised health strategies for symptom management.

This funding opportunity announcement focuses on both preclinical and clinical research.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-029, which solicits applications



under the NIH exploratory or developmental research (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-16-030.

Closing date: 07 Sep 16

Deadline information: Applications open on 5 January 2016 and are due every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 04 Nov 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-030.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biological Markers & Sensor Mechanisms; HIV/Aids; Diagnostic Sciences; Metabolomics

Contact Details

Tel: +1 301 594 2775

Email: matocham@mail.nih.gov

A NCILLARY STUDIES TO MAJOR ONGOING CLINICAL RESEARCH STUDIES TO ADVANCE AREAS OF SCIENTIFIC INTEREST WITHIN THE MISSION OF THE NIDDK (R01): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its ancillary studies to major ongoing clinical research studies to advance areas of scientific interest within the mission of the NIDDK (R01) funding opportunity announcement. This Aids-related announcement seeks to accelerate the pace and expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within its mission by leveraging ongoing large, multi-centre clinical research studies through ancillary studies. The goal is to obtain novel scientific information for the diseases within the mission of NIDDK. Areas of research interest include:

- identifying additional, unique or emerging risk factors for the diseases of interest to NIDDK;
- delineating pathogenic mechanisms of diseases;
- identifying mechanisms or factors that influence and predict response to treatment;
- discovering or validating biomarkers of disease development and progression;
- identifying or characterising co-morbid illnesses associated with the diseases of interest to NIDDK;
- describing the natural history and risk factors for additional diseases;
- determining the effects of the parent study interventions on additional outcomes or diseases.



Applications must propose to collect new information and biological samples directly from participants of the ongoing parent study and must address new research questions that are beyond those specified in the approved protocol of the parent study and are within the scientific mission of the NIDDK.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-16-034 (replaces PAR-12-265).

Closing date: 07 Sep 16

Deadline information: Applications open on 5 January 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 09 Nov 15

Award type: Clinical trials, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-034.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Nephrology & Kidneys; Diabetes; Urology; Hormones & Endocrinology; Gastroenterology

Contact Details

Tel: +1 301 594 4578

Email: evansmary@niddk.nih.gov

NATURAL HISTORY OF DISORDERS IDENTIFIABLE BY SCREENING OF NEWBORNS (R01): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its natural history of disorders identifiable by newborn screening (R01) funding opportunity announcement. This Aids-related announcement aims to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. The NICHD encourages projects related to disorders that could potentially benefit from newborn screening but for which screening is currently not available or conditions that are currently screened for but could benefit from

expanded knowledge of the natural history of the disorder. Applicants are also encouraged to consider submitting multi-state consortia of screening programs that are able to provide natural history information for one or more disorders. Applicants are strongly encouraged to apply for the use of infrastructure and resources provided by the newborn screening translational research network co-ordinating centre.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.



Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-16-061 (replaces RFA-HD-10-019).

Closing date: 07 Sep 16

Deadline information: Applications open on 5 May 2016 and are due by 5pm local time of applicant organisation.

Posted date: 14 Dec 15

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-061.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Foetal Health & Prenatal Development; Diagnostic Sciences; Infant Paediatrics; HIV/Aids; Pregnancy & Birth; Preventive Medicine; Neonatal Disorders; Screening for Diseases

Contact Details

Tel: +1 301 402 7015

Email: urvtiin@mail.nih.gov



ANCILLARY STUDIES TO THE NIDDK INTESTINAL STEM CELL CONSORTIUM (R01): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its ancillary studies to the NIDDK intestinal stem cell consortium (R01) funding opportunity announcement. This Aids-related announcement seeks applications to conduct ancillary studies to the NIDDK intestinal stem cell consortium. Studies will make use of consortium collaborations, techniques or resources to accelerate research into intestinal stem cells. The proposed ancillary study must be designed to advance the scientific research mission of NIDDK by focusing on diseases and areas of interest to the institute and should be commensurate with the interests and intent of the ISCC.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but should reflect actual needs of the proposed projects. The maximum period is five years.

Ref: PA-16-062 (replaces PAR-13-066).

Closing date: 07 Sep 16

Deadline information: Applications open 5 January 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 16 Dec 15

Award type: Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-062.html>

Eligibility profile



Country of applicant institution: Any

Disciplines

Stem Cell; Internal Medicine;
Gastroenterology; HIV/Aids

Contact Details

Tel: +1 301 402 0671

Email: carringj@mail.nih.gov

CLINICAL DEVELOPMENT OF MINIMALLY INVASIVE BIOASSAYS TO SUPPORT OUTPATIENT CLINICAL TRIALS OF THERAPEUTICS FOR SUBSTANCE USE DISORDERS (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related clinical development of minimally invasive bioassays to support outpatient clinical trials of therapeutics for substance use disorders (R01) funding opportunity announcement. This Aids-related announcement encourages applications that propose to develop non-invasive methods to support outpatient clinical trials of pharmacotherapies for substance use disorders. Clinical trials evaluating the efficacy of medications to treat SUDs are limited by two major issues: an uncertainty in assessing the level of a subject's adherence to the trial medication regimen and an inability to accurately and quantitatively monitor the frequency and level of a subject's illicit drug exposure. This FOA encourages the development of systems that address at least one of these issues. Applications submitted to this opportunity should focus around an outpatient clinical trial with or without preclinical system development studies. This announcement has two main aims:

- to encourage the development of systems that will improve estimations of level adherence to the medication regimen in a manner that is non- or minimally invasive and can be conducted at "point of care";
- to encourage the development of systems that can accurately assess the quantity and frequency of consumption of

abused drug during an outpatient clinical trial.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-076, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$500,000 per year over the maximum project period of three years.

Ref: PA-16-076 (replaces PAR-12-239).

Closing date: 07 Sep 16

Deadline information: Applications are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.

Posted date: 11 Jan 16

Award type: Clinical trials, Directed grants to institutions, research groups etc

Award amount max: \$1,500,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-076.html>

**Eligibility profile**

Country of applicant institution: Any

HIV/Aids; Immunological & Bioassay
Methods; Pharmacotherapy; Drug &
Substance Abuse

Disciplines**Contact Details**

Email: aidan.hampson@nih.gov

OOCYTE MITOCHONDRIAL FUNCTION IN RELATION TO FERTILITY, AGEING AND MITOCHONDRIAL DISEASES (R21): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its oocyte mitochondrial function in relation to fertility, aging and mitochondrial diseases (R21): Aids-related funding opportunity announcement. This Aids-related announcement encourages applications from the scientific community to support outstanding research in the area of oocyte mitochondrial function in relation to fertility, ageing and mitochondrial disease transmission to offspring. The overarching goal is to gain fundamental insight into the role of mitochondria and long-term consequences of their dysfunction in the oocyte and to develop therapeutic or alternative approaches to treat mitochondrial dysfunction for improving oocyte quality and competency, and health of the resultant offspring. The anticipated results from studies supported by this FOA is to provide women, suffering from infertility or subfertility and other illnesses due to mitochondrial dysfunction, practical approaches to enhance their fertility and the well-being of their offspring. A major goal is to stimulate research that will broaden our understanding of how stage-specific formation and function of mitochondria impact upon the oocyte quality and fertility in women and on mitochondrial disease transmission to the offspring. Research topics of interest include:

- mitochondrial function in all aspects of mammalian reproduction including oocyte development and maturation, fertilization and embryonic development;
- role of mitochondria in stem cell maintenance and lineage specification in the embryo;
- assisted reproductive technologies and their impact on mitochondrial function in oocytes and embryos;
- mitochondrial function in oocytes and embryos during maternal aging;
- studies on the link between diminished ovarian follicle reserve and mitochondrial function;
- metabolic disorders and their impact on mitochondrial function in oocytes and embryos;
- fundamental studies on mitochondrial mutations and their transmission to the offspring and characterisation of mitochondrial diseases;
- approaches to enhance mitochondrial function in the oocyte through therapeutic agents;
- preclinical studies in animal models systems for development of novel procedures for mitochondrial replacement in the oocytes.



This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-088, which solicits applications under the NIH research project (R01) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$275,000 for the maximum period of two years. No more than US\$200,000 may be requested in any single year.

Ref: PA-16-087.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 26 Jan 16

Award type: Innovation grants, Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-087.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Mitochondria; HIV/Aids; Reproduction & Fertility; Human Physiology

Contact Details

Tel: +1 301 435 6889

Email: ravindr@n@mail.nih.gov

OOCYTE MITOCHONDRIAL FUNCTION IN RELATION TO FERTILITY, AGEING AND MITOCHONDRIAL DISEASES (R01): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its oocyte mitochondrial function in relation to fertility, ageing and mitochondrial diseases (R01): Aids-related funding opportunity announcement. This Aids-related announcement encourages applications from the scientific community to support outstanding research in the area of oocyte mitochondrial function in relation to fertility, aging and mitochondrial disease transmission to offspring. The overarching goal is to gain fundamental insight into the role of mitochondria and long-term consequences of their dysfunction in the oocyte and to develop therapeutic or alternative approaches to treat

mitochondrial dysfunction for improving oocyte quality and competency, and health of the resultant offspring. The anticipated results from studies supported by this FOA is to provide women, suffering from infertility or subfertility and other illnesses due to mitochondrial dysfunction, practical approaches to enhance their fertility and the well-being of their offspring. A major goal is to stimulate research that will broaden our understanding of how stage-specific formation and function of mitochondria impact upon the oocyte quality and fertility in women and on mitochondrial disease transmission to the offspring. Research topics of interest include:



- mitochondrial function in all aspects of mammalian reproduction including oocyte development and maturation, fertilization and embryonic development;
- role of mitochondria in stem cell maintenance and lineage specification in the embryo;
- assisted reproductive technologies and their impact on mitochondrial function in oocytes and embryos;
- mitochondrial function in oocytes and embryos during maternal aging;
- studies on the link between diminished ovarian follicle reserve and mitochondrial function;
- metabolic disorders and their impact on mitochondrial function in oocytes and embryos;
- fundamental studies on mitochondrial mutations and their transmission to the offspring and characterisation of mitochondrial diseases;
- approaches to enhance mitochondrial function in the oocyte through therapeutic agents;
- preclinical studies in animal models systems for development of novel procedures for mitochondrial replacement in the oocytes.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-087, which solicits applications under the NIH exploratory or developmental (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-16-088.

Closing date: 07 Sep 16

Deadline information: Applications are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 26 Jan 16

Award type: Directed grants to institutions, research groups etc

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-088.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Reproduction & Fertility; Human Physiology; HIV/Aids; Mitochondria

Contact Details

Tel: +1 301 435 6889

Email: ravindrn@mail.nih.gov

MULTIDISCIPLINARY RESEARCH IN VULVODYNIA (R03): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute Child Health and Human Development invite applications for its

multidisciplinary research in vulvodynia (R03): Aids-related funding opportunity announcement. This Aids-related



announcement aims to encourage new research applications in the exploration of etiology, prevention, diagnosis and therapeutics in the field of vulvodynia. In addition, the purpose of this FOA is to indicate a continued interest in the topic area of vulvodynia or chronic vulvar pain of unknown etiology as an integral area of branch research. Applications utilising multidisciplinary approaches and interdisciplinary investigative teams are of particular interest to advance this research agenda. Research topics relevant to this program announcement include:

- pilot or feasibility work for prospective cohort or clinical trials such as exploration of an important component of a pharmacologic, surgical, behavioural, and/or physical therapy treatment;
- selective investigations into the role of nerve damage, regional autonomic dysfunction, muscle instability or tissue disruption and repair on the development, severity, persistence, or resistance to therapy of vulvodynia;
- small studies contributing to the development of surrogate animal models to assess the mechanism of vulvodynia formation or as potential pathways to screen for candidate therapeutic agents;
- preliminary laboratory studies to identify and characterise genetic or epigenetic processes involved in well-delineated vulvar pain conditions;
- exploratory laboratory or clinical studies to contribute to the investigation of biomarkers at the molecular, gene or protein and cell level;
- formative work to lay the groundwork for the development of patient reported outcome questionnaire design and validation using standardised techniques such as focus groups and other qualitative techniques.

This funding opportunity uses the NIH small grant (R03) programme and runs in parallel with two of identical scientific scope, PA-16-102, which solicits applications under the NIH research project (R01) grant mechanism and PA-16-100 which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

Eligible organisations include domestic and foreign for-profit and non-profit organisations and public or private institutions.

Application budgets are limited to US\$100,000 over the maximum period of two years. No more than US\$50,000 in direct costs may be requested in any single year.

Ref: PAR-16-101 (replaces PAR-10-191).

Closing date: 07 Sep 16

Deadline information: Applications are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 19 Feb 16

Award type: Innovation grants, Clinical trials, Directed grants to institutions, research groups etc

Award amount max: \$100,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-101.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Obstetrics & Gynaecology; HIV/Aids

Contact Details

Tel: +1 301 273 8541

Email: meikles@mail.nih.gov



M

ULTIDISCIPLINARY RESEARCH IN VULVODYNIA (R21): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute Child Health and Human Development invite applications for its multidisciplinary research in vulvodynia (R21): Aids-related funding opportunity announcement. This Aids-related announcement aims to encourage new research applications in the exploration of etiology, prevention, diagnosis and therapeutics in the field of vulvodynia. In addition, the purpose of this FOA is to indicate a continued interest in the topic area of vulvodynia or chronic vulvar pain of unknown etiology as an integral area of branch research. Applications utilising multidisciplinary approaches and interdisciplinary investigative teams are of particular interest to advance this research agenda. Research topics relevant to this program announcement include:

- pilot or feasibility work for prospective cohort or clinical trials such as exploration of an important component of a pharmacologic, surgical, behavioural or physical therapy treatment;
- selective investigations into the role of nerve damage, regional autonomic dysfunction, muscle instability or tissue disruption and repair on the development, severity, persistence, or resistance to therapy of vulvodynia;
- small studies contributing to the development of surrogate animal models to assess the mechanism of vulvodynia formation or as potential pathways to screen for candidate therapeutic agents;
- preliminary laboratory studies to identify and characterise genetic or epigenetic processes involved in well-delineated vulvar pain conditions;

- exploratory laboratory or clinical studies to contribute to the investigation of biomarkers at the molecular, gene/protein and cell level;
- formative work to lay the groundwork for the development of patient reported outcome questionnaire design and validation using standardised techniques such as focus groups and other qualitative techniques.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with two of identical scientific scope, PA-16-102, which solicits applications under the NIH research project (R01) grant mechanism and PA-16-101 which solicits applications under the NIH small grant (R03) programme.

Eligible organisations include domestic and foreign for-profit and non-profit organisations and public or private institutions.

Application budgets are limited to US\$275,000 over the maximum period of two years. No more than US\$200,000 may be requested in any single year.

Ref: PAR-16-100 (replaces PAR-10-192).

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 19 Feb 16

Award type: Directed grants to institutions, research groups etc, Clinical trials, Networking/collaboration

Award amount max: \$275,000

Award budget total: -

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-16-100.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Obstetrics & Gynaecology; HIV/ Aids

Contact Details

Tel: +1 301 273 8541

Email: meikles@mail.nih.gov

MULTIDISCIPLINARY RESEARCH IN VULVODYNIA (R01): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute Child Health and Human Development invite applications for its multidisciplinary research in vulvodynia (R01): Aids-related funding opportunity announcement. This Aids-related announcement aims to encourage new research applications in the exploration of etiology, prevention, diagnosis and therapeutics in the field of vulvodynia. In addition, the purpose of this FOA is to indicate a continued interest in the topic area of vulvodynia or chronic vulvar pain of unknown etiology as an integral area of branch research. Applications utilising multidisciplinary approaches and interdisciplinary investigative teams are of particular interest to advance this research agenda. Research topics relevant to this program announcement include:

- pilot or feasibility work for prospective cohort or clinical trials such as exploration of an important component of a pharmacologic, surgical, behavioural, and/or physical therapy treatment;
- selective investigations into the role of nerve damage, regional autonomic dysfunction, muscle instability or tissue disruption and repair on the

development, severity, persistence, or resistance to therapy of vulvodynia;

- small studies contributing to the development of surrogate animal models to assess the mechanism of vulvodynia formation or as potential pathways to screen for candidate therapeutic agents;
- preliminary laboratory studies to identify and characterise genetic or epigenetic processes involved in well-delineated vulvar pain conditions;
- exploratory laboratory or clinical studies to contribute to the investigation of biomarkers at the molecular, gene/protein and cell level;
- formative work to lay the groundwork for the development of patient reported outcome questionnaire design and validation using standardised techniques such as focus groups and other qualitative techniques.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two of identical scientific scope, PA-16-101, which solicits applications under the NIH small grant (R03) programme and PA-16-100 which solicits applications



under the NIH exploratory or developmental research (R21) grant mechanism.

Eligible organisations include domestic and foreign for-profit and non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-16-102 (replaces PAR-10-190).

Closing date: 07 Sep 16

Deadline information: Applications open 5 May 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 19 Feb 16

Award type: Clinical trials, Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-102.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Obstetrics & Gynaecology

Contact Details

Tel: +1 301 273 8541

Email: meikles@mail.nih.gov

MODELLING OF INFECTIOUS DISEASE AGENT STUDY RESEARCH PROJECTS (R01): AIDS-RELATED NIH: National Institute of General Medical Sciences

Description:

The National Institute of General Medical Sciences invites applications for its modelling of infectious disease agent study research projects (R01) funding opportunity announcement. This Aids-related announcement supports innovative research that will develop and apply computational tools and methods for modelling interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. Areas of interest include infectious disease research and computational, mathematical and statistical model research. The models should be useful to researchers, policymakers, or public health workers who want to better understand and respond to infectious diseases. This research opportunity encourages applications from institutions or organisations that propose to

provide the scientific and public health communities better resources, knowledge, and tools to improve their ability to prepare for, identify, detect, control, and prevent the spread of infectious diseases caused by naturally occurring or intentionally released pathogens, including those relevant to biodefense.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-16-107 (replaces RFA-GM-14-007).



Closing date: 07 Sep 16

Deadline information: Applications open on 5 May 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 23 Feb 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-107.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Disease Models; Medical Models, Mathematical; Animal Models; Computer Simulation & Modelling; Infection Agents & Pathogens; Infectious Diseases

Contact Details

Tel: +1 301 451 9822

Email: veerasamy.Ravichandra@nih.gov

D **EADLINE BROUGHT FORWARD: IMPROVEMENT OF ANIMAL MODELS FOR STEM-CELL-BASED REGENERATIVE MEDICINE (R21): AIDS-RELATED**

NIH: Office of the Director

Description:

The Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs, the National Institute of Allergy and Infectious Diseases, the National Institute of Dental and Craniofacial Research and the National Institute of Environmental Health Sciences have brought forward their opening date for their improvement of animal models for stem-cell-based regenerative medicine (R21) funding opportunity announcement. The previous opening date 16 May has been brought forward and the call is now open. The first application due date is 4 April 2016 followed by standard Aids-related application due dates. All other call information remain the same.

This Aids-related announcement aims to characterise animal stem cells and improve existing and create new animal models for human disease conditions. This initiative focuses on the following areas:

- comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems;
- development of new technologies for stem cell characterisation and transplantation;
- improvement of animal disease models for stem-cell-based therapeutic applications.

This FOA will use the R21 exploratory/developmental award mechanism, and runs in parallel with an FOA of identical scientific scope, PAR-16-093, which encourages applications under the R01 research project grant mechanism.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.



Application budgets are limited to US\$275,000 over a two-year period, with no more than US\$200,000 in any year.

Ref: PAR-16-094 (replaces PAR-13-115).

Closing date: 07 Sep 16

Deadline information: Applications are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 09 Mar 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-094.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Stem Cell; Regenerative Medicine; Animal Models

Contact Details

Tel: +1 301 435 0748

Email: oleg.mirochnitchenko@nih.gov

IMPROVEMENT OF ANIMAL MODELS FOR STEM-CELL-BASED REGENERATIVE MEDICINE (R01): AIDS-RELATED

NIH: Office of the Director

Description:

The Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs, the National Institute of Allergy and Infectious Diseases, the National Institute of Dental and Craniofacial Research and the National Institute of Environmental Health Sciences invite applications for their improvement of animal models for stem cell-based regenerative medicine funding opportunity announcement. This Aids-related announcement aims to characterise animal stem cells and improve existing and create new animal models for human disease conditions. This initiative focuses on the following areas:

- comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems;

- development of new technologies for stem cell characterisation and transplantation;
- improvement of animal disease models for stem-cell-based therapeutic applications.

This FOA will use the R01 research project grant mechanism, and runs in parallel with an FOA of identical scientific scope, PAR-16-094, which encourages applications under the R21 exploratory/developmental award mechanism.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. Application budgets are not limited, but must reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-16-03 (replaces PAR-13-114).



Closing date: 07 Sep 16
 Deadline information: Applications open on 5 May 2016 and are due by 5pm local time of applicant organisation, every 7 May, 7 September and 7 January until 8 May 2019.
 Posted date: 26 Feb 16
 Award type: Directed grants to institutions, research groups etc
 Award amount max: -
 Award budget total: -
 Website:
<http://grants.nih.gov/grants/guide/pa-files/PA-16-093.html>

Email: oleg.mirochnitchenko@nih.gov

Eligibility profile

Country of applicant institution: Any

Disciplines

Stem Cell; HIV/Aids; Regenerative Medicine; Animal Models

Contact Details

Tel: +1 301 435 0749

ROLE OF ASTROCYTES AND ASTROCYTIC NETWORKS IN DRUG ABUSE (R21): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its role of astrocytes and astrocytic networks in drug abuse (R21): Aids-related funding opportunity announcement. This Aids-related announcement aims to examine the effects of drugs of abuse on the structural connectivity of astrocytic networks within the central nervous system, and the generation, processing and spatiotemporal control of activities within these networks. Areas of interest include:

- determining how drugs of abuse interact with astrocytes to alter neurotransmission, synaptic plasticity, and neural communication;
- characterising the effects of drugs of abuse on the regulation of astrocyte and astrocytic networks;
- identifying the effects of drugs of abuse acting on astrocytes in cognition and behaviour;
- examining the contributions of additive substances on astrocyte-

mediated guidance and regulation of neurodevelopment.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-144, which solicits applications under the NIH research project (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$275,000 in direct costs over a maximum period of two years. No more than US\$200,000 in direct costs may be requested in any single year.

Ref: PA-16-145.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation



every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 23 Mar 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-145.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Central Nervous System; HIV/Aids; Drug & Substance Abuse

Contact Details

Tel: +1 301 443 3205

Email: rsorensen@mail.nih.gov

POPULATION HEALTH INTERVENTIONS: INTEGRATING INDIVIDUAL AND GROUP LEVEL EVIDENCE (R21): AIDS-RELATED

NIH: Office of the Director

Description:

A total of five institutes and offices of the National Institutes of Health invite applications for their population health interventions: integrating individual and group level evidence (R21): Aids-related funding opportunity announcement. This Aids-related announcement supports multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes. Applications submitted to this funding announcement should recognise the complexities of the multi-factorial origins of health outcomes, and target more than one of the following:

- individual-level factors, such as self-management for health or disease risk factors, stress, and social support;
- environmental factors, such as culture, social system, social context, and the built environment;
- provider-level factors, such as improvements in access, quality of care, communication, systems for

promoting trust and adherence, and patient support services;

- community factors, such as place, developing a social culture of healthy lifestyles, safe environments, and increased choices of healthy foods and leisure activities.

Applicants are strongly encouraged to build multidisciplinary teams comprised of researchers from multiple social and behavioural science fields as well as basic health science and clinical researchers.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-146, which solicits applications under the NIH research project (R01) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$275,000 in direct costs over the maximum period of



two years. No more than US\$200,000 may be requested in any single year.

Ref: PA-16-147.

Closing date: 07 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 23 Mar 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-147.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Community Health Services; Public Health; HIV/Aids

Contact Details

Tel: +1 301 451 4286

Email: spittelm@mail.nih.gov

ROLE OF ASTROCYTES AND ASTROCYTIC NETWORKS IN DRUG ABUSE (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its role of astrocytes and astrocytic networks in drug abuse (R01): Aids-related funding opportunity announcement. This Aids-related announcement aims to examine the effects of drugs of abuse on the structural connectivity of astrocytic networks within the central nervous system, and the generation, processing and spatiotemporal control of activities within these networks. Areas of interest include:

- determining how drugs of abuse interact with astrocytes to alter neurotransmission, synaptic plasticity, and neural communication;
- characterising the effects of drugs of abuse on the regulation of astrocyte and astrocytic networks;
- identifying the effects of drugs of abuse acting on astrocytes in cognition and behaviour;

- examining the contributions of addictive substances on astrocyte-mediated guidance and regulation of neurodevelopment.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-145, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-16-144.



Closing date: 07 Sep 16

Deadline information: Applications are due by 5pm local time of applicant organisation every 7 January, 7 September and 7 May until 8 May 2019.

Posted date: 23 Mar 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-144.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Central Nervous System; HIV/Aids; Drug & Substance Abuse

Contact Details

Tel: +1 301 443 3205

Email: rsorensen@mail.nih.gov

POPULATION HEALTH INTERVENTIONS: INTEGRATING INDIVIDUAL AND GROUP LEVEL EVIDENCE (R01): AIDS-RELATED

NIH: Office of the Director

Description:

A total of five institutes and offices of the National Institutes of Health invite applications for their population health interventions: integrating individual and group level evidence (R01): Aids-related funding opportunity announcement. This Aids-related announcement supports multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes. Applications submitted to this funding announcement should recognise the complexities of the multi-factorial origins of health outcomes, and target more than one of the following:

- individual-level factors, such as self-management for health or disease risk factors, stress, and social support;
- environmental factors, such as culture, social system, social context, and the built environment;
- provider-level factors, such as improvements in access, quality of care, communication, systems for

promoting trust and adherence, and patient support services;

- community factors, such as place, developing a social culture of healthy lifestyles, safe environments, and increased choices of healthy foods and leisure activities.

Applicants are strongly encouraged to build multidisciplinary teams comprised of researchers from multiple social and behavioural science fields as well as basic health science and clinical researchers.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-147, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed



project. The maximum project period is five years.

Ref: PA-16-146.

Closing date: 07 Sep 16

Deadline information: Applications are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 23 Mar 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-146.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Public Health; Community Health Services; HIV/Aids

Contact Details

Tel: +1 301 451 4286

Email: spittelm@mail.nih.gov

TAILORING DENTAL TREATMENT FOR INDIVIDUALS WITH SYSTEMIC DISEASES THAT COMPROMISE ORAL HEALTH (R21): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research invites applications for its tailoring dental treatment for individuals with systemic diseases that compromise oral health (R21) Aids-related funding opportunity announcement. This Aids-related announcement aims to encourage developmental or exploratory clinical research related to addressing gaps in our knowledge of how best to treat oral diseases of patients with systemic diseases or conditions known to compromise oral health, to identify factors predictive of treatment outcomes within patient groups, and to generate evidence for more precise dental treatment guidelines tailored to patient needs. It is expected that research applications will propose studies utilising established cohorts of individuals with the disease of interest. Examples of research topics include:

- research utilising existing medical and dental treatment records to assess the

survival of dental implants, crowns or prosthetics to restore oral function in medically complex patients, such as those with ectodermal dysplasias or Sjögren's syndrome;

- retrospective data analysis to study the effectiveness of standard of care periodontal therapy for those with type 1 or type 2 diabetes and factors that predict response to therapy;
- research utilising existing medical and dental treatment records and retrospective or prospective data collection to determine long-term oral health outcomes in patients who develop chronic graft versus host disease following hematopoietic stem cell transplant;
- retrospective data analysis to assess the effectiveness of prophylactic interventions upon oral health outcomes;



- research utilising existing medical and dental treatment records and retrospective or prospective data collection to assess temporomandibular joint and pain outcomes following orthodontic treatment in patients with chronic temporomandibular disorders.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-16-154, which solicits applications under the NIH research project (R01) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$275,000 in direct costs over the maximum two year period. No more than US\$200,000 is allowed in any single year.

Ref: PAR-16-153.

Closing date: 07 Sep 16

Deadline information: Applications open 16 May 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 29 Mar 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-153.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Dentistry; Oral Medicine; HIV/ Aids

Contact Details

Tel: +1 301 594 4876

Email: dena.fischer@nih.gov

UNDERSTANDING FACTORS IN INFANCY AND EARLY CHILDHOOD THAT INFLUENCE OBESITY DEVELOPMENT (R01): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

A total of four institutes and offices of the National Institutes of Health invite applications for their understanding factors in infancy and early childhood that influence obesity development (R01): Aids-related funding opportunity announcement. This Aids-related announcement seeks applications that propose to characterise or identify factors in early childhood that may increase or mitigate risk for obesity or excessive weight gain or to fill methodological research gaps relevant to the understanding of risk for development of obesity in children.

Studies should propose research in children from birth to 24 months, although any proposed follow-up assessments, if applicable, may continue past this period. Studies may also assess factors relevant to families and/or caregivers of children from birth to 24 months. Applications should seek to fill unique research needs and involve expertise across disciplines as appropriate for the proposed research question. The following topics are identified as high priority:



- behavioural and physiological phenotypes, such as individual differences in appetite, food preference, temperament, self-regulation and other factors related to excessive weight gain that may predict obesity development and treatment response;
- infant and early childhood feeding practices, sleep, physical activity or sedentary behaviours that may influence weight gain and risk for obesity;
- patterns of weight gain and growth trajectories during infancy and early childhood that are associated with risk for development of obesity;
- family and caregiver aspects that may influence weight gain, such as parenting style, responsiveness to infant or child needs, stress, and other psychosocial characteristics;
- impact of food type, composition, or introduction during infancy on weight gain trajectory;
- emerging obesity risk factors, including the hormonal milieu, microbiome, and epigenetic modifications;
- development and validation of methods to assess body composition, dietary intake or composition, and physical activity or sedentary behaviours as well as sleep duration and quality in infants and young children;
- development and validation of methods to assess infant or child behavioural factors that contribute to weight gain trajectory and obesity risk, such as appetite, temperament, learning, and other attributes;
- development and validation of methods to assess behavioural factors

in caregivers that may influence the child's weight gain trajectory and obesity risk.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-16-169 (replaces PAR-14-323).

Closing date: 07 Sep 16

Deadline information: Applications open 5 May 2016 and are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 07 Apr 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-169.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Public Health; Nutrition & Dietetics; Behavioural Medicine; Obesity; HIV/Aids; Developmental Psychology; Paediatrics; Infant Paediatrics

Contact Details

Tel: +1 301 594 4578

Email: evansmary@niddk.nih.gov



R ESearch DISSERTATION FELLOWSHIP FOR AuD AUDIOLOGISTS (F32): AIDS-RELATED

NIH: National Institute on Deafness and other Communication Disorders

Description:

The National Institute on Deafness and Other Communication Disorders invites applications for its research dissertation fellowship for AuD audiologists (F32): Aids-related. This enables scientists to undertake comprehensive and rigorous biomedical research training and dissertation research leading to a research doctorate in the biomedical, behavioural, or clinical sciences. The overall goal of the NIH Ruth L. Kirschstein national research service award programme is to help ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to address the Nation's biomedical, behavioural, and clinical research needs. NRSA fellowships support the training of pre-and postdoctoral scientists, dual-degree investigators, and senior researchers. The training plan should facilitate the fellow's transition to the next stage of his or her career.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Applicants may receive up to five years of support at the pre-doctoral level and up to six years for dual degree training; three years of support at the postdoctoral level including any combination of support from institutional

training grants and an individual fellowship award.

Ref: PAR-16-210.

Closing date: 07 Sep 16

Deadline information: Applications open 8 July 2016 and are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 22 Apr 16

Award type: Directed grants for individual investigators, Postdoctoral training fellowships, Directed grants to institutions, research groups etc, Personal development

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-210.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Bio/Medical; HIV/ Aids

Contact Details

Tel: +1 301 496 1804

Email: riverara@nidcd.nih.gov

P RECLINICAL RESEARCH ON MODEL ORGANISMS TO PREDICT TREATMENT OUTCOMES FOR DISORDERS ASSOCIATED WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (R01): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute of Child Health and Human

Development invites applications for its preclinical research on model organisms to



predict treatment outcomes for disorders associated with intellectual and developmental disabilities (R01): Aids-related funding opportunity announcement. This Aids-related announcement encourages preclinical research in model organisms of neurodevelopmental disorders. Applications submitted to this call should propose to develop, validate, and calibrate outcome measures, surrogate markers, and biomarkers in model organisms that can inform and effectively translate to human clinical trials for individuals with intellectual and developmental disabilities. In addition, applications may propose to conduct rigorous, controlled and standardised preclinical animal trials designed for safety, toxicity, and efficacy prediction or to perform an independent validation of efficacy in animals prior to human clinical trials. This FOA addresses a significant need in the field: the identification of sensitive, reliable, reproducible, valid, and relevant endpoints that can be used in preclinical animal testing and human clinical trials of therapeutic compounds for intellectual and developmental disabilities. Its goal is to accelerate and improve the preclinical testing of candidate treatments and therapeutic compounds in order to move promising new drug therapies into clinical trials.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PAR-16-216, which solicits applications under the same NIH mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$499,999 per year over a period of up to five years.

Ref: PAR-16-215 (replaces PAR-13-195).

Closing date: 07 Sep 16

Deadline information: Applications are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2019.

Posted date: 27 Apr 16

Award type: Clinical trials, Directed grants to institutions, research groups etc

Award amount max: \$2,500,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-215.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biochemical Markers; Pharmacy & Pharmacology; Neurology; HIV/ Aids; Animal Models; Central Nervous System

Contact Details

Tel: +1 301 435 6880

Email: parisima@mail.nih.gov

OUTCOME MEASURES FOR USE IN TREATMENT TRIALS FOR INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (R01): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:

The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of

Mental Health invite applications for their outcome measures for use in treatment trials for individuals with intellectual and



developmental disabilities (R01): Aids-related funding opportunity announcement. This Aids-related announcement aims to develop informative outcome measures for use in clinical trials for individuals with intellectual and developmental disabilities. This FOA will address a significant need in the field, one that is especially apparent in efforts to develop pharmacological treatments for these populations. It will focus on ongoing clinical and translational research on a neglected area essential for therapy and pharmacological treatment development. Research appropriate for this FOA may include:

- research that identifies and demonstrates the efficacy of measures or instruments that currently exist and that can be used to effectively assess treatments for intellectual and developmental disabilities population;
- research that identifies and demonstrates the efficacy of measures or instruments that currently exist but need modification to be used to effectively assess treatments for IDD population;
- research that develops and demonstrates the efficacy of new measures or instruments that can be used to effectively assess treatments for IDD population;
- development of measures or instruments for specific disorders or for combinations of phenotypes commonly observed in multiple disorders across IDD populations;
- development of clinical rating scales for use in groups that are challenging to assess.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PAR-16-215, which solicits applications under the same NIH mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$499,999 per year over a five-year period.

Ref: PAR-16-215 (replaces PAR-13-213).

Closing date: 07 Sep 16

Deadline information: Applications are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2019.

Posted date: 27 Apr 16

Award type: Directed grants to institutions, research groups etc, Clinical trials

Award amount max: \$2,500,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-216.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Pharmacy & Pharmacology; Developmental Disorders

Contact Details

Tel: +1 301 496 1385

Email: kaua@mail.nih.gov





C **LINICAL SEQUENCING EVIDENCE-GENERATING RESEARCH – CLINICAL SITES WITH ENHANCED DIVERSITY (U01): AIDS-RELATED** NIH: National Human Genome Research Institute

Description:

The National Human Genome Research Institute, the National Cancer Institute and the National Institute on Minority Health and Health Disparities invite applications for its clinical sequencing evidence-generating research – clinical sites with enhanced diversity (U01): Aids-related funding opportunity announcement. This Aids-related announcement aims to establish clinical sites with enhanced diversity that collectively encompass a broad spectrum of healthcare settings and serve ancestrally and socioeconomically diverse patients with a wide range of clinical conditions.

The main objectives of this call are to:

- define, generate and analyse evidence regarding the clinical utility of genome sequencing;
- research the critical interactions among patients, family members, health practitioners, and clinical laboratories that influence implementation of clinical genome sequencing;
- identify and address real-world barriers to integrating genomic, clinical, and healthcare utilisation data within a healthcare system to build a shared evidence base for clinical decision-making.

Applicants are expected to recruit a minimum of 60 per cent of patients who come from racial or ethnic minority populations, underserved populations, or populations who experience poorer medical outcomes.

This funding opportunity uses the NIH research project – co-operative agreements (U01) mechanism and runs in parallel with two of identical scientific scope, RFA-HG-16-010, which solicits applications under the

same NIH (U01) mechanism and RFA-HG-16-012, which solicits applications under the NIH resource-related research projects – co-operative agreements mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

NHGRI intends to commit up to US\$20.8 million to support two related FOAs establishing clinical sites with enhanced diversity. It is expected that three to six awards will be supported under this call and three to six awards under RFA-HG-16-010. NCI intends to commit up to US\$1m total costs per year to co-fund applications relevant to the NCI mission. Applications may be submitted to either the general clinical sites with enhanced diversity FOA or the general clinical sites FOA RFA HG-16-010. NIMH intends to commit up to US\$2.3m total costs per year to co-fund applications relevant the NIMHD mission. Application budgets are limited to US\$2.5m in direct costs per year for a total period of four years.

Ref: RFA-HG-16-011 (replaces RFA-HG-009).

Closing date: 07 Sep 16

Deadline information: Applications open 6 July and are due by 5pm local time of applicant organisation, 7 September 2016.

Posted date: 09 May 16

Award type: Directed grants to institutions, research groups etc, Research centres

Award amount max: \$10,000,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-16-011.html>

Eligibility profile

Country of applicant institution: Any



Disciplines

Chronic Care; Preventive Medicine;
Diagnostic Sciences; Disadvantaged &
Minority Groups; HIV/Aids; Clinical

Decision-making & Analysis; Health of
Minority Groups; Genomics

Contact Details

Tel: +1 240 271 1509
Email: hindorff@mail.nih.gov

C LINICAL SEQUENCING EVIDENCE-GENERATING RESEARCH – CLINICAL SITES (U01): AIDS-RELATED

NIH: National Human Genome Research Institute

Description:

The National Human Genome Research Institute and the National Cancer Institute invite applications for its clinical sequencing evidence-generating research – clinical sites (U01): Aids-related funding opportunity announcement. This Aids-related announcement aims to establish clinical sites with enhanced diversity that collectively encompass a broad spectrum of healthcare settings and serve ancestrally and socioeconomically diverse patients with a wide range of clinical conditions.

The main objectives of this call are to:

- define, generate and analyse evidence regarding the clinical utility of genome sequencing;
- research the critical interactions among patients, family members, health practitioners, and clinical laboratories that influence implementation of clinical genome sequencing;
- identify and address real-world barriers to integrating genomic, clinical, and healthcare utilisation data within a healthcare system to build a shared evidence base for clinical decision-making.

Applicants are expected to recruit a minimum of 25 per cent of patients who come from

racial or ethnic minority populations, underserved populations, or populations who experience poorer medical outcomes.

This funding opportunity uses the NIH research project – co-operative agreements (U01) mechanism and runs in parallel with two of identical scientific scope, RFA-HG-16-011, which solicits applications under the same NIH (U01) mechanism and RFA-HG-16-012, which solicits applications under the NIH resource-related research projects (U24) – co-operative agreements mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

NHGRI intends to commit up to US\$20.8 million to support two related FOAs establishing clinical sites with enhanced diversity. It is expected that three to six awards will be supported under this call and three to six awards under RFA-HG-16-011. NCI intends to commit up to US\$1m total costs per year to co-fund applications relevant to the NCI mission. Applications may be submitted to either the general clinical sites with enhanced diversity FOA or the general clinical sites FOA RFA HG-16-011. Application budgets are limited to US\$2m in direct costs per year for a total period of four years.



Ref: RFA-HG-16-010 (replaces RFA-HG-12-009).

Closing date: 07 Sep 16

Deadline information: Applications open 5 July and are due by 5pm local time of applicant organisation, 7 September 2016.

Posted date: 09 May 16

Award type: Directed grants to institutions, research groups etc, Research centres

Award amount max: \$8,000,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-16-010.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Diagnostic Sciences; HIV/Aids; Disadvantaged & Minority Groups; Clinical Decision-making & Analysis; Preventive Medicine; Genomics; Chronic Care; Health of Minority Groups

Contact Details

Tel: +1 240 271 1509

Email: hindorff@mail.nih.gov

METABOLIC REPROGRAMMING TO IMPROVE IMMUNOTHERAPY (R01): AIDS-RELATED

NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its metabolic reprogramming to improve immunotherapy (R01): Aids-related funding opportunity announcement. This Aids-related announcement aims to generate a mechanistic understanding of the metabolic processes that support robust anti-tumour immune responses in vivo, determine how the metabolic landscape of the tumour microenvironment affects immune effector functions, and then use this information to manipulate the metabolic pathways used by the tumour, the immune response, or both to improve cancer immunotherapy. The objective of this call is to develop approaches to reprogramme the metabolic qualities of anti-tumour immune cells, either ex vivo or in vivo, to improve immunotherapy and approaches that target cancer cell metabolic pathways to impair cancer cell survival without compromising endogenous anti-tumour immunity.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PAR-16-229, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-16-228.

Closing date: 07 Sep 16

Deadline information: Applications open 5 September 2016 and are due by 5pm local time of applicant organisation every 7



January, 7 May and 7 September until 8 September 2019.

Posted date: 09 May 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-228.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Immunotherapy; Cell Physiology & Metabolism; Cancer Immunology

Contact Details

Tel: +1 240 276 6200

Email: mccarths@mail.nih.gov

NON-HEALING ULCERATIVE WOUNDS IN AGEING (R01): AIDS-RELATED

NIH: National Institute on Aging

Description:

The National Institute on Aging and the National Institute of Nursing Research invite applications for their non-healing ulcerative wounds in ageing (R01): Aids-related funding opportunity announcement. This Aids-related announcement seeks applications that propose basic, clinical, or translational research on non-healing ulcerative wounds and their consequences in ageing and in older persons. Applications should focus on the biology, aetiology and pathophysiology of non-healing ulcerative wounds in animal models and older adults; translation of basic or clinical research into clinical practice and health decision-making; diagnosis, prevention, management and clinical outcomes of non-healing wounds in older adults. Proposed research should enhance knowledge of non-healing wounds and their consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of non-healing wounds in older persons. Areas of interest include:

- biology, aetiology and pathophysiology;

- translation into clinical research;
- diagnosis, prevention and management.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-231, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-16-230.

Closing date: 07 Sep 16

Deadline information: Applications open 5 September 2016 and are due by 5pm local time of applicant organisation every 7



January, 7 May, 7 September until 8 September 2019.
 Posted date: 09 May 16
 Award type: Directed grants to institutions, research groups etc
 Award amount max: -
 Award budget total: -
 Website:
<http://grants.nih.gov/grants/guide/pa-files/PA-16-230.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Wound Healing; Diagnostic Sciences; Animal Models; Geriatrics & Gerontology

Contact Details

Tel: +1 301 496 6761

Email: saliveme@mail.nih.gov

FACTORS UNDERLYING DIFFERENCES IN FEMALE AND MALE PRESENTATION FOR DENTAL, ORAL AND CRANIOFACIAL DISEASES AND CONDITIONS (R01): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research, the National Institute on Aging and the Office of Research on Women's Health invite applications for their factors underlying differences in female and male presentation for dental, oral and craniofacial diseases and conditions (R01): Aids-related funding opportunity announcement. This Aids-related announcement supports research on mechanisms underlying the manifestations of sex-based differences in dental, oral and craniofacial related diseases and conditions. Studies aimed at understanding immune reactivity, genetic variation, environmental triggers, ageing, and hormonal changes as they affect sex-based differences in dental, oral and craniofacial related diseases and conditions including Sjögren's syndrome, orofacial pain, temporomandibular joint disorder, salivary gland tumours and human papillomavirus-associated oropharyngeal cancers are encouraged. The objectives are to determine the role of sex in the manifestation of such diseases or conditions. Specific areas of interest include:

- to identify and delineate genetic risk or protective factors, gene polymorphisms and gene-environment interactions that contribute to sex-based differences in incidence rate of dental, oral or craniofacial diseases and conditions;
- to identify and delineate X chromosome-linked regions that may determine male-female bias in incidence rate of dental, oral or craniofacial diseases and conditions and elucidation of cellular and molecular mechanisms responsible for this bias;
- to identify and delineate molecular pathways and cellular networks controlling sex-based differences and elucidation of how these pathways and networks influence disease onset, progression, and persistence as well as responses to treatment;
- to elucidate sex hormone influence on the development of dental, oral or craniofacial diseases and conditions and differentiate and improve understanding of mechanisms



mediating effects of ageing and multiple morbidities on symptoms or functional capacity in dental, oral or craniofacial diseases and conditions in males versus females.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-296, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-16-295.

Closing date: 07 Sep 16
Deadline information: Applications open 5 September 2016 and are due by 5pm local time of applicant organisation every 7

January, 7 May and 7 September until 8 September 2019.

Posted date: 31 May 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-295.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Genetics & Systems Biology; Hormones & Endocrinology; Immunology; Geriatrics & Gerontology; Men's Health; Craniofacial Disorders; Oral Medicine; Dental Health & Hygiene; Women's Health; HIV/Aids; Environmental Impact Assessment

Contact Details

Tel: +1 301 594 9718

Email: amanda.melillo@nih.gov

NOVEL STRATEGIES FOR TARGETING HIV-CNS RESERVOIRS WITHOUT REACTIVATION (R21)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute on Drug Abuse as well as the National Institute of Neurological Disorders and Stroke invite applications for their novel strategies for targeting HIV-CNS reservoirs without reactivation (R21) funding opportunity announcement. This announcement aims to identify HIV-1-infected cells in the central nervous system compartment that are latently infected, develop strategies for targeting these latently infected cells, and to achieve viral silencing leading to inhibition of viral production,

without the need for pro-viral reactivation. Areas of interest include:

- developing innovative strategies to selectively identify and eliminate latently infected CNS-derived cells without reactivation of pro-virus;
- developing novel approaches for viral silencing, including synthetic ribonucleic acid duplex targeting of HIV-infected CNS derived myeloid cells;



- developing unique classes of HIV drugs that inhibit viral production from stable reservoirs and reduce residual viral presence in the periphery and the CNS;
- using novel gene-editing technologies, such as ribonucleic acid-directed gene editing and CRISPR associated protein 9 or guide RNA, for targeting HIV pro-virus within cells of the CNS compartment;
- designing new assays and in-vitro and in-vivo model systems, including a non-human primate model as appropriate, to study HIV latency;
- developing a new class of delivery agents that can increase the bioavailability of drugs within the CNS and target HIV-1 infected cells;
- developing immunotherapy-based anti-viral approaches that can be used to eliminate CNS HIV-1 reservoirs;
- investigating the effects of drugs of abuse on CNS HIV latency and how drugs might impact viral silencing or activation process.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, RFA-MH-17-101, which solicits applications under the NIH research project (R01) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

NIMH intends to commit an estimate of US\$2 million in fiscal year 2017 to fund four to five awards in response to this FOA and its

companion; NINDS intends to commit approximately US\$1.5m in fiscal year 2017 to fund three to four awards; NIDA will commit approximately US\$1.5m in fiscal year 2017 to fund two to four awards. Application budgets are limited US\$275,000 for the maximum period of two years and no more than US\$200,000 may be requested in any single year.

Ref: RFA-MH-17-100.

Closing date: 09 Sep 16

Deadline information: Applications open 9 August and due by 5pm local time of applicant organisation, 9 September 2016.

Posted date: 07 Apr 16

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-100.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Infectious Diseases; Central Nervous System; HIV/Aids; Biochemical Markers; Animal Models; Immunotherapy; Genetic Engineering

Contact Details

Tel: +1 240 627 3869

Email: jjeymoha@mail.nih.gov



NOVEL STRATEGIES FOR TARGETING HIV-CNS RESERVOIRS WITHOUT REACTIVATION (R01)

NIH: National Institute of Mental Health

Description:

The National Institute of Mental Health and the National Institute on Drug Abuse as well as the National Institute of Neurological Disorders and Stroke invite applications for their novel strategies for targeting HIV-CNS reservoirs without reactivation (R01) funding opportunity announcement. This announcement aims to identify HIV-1-infected cells in the central nervous system compartment that are latently infected, develop strategies for targeting these latently infected cells, and to achieve viral silencing leading to inhibition of viral production, without the need for pro-viral reactivation. Areas of interest include:

- developing innovative strategies to selectively identify and eliminate latently infected CNS-derived cells without reactivation of pro-virus;
- developing novel approaches for viral silencing, including synthetic ribonucleic acid duplex targeting of HIV-infected CNS derived myeloid cells;
- developing unique classes of HIV drugs that inhibit viral production from stable reservoirs and reduce residual viral presence in the periphery and the CNS;
- using novel gene-editing technologies, such as ribonucleic acid-directed gene editing and CRISPR associated protein 9 or guide RNA, for targeting HIV pro-virus within cells of the CNS compartment;
- designing new assays and in-vitro and in-vivo model systems, including a non-human primate model as appropriate, to study HIV latency;
- developing a new class of delivery agents that can increase the bioavailability of drugs within the CNS and target HIV-1 infected cells;

- developing immunotherapy-based anti-viral approaches that can be used to eliminate CNS HIV-1 reservoirs;
- investigating the effects of drugs of abuse on CNS HIV latency and how drugs might impact viral silencing or activation process.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, RFA-MH-17-100, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

NIMH intends to commit an estimate of US\$2 million in fiscal year 2017 to fund four to five awards in response to this FOA and its companion; NINDS intends to commit approximately US\$1.5m in fiscal year 2017 to fund three to four awards; NIDA will commit approximately US\$1.5m in fiscal year 2017 to fund two to four awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: RFA-MH-17-101.

Closing date: 09 Sep 16

Deadline information: Applications open 9 August and due by 5pm local time of applicant organisation, 9 September 2016.

Posted date: 07 Apr 16

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-101.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Animal Models; Biochemical Markers; Genetic Engineering; HIV/Aids; Immunotherapy; Central Nervous System; Infectious Diseases

Contact Details

Tel: +1 240 627 3869

Email: jjeymoha@mail.nih.gov

BIOENGINEERING RESEARCH PARTNERSHIPS (U01)

NIH: National Institute of Biomedical Imaging and Bioengineering

Description:

A total of 8 participating institutes and offices of the National Institutes of Health invite applications for their bioengineering research partnerships (U01) funding opportunity announcement. This announcement aims to accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterised solutions that fulfil an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. This call focuses on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies and engage biomedical researchers or clinicians throughout the project. The goal of the programme is to support projects that can realise meaningful solutions within five to 10 years. In addition, other objectives may include establishing proof of concept, pre-commercial prototype production, licenser, release of software packages, designs or models, demonstrating the biological effectiveness of engineered constructs, elucidating the structural and functional relevance of biomolecules or tissues, first-in-human testing, or starting the investigational

device exemption or investigational new drug process. It is also of interest to encourage collaborations and partnerships among allied quantitative and biomedical disciplines.

This FOA will use the NIH research project (U01) co-operative agreements mechanism and runs in parallel with two FOAs of similar scientific scope, PAR-13-137, which solicits applications under the NIH research project (R01) grant mechanism and PA-16-040, which also solicits applications under the NIH exploratory or developmental (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-16-116 (replaces PAR-14-092).

Closing date: 13 Sep 16

Deadline information: Applications open on 18 April 2016 and are due by 5pm local time of applicant organisation, 18 May and 13



September 2016 and 2017, 8 May and 13 September 2018 until 8 January 2019.

Posted date: 03 Mar 16

Award type: Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-116.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biomolecular Modelling; Bioengineering

Contact Details

Tel: +1 301 451 0707

Email: kpeterso@mail.nih.gov

NIAID CLINICAL TRIAL PLANNING GRANT (R34)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites applications for its clinical trial planning grant (R34) funding opportunity announcement. This announcement supports applications that propose the complete planning, design and preparation of the documentation necessary for the implementation of investigator-initiated clinical trials. The trials must be hypothesis driven, milestone-defined, related to the research mission of the NIAID and considered a high priority by the institute. Sufficient preclinical data to support the planning of the clinical trial should be available prior to submission of the grant application

This funding opportunity announcement uses the NIH R34 grant mechanism and runs in parallel with two FOAs of identical scope, PAR-16-270, which solicits applications under the U01 grant mechanism, and PAR-16-271, which solicits applications under the R01 grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to US\$150,000 in direct costs and the maximum project period is one year.

Ref: PAR-16-272 (replaces PAR-13-150).

Closing date: 13 Sep 16

Deadline information: Applications open on 13 August 2016 and are due by 5pm local time of applicant organisation on deadline dates. Deadlines on: 13 September 2016, 13 January 2017, 12 May 2017, 13 September 2017, 12 January 2018, 14 May 2018, 13 September 2018, 14 January 2019, 13 May 2019.

Posted date: 19 May 16

Award type: Directed grants to institutions, research groups etc, Clinical trials

Award amount max: \$150,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-272.html>



Eligibility profile

Country of applicant institution: Any

Pharmacology; Diagnostic Sciences; Drug Design; Pharmaceutical Drugs; Medical & Diagnostic Tests; HIV/Aids

Disciplines

Infection Agents & Pathogens; Infectious Diseases; Pharmacy & Pharmacology; Preventive Medicine; Clinical Pharmacy &

Contact Details

Tel: +1 240 627 3502

Email: egoldmuntz@niaid.nih.gov

NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites applications for its clinical trial implementation co-operative agreements (U01) funding opportunity announcement. This announcement supports cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. The trials must be hypothesis driven, milestone-driven, related to the research mission of the NIAID and address a research area considered a high priority by the institute.

This funding opportunity announcement uses the NIH U01 grant mechanism and runs in parallel with two FOAs of identical scope, PAR-16-269, which solicits applications under the R01 grant mechanism, and PAR-16-272, which solicits applications under the R34 grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but must reflect the actual needs of the proposed project. The maximum funding period is five years.

Ref: PAR-16-270 (replaces PAR-13-151).

Closing date: 13 Sep 16

Deadline information: Applications open on 13 August 2016 and are due by 5pm local time of applicant organisation on deadline dates. Deadlines on: 13 September 2016, 13 January 2017, 12 May 2017, 13 September 2017, 12 January 2018, 14 May 2018, 13 September 2018, 14 January 2019, 13 May 2019.

Posted date: 19 May 16

Award type: Directed grants to institutions, research groups etc, Clinical trials

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-270.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Pharmaceutical Drugs; Medical & Diagnostic Tests; Preventive Medicine; Drug Design; Clinical Pharmacy & Pharmacology; HIV/Aids



Contact Details

Tel: +1 240 627 3502

Email: egoldmuntz@niaid.nih.gov

NIAID CLINICAL TRIAL IMPLEMENTATION GRANT (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites applications for its R01 NIAID clinical trial planning grants. This R01 funding opportunity announcement encourages applications for implementation of investigator-initiated, non-high-risk clinical trials. The trials must be hypothesis driven, related to the research mission of the NIAID and address a research area considered a high priority by the institute.

This funding opportunity announcement will utilise the NIH R01 grant mechanism and runs in parallel with two related FOAs, PAR-16-270, which solicits applications under the U01 grant mechanism, and PAR-16-272, which solicits applications under the R34 grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but must reflect the actual needs of the proposed project. The maximum funding period is five years.

Ref: PAR-16-269 (replaces PAR-13-149).

Closing date: 13 Sep 16

Deadline information: Applications open on 13 August 2016 and are due by 5pm local time of applicant organisation on deadline dates. Deadlines on: 13 September 2016, 13 January 2017, 12 May 2017, 13 September 2017, 12 January 2018, 14 May 2018, 13 September 2018, 14 January 2019, 13 May 2019.

Posted date: 19 May 16

Award type: Directed grants to institutions, research groups etc, Clinical trials

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-269.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Preventive Medicine; Pharmacy & Pharmacology; Medical & Diagnostic Tests; Infection Agents & Pathogens; Pharmaceutical Drugs; Diagnostic Sciences; Infectious Diseases; Drug Design; HIV/Aids

Contact Details

Tel: +1 240 627 3502

Email: egoldmuntz@niaid.nih.gov



ROLE OF MOBILE GENETIC ELEMENTS IN CANCER (R21)

NIH: National Institutes of Health

Description:

The National Cancer Institute (NCI) and the National Institute of Aging (NIA) invites applications for their funding opportunity announcement on the role of mobile genetic elements in cancer (R21). This R21 funding opportunity announcement encourages applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements in cancer.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US\$275,000 in direct costs with a maximum of US\$200,00 in direct costs per year. The maximum project period is two years.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-17-227, which solicits applications under the NIH research project (R01) grant mechanism.

Ref: PAR-16-226.

Closing date: 16 Sep 16

Deadline information: Applications open 16 September and are due by 5pm local time of applicant organisation on every 16 February, 16 June and 16 October until 8 September 2019. Deadlines on: 16 June 2016, 16 October 2016, 16 February 2017, and repeated annually.

Posted date: 06 May 16

Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-16-226.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Cancer Studies & Oncology; Genetics & Systems Biology

Contact Details

Tel: +1 240 276 6200

Email: howcroft@mail.nih.gov

PHYSICAL SCIENCES-ONCOLOGY NETWORK: PHYSICAL SCIENCES-ONCOLOGY PROJECTS (U01)

NIH: National Institutes of Health

Description:

The National Cancer Institute, the National Institute of Biomedical Imaging and Bioengineering and the Eunice Kennedy

Shriver National Institute of Child Health and Human Development invite applications, under the physical sciences-oncology



network, for their physical sciences-oncology project grants. These U01 grants enable physical scientists and cancer biologists to form small transdisciplinary teams that address complex and challenging questions in cancer research. Research projects may focus on one of the following areas:

- understanding and applying physical science perspectives and approaches to cancer biology and oncology, for example studying the physical dynamics of cancer or the spatio-temporal organisation and information transfer in cancer;
- the development of innovative technologies and analytical and computational tools to explore the process of tumour initiation and progression;
- developmental mechanisms relevant to cancer cell biology, with studies conducted in vivo only;
- other physical sciences-based thematic areas, such as the role of evolutionary theory in cancer or de-convoluting the complexity of cancer, or integrating multiple thematic areas into one project.

This funding announcement opportunity solicits applications under the research project – cooperative agreements U01 grants mechanism and runs in parallel with one of identical scientific scope, PAR-14-169, which solicits applications from US organisations under the specialised centre – cooperative agreements (R01) grant mechanism.

Applicant organisations may be higher education institutions, non-profit institutions, for-profit organisations and governments based anywhere in the world. Each team should include cancer researchers and physical scientists, who may be engineers, physicists, mathematicians, chemists or computer scientists. The use of multiple principal investigators is strongly encouraged.

Grants cover direct costs up to a maximum of US\$500,000 per year for a maximum period of five years. Cost-sharing is not required.

Ref: NIH PAR-15-021.

Closing date: 21 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on deadline dates. Deadlines on: 26 February 2015, 25 November 2015, 26 May 2016, 21 September 2016, 26 May 2017, 21 September 2017.

Posted date: 22 Oct 14

Award type: Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: \$2,500,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-R-15-021.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true?oppNum=PAR-15-021>

Eligibility profile

Country of applicant institution: Any

Disciplines

Human Biological Sciences; Gynaecological Cancers; Cancer Studies & Oncology; Prostate & Testicular Cancers; Oncology Nursing; Lung Cancer; Leukaemia & Other Blood Cancers; Breast Cancer; Nursing; Clinical Medicine; Chemotherapy; Melanoma & Other Skin Cancers; Physiology; Diagnostic Sciences; Cancer Cell Biology; Physics; Carcinogenesis; Molecularly Targeted Therapy; Brain Cancer; Cancer Immunology; Non-cancerous Tumours; Chemistry; Colorectal, Pancreatic & Stomach Cancers

Contact Details

NIH NCI
Building 9609, Room 6W560



9609 Medical Center Drive
Rockville, MD 20850

Tel: +1 240 276 6333
Email: nas.khun@nih.gov

MULTILEVEL INTERVENTIONS IN CANCER CARE DELIVERY: BUILDING FROM THE PROBLEM OF FOLLOW-UP TO ABNORMAL SCREENING TESTS (U01)

NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its multilevel interventions in cancer care delivery: building from the problem of follow-up to abnormal screening tests (U01) funding opportunity announcement. This announcement encourages applications that strengthen the science of multilevel effects of cancer care interventions by addressing the problem of incomplete follow-up to abnormal screening tests for breast, colorectal, cervical and lung cancers. Special emphasis is placed on multilevel interventions that anticipate the need to understand and change the context of an intervention during the efficacy phase of testing, in order to facilitate subsequent dissemination of proven interventions.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The maximum budget is US\$750,000 in direct costs per year. The maximum project period is four years.

Ref: PAR-15-108.

Closing date: 21 Sep 16
Deadline information: Applications open on 9 March and are due by 5pm local time of applicant organisation 9 April and 25

November 2015, 26 May and 21 September 2016, and 26 May and 21 September 2017.

Posted date: 02 Feb 15

Award type: Directed grants to institutions, research groups etc

Award amount max: \$750,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-108.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-R-15-108>

Eligibility profile

Country of applicant institution: Any

Disciplines

Breast Cancer; Screening for Diseases; Colorectal, Pancreatic & Stomach Cancers; Gynaecological Cancers; Lung Cancer

Contact Details

NCI
BG 9609 Room 3E522
9609 Medical Centre Drive
Rockville MD 20850
Tel: +1 240 276 6947
Email: taplins@mail.nih.gov



PANCREATIC CANCER DETECTION CONSORTIUM (U01)

NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its pancreatic cancer detection consortium (U01) funding opportunity announcement. This announcement enables multidisciplinary teams of researchers and clinicians to establish the pancreatic cancer detection consortium to conduct research to improve the detection of early-stage pancreatic ductal adenocarcinoma and characterisation of its precursor lesions.

Studies should address the following areas:

identification and testing of biomarkers measurable in body fluids for early detection of PDAC or its precursor lesions;

- determine which pancreatic cysts are likely to progress to cancer;
- develop molecular- or imaging-based approaches for screening populations at high risk of PDAC;
- conduct biomarker validation studies;
- collect longitudinal biospecimens for the establishment of a biorepository.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions as well as higher education institutions. The research is expected to be conducted by appropriate multidisciplinary teams.

Application budgets must reflect the actual needs of the project. The maximum project period is five years.

Ref: NIH PAR-15-289.

Closing date: 21 Sep 16

Deadline information: Applications open on 25 October 2015 and are due by 5pm local time of applicant organisation on deadline dates. Deadlines on: 25 November 2015, 26 May 2016, 21 September 2016, 26 May 2017, 21 September 2017, 6 April 2018.

Posted date: 01 Jul 15

Award type: Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

http://grants.nih.gov/grants/guide/pa-files/PAR-15-289.html#_Section_III_Eligibility

Application form:

<http://www.grants.gov/view-opportunity.html?dpp=1&oppId=277580>

Eligibility profile

Country of applicant institution: Any

Disciplines

Hepatology; Colorectal, Pancreatic & Stomach Cancers

Contact Details

Tel: +1 240 276 7028

Email: srivasts@mail.nih.gov



DESIGN AND DEVELOPMENT OF NOVEL TECHNOLOGIES FOR HEALTHY INDEPENDENT LIVING (R21)

NIH: National Institute of Biomedical Imaging and Bioengineering

Description:

A total of six institutes and offices of the National Institutes of Health invite applications for their design and development of novel technologies for healthy independent living (R21) grants. This R21 funding opportunity announcement supports the design and development of novel technologies to monitor health or deliver care in a real-time, accessible, effective and minimally obtrusive way. Systems may be novel sensor or monitoring systems, home-use point-of-care devices, home or mobile therapy or rehabilitation tools, or information systems. Systems should also have the goal of fostering healthy and independent living.

This funding opportunity announcement will use the NIH R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-118, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in any year.

Ref: PAR-14-119 (replaces PAR-11-021).

Closing date: 23 Sep 16

Deadline information: Applications due by 5pm proposer's local time. Deadlines on: 23 September 2014, 23 September 2015, 23 September 2016.

Posted date: 27 Feb 14

Award type: Innovation grants, Networking/collaboration

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-119.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Health Systems, Consumer Choice; Assistive Technology; Health Systems, Administration; Innovation & Technology Management; Biological Sciences; Diagnostic Sciences; Research Management; Scientific Instrumentation; Community Health Services; Biological Markers & Sensor Mechanisms; Engineering Standards & Specifications; Home Health Care Services; Biotechnology

Contact Details

NIBIB

Tel: +1 301 402 1337

Email: rodgersmm@mail.nih.gov



TECHNOLOGIES FOR HEALTHY INDEPENDENT LIVING (R01)

NIH: National Institute of Biomedical Imaging and Bioengineering

Description:

A total of six institutes and offices of the National Institutes of Health invite applications for their technologies for healthy independent living (R01) grants. This R01 funding opportunity announcement supports research and development of technologies to monitor and deliver healthcare in a real-time, accessible, effective and minimally obtrusive way. Systems should integrate, process, analyse communicate and present data in order to engage individuals and empower them in their own healthcare.

This funding opportunity announcement will use the NIH R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-119, which solicits applications under the R21 exploratory/developmental research grant award mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-118 (replaces PAR-11-020).

Closing date: 23 Sep 16

Deadline information: Applications due by 5pm proposer's local time. Deadlines on: 23

September 2014, 23 September 2015, 23 September 2016.

Posted date: 27 Feb 14

Award type: Innovation grants, Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-118.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Engineering Standards & Specifications; Diagnostic Sciences; Health Systems, Administration; Community Health Services; Biotechnology; Scientific Instrumentation; Innovation & Technology Management; Biological Sciences; Home Health Care Services; Assistive Technology; Research Management; Health Systems, Consumer Choice; Biological Markers & Sensor Mechanisms

Contact Details

NIBIB

Tel: +1 301 402 1337

Email: rodgersmm@mail.nih.gov

CLINICAL VISION RESEARCH: RESOURCE CENTRE GRANT (UG1)

NIH: National Eye Institute

Description:

The National Eye Institute invites applications for its clinical vision research: resource centre grant (UG1). This UG1 funding opportunity

announcement supports single component resource centres to provide imaging, laboratory or other requisite services for a



multi-centre clinical trial or other complex or high-risk clinical vision research study.

This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-098, PAR-14-099 and PAR-14-100, each of which invites applications under the UG1 mechanism.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-097.

Closing date: 25 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 25 January, 25 May and 25 September until 8 May 2017.

Posted date: 13 Feb 14

Award type: Clinical trials, Directed grants to institutions, research groups etc, Research centres

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-097.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do>

Eligibility profile

Country of applicant institution: Any

Disciplines

Epidemiology; Eye Diseases; Drug Design; Diagnostic Sciences; Vision Science; Optometry; Sensory Systems

Contact Details

NEI

5635 Fishers Lane

Bethesda, MD 20892-9300

Tel: +1 301 451 2020

Email: everettd@mail.nih.gov

CLINICAL VISION RESEARCH: CHAIR'S GRANT (UG1)

NIH: National Eye Institute

Description:

The National Eye Institute invites applications for its clinical vision research: chair's grant (UG1). This UG1 funding opportunity announcement supports the scientific rationale, study aims and significance of the research project.

This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under

the U10 mechanism, and PAR-14-097, PAR-14-099 and PAR-14-100, each of which invites applications under the UG1 mechanism.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.



Ref: PAR-14-098.

Closing date: 25 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 25 January, 25 May and 25 September until 8 May 2017.

Posted date: 13 Feb 14

Award type: Research centres, Directed grants to institutions, research groups etc, Clinical trials

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-098.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do>

Eligibility profile

Country of applicant institution: Any

Disciplines

Sensory Systems; Diagnostic Sciences; Drug Design; Optometry; Epidemiology; Eye Diseases; Vision Science

Contact Details

NEI

5635 Fishers Lane

Bethesda, MD 20892-9300

Tel: +1 301 451 2020

Email: everettd@mail.nih.gov

CLINICAL VISION RESEARCH: CLINICAL CENTRE GRANT (UG1)

NIH: National Eye Institute

Description:

The National Eye Institute invites applications for its clinical vision research: clinical centre grant (UG1). This UG1 funding opportunity announcement supports the organisation and operations of the clinical centre responsible for recruitment and retention of study participants and implementation of the study protocol.

This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-097, PAR-14-098 and PAR-14-100, each of which invites applications under the UG1 mechanism.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-099.

Closing date: 25 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 25 January, 25 May and 25 September until 8 May 2017.

Posted date: 13 Feb 14

Award type: Research centres, Directed grants to institutions, research groups etc, Clinical trials

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-099.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do>



Eligibility profile

Country of applicant institution: Any

Disciplines

Sensory Systems; Optometry; Epidemiology; Diagnostic Sciences; Drug Design; Eye Diseases; Vision Science

Contact Details

NEI
5635 Fishers Lane
Bethesda, MD 20892-9300
Tel: +1 301 451 2020
Email: everettd@mail.nih.gov

C

CLINICAL VISION RESEARCH: COORDINATING CENTRE GRANT (UG1)

NIH: National Eye Institute

Description:

The National Eye Institute invites applications for its clinical vision research: coordinating centre grant (UG1). This UG1 funding opportunity announcement supports the provision of details of the coordinating centre's responsibilities and operations.

This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-097, PAR-14-098 and PAR-14-099, each of which invites applications under the UG1 mechanism.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-100.

Closing date: 25 Sep 16

Deadline information: Applications due by 5pm proposer's local time, every 25 January, 25 May and 25 September until 8 May 2017.

Posted date: 13 Feb 14

Award type: Directed grants to institutions, research groups etc, Clinical trials, Research centres

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-100.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do>

Eligibility profile

Country of applicant institution: Any

Disciplines

Epidemiology; Eye Diseases; Optometry; Drug Design; Sensory Systems; Vision Science; Diagnostic Sciences

Contact Details

NEI
5635 Fishers Lane
Bethesda, MD 20892-9300
Tel: +1 301 451 2020
Email: everettd@mail.nih.gov

Description:

The National Human Genome Research Institute invites application genomic resource grants for community resource projects (U41). This U41 funding announcement supports the development and distribution of genomic resources that will be available to and valuable for the broad research community, using cost-effective approaches. The research projects should have the following characteristics:

- they fill a demonstrable need and have a wide impact, well beyond the field of genomics itself;
- they are comprehensive in scope, covering the entire genome or all genes of an organism;
- they make data or materials broadly available to all researchers in a user-friendly manner;
- they use established, state-of-the-art, cost-efficient and robust production methods to generate and distribute high-quality products of lasting value;
- they are unique and do not duplicate resources that are otherwise available.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but should reflect the needs of the proposed project over a maximum period of five years.

Ref: PAR-14-191.

Closing date: 25 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation.

Posted date: 25 Apr 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-191.html>

Application form:

<http://www.grants.gov/applicants/apply-for-grants.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biological Sciences; Deoxyribonucleic Acid, DNA; Bioengineering; Molecular Genetics; Bioinformatics; Biochemistry & Molecular Biology; Human Genome; Applied Mathematics; Biomedical Engineering; Medical Research of Selected Fields; Medical Models, Mathematical; Genomics; Computer Science & Informatics; Quantitative Genetics; Systems Biology; Genetics & Systems Biology; Health & Medical Informatics; Medical Genetics; Diagnostic Sciences

Contact Details

Tel: +1 301 435 5544

Email: lisa.brooks@nih.gov





INNOVATIVE TECHNOLOGIES FOR CANCER-RELEVANT BIOSPECIMEN SCIENCE (R21)

NIH: National Cancer Institute

Description:

The National Cancer Institute, as part of its innovative molecular analysis technologies programme, invites applications for its innovative technologies for cancer-relevant biospecimen science (R21) funding opportunity announcement. This announcement solicits exploratory research projects focused on the early-stage development of technologies that improve the quality of the samples used for cancer research or clinical care. This includes innovative technologies that address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling and storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximising or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This call supports the development of tools, devices, instrumentation and associated methods to assess sample quality, preserve or protect sample integrity and establish verification criteria for quality assessment and quality control and handling under diverse conditions.

This funding opportunity announcement uses the NIH exploratory or developmental grant (R21) award mechanism and runs in parallel with three announcements of similar scientific scope, RFA-CA-16-001, which uses the same grant mechanism, RFA-CA-16-002 and RFA-CA-16-004, which both use the R33 phase two grant mechanism.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

NCI intends to commit US\$1.2 million in fiscal year 2017 to support an estimated five awards. Application budgets are limited to US\$400,000 over a three-year period, with no more than US\$200,000 in direct costs allowed in any single year.

Ref: RFA-CA-16-003 (replaces RFA-CA-15-004).

Closing date: 26 Sep 16

Deadline information: Applications open on 26 January and are due by 5pm local time of applicant organisation, 26 February, 26 May and 26 September 2016.

Posted date: 10 Dec 15

Award type: Innovation grants, Directed grants to institutions, research groups etc, Technology innovation/development

Award amount max: \$400,000

Award amount min: -

Award budget total: \$1,200,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-16-003.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Screening for Diseases; Medical Instrumentation; Automated Clinical Analysis; Cancer Diagnosis; Cancer Cell Biology; Medical Devices

Contact Details

Tel: +1 301 547 9980

Email: dickherberaj@mail.nih.gov



A ADVANCED DEVELOPMENT AND VALIDATION OF EMERGING MOLECULAR AND CELLULAR ANALYSIS TECHNOLOGIES FOR BASIC AND CLINICAL CANCER RESEARCH (R33)

NIH: National Cancer Institute

Description:

The National Cancer Institute, under its innovative molecular analysis technologies programme, invites applications for its advanced development and validation of emerging molecular and cellular analysis technologies for basic and clinical cancer research (R33) funding opportunity announcement. This announcement seeks grant applications proposing exploratory research projects focused on the advanced development of emerging molecular or cellular analysis technologies for basic or clinical cancer research. This call solicits applications where proof-of-principle for the emerging technology or methodology has been provided with supportive preliminary data demonstrating a novel capability for targeting, probing or assessing molecular and cellular features of cancer biology. Projects proposed to this funding opportunity announcement should reflect the potential to accelerate and enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology and cancer health disparities.

This funding opportunity uses the NIH (R33) grant mechanism and runs in parallel with three announcements of similar scientific scope, RFA-CA-16-001 and RFA-CA-16-003, which both use the R21 exploratory/developmental grant mechanism, and RFA-CA-16-00, which uses the R33 phase two grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

The NCI intends to commit US\$4 million in fiscal year 2017 to fund an estimate of 10 awards. Application budgets are limited to US\$300,000 per year for a maximum project period of three years.

Ref: RFA-CA-16-002 (replaces RFA-CA-15-003).

Closing date: 26 Sep 16

Deadline information: Applications open on 26 January and are due by 5pm local time of applicant organisation, 26 February, 26 May and 26 September 2016.

Posted date: 10 Dec 15

Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc

Award amount max: \$900,000

Award budget total: \$4,000,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-16-002.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Molecular Modelling; Epidemiology; Cellular Interactions; Cytopathology; Cancer Cell Biology; Molecular Mechanics; Cancer Studies & Oncology

Contact Details

Tel: +1 301 547 9980

Email: dickherberaj@mail.nih.gov



VALIDATION AND ADVANCED DEVELOPMENT OF EMERGING TECHNOLOGIES FOR CANCER-RELEVANT BIOSPECIMEN SCIENCE (R33) NIH: National Cancer Institute

Description:

The National Cancer Institute, as part of its innovative molecular analysis technologies programme, invites applications for its innovative technologies for cancer-relevant biospecimen science (R33) funding opportunity announcement. This announcement seeks projects focused on the advanced development and validation of emerging technologies that improve quality of the samples used for cancer research or clinical care. This includes technologies that address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling and storage of cancer-relevant biospecimens. The proposed project must be focused on innovative, biospecimen science-relevant technologies and methodologies that either improve the quality and utility of biospecimens or samples derived from biospecimens for cancer research or clinical care or otherwise seek to measure the quality of those samples and determine their fitness for downstream analyses. The proposed technology may be targeted for the needs of basic, preventative, diagnostic, translational, epidemiological, health disparities or clinical cancer research or for broad potential use in cancer research.

This funding opportunity announcement uses the NIH exploratory or developmental grant (R33) award mechanism and runs in parallel with three calls of similar scientific scope, RFA-CA-16-001 and RFA-CA-003, which both use the R21 exploratory/developmental grant mechanism, and RFA-CA-16-002, which uses the R33 phase two grant mechanism.

Eligible applicants include foreign or domestic for-profit and non-profit

organisations and public and private organisations.

The NCI intends to commit US\$800,000 in fiscal year 2017 to support an estimated two awards. Application budgets are limited to US\$300,000 in direct costs per year for a maximum period of three years.

Ref: RFA-CA-16-004 (replaces RFA-CA-15-005).

Closing date: 26 Sep 16

Deadline information: Applications open on 26 January and are due by 5pm local time of applicant organisation, 26 February, 26 May and 26 September 2016.

Posted date: 10 Dec 15

Award type: Technology innovation/development, Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$300,000

Award budget total: \$800,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-16-004.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Screening for Diseases; Medical Instrumentation; Cancer Diagnosis; Automated Clinical Analysis; Medical Devices; Cancer Cell Biology

Contact Details

Tel: +1 301 547 9980

Email: dickherberaj@mail.nih.gov



FROM ASSOCIATION TO FUNCTION IN THE ALZHEIMER'S DISEASE POST GENOMICS ERA (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute on Aging invites applications for its from association to function in the Alzheimer's disease post genomics era (R01) funding opportunity announcement. This announcement supports innovative and collaborative research focused on understanding the structure and function of proteins or protein complexes regulated by different AD genetic variants that have been identified to be associated with the sporadic and late onset AD. Specifically, this FOA seeks to identify and develop more effective and integrated platforms to screen protein functions, protein-protein interaction, protein complexes and their regulation by AD genetic variants prior to any in-depth mechanistic studies. Collaborative research projects that will translate initial genome wide association study discovery into functional and phenotypical insights and ultimately lead to understand the complex biology of AD are encouraged.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, RFA-AG-17-011, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

The NIA intends to commit \$4,000,000 in fiscal year 2017 to support six to eight awards. Application budgets are limited to \$350,000 in direct costs per year for a maximum period of five years.

Ref: RFA-AG-17-010.

Closing date: 27 Sep 16

Deadline information: Applications open 27 August and are due by 5pm local time of applicant organisation, 27 September 2016.

Posted date: 12 May 16

Award type: Innovation grants, Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: \$1,750,000

Award budget total: \$4,000,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-010.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Protein Synthesis, Modification & Turnover; Genomics; Alzheimer's Disease & Senile Dementia

Contact Details

Tel: +1 301 496 9350

Email: yangj13@mail.nih.gov



FROM ASSOCIATION TO FUNCTION IN THE ALZHEIMER'S DISEASE POST GENOMICS ERA (R21)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute on Aging invites applications for its from association to function in the Alzheimer's disease post genomics era (R21) funding opportunity announcement. This announcement supports early stage innovative and exploratory research focused on understanding the structure and function of proteins or protein complexes regulated by different AD genetic variants that have been identified to be associated with the sporadic and late onset AD. Specifically, this FOA seeks to identify and develop novel and effective platforms to screen protein functions, protein-protein interaction, protein complexes and their regulation by AD genetic variants. Areas of interest include:

- development of novel proteome-wide analysis of disease-associated single nucleotide polymorphisms platform to identify allele-specific transcription factors and RNA binding proteins in AD;
- implementation of ribosomal pausing analysis to evaluate the roles of SNP variants on protein synthesis and translational efficiency;
- development of disruptive proteomics technologies to determine the roles of SNPs on protein-protein interaction networks and assembly of protein complexes using induced pluripotent stem cells, other cell models or in vivo animal models;
- targeted and functional proteomics analyses to identify the biological impact of genome wide association study variants in modulating the early pathogenesis of AD;
- testing the function of coding genetic variants and to determine the roles of genetic variants on post-translational

modifications, cell signalling and protein homeostasis in sporadic AD;

- implementation of local and web-based in silico model systems to predict the structure and function of mutant versus wild type AD risk proteins, particularly if the mutations are located within the protein coding sequence;
- development and implementation of novel or existing methodologies and high throughput systems to rapidly screen and determine the biological or biochemical function of SNP variants.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, RFA-AG-17-010, which solicits applications under the NIH research project (R01) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

The NIA intends to commit \$1,000,000 in fiscal year 2017 to support four awards. Application budgets are limited to \$275,000 in direct costs for a maximum period of two years. No more than US\$200,000 may be requested in any single year.

Ref: RFA-AG-17-011.

Closing date: 27 Sep 16

Deadline information: Applications open 27 August and are due by 5pm local time of applicant organisation, 27 September 2016.

Posted date: 12 May 16

Award type: Networking/collaboration, Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$275,000

Award budget total: \$1,000,000

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-011.html>

Genomics; Protein Synthesis, Modification & Turnover; Alzheimer's Disease & Senile Dementia

Eligibility profile

Country of applicant institution: Any

Contact Details

Tel: +1 301 496 9350

Email: yangj13@mail.nih.gov

Disciplines

IMPACT OF AGEING IN HUMAN CELL MODELS OF ALZHEIMER'S DISEASE (R01)

NIH: National Institute on Aging

Description:

The National Institute of Aging invites applications for its impact of ageing in human cell models of Alzheimer's disease (R01) funding opportunity announcement. This announcement aims to establish the impact of ageing on the expression or modulation of Alzheimer's disease pathological processes and to assess age-related Alzheimer's disease genotype-phenotype relationships in human cell models. Consideration should be given to incorporating different brain cell types to promote neural circuit maturation and complexity in such cell models to better recapitulate Alzheimer's disease pathology. Integrative and multidisciplinary approaches to study ageing and cell type complexity in human cell models are encouraged. Human iPS cells, human iNeurons, and brain cells isolated from human brain tissue are appropriate human cell models for this funding announcement. Areas of research interest include, but are not limited to:

- develop age-relevant human cell models of AD that more fully recapitulate the AD phenotype;
- define potential early vs late stage features of the AD phenotype in human neural cells;
- characterise age-dependent AD genotype-phenotype relationships in

human neural cells to define the genetic, molecular and physiological function of genetic variants identified from GWAS and DNA sequencing studies;

- manipulate cellular and molecular markers of physiological ageing processes to induce ageing phenotype in human AD cell models;
- manipulate genes that specifically affect neural ageing in human AD cell models;
- explore use of genes involved in premature ageing and that also exert cellular or physiological effects in brain to induce ageing in human AD cell models;
- direct reprogramming of human cells to make iNeurons and other neural cell types that maintain ageing marks and phenotypes;
- characterise neural cells derived from human AD brain tissue as models of AD;
- integrate different relevant neural cell types to promote cellular and physiological maturation and complexity of human AD iPSC-derived cells or iNeurons;
- utilise 3D culture approaches to achieve complex, circuit level



structures to study systems biology, physiology and connectivity in the development of AD in human AD cell models;

- define non-genetic approaches to study impact of ageing on human AD cell models.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

NIA intends to commit US\$2.25 million to fund five to seven awards. Direct costs are limited to US\$275,000 over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year. The maximum funding period is two years.

Ref: RFA-AG-17-009.

Closing date: 28 Sep 16

Deadline information: Applications open on 28 August and are due by 5pm local time of

the application organisation 28 September 2016.

Posted date: 10 May 16

Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc

Award amount max: \$275,000

Award budget total: \$2,250,000

Website:

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-009.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Alzheimer's Disease & Senile Dementia

Contact Details

Tel: +1 301 496 9350

Email: wiseb@nia.nih.gov

PREDICTIVE MULTISCALE MODELS FOR BIOMEDICAL, BIOLOGICAL, BEHAVIOURAL, ENVIRONMENTAL AND CLINICAL RESEARCH (INTERAGENCY U01)

NIH: National Institute of Biomedical Imaging and Bioengineering

Description:

A total of 23 participating institutes and centres of the National Institutes of Health, the US Army Research Office, the Department of Energy, the US Food and Drug Administration, the National Aeronautics and Space Administration, the National Science Foundation and the Office of Naval Research invite applications for their predictive multiscale models for biomedical, biological, behavioural, environmental and clinical research (interagency U01) funding opportunity announcement. This announcement aims to support the development of multiscale models to accelerate biological, biomedical, behavioural, environmental and clinical research.

Furthermore, funding supports the development of non-standard modelling methods and experimental approaches to facilitate multiscale modelling and active participation in community-driven activities through the Multiscale Modeling (MSM) Consortium.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Direct costs are limited to US\$500,000 per year and the maximum project period is five years.



Ref: PAR-15-085 (replaces PAR-11-203).

Closing date: 29 Sep 16

Deadline information: Applications due by 5pm local time of applicant organisation on 9 March 2015, 29 May 2015, 29 September 2015, 29 January 2016, 30 May 2016, 29 September 2016, 30 January 2017, 29 May 2017, 29 September 2017.

Posted date: 09 Jan 15

Award type: Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration

Award amount max: \$2,500,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-15-085.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application->

[package.html#download=true?oppNum=PA-15-085](http://grants.nih.gov/grants/guide/pa-files/PA-15-085.html#download=true?oppNum=PA-15-085)

Eligibility profile

Country of applicant institution: Any

Disciplines

Disease Models; Biomolecular Modelling; Computer Simulation & Modelling; Computational Biology; Data Analysis; Medical Models, Mathematical

Contact Details

NIBIB

BG 2 Dem Room 200

6707 Democracy Boulevard

Bethesda, MD 20817

Tel: +1 301 451 4778

Email: grace.peng@nih.gov

EXTENDED DEADLINE: CLINICAL AND TRANSLATIONAL EXPLORATORY OR DEVELOPMENTAL STUDIES (R21)

NIH: National Cancer Institute

Description:

The National Cancer Institute has extended the expiration date for its clinical and translational exploratory or developmental studies (R21) funding opportunity announcement. The previous expiration date of 23 March 2018 has been extended to 23 March 2019. All other call information remains unchanged.

This announcement supports new exploratory research in cancer diagnosis, treatment, imaging, symptom or toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom or toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies. The use of new clinically-relevant

models and imaging technologies are sought as they could lead to first-in-human clinical trials. Clinical and preclinical studies that focus on the development and testing of anti-cancer, symptom management, and cancer prevention agents, including combinations; discovery of new molecular targets; diagnostic and treatment methodologies; and predictive biomarkers are appropriate for projects submitted to this FOA. The following studies are appropriate for this call:

- clinical studies;
- correlative studies or biomarker development;
- target and agent discovery and development;
- model development and analysis.



Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US\$275,000 in direct costs per year for the maximum period of two years. No more than US\$200,000 may be requested in any single year.

Ref: PAR-16-176.

Closing date: 19 Jul 16

Deadline information: Applications open 19 June 2016 and due by 5pm local time of applicant organisation, every 19 July, 22 November and 22 March until 23 March 2019.

Posted date: 19 Apr 16

Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$275,000

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/notice-files/NOT-CA-16-037.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biochemistry & Molecular Biology; Biochemical Markers; Drug Design; Cancer Studies & Oncology; Diagnostic Sciences; Animal Models

Contact Details

Tel: +1 240 276 6130

Email: william.timmer@nih.gov

R ESearch Education Programme for Clinical Researchers and Clinicians (R25) NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its research education programme for clinical researchers and clinicians (R25) grants. This R25 funding opportunity announcement supports educational activities that complement and enhance the training of a workforce to meet the nation's biomedical, behavioural and clinical research needs. The announcement is intended to support research education activities that enhance the knowledge of substance abuse and addiction research. The programme is intended for those in clinically focused careers or those training for careers as clinicians or service providers, clinical researchers or optimally a combination of the two. This mechanism may not be used for

support of non-research-related clinical training.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US\$350,000 in direct costs allowed in any single year. The maximum project period is five years.

Ref: PAR-16-224 (replaces PAR-13-084).

Closing date: 21 Jul 16

Deadline information: Applications due by 5pm local time of applicant organisation.

Deadlines on: 21 July 2016, 21 July 2017, 20 July 2018.



Posted date: 06 May 16
Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc
Award amount max: \$1,750,000
Award budget total: -
Website:
<http://grants.nih.gov/grants/guide/pa-files/PA16-224.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse; Medical Education; Addiction

Contact Details

Tel: +1 301 402 1533

Email: bsims@nida.nih.gov

